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ABSTRACT
Much is known about the structural appearance of the HSV-1 capsid however, the aim of 
this project was to build on existing knowledge by studying the interactions and properties 
o f individual capsid proteins, principally VP26, but also VP5 and preVP22a.
As good antibodies to many capsid proteins were not available, a short amino acid 
sequence tag, derived from the HCMV pp65 protein was inserted. This approach provided 
a tool for monitoring VP26, VP5 and VP 19c in a series of interaction studies using an anti- 
pp65 monoclonal antibody. Extensive immunofluorescence studies of plasmid transfection 
experiments, showed that VP 19c had an intrinsic ability to localise to the nucleus. 
Furthermore, nuclear localisation o f VP26 was only observed when VP5 was present 
together with either VP 19c or preVP22a (see Chapter 3). In an attempt to produce an 
unrelated tag, a short amino acid sequence derived from the CAT enzyme and recognised 
by an anti-CAT monoclonal antibody, was mapped and characterised. An oligopeptide of 
this sequence was synthesised and used in an unsuccessful attempt to raise monospecific 
antisera in rabbits for use in double labelling experiments.
The VP26 ORF was sub-cloned into a bacterial expression vector to allow more detailed 
studies of the protein to be performed. The pET expression plasmid offered a system where 
high quantities o f protein could be produced, readily purified (using a 6xhis tag and nickel 
affinity chromatography) and easily manipulated to produce mutant proteins. Although the 
VP26 tagged protein was induced to high levels, it was extremely insoluble. A successful 
procedure was developed by which VP26 was purified in a denatured form and renatured 
by dialysis against buffer. This process consistently produced concentrations of purified 
VP26 protein at 0.5-1 .Omg/ml (see Chapter 4).
The functionality o f the purified renatured VP26 was demonstrated by its ability to 
assemble correctly on capsids. An experimental protocol was developed for attaching the 
tagged VP26 to capsids lacking VP26. Cryo-EM analysis o f these capsids confirmed that 
the VP26 protein had attached at the correct location and in the expected orientation,
forming a star shaped ring on the tips of the VP5 hexons. This provided proof that the 
bacterially expressed protein mimicked the properties of the natural VP26 protein and that 
the extra sequences, contributed by the epitope and 6xhis tags, did not interfere with the 
binding of VP26 to VP5. An area of extra mass that was detected in the hexons with the 
tagged VP26 protein attached, was considered to be indicative of the tag sequence. As the 
tag had been inserted into the N-terminus of the UL35 ORF, this identified the probable 
location of the N-terminus o f VP26 (see Chapter 5).
To analyse sequences important for the interaction of VP26 with VP5 an ELISA assay was 
developed. Initially, binding o f purified VP26 to capsids which lacked the endogenous 
VP26 were examined. Subsequently, the assay was refined by replacing the VP26 minus 
capsids with purified and soluble VP5, expressed from a baculovirus vector. Using this 
assay, it was possible to map the points of contact between the two proteins. Ten 
overlapping oligopeptides, spanning the entire UL35 ORF, were made and tested for their 
ability to block binding o f VP26 to VP5 in an inhibition type ELISA assay. Several of the 
oligopeptides had an inhibitory effect, most notably those containing sequences between 
amino acid residues 31 and 70 in the UL35 ORF (see Chapter 5).
The solubility o f the VP26 tagged protein was not high enough to allow X-ray 
crytallography or NMR studies. Therefore a protein predict computer package was used to 
try and gain an insight into the secondary structure of the protein. The protein predict 
model was used to guide the construction of a series of mutant VP26 proteins. Although 
the prediction has since proved inaccurate, through CD analysis, the mutant proteins 
produced have been extremely useful. Experiments using VP26 proteins, with three 
glycine insertions at different locations, showed that insertion in the region between amino 
acid residues 40 and 60 on the UL35 ORF (a region incorrectly predicted to consist largely 
o f alpha helix) affected the binding o f VP26 to capsids. These insertions mapped within 
the region of VP26 previously shown to be important for binding in the oligopeptide 
inhibition studies, suggesting that this region contains sequences involved in the 
interaction with VP5.
To account for the presence of VP26 on hexons but not pentons (which are also formed by 
VP5) it had been suggested that VP26 formed 6-mers prior its binding to capsids. Analysis 
o f the oligomeric status o f purified VP26 suggested that the protein was present as 
monomers and dimers (in a ratio of 3:1) but not 6-mers. The implications of this result, 
with regard to capsid assembly models, is discussed in Chapter 5.
This project also sought to study the interaction between the uncleaved scaffolding protein, 
preVP22a, and the major capsid protein VP5. It was known that the uncleaved scaffolding 
protein formed contacts with VP5 through 25 of its C-terminal amino acids. Cleavage, by 
the protease, breaks the link between scaffold and large cored B capsids are converted to 
small cored B capsids. Large and small cored B capsids were produced and analysed by 
cryo-EM. This revealed areas of icosahedrally ordered mass, present in only the protease 
minus capsids and attached to the inner shell. Further analysis showed rod like densities, 
present underneath the triplexes surrounding the c hexon. These results have allowed the 
probable points o f contact between preVP22a and VP5 to be identified (see Chapter 6).
The results attained in this thesis have increased our knowledge of capsid structure and the 
process involved in capsid assembly. In particular, the studies on VP26 have refined the 
understanding o f the nature o f the interaction between the two shell proteins VP26 and 
VP5.
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CHAPTER 1 
INTRODUCTION
Figure 1.1: Electron Micrograph of 
an HSV-1 Virion '
Figure 1.1: Electron micrograph of a frozen hydrated HSV-1 virion. The major 
structural features are indicated by A- the capsid, B- the tegument and C- the envelope, 
with associated glycoproteins.
This figure was reproduced with permission from W Chiu, Baylor College o f Medicine, 
USA.
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1. HISTORICAL PERSPECTIVE
Herpesviruses were named after the clinical manifestation of the diseases which some of 
them cause. The word 'herpes' has been used in medicine for the last 25 centuries and 
derives from the Greek meaning to creep or to crawl (Beswick, 1962). The word 
'herpes' was used in writings dating back to Hippocrates, but probably denoted a type of 
lesion as opposed to a specific disease and would describe eczemas, cancers of the skin 
and, up until 1938, ringworm (reviewed by Wildy, 1973). Probably few of the conditions 
designated as being a Herpesvirus infection today, would have been called so by the 
original definition of the word.
It was not until the late nineteenth century and early twentieth century that specific 
diseases were attributed to specific herpesviruses. After the introduction of negative 
staining, which was first performed on HSV-1 in 1959 (Brenner & Horne, 1959), 
viruses began to be classified on their structural appearance under the microscope.
2. CLASSIFICATION OF HERPESVIRUSES
Herpesviruses belong to the family of Herpesviridae and have been isolated from almost 
every vertebrate species investigated indeed, at least 112 distinct species have thus far 
been recognised (Roizman et al, 1992), eight of which are known to infect humans. The 
virions within the family vary in their antigenic properties, size and composition, 
however, membership to the Herpesviridae family is based on rigid criteria governing 
the architecture of the virion. The virion is composed of 3 distinct layers (see figure 1.1):
• the capsid - this contains the double stranded DNA genome
• the tegument - this amorphous protein layer surrounds the capsid
• the envelope - this is the outermost layer which is composed of a lipid bilayer and 
has glycoprotein spikes protruding from it.
During the course of evolution, members of the family have evolved to form three 
distinct subfamilies: Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae, 
which each contain 2 or 3 genera (see table 1.1). These 3 sub-families were initially 
classified on the basis o f their biological properties such as host range, reproductive 
cycle patterns, cytopathology and latency characteristics (Roizman et al, 1981).
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Recently a more consistent re-classification has been drawn on the basis o f lineages of 
gene content and sequence homology (Roizman et al, 1992).
2.1 Alphaherpesvirinae
Historically this sub-type includes viruses which can infect a wide range of cell types in 
tissue culture, have a short (less than 24 hours) reproductive cycle, a rapid spread in cell 
culture and establishment of latency primarily, but not exclusively, in ganglia. The virus 
genome has a Mw range of 85-110 x 106.
2.2 Betaherpesvirinae
The biological properties o f this set of viruses include a long incubation period with 
slow spread. This often results in the development of a cytomeglia where infected cells 
become grossly enlarged. Latency is generally established in the secretory glands, 
lymphoreticular cells, kidneys and other tissues. The virus genome ranges from Mw 
110-150 x 106.
2.3 Gammaherpesvirinae
Herpesviruses are classified to this category when they replicate in vitro in 
lymphoblastoid (T or B) cells and have variable cytopathology and reproductive cycles. 
Establishment of latency is in the lymphoid tissue and the genome has a Mw of less than 
110 x 106.
2.4 Future Trends in Classification
On the whole the classification based on biological properties has proved accurate and 
few viruses have needed to be re-classified. Generally a high degree o f sequence 
homology and genome relatedness is observed between current genera. There are of 
course notable exceptions: Marek's disease virus (a contagious virus in chickens 
characterised by lymphoid tumours) and herpesvirus of turkeys, were regarded as 
belonging to the Gammaherpesvirinae sub-family. Sequence analysis has re-assigned 
them to the Alphaherpesvirinae (Buckmaster et al, 1988). Similarly, the newly described 
viruses HHV-6 and HHV-7 were initially classified as Gammaherpesviruses as they 
exhibited lymphotropism, but sequence analysis re-assigned them to the 
Betaherpesvirinae.
Figure 1.2: Phylogenetic Tree
HVS EHV-2
EBV
HSV-1 
A HSV-2
EHV-1
PRV
VZV
HHV-6 0.2 Divergence
HCMV
Figure 1.2: This figure is reproduced from McGeoch et al 1995) and shows 
a phylogenetic tree of a selection of herpesvirus genes (see reference). This 
figure highlights three major sublineages which correspond to the three 
subfamilies (ie Alpha-, Beta- and Gamma- herpesvirinae) and indicates 
their relative sequence relatedness.
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It is clear from sequence comparisons and detailed phylogenetic analysis that the Alpha-, 
Beta- and Gamma- herpesvirinae evolved from a common ancestor (McGeoch et al,
1995). Figure 1.2 shows an example of the sequence relatedness between some 
herpesviruses.
VZV (an Alphaherpesvirus) and EBV (a Gammaherpesvirus) share a sizeable subset of 
conserved genes. These were probably part of the progenitor virus's genetic components 
(Davison & Taylor, 1987). However, when the herpesvirus channel catfish virus (CCV) 
was sequenced, no homology was seen with any of the other herpesviruses (Davison, 
1992). This data can be interpreted in 2 different ways:
• the lack o f homology is indicative of a separate origin for CCV from other
herpesviruses and therefore it should no longer be included in the family
• the presence of a common virion and capsid morphology in CCV and other
herpesviruses (Wolf & Darlington, 1971) indicates a very distant, but still related
origin.
More detailed analysis has since established that CCV does belong to the herpesvirus 
family (Booy et al, 1996). Recently, other fish viruses have been isolated which have 
homology to CCV but are unrelated to mammalian herpesviruses (Davison, 1998; 
Davison et al, 1999).
It has also been proposed that the herpesviruses should be re-named (Roizman et al, 
1992) taking into account their taxonomic unit and host. Although this can be applied to 
newly discovered viruses, it is unlikely that traditional nomenclature will be dropped 
readily. Also, in future herpesvirus classification may be required to take account of 
complete nucleotide sequences of the virus. Such factors as: (i) the arrangement of 
terminal sequences involved in packaging, (ii) conservation and positioning of genes and 
gene clusters, (iii) the presence of nucleotides subject to methylation, should all be 
considered.
3. Herpesviruses Which Infect Humans
Currently 8 herpesviruses are known to infect humans (see table 1.1). Most of these 
herpesviruses are widespread in both the developed and the underdeveloped world 
(reviewed by Whitley & Schlitt, 1991).
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Natural animal vectors have not been described and humans remain the sole reservoir for 
transmission. Virus is transmitted by person to person contact and it is estimated that, at 
any given time, over one third of the World's population has a productive herpesvirus 
infection. Symptoms o f the viruses cover a broad spectrum of clinical manifestations. 
For example HSV-1 can range from minor lesions (indiscernible to many patients) to 
severe and life-threatening encephalopathies, generally observed in the 
immunocompromised host. In fact, HSV has been recognised as the most common 
cause o f sporadic and fatal encephalitis in the USA (Whitley & Schlitt, 1991)
All herpesviruses are capable o f existing within their host in a dormant or latent state. 
Thus, after infection with a herpesvirus, DNA remains in the individual for their entire 
lifetime. Reactivation o f the virus may occur after months or even years and the trigger 
is poorly understood. Both internal and external factors, such as mental and physical 
stress, hormone changes, age and exposure to UV radiation, appear to be important for 
reactivation.
3.1 HSV-1 (HHV-1)
HSV-1 (reviewed by Subak-Sharpe & Dargan, 1998) is closely related to HSV-2 and it 
was not until the mid-1960's that 2 distinct antigenic sub-types o f HSV were recognised 
(Nahmias & Dowdle, 1968). HSV-1 has a predilection for oral and facial regions 
although this is not exclusive and it can also be detected in genital areas. Viral infection 
is dependant on close personal contact and it is generally transmitted through oral 
secretions or respiratory droplets.
HSV-1 must come in to contact with abraded skin or mucosal surfaces for infection to 
be initiated. The most common manifestation is the appearance o f lesions on the face or 
lip, known as 'cold sores'. The lesion is induced by a combination of viral replication in 
the mucous membranes and epithelial cells and the inflammatory immune response. The 
virion also travels through the neurons to the trigeminal ganglia where it remains in a 
latent state until subsequent reactivation, when a new round o f lesions may occur.
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3.2 HSV-2 (HHV-2)
HSV-2 (reviewed by Levine, 1992) is usually acquired through sexual contact and so 
individuals with multiple sexual partners are most at risk. As with HSV-1 the virus 
causes lesions by first infecting epithelial cells and mucous membranes, generally but not 
exclusively, o f the genitalia. It then travels along axons of the sensory neurons to the 
sacral ganglia, where it becomes latent. Reactivation may result in the recurrence of 
painful and uncomfortable lesions, however it may also produce an asymptomatic 
infection, which obviously will aid viral spread.
One o f the most damaging aspects of HSV-2 is that it can be passed from infected 
mothers to their babies either in the uterus, during childbirth (75-80% of neonatal 
infections occur this way), or after childbirth due to poor hygiene practice. The 
consequences o f newborn infection can be extremely serious with encephalitis and 
extensive skin lesions not uncommon. For this reason HSV-2 positive mothers, with 
active infections, will usually deliver by caesarean section to avoid passage of the baby 
through the birth canal.
3.3 VZV (HHV-3)
VZV (reviewed by Gelb, 1990) causes two distinct diseases, chickenpox and shingles. 
Chickenpox is the primary infection and generally occurs during childhood. The virus 
enters through the oral cavity and replicates in the upper respiratory tract. After a few 
days it spreads and begins to infect organs, seeding the skin to form the distinctive 
pockmarks. The immune system clears productive virus within a few weeks however, 
the viral DNA enters the sensory neurons where it becomes latent. The virus can remain 
here for several decades causing no apparent effects. In some elderly or 
immunocompromised individuals the virus reactivates, travels down the sensory neurons 
to the skin where it causes the painful and distinctive rash, characteristic o f shingles.
3.4 EBV (HHV-4)
EBV (reviewed by Miller, 1990) can cause mononucleosis if contracted in early 
adulthood. The disease is more commonly known as glandular fever or the kissing 
disease, as it is passed through oral secretions. The virus replicates actively in the mouth 
tongue and salivary glands causing a sore throat and lymphadenopathy. It then spreads 
to T and B cells o f the immune system where it can become latent. Infiltration o f B cells
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in the nervous system can create a severe malaise which can last anything from a week 
to a few months.
EBV has also been associated with certain cancers such as nasopharyngeal carcinoma 
and Burkitt's lymphoma (Levine, 1992). In immunodeficient individuals such as AIDS 
patients, fatal B-cell lymphomas may develop after infection with EBV.
3.5 HCMV (HHV-5)
HCMV (reviewed by Britt, 1996b) has nearly universal occurrence in the human 
population where the virus establishes life-long infection. However, it rarely shows 
definable symptoms in healthy individuals. Immunosuppression, which results in T 
lymphocyte depression, correlates highly with susceptibility to HCMV disease 
suggesting that the cellular immune response is involved in suppressing HCMV 
associated disease. It is not surprising therefore that AIDS patients often exhibit HCMV 
associated clinical manifestations, such as retinitis and gastrointestinal dysfunction. 
Occasionally HCMV causes clinical symptoms in adults indistinguishable from EBV 
mononucleosis however, the major damaging effects o f the virus are seen in neonates.
Congenital HCMV is a major cause of brain damage in infants (Britt, 1996a). For 
example in the USA it is estimated that 1-2% annually of all live births have congenital 
defects due to this virus. A variable percent of these children will show defects in their 
CNS or permanent brain damage and/or reduced perception functions during the first 2 
years o f their life. This may develop into continuing and severe learning difficulties. 
Acquisition of HCMV during pregnancy seems to pose the greatest risk, but this is 
difficult to monitor as the mother often does not show clinical symptoms of disease. 
There has been limited success in preventing in utero spread using gancyclovir.
3.6 HHV-6
HHV-6 (reviewed by Levy, 1997) was first recognised in 1987 from the blood of an 
AIDS patient who exhibited lymphoma (Salahuddin et al, 1986). Two major variants A 
and B have been identified on the basis of monoclonal antibody reactions and cell culture 
properties (Ablashi et al, 1991). It would appear that the B variant can be isolated more 
frequently from the population, except in AIDS patients where the A variant is more 
common.
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The virus replicates mainly in CD 8+ T cells but also has tropism for other cells o f the 
immune system and it appears to form a latent state in peripheral mononuclear cells. 
Infection is spread through saliva and is estimated to occur naturally in >85% of the 
population. Symptoms are rare and appear to be associated with a benign childhood 
illness, Exanthum subitum. In most cases infants will exhibit a sudden fever which 
resolves in a few days. A rash appears as the fever subsides. In previously healthy adults 
a mononucleosis-like illness can occur but, in HIV and AIDS individuals, the virus has 
been associated with retinal disorders, lymphomas and leukaemias.
3.7 HHV-7
HHV-7 (reviewed by Levy, 1997) can be found in the peripheral blood o f the general 
population with transmission occurring early in childhood. The virus was first isolated 
from CD4+ T cells o f a healthy individual (Frenkel et al, 1990) and shows a high 
homology with HHV-6 (see figure 1.2).
The virus is capable o f down-modulating CD4 cells however, a direct association with 
human disease has not been recognised although increased virus levels have been 
isolated from individuals with chronic fatigue syndrome. It has also been suggested that 
HHV-7 is able to reactivate HHV-6 from latency and boost viral replication but further 
study o f  this is required.
3.8 HHV-8
Recently a new candidate human tumour virus HHV-8, previously termed KSHV, has 
been identified associated with Kaposi's sarcoma (KS) (reviewed by Levy, 1997; 
Brooks et al, 1997). The virus was first discovered by a PCR based technique where 
DNA in a KS lesion was compared with DNA from normal skin (Chang et al, 1994). 
This novel approach revealed KS specific sequences which had homology with y- 
herpesviruses.
KS was first described in 1872 by Moritz Kaposi as a rare and benign skin tumour 
associated with elderly Mediterranean men. Over the last 20 years there has been an 
increasing incidence which, it is now clear, is associated with the AIDS pandemic. These 
individuals show atypical and aggressive KS which is frequently fatal.
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Figure 1.3: The HSV viral genome consists o f 2 covalently linked components, L and 
S (double headed arrows) which contain unique sequences UL and US (solid lines). 
These are flanked by terminal and internal repeat elements (open and shaded boxes). 
The a sequence is represented by the unshaded box and is present at each end of the 
genome and in an inverted orientation at the L-S junction. The L and S regions can 
invert relative to each other to produce 4 isomers (single headed arrows). These are P 
(prototype), IL (inversion of L), LS (inversion of S) and ISL (inversion of L and S).
The figure is not drawn to scale.
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HHV-8 resembles EBV in its tropism for B cells and its existence in a latent state. 
Indeed, the viral DNA is usually found associated with EBV in tumours however, some 
lymphomas contain HHV-8 alone, suggesting that the virus has a direct role in the 
transformation process.
Transmission of HHV-8 has been difficult to demonstrate and unlike HHV-6 and HHV- 
7, seropositivity is not common before puberty (<5%). This together with the high 
incidence in HIV positive homosexual males is indicative of the role of anal intercourse 
as the major transmission route.
4. HSV-1 Viral Architecture
The macromolecular structure of the virion is conserved throughout the Herpesviridae, 
however, this study was concerned with HSV-1 and so the description of the virion 
architecture will centre around this virus, with particular emphasis on the capsid 
structure. It is nevertheless important to understand the nature of the whole virion. The 
DNA, tegument, envelope and capsid will each be discussed in turn.
4.1 The Genome
The complete sequence of the dsDNA genome (strain 17 ) was published in 1988 and 
was shown to contain 152260 residues, which was predicted to contain 72 genes 
encoding 70 proteins (McGeoch et al, 1988). 56 ORFs were identified within the unique 
long region and 12 within the unique short region. UL15 was spliced and the intron 
contained both the UL16 and UL17 ORFs. Since this publication several other genes 
have been identified and currently 84 protein encoding genes have been identified 
(Roizman, 1996).
4.1.1 Organisation of the Genome
The genome is composed of 2 unique regions, the unique long region (UL) and the 
unique short region (US) (see figure 1.3). Each unique segment is flanked and linked by 
a set o f internal repeats (IR) and terminal repeats (TR) (Sheldrick & Berthelot, 1974; 
Delius & Clements, 1976); TRL/IRL and IRS/TRS. There is also a variable short 
sequence (250-500bp), termed the ‘a’ sequence, present as a direct repeat at each
- 8 -
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terminus and in an inverted orientation at the L-S junction (Sheldrick & Berthelot, 1974; 
Wadsworth et al, 1976; Delius & Clements, 1976; Hayward et al, 1975; Davison & 
Wilkie, 1981). This sequence is composed of unique (U) and direct repeat (DR) regions. 
For example, the HSV-1 strain F a sequence can be represented as DR1 -  Ub -  DR2n -  
DR4m — Uc — DR1, where Ub and Uc equal 65 and 58 bp respectively (Mocarski & 
Roizman, 1982). The DR2 (12bp) varies from 19-22 copies and DR4 (37bp) from 2-3 
copies. It is this variation which accounts for the difference in size o f the a sequence 
between virus strains.
The a sequence appears to be important for a number o f functions including 
circularisation o f DNA and site specific recombination events (Davison, 1983; 
Poffenberger & Roizman, 1985; Mocarski & Roizman, 1981; 1982). It also has 
functions in the cleavage and packaging processes (Varmuza & Smiley, 1985; Deiss et 
al, 1986; reviewed by Roizman & Sears, 1996).
During virus infection US and UL can invert, relative to one another, to form 4 isomeric 
arrangements (summarised in figure 1.3). These have been designated P (prototype), IL 
(inversion o f long segment), IS (inversion o f short segment) and ISL ( inversion o f long 
and short segments) (Clements et al, 1977; Wilkie, 1976; Roizman, 1979). The isomers 
occur with equal frequency in virions.
4.1.2 Packaged State of the Genome
Originally the DNA was considered to exist as a toroid arrangement (Furlong et al, 
1972) around a central protein plug, thought to consist of VP21 (Gibson & Roizman, 
1972). This hypothesis evolved from a series of electron micrographs produced in the 
late 1970’s (reviewed by Dargan, 1986) which appeared to show convincing evidence o f 
a toroid-like arrangement within the nucleocapsid. Despite the fact that the DNA was 
mainly seen as a uniform and densely staining area, the toroid model became firmly 
established. Indeed, when a toroid pattern was not observed, its absence was attributed 
the plane o f section or preparation procedure,
Cryo-EM examinations have provided no evidence for a toroid structure. Instead it
would appear that packaged DNA exists in a liquid crystalline state (Booy et al, 1991a),
- 9 -
Table 1.2: Tegument Proteins
Gene Protein Approx
Mr(kDa)
Properties
UL4 function unknown
UL11 11 myristylated, role in envelopment & 
transport of nascent virions
UL13 VP18.5 57 protein kinase, phosphorylates UL49
UL21 function unknown
UL25 63 role in penetration, cleavage & 
packaging DNA
UL36 VP 1/2 336 role in releasing DNA at the nuclear 
pore
UL37 121 phosphoprotein, function unknown
UL41 vhs 55 virion host shut off protein
UL46 VP11/12 79 modulates Vmw65 transactivation
UL47 VP13/14 74 modulates Vmw65 transactivation
UL48 Vmw65 54 transactivates IE genes
UL49 VP22 32 secreted & exported to surrounding 
cells via microtubules
UL54 Vmw63 55 IE2 transcription / post transcription 
regulator
UL56 function unknown
RL2 Vmwl 10 79 IE1 transcription regulator
RSI Vmwl75 133 1E3 transcription regulator
US3 53 protein kinase, phosphorylates UL34
US9 10 phosphoprotein, function unknown
US10 34 function unknown
US11 18 involved in translation at ribosomes
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similar to that o f bacteriophage X and T4, and arranged as parallel bundles (Booy et al, 
1991b). Recent cryo-electron microscopy images (Zhou et al, 1999) have produced 
characteristic patterns expected for a spool model. However, unlike the bacteriophage 
T7, HSV does not have a central protein plug around which the genome is arranged. 
Instead, the molecule is proposed to wrap itself around the inner surface o f  the capsid 
shell, accumulating one layer at a time and becoming less ordered. Up to 10 concentric 
DNA layers have been observed (Zhou et al, 1999). Therefore it would seem that this 
featureless appearance of the majority o f DNA containing capsids, in thin section, is an 
accurate reflection o f their structure and the toroid model is an artefact (Puvion- 
Dutilleul et al, 1987). However, the spooling model does account for the changing 
appearance of DNA under negative staining. As the molecule is formed along a definite 
axis certain sections may appear to resemble a toroidal core.
4.2 The Tegument
The tegument is an amorphous protein layer (Zhou et al, 1999) which lies between the 
nucleocapsid and envelope (Wildy et al, 1960). It is a poorly understood structure and it 
is not entirely clear how it interacts with adjacent structural components however, Zhou 
et al (1999) have produced some interesting cryo-EM images which shall be discussed 
later. The tegument is known to consist o f at least 18 proteins (see table 1.2), many o f 
whose functions have not been fully elucidated.
4.2.1 Assembly of the Tegument
Studies with Light (L) particles (Szilagi & Cunningham, 1991) have shown that 
tegument proteins have the ability to assemble into stable structures in the absence o f 
capsids. L-particles consist solely of envelope and tegument (Rixon et al, 1992). They 
are able to attach and fuse to host cells but cannot initiate infection, as they contain no 
DNA (McLauchlan et al, 1992a). The tegument proteins in these particles appear to be 
very similar to virion tegument (McLauchlan & Rixon, 1992) indicating that capsids are 
not required for assembly o f apparently normal tegument in vitro.
4.2.2 Function of the Tegument
The precise role o f the tegument is unclear however functions related to morphogenesis, 
uncoating and regulation o f gene expression, have been assigned to its component 
proteins. Currently VP 16 (UL48) and the product o f UL11 have been implicated in 
assembly, as deficient mutants fail to form an envelope (Wemheimer et al, 1992; Baines
- 10 -
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& Roizman, 1992; MacLean et al, 1992). VP 16 trans-induces HSV-1 IE gene 
transcription (Post et al, 1981; Batterson & Roizman, 1983; Campbell et al, 1984) and 
will be discussed in more detail later (Section 5.2). Other tegument proteins also appear 
to play an important role early in infection. For example UL41 (designated virion host 
shut-off protein, vhs) and UL13 disrupt host cell functions (see section 5.2).
The pathway of the HSV-1 life cycle (see section 5) is such that after envelope fusion 
with the host cell, the tegument and capsid are released into the cytoplasm. It appears 
that tegument proteins, VP 1-3 (UL36), have a role in facilitating release o f DNA from 
the capsid. Ts mutants of this gene (tsB7), fail to release the genome at the non- 
permissive temperature (Batterson et al, 1983). It has recently been suggested that this 
protein may be interacting directly with the pentonal sites of the capsid. Zhou et al, 
1999, visualised the intact virion (by cryo-electron microscopy) and produced a 3D 
image which highlighted a small area of ordered tegument attached to this outer capsid 
surface. As VP 1-3 has been detected as one o f the few remaining tegument proteins in 
cap sid/tegument fractions treated with detergents (Spear, 1972; Vernon, 1978) this 
protein is strongly tipped to be forming this interaction.
Two tegument proteins, VP18.5 (UL13) and the product of US3, are protein kinases. 
VP22 (UL49) is a substrate for VP 18.5 (Coulter et al, 1993) and UL34 envelope 
protein is a substrate for US3 (Purves & Roizman, 1992). VP22 is one of the most 
abundant tegument components, however, it would seem that its abundance in the 
tegument is not fixed. Leslie et al (1996) showed that increasing the levels of VP22 
expression allowed more of this protein to be incorporated into the tegument. However, 
this resulted in a decrease of VP 13/14, demonstrating that the composition o f the 
tegument can vary. Elliott & O ’Hare (1997) have convincingly shown that VP22 has a 
mechanism which allows it to travel intercellularly. This process is so efficient that, 
following expression in a small population of cells, the protein spreads to the whole 
monolayer. The transport mechanism has been visualised using time lapse photography 
of VP22 fused to a green fluorescent protein (Elliott & O’Hare, 1999). This study 
revealed that when VP22 was initially expressed, it was present in diffuse cytoplasmic 
locations. However, particulate material formed which travelled through an exclusively
Table 1.3: Envelope Glycoproteins
Protein Gene Approx 
Mr (kDa)
Properties
SB UL27 100 Role in entry, protein present as a 
dimer
g c UL44 44 Role in attachment to host cells, binds 
to heparin sulphate
gD US6 43 Role in entry
gE US8 59 protects against immune neutralisation 
by binding to Fc portion of IgG
gG US4 25 Function unknown
gH UL22 90 complexes with gL to mediate viral 
entry
gl US7 41 complexes with gE
gJ US5 10 function unknown
gK UL53 38 role in envelopment and egress
gL UL1 25 complexes with gFl to mediate viral 
entry
gM UL20 24 role in egress
(The genes underlined are essential for virion infectivity).
Introduction Chapter 1
cytoplasmic pathway to the cell periphery. VP22 may have a role in trafficking proteins 
between cells.
Recent mutational analysis has revealed that the UL17 gene products are associated with 
the virion tegument and are required for cleavage and packaging o f DNA. This is the 
first tegument protein to be definitively shown to be required for these process (Salmon 
etal, 1998).
4.3 The Envelope
The virion is enclosed by a trilaminar envelope (Wildy et al, 1960) which is 
approximately spherical and has prominent protein spikes protruding from it, visible 
under negative staining (Wildy et al, 1960; Stannard et al, 1987). These spikes are 
known to consist o f glycoproteins which have been shown, by immunogold labelling, to 
vary in size from approximately 80-240A (Stannard et al, 1987). Currently 11 
glycoproteins have been identified (reviewed by Spear, 1993 and Haar & Skulstad, 
1994). These have each been given an alphabetical designation, in chronological order of 
discovery, preceded by a g. No glycoprotein A (Spear, 1976) exists, as it was found to 
be identical to gB (Eberle & Courtney, 1980) and gF (Balachandran et al, 1981) was 
renamed gC-2, as it was found to be a gC homologue in HSV-2 (Zezulak & Spear, 
1984). The exact number o f envelope proteins is unknown but, the 11 which have thus 
far been identified in the virion, are detailed in table 1.3.
It is interesting to note that none o f the glycoproteins have been shown to be essential 
for assembly or envelopment. However, gB, gD, gH and gL are required for infectivity 
(Cai et al, 1988; Ligas & Johnson, 1988; Desai et al, 1988; Hutchinson et al, 1992).
4.4 The Capsid
The capsid is an icosahedral lattice which surrounds the viral DNA. It has T=16 
icosahedral symmetry and is composed o f 162 capsomeric sub-units. There are 3 main 
types o f HSV-1 capsid, which have been distinguished in thin section:
• A (or empty capsids), which are seemingly empty shells
• B (or intermediate capsids), which contain scaffold
• C (or full capsids), which contain the viral DNA
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Table 1.4: HSV-1 capsid proteins and the genes which encode them. The seven major 
capsid proteins are detailed in panel (i). The approximate Mr of each varies slightly in 
the published literature. The references (Ref) quoted in this table are:
a Gibson & Roizman, 1972
b Zweig et al, 1979
c Cohen et al, 1980
d Rixon et al, 1990
The five minor capsid proteins, thus far identified, are detailed in panel (ii).
The genes underlined are essential for virion infectivity.
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The 3 species have also been designated as lights, intermediates and heavies, 
respectively, based on their sedimentation position on a sucrose density gradient. All 3 
capsid types have a common shell composition, however, A and C capsids lack the 
internal scaffold (Newcomb et al, 1993). A series o f pulse-chase experiments have 
indicated that B capsids mature into C capsids, with A capsids representing failed DNA 
packaging products (Perdue et al, 1976). The situation may not be as straight forward as 
previously thought as a procapsid has recently been identified (Newcomb et al, 1994). 
This aspect is fully discussed in Chapter 7, Conclusion.
4.4.1 Molecular Composition
The capsid is composed o f 7 major proteins and several minor proteins. The proteins 
which make up the capsid are detailed in table 1.4 and shall now be discussed 
individually.
4.4.1.1 VPS (UL19)
VP5 is the major capsid protein (MCP) having both a highest Mr o f all the capsid 
proteins and constituting 72%, by mass, of the capsid shell (Gibson & Roizman, 1972; 
Newcomb et al, 1989).
It is encoded by the UL19 gene (Costa et al, 1984; McGeoch et al, 1988) which initiates 
at position 40528 and terminates at position 36406 (McGeoch et al, 1988), being 
transcribed from right to left. This results in an ORF of 4122bp, which corresponds to a 
predicted protein M r= l49075 Da. This approximately matches the observed Mr o f 
155kDa, (Gibson & Roizman, 1972; Zweig et al, 1979b) 154kDa, (Cohen et al, 1980) 
and 150kDa (Rixon et al, 1990) indicating that the protein does not undergo extensive 
post-translational modifications.
VP5 is the major component o f both the hexons and pentons (Newcomb et al, 1993; 
Zhou et al, 1994). Five copies interact to form each o f the 12 pentons and six copies 
interact to from each o f the 150 hexons, totalling 960 copies of VP5 per capsid. It is not 
therefore surprising that VP5 is essential for capsid formation. A VP5 null mutant virus 
(Desai et al, 1993) and a ts mutant, tsG8, which had a lesion in the U L19 gene (Weller 
et al, 1987), were both unable to form capsids. Similarly, work using the baculovirus
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system has confirmed that VP5 is essential for capsid formation, as when the protein is 
absent, no capsids are formed (Tatman et al, 1994; Thomsen et al, 1994).
4.4.1.2 VP 19c
VP 19c was originally designated VP 19, after a 53 kDa virion protein (Gibson & 
Roizman, 1972) which co-migrated with the capsid protein. The 2 proteins were later 
resolved and the capsid protein was designated VP 19c (Heine et al, 1974).
A series o f lengthy and confused investigations were undertaken to try and locate the 
gene encoding VP 19c (Costa et al, 1983; Braun et al, 1984; Pertuiset et al, 1989). 
Finally, Rixon et al (1990) sequenced the amino terminus of the protein, from purified 
capsids, and aligned it with the amino terminus of the UL38 ORF, confirming that UL38 
encoded VP 19c.
UL38 initiates at position 84531 and terminates at position 85926 (McGeoch et al, 
1988), being transcribed from left to right. This results in an ORF of 1395bp, which 
corresponds to a predicted protein Mr=50260 Da. This approximately matches the 
observed Mr of 53kDa, (Gibson & Roizman, 1972) 50kDa, (Zweig et al, 1979a; Cohen 
et al, 1980) and 54kDa (Rixon et al, 1990) indicating that the protein does not undergo 
extensive post-translational modifications.
In HSV-2 VP 19c is linked by disulphide bonds to VP5 (Zweig et al, 1979a) and it is 
known that this protein forms part of the triplex complex, linking adjacent capsomeres, 
in HSV-1 and HSV-2 (Newcomb et al, 1993). One copy of VP 19c and two copies of 
VP23 interact to form the triplex structure.
Baculovirus studies have shown that this protein is essential for capsid formation 
(Tatman et al, 1994; Thomsen et al, 1994). Similarly, mutant studies have confirmed the 
finding that VP 19c is essential for capsid formation as null mutants do not produce 
detectable virions (Desai et al, 1998).
4.4.1.3 VP23
VP23 was identified as a 33kDa protein in 1972 (Gibson & Roizman, 1972). The 
protein was originally designated as being a component, or substrate, o f the protein
- 1 4 -
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kinase, as it was thought to be phosphorylated (Lemaster & Roizman, 1980). However, 
it was later discovered that VP23 had been contused with a tegument protein with 
similar elecrophoretic mobility (Braun et al, 1984).
VP23 is encoded by the UL18 gene (Rixon et al, 1990), which is co-terminal with 
UL19. UL18 initiates at position 36051 and terminates at position 35097 (McGeoch et 
al, 1988), being transcribed from right to left. This results in an ORF of 954bp, which 
corresponds to a predicted protein Mr=34268 Da. This approximately matches the 
observed Mr o f 33kDa, (Gibson & Roizman 1972; Cohen et al, 1980) 32kDa, (Zweig et 
al, 1979b) and 34kDa (Rixon et al, 1990) indicating that the protein does not undergo 
extensive post-translational modifications.
Two copies o f this protein interact with one copy of VP19c (Newcomb et al 1993) to 
form the triplex. Therefore, like VP 19c, this protein is essential for capsid assembly. A 
null mutant lacking VP23 failed to produce capsids (Desai et al, 1993) and baculovirus 
work has shown that when this is the only absent capsid protein, only densely staining, 
smaller particles are produced (Tatman et al, 1994; Thomsen et al, 1994; Rixon et al,
1996).
4.4.1.4 VP26
The smallest capsid protein, VP26, was not discovered as a capsid component until 
1979 (Heilman et al, 1979) when it was designated pi 2, by virtue o f its Mr. The ORF of 
VP26 was mapped by sequencing fragments of VP26, from purified capsids, and 
aligning them to the UL35 ORF (Davison et al, 1992).
UL35 initiates at position 70566 and terminates at position 70902 (McGeoch et al, 
1988), being transcribed from left to right. This results in an ORF of 336bp which 
corresponds to a predicted protein Mr= 12095 Da. This closely matches the observed Mr 
o f 12kDa (Heilman et al, 1979; Cohen et al, 1980; Rixon et al, 1990) indicating that the 
protein does not undergo extensive post-translational modifications.
VP26 is located at the tips o f the VP5 hexons but not the pentons (Booy et al, 1994;
Zhou et al, 1994; 1995). Six copies of VP26 are arranged in a star shaped pattern at
these positions (Zhou et al, 1995) amounting to 900 copies o f VP26 per capsid.
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Figure 1.4: Organisation of UL26 and UL26.5 ORFs
(i) UL26 ORF R M
VP24 V/P21
247 (Ala) -  248 (Ser)
(ii) UL26.5 ORF
610 (Ala)-611 (Ser)
M
V P22a
610 (Ala)-611 (Ser)
Figure 1.5: Processing Products of UL26 and UL26.5
(i) Pra (80kDa)
(ii) Prb (75kDa)
I
(iii) VP24 (27kDa)
1 247
r~ i
(iv) preVP21 (50kDa)
248
(v) VP21 (45kDa)
248
(vi) preVP22a (40kDa)
307
________
(vii) VP22a (38kDa)
307
635
610
I
635
610
i 635
610
Figure 1.4: The 3’ co-terminal transcripts are shown by arrows which are overlayed 
by open boxes, indicating the position of the ORF, specifying UL26 [panel (i)] and 
UL26.5 [panel (ii)] gene products. Proteolytic cleavage takes place between the 
alanine and serine residues, indicated by R and M
Figure 1.5: The proteolytic cleavage products are described in the text. The 
arrowheads indicate HSV 1 cleavage sites.
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Baculovirus studies have shown that it is not essential for capsid formation as 
recognisable capsids are formed when only this protein is absent (Tatman et al, 1994; 
Thomsen et al, 1994). VP26 can also be removed from capsids by treatment with 2M 
GuHCl, leaving the capsid shell largely intact (Newcomb & Brown, 1991; Booy et al, 
1994) and illustrating that this protein is not vital for capsid stability.
Recent studies with VP26 null mutants has shown that VP26 is not required for viral 
growth in cell culture however, the protein does appear to be important for production 
o f infectious virus in the nervous system (Person & Desai, 1998). Studies with mice 
have shown that virus yield and reactivation is greatly reduced in the VP26 null mutants, 
compared to wild type virus.
4.4.1.5 VP21, VP22a and VP24
VP21, VP24 and VP22a have been grouped together as they are 3 capsid proteins, 
which are derived from 2 overlapping genes (figure 1.4) and form a central scaffold 
structure. There was initially much confusion as to the nature and relationship of these 
proteins to each other and the capsid. Firstly, VP21 and VP22a are only present in B 
capsids and absent from mature C capsids (Gibson & Roizman, 1972) whereas, VP24 is 
also a component o f A and C capsids. Secondly, there are a number o f  variants o f these 
proteins due to the nature o f the proteolytic processing o f the genes which encode them 
(see figure 1.5) (Liu & Roizman, 1991b; Preston et al, 1992) and this aspect shall now 
be discussed.
VP24 and VP21 are the products o f the UL26 gene (Davison et al, 1992) which initiates
at position 50809 and terminates at position 52714 (McGeoch et al, 1988), being
transcribed from left to right. This results in an ORF of 1905bp , which corresponds to a
predicated protein Mr=62466. This is considerably larger than any single capsid protein
whose sequence has been aligned to this area. In fact, UL26 encodes both VP24 and
VP21. VP24 is encoded by the 5’ portion and VP21 is encoded by the 3’ portion o f the
gene (Davison et al, 1992). UL26 encodes a maturational protease, which is essential
for the formation o f C capsids, containing DNA (Preston et al, 1983; Gao et al, 1994).
The full-length product o f UL26 is designated pra [figure 1.5, panel (i)]. Self cleavage at
site R, can occur between alanine 247 and serine 248, to generate two cleavage
products, VP24 [figure 1.5, panel (iii)] and preVP21 [figure 1.5, panel (iv)] (Dilanni et
-  1 6 -
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al, 1993). The N-terminal product, VP24, contains the active catalytic viral protease 
(Weinheimer et al, 1993). VP24 has an observed Mr o f 25kDa, (Gibson & Roizman, 
1972; Zweig et al, 1979b) 26kDA, (Cohen et al, 1980) 24kDa (Rixon et al, 1990).
Cleavage at site M, occurs between alanine 610 and serine 611, to generate either prb 
[figure 1.5, panel (ii)], where this single cleavage has occurred and removed the C- 
terminal 25 amino acids or, VP21, [figure 1.5, panel (v)] where the double cleavage 
(R+M) has occurred. The C-terminal product encoding VP21 has an observed Mr of 
44kDa, (Gibson & Roizman, 1972) 40kDa (Cohen et al, 1980) and 42kDa (Rixon et al, 
1990).
In addition, a third protein, VP22a, was initially identified as the product of the UL26 
gene (Preston et al, 1983). However, as previously discussed, the predicted Mr of 
62466 was much greater than the observed Mr o f 38.8kDa, (Gibson & Roizman, 1972) 
40kDa (Zweig et al, 1979b; Rixon et al, 1990) and 38kDa (Cohen et al, 1980). This 
puzzle was resolved when Liu & Roizman (1991a) mapped a transcriptional unit which 
overlapped the C-terminal 329 amino acids o f UL26. This gene initiated at position 
51727 (within the UL26 ORF) and terminated at the same site as UL26, position 52714 
(McGeoch et al, 1988), being transcribed from left to right. This ORF encoded 987bp 
and was designated UL26.5 [figure 1.4, panel (ii)].
The full-length product o f the UL26.5 ORF is termed preVP22a [see figure 1.5, panel
(vi)]. However, as UL26.5 and UL26 carry identical 3’ residues, the M site present in 
UL26 is therefore also found in UL26.5 and proteolytically cleaved between alanine 610 
and serine 611. This removes the C-terminal 25 amino acids o f preVP22a (Liu & 
Roizman, 1992; Preston et al, 1992) and generates VP22a [figure 1.5, panel (vii)]. It is 
known that preVP22a interacts with VP5, in the capsid shell, through these C-terminal 
25 amino acids (Hong et al, 1996). Proteolytic cleavage therefore breaks the connection 
between the scaffold and shell.
Interestingly, VP22a is in much higher abundance (approximately 1000 to 1500 copies 
per capsid) than VP21 and VP24 combined (approximately 100 copies per capsid) (Liu 
& Roizman 1991b; Newcomb et al, 1993). This situation appears to relate to differential
- 17-
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expression o f the promoters controlling UL26 and UL26.5. The transcriptional initiation 
site o f UL26 mRNA is approximately 180 nucleotides upstream of the ATG (Liu & 
Roizman, 1991a). However, the promoter controlling the UL26.5 transcript is found in 
the 5’ terminal domain o f UL26, approximately 99 nucleotides upstream of the ATG 
(Liu & Roizman, 1991a; 1991b). The 2 promoters are therefore more than 1000 
nucleotides apart and expression o f the 2 genes UL26 and UL26.5 is separately 
controlled.
4.4.1.6 Minor Capsid Proteins
Relatively recently five proteins, UL6, UL12.5, UL15, UL25 and UL28 have been 
identified as minor components o f the capsid shell [table 1.4, panel (ii)].
The product o f the UL6 gene, has been identified as a minor component of A, B and C 
capsids (Patel & Maclean, 1995). The exact location o f the UL6 protein within the 
capsid remains to be determined however, it is obviously tightly associated as treatment 
with 2M GuHCl does not remove it. Baculovirus studies have shown that this protein is 
not essential for capsid formation (Patel & Maclean, 1995). However, studies with 
HSV-1 mutants defective in the UL6 gene showed that only B type capsids accumulated 
(Patel et al, 1996). This indicates that these capsids were unable to package DNA and 
implies that the UL6 protein has a role in packaging DNA.
UL12.5 was identified as a capsid associated deoxyribonuclease by Western blot analysis 
(Bronstein et al, 1997). It appears to be tightly associated with the capsid and is not 
removed by treatment with 2M GuHCl. It has been suggested that the protein has a role 
in processing genomic DNA.
UL15 is a spliced gene encoding 2 distinct proteins with a molecular weight of 81kDa
and 87kDa respectively (Yu et al, 1997). The products o f the UL15 gene are essential
for cleavage and packaging of DNA (Poon & Roizman, 1993; Baines et al, 1994) and
appear to form a close association with UL28. UL15 carries a NLS (Yu & Weller,
1998) which relocates UL28 to the nucleus o f infected cells (Koslowski et al, 1997).
UL15 has recently been identified in highly purified B capsids (Salmon & Baines, 1998).
It is tightly associated and not removed by treatment with 2M GuHCl. Mutant studies
have revealed that UL28, UL17 and UL6 require to be present in order for UL15 to
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Figure 1.6: 3D Image Reconstruction of a Wild 
Type HSV-1 B Capsid
Figure 1.6: 3D image reconstruction of the HSV-1 B capsid, from cryo-EM analysis 
(reproduced with permission from Dr Wah Chui, Baylor College of Medicine, 
Texas).
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complex to capsids (Salmon & Baines, 1998). UL17 has recently been shown to be a 
tegument protein, required for cleavage and packaging DNA (Salmon et al, 1998). As 
UL28 has been shown to complex with UL15, it is possible that this protein is also 
associated with the capsid.
UL25 has been confirmed as a virion component (Ali et al, 1996) and implicated as 
having a role in virus penetration of the host cell (Addison et al, 1984). Recently, UL25 
has been detected associated with A, B and C capsids (McNab et al, 1998). This group 
found that UL25 was essential for packaging but not cleavage of DNA.
4.4.2 Molecular Arrangement of the Capsid Proteins
Cryo-electron microscopy has allowed the 3D structure of the capsid to be accurately 
visualised (see figure 1.6) (Schrag et al, 1989; Baker et al, 1990; Booy et al, 1991a; 
Trus et al, 1992; Newcomb et al, 1993; Zhou et al 1994) to a resolution of 13A (Zhou 
et al, 1998b). This data together with baculovirus generated (Tatman et al, 1994; 
Thomsen et al, 1994) and GuHCl treated capsids (Newcomb & Brown 1991; Trus et al,
1992) has allowed the location o f individual capsid proteins to be elucidated and thus 
the structural components defined.
The capsid is 125pm in diameter and varies in its composition, depending on capsid 
type. A, B and C capsids are all composed of a shell (with an outer, middle and inner, 
or floor, area) which is approximately 150A thick. The shell is composed of capsomeres 
and triplexes. In addition, B capsids contain an inner scaffold layer and C capsids contain 
the viral DNA.
4.4.2.1 Asymmetric Unit
An asymmetric unit is a single building block, which contains all the information 
necessary to build the entire capsid shell by repeating these units. An HSV-1 capsid 
asymmetric unit consists of one fifth o f a penton, one c hexon, one p hexon, one half of 
an e hexon, one of each of Ta-Te triplexes and one third of Tf (see section 4.4.2.3 for 
further clarification on triplex types).
Figure 1.7: Capsid Hexon Arrangement
(i)
(ii)
Figure 1.7: Panel (i) shows a section of a 3D image reconstruction of a wild type B 
capsid. The dashed white outlines represent an icosahedral facet. An example of a p, 
e and c hexon are marked in white and the numbers 2, 3 and 5 indicate the symmetry 
at these points. Panel (ii) shows a schematic representation of the distribution of the 
3 classes o f hexon (p, e and c) on an icosahedral facet.
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4.4.2.2 Capsomeres
(i) VP5
As early as 1975, VP5 was considered to be present on the capsid surface (Powell & 
Watson, 1975). Surface erosion o f capsids by Ar ions resulted in the rapid loss o f VP5 
(Newcomb et al, 1989) and confirmed that this protein was indeed a surface component.
There are 162 capsomeres, o f which 12 are pentons (pentamers o f VP5) and 150 are 
hexons (hexamers o f VP5 and VP26). In order for VP5 to adopt both a pentameric and 
hexameric arrangement, it must have the ability to alter its conformational state. Indeed 
the two types o f capsomeres have distinct properties.
Monoclonal antibody studies (Trus et al, 1992) have shown that 2 separate antibodies 
bind to hexons and pentons and do not cross react with each other. Similarly VP26 [see 
next subsection (ii)] is found only on the tips o f the VP5 hexons, as a horn shaped mass, 
and not on pentons (Zhou et al, 1994). Finally, treatment of capsids with 2M GuHCl or 
4M urea (Newcomb & Brown, 1991; Newcomb et al, 1993) readily removes pentons. 
However, the structural integrity o f the hexons and indeed the capsid, remains intact. 
These points illustrate that while the hexons and pentons are both composed of VP5, 
their symmetry and positioning in the capsid affects their properties.
The capsomeres are arranged on a T=16 icosahedral lattice. Due to the nature o f the 
symmetry, the pentons are found at the vertices and the hexons are found at the faces 
and edges. Three classes o f hexon exist, P, E and C, which vary slightly due to their 
quasiequivelant environments in an icosahedral facet (figure 1.7). P hexons are found 
adjacent to pentons. C hexons lie at the centre of the facet and E hexons form an edge, 
which is not adjacent to the vertex (Steven et al, 1986; Schrag et al, 1989).
VP5 capsomeres traverse the capsid shell, extending from the outermost radius to the 
capsid floor (Baker et al, 1990). PreVP22a, representing uncleaved scaffold, has been 
shown attached to VP5 in the capsid floor (Zhou et al, 1998a and Chapter 6).
The capsomeres all have axial channels running through them. These vary slightly 
between hexons and pentons. Pentons are approximately cylindrical, being 14.5r|m in
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diameter and 14r|m in height with a 5r|m channel running through them (Zhou et al, 
1994). Hexons are also approximately cylindrical, being 17r|m in diameter and 14r|m in 
height (Steven et al, 1986; Schrag et al, 1989; Zhou et al, 1994) with a 5pm channel, 
tapering to 2pm, present from outside to inside of the capsid (Zhou et al, 1994).
(ii) VP26
Initially there was much confusion as to the exact location of VP26, but cryo-electron 
microscopy comparisons o f capsids with and without VP26 have localised the protein to 
the outer tips of the VP5 hexons (Booy et al, 1994; Zhou et al, 1994) (see Results, 
Chapter 5). The VP26 minus capsids were either prepared in the baculovirus system, 
omitting AcUL26 (Tatman et al, 1994; Zhou et al, 1995), or, wild type capsids were 
stripped o f VP26 by treatment with 2M GuHCl (Newcomb & Brown, 1991; Booy et al, 
1994). Both these approaches have defined the location and shown that VP26 is not 
essential for capsid formation and stability.
VP26 forms a star-shaped ring on the tips o f each hexon. Six copies of the protein form 
a continuous ring which overlays the VP5 subunits. The conformation o f each 6-mer 
varies slightly, in concordance with the variation of each hexon type (Zhou et al, 1995). 
VP26 does not attach to the penton subunits, even although they are composed o f the 
VP5 protein.
4.4.2.3 Triplexes
In the 1970’s 2.5r|m long fibrillic densities were observed under negative staining, 
connecting adjacent capsomeres (Vernon et al, 1974; Palmer et al, 1975; Almeida et al, 
1978). Early computer reconstructions wrongly detected this area, now designated the 
triplex, as a Y-shaped mass (Schrag et al, 1989; Baker et al, 1990; Booy et al, 1991). 
Partial removal o f VP 19c and VP23 with 2M GuHCl correlated with the loss o f 120 o f 
the 320 triplexes (Newcomb et al, 1993) and implicated these proteins as forming the 
triplex. It is now accepted that the triplex is a heterotrimer consisting o f one copy o f 
VP 19c (totalling 320 copies per capsid) and two copies of VP23 (totalling 640 copies 
per capsid) (Newcomb et al, 1993).
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Higher resolution images have revealed that the triplexes are located in the midlayer of 
the capsid and do not form a Y-shaped arrangement (Zhou et al, 1994). Some triplexes 
connect only two adjacent capsomere subunits, whereas others connect 3. In fact 6 
different types o f triplex have been identified and designated Ta to T f (figure 6.5) (Zhou 
et al, 1994). These vary due to their position in the capsid and thus their respective 
interactions with capsomeres. Ta to Te are asymmetric, whereas Tf, appears to have 3- 
fold symmetry. However, as it is found at the 3-fold axis, this may be an artefact o f the 
reconstruction.
The triplex may interact with VP5 only through VP 19c, VP23 does not appear to 
participate in the interaction (Nicholson et al, 1994; Rixon et al, 1996; Chapter 3). Four 
types o f interaction have been described between VP 19c and VP5, these are strong, 
weak, tail and arm (Zhou et al, 1998b). It would seem that the triplexes play a role in 
helping to define the curvature o f the capsid (this aspect is fully discussed in Chapter 7, 
Conclusion).
4.4.2.4 Scaffold
The scaffold o f B capsids is composed o f one major (VP22a, or scaffold) and two minor 
(VP21 and VP24) proteins. It exists, encased by the capsid shell, in two forms, large and 
small cored. Large cored B capsids result when preVP22a is not cleaved by the 
protease. These capsid types can be made in the baculovirus system by omitting the 
UL26 gene (Tatman et al, 1994; Thomsen et al, 1994). They are also found in tsl201 
mutants at the NPT. Tsl201 has a lesion within the UL26 gene (Preston et al, 1983). 
which results in a defective protease. This is unable to cleave itself at positions M and R 
(see figure 1.4 and figure 1.5) to release VP21 and VP24 and convert preVP22a to 
VP22a. However, this situation is reversible. When the mutant is downshifted to the PT, 
small cored capsids and C capsids containing DNA are produced (Preston et al, 1983).
VP22a, the processed scaffolding protein, was first identified as an internal component 
o f the B capsids by antibody studies when Rixon et al (1988) observed VP22a along the 
inner margin o f B capsids by immunoelectron microscopy.
As previously described (Section 4.4.1.5), the scaffold protein is initially transcribed as
preVP22a. It appears that this molecule is associated with capsids during assembly but,
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Table 1.5: Herpesvirus Capsid Protein Homologues
Approx Mr of Capsid Proteins ( kDa)
HSV-1
protein
name
HSV-1 HSV-2 EHV-1 HCMV EBV PRV vzv
VP 5 155 155 148 153 160 150 155
VP 19c 53 53 59 30 52 63 57
VP21 42 44 * 37 46 41 36
VP22a 38 38 46 36 40 35 32
VP23 33 33 36 34 37 27 34.5
VP24 25 25 30 28 28 22.5 31.5
VP26 12 12 12 11 18 * 17.5
Ref a b c d/e/f g h i
Table 1.5: The capsid proteins o f HSV-1 are compared to equivalent proteins o f other 
herpesviruses. A * represents a protein which has not been identified. The references 
(ref) for each set of data are:
a Gibson & Roizman, 1972; Rixon et al, 1990
b Gibson & Roizman, 1972; Heilman et al, 1979
c Perdue et al, 1975; 1976; Newcomb et al, 1989
d Irmiere & Gibson, 1985
e Gibson et al, 1996
f  Gibson et al, 1998
g Dolyniuk et al, 1976; Van Grunsven et al, 1993
h Stevenly, 1975; Ladin et al, 1982
i Zweerink & Neff, 1981; Friedrichs & Grose, 1986
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is lost when DNA is packaged (Rixon et at, 1998). Cleavage of preVP22a by the viral 
protease removes the C-terminal 25 amino acids of the protein (Lui & Roizman, 1992; 
Preston et al, 1992), generating VP22a and breaking the connection between scaffold 
and shell. These connection points have recently been visualised (Chapter 6 and Zhou et 
al, 1998a).
The minor scaffold components, VP21 and VP24, constitute less than 5% of the B 
capsid mass (Newcomb et al, 1993). Baculovirus studies have revealed that when both 
o f these proteins are absent (ie UL26 is omitted), large cored capsids are produced. 
When VP22a is absent (ie UL26.5 is omitted), a very small number of apparently intact 
small cored capsids are visible (Tatman et al, 1994; Thomsen et al, 1994). However, the 
majority of structures resemble aberrant shells. It would therefore appear that the 
products of the UL26 gene can substitute for preVP22a, with a much lower efficiency. 
This is perhaps surprising in view of the fact that VP22a is the major component o f the 
scaffold. However, most of the sequence of VP21 overlaps that of VP22a and it is 
possible that preVP21 substitutes for preVP22a.
When the products o f UL26 and UL26.5 are expressed alone in baculovirus infected 
cells, large numbers o f core-like structures are evident (Preston et al, 1994) indicating 
that these proteins are able to self-assemble into a scaffolding type structure.
The role of scaffold in capsid assembly and the in vitro assembly model are discussed 
further in Chapters 6 and 7.
4.4.3 Capsid Models
The main topic o f this thesis centres around HSV-1 capsids, however a knowledge of 
assembly patterns of other viruses can help interpretation of new HSV-1 results and 
allow models to be derived.
Although the viral capsids of 6 of the eight human herpesviruses have been examined,
the capsid of HSV-1 remains the best studied of all the herpesviruses. Proteins
analogous to most of the HSV-1 capsid proteins have been identified and are
summarised in table 1.5. However, as in most cases, less is known about the assembly
patterns of these capsids, they shall not be discussed further. Instead, the well
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characterised assembly pathways of P22 bacteriophage and adenovirus shall be 
discussed. These viruses were chosen as firstly, the pathway of P22 has many similarities 
to HSV-1 and secondly, adenovirus is a large animal virus which has been well studied 
and characterised.
4.4.3.1 P22 Bacteriophage
P22 is a dsDNA bacteriophage o f Salmonella typhimurium. The assembly pathway o f its 
capsid and DNA packaging mechanism has been extensively studied and is reviewed by 
King and Chiu, 1997. The P22 capsid forms a spherical procapsid intermediate during 
assembly, which subsequently angularises into the mature icosahedron. A similar model 
has recently been suggested for HSV-1 capsids (Newcomb et al, 1993) and is hilly 
discussed in Chapter 7, Conclusion.
P22 structural intermediates have been readily isolated by extensive mutational analysis 
and this has revealed that a spherical procapsid shell is the initial capsid product. The 
procapsid is formed by a portal protein (gpl), the coat protein (gp5), the scaffold 
protein (gp8) and other minor proteins (Prevelige & King, 1993). The scaffold protein is 
extremely important for procapsid assembly but, is removed upon DNA packaging 
(King & Casjens, 1974). This is analogous to preVP22a in HSV-1. However, unlike 
preVP22a, gp8 is recycled by the phage and used in the assembly o f subsequent 
procapsids. In the absence o f  gp8, a very small number o f capsids are formed but, 
aberrant spirals and small capsid forms predominate (Thuman-Commike et al, 1996).
DNA enters through the portal protein (gpl) (Eamshaw & Casjens, 1980). Entry o f 
DNA is associated with shell expansion from 5 80A to 610A diameter in parallel with 
maturation to the polyhedral capsid. The portal protein is also the exit point for DNA 
when it is injected into the host cell.
Cryo-EM analysis o f P22 has revealed that the particle is composed of 60 hexamers and
12 pentamers, composed o f the coat protein (gp5). These are linked by connecting arms
(Prasad et al, 1993). Due to their quasi-equivalent environments, the structural
conformations of the hexons and pentons vary. Indeed, 7 types o f capsomeric subunits
occur, all composed o f the same protein (Prasad et al, 1993). An equivalent situation is
found with HSV-1 VP5 (Section 4.4.2.1).
- 2 4 -
Introduction Chapter 1
Although the procapsid o f P22 is 30A smaller than the mature form, it still has T=7 
symmetry. However, protein arrangements o f the 2 forms vary. For example, the 
procapsid has a more open structure, with holes visible at the centres o f the hexons and 
pentons (Prasad et al, 1993; Thuman-Commike et al, 1996) where it is thought that the 
scaffold protein may be lost (Greene and King, 1994).
The scaffold can be extracted from procapsids under denaturing conditions (Fuller & 
King, 1981) or by heating to 49°C (Galisteo & King, 1993). This situation is reversible 
and when denaturant is removed, scaffold can renter the procapsid (Greene & King, 
1994). However, the scaffold cannot enter the angularised mature capsid, indicating that 
expansion eliminates the scaffold entry point and/or binding site.
The trigger for shell expansion and angularisation is not clear. Several studies have 
shown that small fragments o f DNA can be packaged without expansion occurring 
(Eamshaw & Casjens, 1980; Hohn, 1983). It would appear that longer lengths of DNA 
are necessary to stimulate capsid maturation. Certainly, the expansion and angularisation 
o f the capsid requires energy (Galisteo & King, 1993). One estimate has suggested that 
3 ATP molecules per monomer of shell protein would be required to expand the shell 
(Steven, 1993).
3D reconstructions o f procapsids containing scaffold protein has revealed that the 
scaffold is not icosahedral. It appears to be attached, by finger-like densities extending in 
towards the capsid core, around the internal hexon channel (Thuman-Commike et al,
1996). Similarly rod-like densities, attributable to scaffold, have recently been identified 
in HSV-1 attached to VP5 (see Chapter 6 and Zhou et al, 1998a). In this case, the 
scaffold was also found not to have icosahedral symmetry.
4.43.2 Adenovirus
Adenoviruses o f humans cause a variety of diseases, from mild respiratory infections, to 
life threatening dysentery (Monoto, 1992) and oncogenesis is also associated with these 
viruses (Shenk, 1996). In vitro, some adenoviruses are relatively easy to propagate and 
so have been widely studied.
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The adenovirus virion consists o f a non-enveloped icosahedral capsid, composed o f 252 
capsomeres, 240 hexons and 12 pentons, with fibres protruding from each vertex (Home 
et al, 1959). The capsomeres were initially designated as hexons and pentons however, 
this name is misleading as straightforward 5-mers and 6-mers o f proteins are not 
involved. The hexons are composed o f trimers and not hexamers and so there is not 
exact symmetry. The molecule is therefore designated as having pseudo T=25.
The capsid is composed o f 11 proteins, designated II to XI, by order o f decreasing 
molecular mass on SDS PAGE (Maizel et al, 1968), and p protein, whose function is 
unknown (Hosokawa & Sung, 1976).
Hexons are composed o f homotrimers o f polypeptide II (Grutter & Franklin, 1974). The 
trimer arrangement is extremely stable and resistant to 8M urea treatment (Shenk,
1996). This is the MCP, constituting 63% of the capsid mass.
Pentons are composed of 2 distinct proteins. The penton base is a 5-mer o f polypeptide 
III (Van Oostrum & Burnett, 1985) and the fibres are composed o f polypeptide IV. The 
fibre is a trimer (Ruigrok et al, 1990) and is believed to be involved in attachment to 
host cells (Greber et al, 1993). Polypeptide IX is a major stabilising or cementing 
protein in the capsid. It forms hexon to hexon contacts, linking well defined groups of 
nine hexons (GONs). Mutants lacking this protein are extremely unstable and 
thermolabile (Colby & Shenk, 1981).
Apart from polypeptide VIII, whose location is unknown, all the other proteins are 
found within the capsid shell, forming part of the core. Polypeptides V and VII are 
found tightly associated with the DNA (Black & Centre, 1979). However, it is 
polypeptide VI which appears to have a major role in helping to define the correct 
curvature o f and assembly o f the capsid, before it is proteolytically cleaved.
Polypeptide VI may play a similar role to preVP22a, in HSV-1, and gp8, in P22. The 
protein is assembled as a full length precursor in the immature virion. Here it weakly 
interacts at the inner capsid surface and anchors the peripentonal hexons to the core 
(Stewart et al, 1993). Unlike preVP22a and gp8, cleavage o f the protein by the viral
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protease does not lead to its loss, instead it enhances its binding to the hexon (Matthews 
& Russell, 1995). This suggests a model where there is weak binding to help guide 
assembly and correct errors but, the interaction is locked or cemented upon proteolytic 
cleavage. Proteolysis is essential for correct assembly o f virions (Weber, 1976).
5. HSV-1 Life Cycle
The stages of the life cycle, from initial infection, to release of free virions, will now be 
discussed in turn
5.1 Entry into Host cells
5.1.1 Attachment
The initial stages o f virion infection involve the binding of viral components to the cell 
surface, followed by fusion with the plasma membrane. HSV-1 attaches to cells through 
the glycoprotein spikes, protruding from the envelope (see table 1.3). The virus appears 
to have a selection of mechanisms, with varying efficiencies, for binding to the host cell 
(reviewed by Spear, 1993).
Through studies with deletion and temperature sensitive mutants, only 4 glycoproteins, 
gB (Sarmiento et al, 1979; Haffey & Spear, 1980; Little et al, 1981; Cai et al, 1987) gD 
(Ligas & Johnson, 1988; Johnson & Ligas, 1988) gH and gL (Hutchinson et al, 1992) 
have been shown to be essential for virion infectivity. Infection appears to be initiated by 
viral binding to heparin sulphate proteoglycan (PG), which explains the ability of 
glycosaminoglycan heparin to inhibit infection in vitro (WuDunn &Spear, 1989). PG are 
ubiquitous molecules, present as integral membrane proteins of cells and extracellular 
matrixes.
Although gC is dispensable for viral entry and gC negative mutants have been isolated 
from humans (Hidaka et al, 1990), this protein, when present, plays a principal role in 
the absorption of virus to cells (Herold et al, 1991). It has been shown to be capable of 
tightly binding to heparin sulphate PG. However, as gC mutants can still infect cells, the 
virus obviously has more than one attachment mechanism.
Many investigators have found that gD also appears to interact with cell surface 
receptors other than PG (Campadelli-Fiume et al, 1988; Chase et al, 1993; Johnson et
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al, 1990; Karger & Mettenleiter, 1993; Lee & Fuller, 1993). Recently the gD receptor 
was identified as, a previously undescribed, human TNF receptor (Montgomery et al,
1996) and has since been designated herpesvirus entry mediator A (HveA) (Warner et 
al, 1998). HveA is expressed in many human tissues including lung, liver and kidneys 
however, it is most abundant in lymphoid organs and cells (Hsu et al, 1997; Kwon et al, 
1997; Marsters et al, 1997). Studies with anti-HveA antibodies have shown that HveA is 
a principle receptor for HSV-1 (Montgomery et al, 1996) but, viruses can still infect 
cells which do not carry it. Further studies have revealed a second mediator of HSV-1 
entry. This was shown to be poliovirus receptor related protein 2 (Pvr2) and was 
designated HveB (Warner et al, 1998). Although this receptor facilitated entry o f some 
mutant viruses, it failed to allow entry o f wild type HSV-1 (Warner et al, 1998). 
However, this line o f investigation has lead to the discovery that Pvrl, designated HveC, 
can interact with wild type virus (Geraghty et al, 1998). As this protein is found on 
epithelial and neuronal cells, it may be a prime target for HSV-1 infection of mucousal 
surfaces and subsequent spread to the nervous system.
5.1.2 Penetration
Once initial attachment has been achieved, the viral envelope fuses with the cell plasma 
membrane (Morgan et al, 1968). gB and gD and the products o f the UL25 gene appear 
to have a function in viral fusion and successful penetration (Cai et al, 1988; 
Campadelli-Fiume et al, 1988; Addison et al, 1984). Recent evidence has suggested that 
the gD receptor, HveA, also plays an important role in virus induced cell fusion (Terry- 
Allison et al, 1998).
The nucleocapsid is rapidly transported through the cytoplasm to the nuclear pores. The 
high viscosity inside the cytoplasm means that the capsid cannot travel by free diffusion. 
In neurons, it is transported along the axons to the nucleus (Roizman & Sears, 1990) but 
in other cell types the mechanism is less well understood. Limited evidence has 
suggested that capsids bind to microtubules and use this network to traverse the cell to 
the nuclear pores (Penfold et al, 1994). A study with fibroblast cells has found that the 
capsid sheds most o f its associated tegument proteins and binds to dynein (Sodeik et al,
1997).
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Dynein is a cytoplasmic component responsible for direction of chromosomes and 
membrane organelles along microtubules (Mitchison, 1988). The viral protein which 
binds to this molecule has not yet been identified. However, it would appear that HSV-1 
is utilising the cellular machinery responsible for retrograde transport in host cells.
Once present at the nucleus, the capsid releases its viral DNA through the nuclear pores, 
and itself becomes associated with the pores (Batterson et al, 1983; Lycke et al, 1988) 
and remains intact for a while (Miyamato & Morgan, 1971). The exact mechanism of 
DNA extrusion from capsids is not known. DNA can be removed from capsids in vitro 
by treatment with 0.5M GuHCl (Newcomb & Brown, 1994). In this instance, DNA 
appears to exit at the capsid vertices as thick strands. Studies with mutants indicated 
that the tegument protein VP1 (UL36) has a role in DNA release (Batterson & 
Roizman, 1983).
5.2 Disruption of Host Cell Functions
Viral infection not only results in the replication of viral DNA and assembly of new 
virions, but host cell functions are also affected. Virion components are involved in shut- 
off of host macromolecular synthesis. Early in infection ribosomes are affected and 
mRNA is degraded (reviewed by Roizman & Sears, 1996). Viral DNA replication and 
expression of viral proteins disrupt cell protein synthesis further (delayed shut-off) 
(Nishioka & Silverstein, 1978; Fenwick & Clark, 1982).
The UL41 ORF, which encodes a 53 kDa tegument protein (McLauchlan et al, 1992b), 
appears to be the viral protein which has host shut-off activity. In fact the 53kDa 
protein (UL41) has been designated virion host shut-off protein (vhs) (Kwong et al,
1988). The vhs appears to form a complex with VP 16, which blocks the ability of this 
tegument protein to interact with cellular factors or switch on IE genes (Smibert et al, 
1994). Similarly, the UL13 ORF, which encodes a 57 kDa protein kinase, also appears 
to have shut-off activity.
The host cell microtubule network is also disrupted by viral infection. The virus causes
the cells to lose their integrity as the microtubules and Golgi apparatus are redistributed.
The infected cells appear to round up and have a more spherical appearance as their
supporting network becomes disorganised (Avitabile et al, 1995). The nucleolus appears
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to disintegrate and host chromatin is dispersed to the edge of the nucleus and degraded. 
The nuclear envelope and other cell membranes become distorted too (reviewed by 
Roizman & Sears, 1996).
5.3 The Gene Expression Cascade
5.3.1 Classes of Viral Genes
Herpesvirus genes are all transcribed in the nucleus (Wagner & Roizman, 1969) by the 
cells’ DNA dependent RNA transcriptase (Costanzo et al, 1977) in an ordered 
cascading fashion. They are classified into 3 groups according to their time of expression 
during the replication cycle. The first genes to be transcribed are the immediate early 
(IE) (also known as alpha genes), these are followed by the early (E) (also known as 
beta genes) and finally the late (L) (also known as gamma genes) (Swanstrom & 
Wagner, 1974; Honess & Roizman, 1974). This whole process initiates approximately 
lh  pi and continues for at least 15h (Wilkie, 1973).
The IE genes are transcribed by the pre-existing cellular apparatus, stimulated by the 
tegument component VP 16 (UL48) (Batterson & Roizman, 1983; Campbell et al, 
1984). Five IE proteins have been identified; IE1 (VmwllO), IE2 (Vmw63), IE3 
(Vmwl75), IE4 (Vmw68) and IE5 (Vmwl2) (reviewed by Hayward, 1993; Subak- 
Sharpe & Dargan, 1998).
Transcription of other herpesvirus genes requires IE polypeptides for maximum activity. 
In particular, VmwllO (Everett, 1984) and Vmwl75 (Preston, 1979) appear to have a 
regulatory role in initiating early gene expression. Vmw 175 alone can activate E gene 
expression however, the process is much more efficient when VmwllO is also present 
(Everett, 1984). Recent studies on VmwllO has revealed that this protein binds to a 
135kDa cellular ubiquitin specific protease (Everett et al, 1997) through its C-terminus 
(Meredith et al, 1995) and migrates to discrete nuclear structures. The binding of 
VmwllO to the cellular protein enhances its ability to stimulate E gene expression 
(Everett et al, 1995; 1997).
A third IE protein, Vmw63 is also involved in the activation of transcription from HSV- 
1 promoters, but only in the presence of both VmwllO and Vmwl75. This protein
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appears to enhance expression of some late genes, including the MCP, VP5 (Everett,
1984).
The second class of genes to be transcribed are the E genes. These peak approximately 
5-7h pi and decline at later times (see later). The level of expression is largely 
independent of DNA replication They are never stimulated in the absence o f IE proteins 
(Preston, 1979; Dixon & Schaffer, 1980; O’Hare & Hayward, 1985; Quinlan & Knipe,
1985) illustrating that the IE products are essential for productive viral infection. 
Expression of the E genes signals the onset of viral DNA synthesis.
The third class of genes to be transcribed are the L genes. Although designated as the L 
genes, some of these proteins are expressed quite early during infection. However, their 
transcription levels are enhanced during DNA replication and peak 8-1 Oh pi and persist 
for the remainder of the lytic cycle (Honess & Roizman, 1974; Harris-Hamilton & 
Bachenheimer, 1985). They consist mainly of structural proteins, eg VP5.
5.3.2 Mechanism of Replication
DNA replication appears to initiate at distinct virus specific structures in the nucleus. 
These appear to be induced by infection and have been designated replication 
compartments (Quinlan et al, 1984). However, as infection proceeds, the entire nucleus 
becomes involved (see Roizman & Sears, 1996).
The majority of the progeny viral DNA exists as large concatemeric molecules, which 
suggests that a rolling circle type mechanism exists for replication (Jacob et al, 1979; 
Poffenberger & Roizman, 1985). Replication initiates when an initiator protein 
recognises and binds to an origin of replication. In HSV-1 there are 3 cis-acting origins 
o f replication (ori) (Frenkel et al, 1976; Schroder et al, 1975). In the inverted repeat 
sequence, flanking the short component of the genome, two copies o f oriS exist (oriSl 
and oriS2) (Stow, 1982; Stow & McConagle, 1983). OriL is located in the unique long 
component, between UL29 and UL30 (Weller et al, 1985). Not all origins are required 
for successful viral growth and oriL and 1 copy of oriS have been shown to be 
dispensable (Polvino-Bodnar et al, 1987; Longnecker & Roizman, 1986; Smith et al, 
1989).
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Seven HSV-1 genes (UL5, UL8, UL9, UL29, UL30, UL42, and UL52) appear to fulfil 
the minimal requirements for ori dependent DNA synthesis (Challberg, 1986; Wu et al, 
1988; Stow et al, 1993). All these genes are essential for virus replication and DNA 
synthesis in vitro (Weller, 1991).
UL9: The UL9 gene is the initial protein to bind an ori and has been shown to interact 
with both oriS and oriL (Olivo et al, 1988). It has therefore been designated as an origin 
binding protein (OBP). The exact events which follow UL9 binding are not entirely 
clear, but it is known that the parental DNA must be unwound before replication can be 
initiated and it is thought that this may be mediated by the helicase activity of this 
protein (Bruckner et al, 1991).
UL29: UL29 encodes the major ssDNA binding protein ICP8 (Conley et al, 1981). This 
protein has been shown to interact specifically with several replication proteins (Vaughn 
et al, 1984; Bush et al, 1991; McLean et al, 1994) suggesting that it may have a role in 
organising a multi-protein complex at the replication fork by providing specific contacts 
with other proteins.
U L 30: The DNA polymerase (pol) is encoded by the UL30 ORF (Powell & Purifoy, 
1977; Knopf, 1979; Quinn & McGeoch, 1985) and has intrinsic 3’-5’ exonuclease 
activity which acts as a proof reading function (O’Donell et al, 1987). It also has a 5’-3’ 
exonuclease/ribonuclease, which specifically degrades RNA primers present on the 5' 
Okazaki fragments on the lagging strand during semi-discontinuous synthesis (Crute & 
Lehman, 1989).
UL42: UL42 exists as a heterodimer with pol in a 1:1 ratio (Crute & Lehman, 1989). 
This accessory protein appears to stimulate activity of pol by up to 10-fold (Gallo et al,
1989) and can increase its ability to synthesise longer DNA fragments (Hernandez & 
Lehman, 1990; Gottlieb et al, 1990). This function may be enhanced by the ability o f the 
UL42 protein to strongly bind DNA (Marsden et al, 1987) and so stop the polymerase 
from dissociating from the template after each cycle of catalysis.
Table 1.6: Genes Involved in Cleavage and Packaging DNA
Gene Approx Mr 
(kDa)
Capsid
Protein
Cleavage Packaging
UL6 74 yes yes yes
UL12 67.5 no no no
UL12.5 60 yes no yes
UL15 81 yes yes yes
UL17 77 ? yes yes
UL25 63 yes no yes
UL28 85.5 yes yes yes
UL32 64 ? yes yes
UL33 14 ? yes yes
(? -  not yet known if protein is associated with the capsid)
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UL5, UL8 and UL52: These 3 proteins co-purify from infected cells and constitute 3 
subunits of the helicase-primase complex (Crute et al, 1988; 1989; Wu et al, 1988; 
McGeoch et al, 1988; Dodson et al, 1989; Crute & Lehman, 1991). The enzymatic 
activities o f the complex are associated with UL5 and UL52 (Calder & Stow, 1990; 
Dodson & Lehman, 1991) while UL8 appears to be required for efficient nuclear 
localisation o f the complex (Calder et al, 1992). The helicase activity of this complex 
unwinds duplex DNA, in a 5’—>3’ direction, while the primase component synthesises 
oligoribonucleotide primers. Therefore, the overall function of this complex is to prime 
lagging-strand DNA synthesis as it unwinds DNA at the viral replication fork (Crute et 
al, 1988; Crute & Lehman, 1991).
Although the 7 genes discussed are necessary and sufficient for DNA replication in 
expression systems, there are of course other enzymes and proteins which participate in 
and control the process in vivo. The expression and functions o f these genes shall not be 
discussed further in the context of this study but are reviewed by Challberg, 1991 and 
Roizman & Sears, 1996.
5.4 Cleavage and Packaging of DNA
DNA is cleaved and packaged into preformed B capsids. Capsid assembly takes place in 
the nucleus of infected cells (Morgan et al, 1954; 1959). The mechanism by which the 
proteins are transported to the nucleus is fully explored in Chapter 3 (see also Rixon et 
al, 1996). Baculovirus studies have shown that 6 genes (UL18, UL19, UL26, UL26.5, 
UL35 and UL38) are essential to form apparently normal capsids (Tatman et al, 1994; 
Thomsen et al, 1994).
Aspects o f capsid assembly are more fully discussed elsewhere in the thesis, with a 
proposed model shown in Chapter 7, Conclusion.
Cleavage of DNA is closely associated with packaging into capsids and involves 6 genes 
(see table 1.6), some o f which have been shown to be minor constituents o f the capsid. 
After DNA is replicated as large, probably branched (Sevenni et al, 1994; Zhang et al, 
1994) concatemers, it is cleaved into unit length monomers at a novel a-a joint 
(Mocarski & Roizman, 1981; 1982) and a single copy is packaged into capsids. The a
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sequences are present at both genomic termini and at internal repeats (see Section
4.1.1). The a sequence therefore acts as marker points for unit lengths of DNA.
Cleavage and packaging is also closely linked to capsid formation. For example, deletion 
mutants o f the capsid protein genes UL18 or UL19 replicate DNA but, do not cleave the 
concatemer (Desai et al, 1993).
In the absence of any 5 of the 6 packaging genes (ts packaging mutants) DNA is not 
cleaved and only B capsids are found (reviewed by Homa & Brown, 1997). In addition, 
the product of the UL12 gene is important, though not essential, for the cleavage and 
packaging process. This gene encodes an alkaline nuclease which, when absent, reduces 
virus yield 100 to 1000 fold (Martinez et al, 1996). This protein appears to play a direct 
role in packaging by resolving branched structures formed during replication. An 
alternate reading frame, designated UL12.5, has been identified within the UL12 gene 
and its protein readily detected in intact virions and capsid preparations (Bronstein et al,
1997). The protein has been shown to possess nucleolytic activity and is thought to play 
a role in processing DNA during encapsidation (Bronstein et al, 1997).
UL25, which has recently been shown to be a minor capsid component (see Section 
4.4.1.6) appears to have a role in the packaging process. McNab et al (1998) isolated a 
UL25 null mutant which was able to synthesise viral DNA but could not form plaques or 
produce infectious virus in non-complementing cell lines. Analysis of the nucleus o f cells 
used to propagate the mutant virus revealed large numbers of both A and B capsids but, 
no C capsids. Restriction enzyme digestion and pulse-field gel electrophoresis confirmed 
the presence of genome sized viral DNA in the infected cells. These results have 
generated the assumption that the UL25 gene is required for packaging but not cleavage 
o f replicated viral DNA. This is an example of how the cleavage and packaging genes 
are often coupled with capsid function.
The mechanism by which DNA enters capsids is unknown. In bacteriophage P22 DNA 
enters through a unique vertex formed by the portal protein (see section 4.4.3). No such 
site has been identified for HSV-1. Booy et al (1991b) visualised DNA in C capsids and 
reported it to have a liquid crystalline appearance which was tightly packaged. Recently,
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Figure 1.8: Possible Routes of HSV-1 Egress
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Figure 1.8: The 2 suggested routes o f viral egress are shown schematically 
in this figure. Panel (i) represents the possible envelopment, 
deenvelopment, reenvelopment (EDR) pathway. Virus particles lose their 
initial membrane by fusion at the outer membrane/ER (endoplasmic 
reticulum) and acquire their final membrane at the Golgi/post-Golgi 
compartment. Panel (ii) represents the possible envelope retention from the 
inner nuclear membrane pathway. Virus particles acquire their envelope at 
the inner nuclear membrane and retain this until they leave the cells.
capsids
glycoprotein spikes
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Zhou et al (1999) have suggested that the DNA is packaged as a spool (see section
4.1.2) Obviously the whole packaging process is very complex and involves multiple 
steps.
5.5 Tegumentation and Envelopment
Once DNA has been packaged in to the capsids, they leave the nucleus and acquire a 
tegument and envelope (reviewed by Rixon, 1993). The pathway of envelopment and 
tegumentation is poorly understood. The initial stage appears to involve the capsid 
budding through the inner lamella of the nuclear membrane (Nii et al, 1968a; Darlington 
& Moss, 1968; Roizman & Furlong, 1974). It first attaches to distorted sites on the 
membranes (Asher et al, 1969; Ben-Porat & Kaplan, 1971; Spear & Roizman, 1972), 
which are readily observed in HSV-1 infected cells (Nii et al, 1968b) and thought to be 
present where cellular proteins have been disrupted. It is not clear whether 
tegumentation takes place in the nucleus before, or as a consequence o f , binding to the 
inner membrane, or, whether it occurs in the cytoplasm. Studies with HCMV (Haguenau 
& Michelson-Fiske, 1975; Severi et al, 1988) and HHV-6 (Roffman et al, 1990) have 
shown that tegumentation and envelopment occur in the cytoplasm. If a similar model is 
envisaged for HSV-1, capsids would bud through the inner nuclear membrane acquiring 
an envelope. The envelope would fuse with the outer nuclear membrane and release 
non-enveloped capsids into the cytoplasm. The virus then acquires a new envelope at the 
cytoplasmic membranes, probably those of the Golgi apparatus (Stackpole, 1969; Jones 
& Grose, 1988) and exits via an endocytotic pathway (see figure 1.8).
Support for an envelopment, deenvelopment and reenvelopment pathway (EDR) comes 
from observations that capsids, lacking tegument, have been observed in the cytoplasm 
o f infected cells (Campadelli-Fiume et al, 1991). However, these static images under the 
electron microscope do not allow an accurate mechanism of the pathway to be derived.
In further support o f the EDR pathway, Van Genderen et al (1994) have shown that the
phospholipid content o f the extracellular virions varies significantly from the nuclear
membrane o f cells. However, this work is obviously not conclusive since the host
membrane is known to be altered by virion proteins and the virion membrane may be
altered during transport through the cytoplasm. The best support for this pathway has
come from a genetic approach whereby gH is retained at the inner nuclear membrane by
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means o f an ER targeting signal (Browne et al, 1996). If the inner nuclear membrane 
was retained, then there would have been no effect on the virion’s infectivity however, 
the investigators found that the progeny virus were non-infectious and contained no gH, 
supporting the EDR pathway (see figure 1.6). Further support for this pathway has been 
generated through work by Elliott & O ’Hare (see below).
The mechanism of transport o f the virion through the cytoplasm appears to be through 
Golgi-derived vesicles. Treatment with brefeldin A (BFA), which inhibits transport 
between the endoplasmic reticulum and the Golgi, results in accumulation of non­
enveloped capsids in the cytoplasm (Cheng et al, 1991; Whealy et al, 1991; Eggers et 
al, 1992). Vesicles which reach the cellular plasma membrane, fuse with it releasing the 
virion into the extracellular space.
As mentioned previously, the major tegument protein, VP22, has been shown to 
demonstrate a non-classical Golgi-independent transport mechanism (Elliott & O’Hare,
1997). Recent visualisation of the GFP labelled VP22 protein has shown that the protein 
evolves from a diffuse to particulate material which travels through a cytoplasmic 
pathway to the cell periphery (Elliott & O’Hare, 1999). This pathway is sensitive to 
cytochalasin D, which inhibits actin cytoskeleton transport. It is not clear how this 
relates to virus exit or entry but there is obviously a complex network of reactions 
transporting different proteins and virion assembly products through the cell.
Transport o f the virus from the nucleus to the plasma membrane has been shown to 
involve several gene products. A null mutation of the UL11 gene both reduces the 
efficiency o f envelopment and of viral export (Baines & Roizman, 1992). Similarly, 
deletion o f gE or gl appears to inhibit cell-to-cell spread of the virus (Dingwell et al, 
1994). Obviously the pathway is extremely complex and warrants further study.
5.6 Latency
The lytic cycle of HSV-1 is obviously important and has been discussed however,
herpesviruses are unusual in that they also have the ability to exist in a dormant or latent
state. Herpes simplex virus becomes latent within the human peripheral nervous system.
It can remain there for the entire lifetime of the host and may reactivate to cause
recurrent disease. The mechanism of latent infection is widely studied but shall only be
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very briefly summarised here as it is such an important part of the virion life cycle (for 
review see Steiner & Kennedy, 1995).
A latent viral genome exists in cells without producing any infective virions and is 
undetected by the immune system. However, it has the ability to reactivate and resume 
replication to cause recurrent disease. It appears that, following peripheral infection and 
viral replication, HSV-1 can be transported to the trigeminal ganglia by retrograde 
transport through the axons (Cook & Stevens, 1973; Kristensson et al, 1986). Here it 
establishes latency.
The genome is not integrated into the host genome (Mellerick & Fraser, 1987) and the 
viral DNA content is difficult to estimate. Early experimentation suggested 1.00 
genomes per neuron were present (Efstathiou et al, 1989) but PCR data indicated that 
the viral DNA content was much higher (Mehta et al, 1995). More recent work has 
found that the number of viral genome copies within individual latently infected neurons 
is extremely variable and may be viral strain specific (Sawtell et al, 1998).
The IE gene Vmw65 appears to play an important role in the latency pathway. Lack of 
Vmw65 function is associated with a higher proportion of latently infected cells (Steiner 
et al, 1990; Steiner & Kennedy, 1995). Similarly, cellular factors also appear to aid the 
establishment of latency. Oct-2, a transcriptional factor in nerve cells, appears to inhibit 
viral replication by binding to a protein complex containing Vmw65 (Lillycrop et al,
1993). This action appears to down regulate the replication cascade.
The only expression known to occur during HSV latency is from the latency associated 
genes, which are contained within a 10.4kb fragment within the repeat regions (Stevens 
et al, 1987; Deatly et al, 1987; Stevens et al, 1988). From this area, latency associated 
transcripts, LATs, are transcribed which accumulate during latent infection (Spivack & 
Fraser, 1988). LAT negative mutants have been produced which appear to retain their 
ability to become latent however, their ability to reactivate is hindered (Javier et al, 
1988; Ho & Mocarski, 1989; Hill et al, 1990; Trousdale, 1991).
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Host factors associated with latency are stress, fever, immunosuppression and UV 
radiation (Hill, 1985). Therefore, both viral and cellular factors must be involved in the 
establishment and control of latent viral infection.
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MATERIALS AND METHODS
Materials and Methods Chapter 2
1 Materials
1.1 Chemicals
All chemicals used were o f an analytical grade and supplied by either BDH Chemicals, 
Gibco/BRL or Sigma Chemical Company, except those shown below:
SUPPLIER
Agar Scientific Ltd
CHEMICAL
gluteraldehyde
Aldrich TFA (trifluoroacetic acid)
Bio-Rad Laboratories Ltd APS (ammonium persulphate)
TEMED (N,N,N',N',-tetramethylethylene 
diamine)
Coomassie Brilliant Blue R250
Boehringer Mannheim Tris [2-amino-2(hydroxymethyl)-l,3- 
propandiol]
Citifluor Ltd Citifluor
Difco Laboratories Bactopeptone
BHIB (brain heart infusion broth) 
SAB (sabouraud medium) 
Trypsin
TPB (tryptose phosphate broth)
Koch-Light Laboratories Ltd DMSO (dimethyl sulphoxide)
May and Baker Ltd chloroform
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glycerol
Novabiochem (UK) Ltd F-moc amino acids
Rhone-poulenc Ltd acetic acid
hydrochloric acid
Rathbum DMF (dimethylfluoride)
Walkerbum piperidine 
diethyl ether
7.2 Enzymes
All enzymes and their buffers were obtained from either: Boehringer Mannheim, 
Gibco/BRL, Life Technologies, New England Bio labs, Pharmacia or Sigma.
1.3 Oligomers
(i) Oligonucleotides were synthesised in-house (MRC Institute o f Virology, Glasgow) 
on a Biosearch 8600 DNA Synthesiser by Mr David McNab or Mr Alex Orr.
(ii) Oligopeptides were synthesised in-house by myself on the PSSM-8 Synthesiser on a
4-branched resin, with no glycine spacers, using HBTU chemistry as per the 
manufacturers instructions. The SPOTscan kit was also used to produce oligopeptides 
to map the epitope sequence o f the CAT antibody.
1.4 Tissue Culture Medium
(i) Sf 21 cells: grown in TC100/5 medium which consisted o f TC100 (Gibco/BRL) 
supplemented with 5% foetal calf serum (FCS) and 1% P/S (1000 units/ml penicillin, 
lOmg/ml streptomycin) (Gibco/BRL).
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(ii) BHK21 C13 cells: grown in ETCio which consisted of Glasgow-modified Eagles 
medium (GMEM) (Gibco/BRL) supplemented with 10% (v/v) tryptose phosphate broth, 
10% newborn calf serum (Gibco/BRL) and 1% P/S.
Variations: EMCio Eagles medium containing 1% carboxymethyl cellulose,
10% NBCS
ET-serun, GMEM supplemented with 10% TPB and 1% P/S.
1.5 Cell Lines
(i) Spodoptera frugiperda 21 (Sf21) cells: these insect cells were derived from ovarian 
tissue (Vaughn et al, 1977).
(ii) Baby hamster kidney-21 C l3 (BHK-21 C l3) cells: these are a fibroblastic cell line 
derived from a baby hamster’s kidney (MacPherson & Stoker, 1962).
1.6 Viruses
(i) Baculoviruses: Autographica californica nuclear poyhedrosis virus (AcNPV) and a 
polyhedrin negative derivative which has the lacZ gene under the control o f the 
polyhedrin promoter (AcPAK6). These were both gifts to the department from R 
Possee.
(ii) Wild-type HSV-1: strain 17 syn+, described by Brown et al (1973).
1.7 Bacterial Culture Medium
L-broth: lOg/l NaCl, lOg/l bactopeptone, 5g/l yeast extract
L-broth agar: L-broth with 1.5% (w/v) agar
L-broth / L-broth agar + Antibiotic: Ampicillin, supplement at 50pg/ml
Kanamycin, supplement at 25pg/ml
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1.8 Bacterial Strains
E  coli BL21 (DE3) pLysS: commercially competent bacterial cells (supplied by 
Promega). These can be used with protein expression vectors under the control o f the 
T7 promoter eg pET vectors.
E coli JM109: commercially competent bacteria supplied by Promega
E coli CJ236 duf ling: commercially competent bacteria supplied by New England 
Biolabs (NEB). These can be used for the Kunkel method of site directed mutagenesis 
(Kunkel, 1985).
1.9 Expression Plasmids
pAcYMl: baculovirus transfer vector which contains a section of AcNPV EcoRI 
restriction fragment 1 with a BamHI cloning site situated 3' of the polyhedrin gene 
promoter (Mastuura et al, 1987).
pAcC129.1: baculovirus transfer vector derived from pAcYMl which contains a 
polylinker downstream of the polyhedrin promoter (Livingston & Jones, 1989).
pCMVIO: transient expression plasmid containing the immediate early promoter of 
HCMV and the RNA processing signals of SV40 (Stow et al, 1993).
pET28a-c(+): expression plasmid containing T7 RNA polymerase promoter. Supplied 
by Novagen.
1.10 Antibodies
LP12: mouse monoclonal used against VP5 protein in HSV-1, the product of
UL19 (from Dr A Minson).
1060: mouse monoclonal used against VP23 protein in HSV-1, the product of
UL18 (Nicholson et al, 1994).
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186: rabbit polyclonal used against VP23 protein in HSV-1, the product of
UL18 (from David McClelland)
5010: mouse monoclonal used against HSV-1 preVP22a, the un-processed
product of UL26.5 (Rixon et al, 1988)
20999: rabbit antisera raised against a synthetic peptide (14 amino acids) whose
sequence is contained within the UL26 ORF, immediate upstream of the 
C-terminal residues. Recognises preVP22a (Preston et al, 1992)
pp65 (9220): mouse monoclonal antibody which recognises a 10 amino acid epitope 
from HCMV pp65 protein (McLauchlan et al, 1994). Supplied by 
Capricorn Products Incorporated as 9220 but referred to as pp65.
5/24: mouse monoclonal antibody against CAT (from Dr S Graham) and used
in SPOTscan mapping procedures.
GAM-HRP: goat anti-mouse antibody conjugated to horse radish peroxidase was
supplied by Sigma and used in Western blots, ELISA's and SPOTscan.
TR1TC-GAM: goat anti-mouse antibody with texas red isothiocyanite conjugate. Used 
in immunofluorescence experiments (supplied by Sigma)
FITC-GAM: goat anti-rabbit antibody conjugated to fluoroscein isothiocyanite
(supplied by Sigma) and used in immunofluorescence studies
1.11 Buffers and Solutions
Some commonly used buffers and solutions are detailed below:
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BUFFER / SOLUTION RECIPE
FPLC equilibration buffer 20mM Tris-HCl pH 8.0, 500mM NaCl, 
5% glycerol, 1 mM DTT
HBS 20mM HEPES, 150mM NaCl pH 7.4
loading buffer (5x) 5x TBE, 50% glycerol, bromophenol 
blue, xylene cyanol
NTE 500mM NaCl, 20mM Tris-HCl pH 7.5, 
ImM EDTA
phenol / chloroform (1:1) mix phenol & chloroform 1:1 & saturate 
with lOmM Tris-HCl pH 8.0
PBS A 170mM NaCl, 3.4mM KC1, lOmM 
Na2H P04, 1.8mM KH2P04, pH 7.2
PBS complete PBS A + 6.8mM CaCl2, 4.9mM MgCl2
TAE 40mM Tris-HCl pH 7.8, 20mM acetic 
acid, lOOmM EDTA
TBE 89mM Tris-HCl pH 8.0, 2mM EDTA, 
89mM boric acid
TBS 20mM Tris-HCl pH 7.5, 500mM NaCl
Trypsin 0.25% (w/v) trypsin dissolved in TBS
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Sodium phosphate buffer 
Versene
Bacterial purification:
Sonication buffer
Buffer A
Buffer B
Buffer C 
Buffer D 
Buffer E
ELISA
blocking buffer 
wash solution 
signal developer
Plasmid preparation:
A: Na2H P04 2.84g/l 
B: NaH2P 0 4 3.13g/1 
Add B to A until pH 7.0
600mM EDTA dissolved in PBS A 
containing 0.0002% phenol red
20mM Tris-HCl pH 8.0, 10% glycerol,
0.1% NP40
6M GuHCl, lOOmM NaH2P 0 4, lOmM 
Tris-HCl pH 8.0
8M urea, lOOmM NaH2P 0 4, lOmM Tris- 
HCl pH 8.0
20mM imidazole + buffer B 
60mM imidazole + buffer B 
200mM imidazole + buffer B
PBS A + 2% BSA 
PBS complete + 2% Tween 20 
ABTS peroxidase substrate : peroxidase 
solution B (1:1) (supplied by Kindergaard 
& Perry Laboratories)
solution 1 25mM Tris-HCl pH 8.0, lOmM EDTA, 
50mM glucose
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solution 2 
solution 3
200mM NaOH, 1% (w/v) SDS 
3M KAc, 2M acetic acid
Peptide cleavage:
Reagent K
Trp cleavage mixture
81.5% TFA, 5% thioanis, 5% phenol, 5% 
dH20 , 2.5% EDT (1,2 ethanedithiol), 1% 
TIPS (triisopropylsilanes)
93% TFA, 3% thioanis OR phenol, 1% 
TIPS, 3% 2-methylindole
SDS-PAGE:
Dissociation mix
RGB
SGB
tank buffer 
Coomassie blue stain
fix
destain
Silver staining:
solution 1 
solution 2
solution 3 
solution 4 
solution 5
40% SGB, 10% glycerol, 4.75% 2- 
mercaptoethanol, 2% SDS, 0.01% 
bromophenol blue 
0.47M Tris-HCl pH 8.9, 1% SDS 
0 .122M Tris-HCl pH 6.7, 0.1% SDS 
52mM Tris, 53mM glycine, 0.1% SDS 
methanol: H20 : acetic acid (50 : 880 : 
70) 0.2% Coomassie brilliant blue R250 
m ethanol: H20 : acetic acid (50:50:7) 
m ethanol: H20 : acetic acid (50:880:70)
30% ethanol, 10% acetic acid 
30 % ethanol, 500mM sodium acetate, 
500mM gluteraldehyde, 0.2% Na2S20 2 
dH20
0.1% silver nitrate, 0.02% formaldehyde 
2.5% sodium carbonate, 0.01% 
formaldehyde
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SPOTscan:
regeneration Buffer A 
regeneration Buffer B 
Western Blotting:
8M urea, 1%SDS, 0.01% 2-
mercaptoethanol
50% ethanol, 10% acetic acid
transfer buffer
blocking buffer 
TTBS
antibody buffer 
stripping buffer
40mM Tris, 48mM glycine, 20%
methanol, 0.4% SDS
TBS + 1% gelatin
TBS + 0.1% Tween 20
TTBS + 1% gelatin
lOOmM (3-mecarptoethanol, 62.5mM
Tris-HCl, pH 7.0, 2% SDS
1.12 Commercial Kits 
SUPPLIER
Anachem
Hybaid
National Diagnostics
Pharmacia
Bio-101
Qiagen
KIT
Gene clean II
Recovery Plasmid midi prep kit 
Sequagel1N1
Sephaglass1M bandprep 
Mermaid DNA prep kit 
Plasmid midi kit (50)
1.13 Miscellaneous materials and Suppliers 
SUPPLIER MATERIAL
Amersham International Pic rainbowlM protein molecular weight
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Beecham Research Laboratories Ltd 
Bio-Rad
Dynatech Laboratories
Gibco/BRL Ltd 
Kodak Ltd 
Life Technologies
New England Biolabs 
Qiagen
marker
ampicillin
protein assay solution
gene pulser cuvette (0.1cm)
poly-prep columns (0.8 x 4.0 cm)
Immunlon-2 flat bottomed UV irradiated
microtitre plate
100 bp DNA marker
X-Omat-S-film
SOC medium
IPTG
X BstE II (lkb) DNA marker 
Ni-NTA agarose (slurry)
2 Methods
2.1 Gel Electrophoresis and Western Blotting
2.1.1 Analytical Agarose Gels of DNA
A 1% (w/v) agarose gel dissolved in lx  TBE and containing 0.5pg EtBr per ml was 
submerged in lx  TBE and run at 50V for 30-40 minutes. Restriction enzyme digests or 
DNA preparations were checked by mixing DNA 5:1 with loading buffer. DNA was 
examined and photographed under UV transillumination. Size markers were run in 
adjacent wells to the DNA to determine the size o f the fragments.
2.1.2 Isolation of DNA from Agarose Gels
5-20pg o f DNA was mixed with loading gel buffer and was loaded onto a 1% (w/v) 
TAE agarose gel and electrophoresed at 40V. The DNA profile was visualised under
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long wave UV light and the appropriate fragments excised with a sterile scalpel. The gel 
slice was stored in a 1.5ml reaction vial at 4°C until required for purification (Section 
2.5.9).
2.1.3 Purification of Synthetic Oligonucleotide from Polyacrylamide Gels
Dried oligonucleotide pellets were resuspended in a 50:50 mix of dH20:formamide by 
boiling for 5 min. The product of a preparation was run between 4 adjacent wells using a 
10% Sequagel in 0.5x TBE. lx  loading gel buffer was run in adjacent wells, to monitor 
progression of fragments. The gel was electrophoresed at 50mA until the loading dye 
had reached the bottom of the gel. The gel was carefully removed, wrapped in cling film 
and viewed on a silica gel thin layer chromatography plate under short wave UV 
radiation. The band was excised with a sterile scalpel and placed into a glass universal 
containing 500pl o f dH20. The sample was agitated o/n at 37°C to allow the 
oligonucleotide to diffuse. The oligonucleotide solution was transferred into a 1.5ml 
reaction vial, phenol/chloroform extracted, isopropanol precipitated and resuspended in 
1 OOptl o f dH20. The oligonucleotide was then quantified (Section 2.8) and stored at 
-20°C until required.
2.1.4 SDS-PAGE of Protein Samples
Analysis o f protein samples was typically carried out on 'mini-gels' run on a Bio-Rad 
Mini Protean II1M apparatus. Single concentration gels were prepared with commercial 
polyacrylamide (30% acrylamide / Bis-acrylamide 37.5:1, Bio-Rad) at concentrations of 
either 10% or 15%. A 5% stacking gel was polymerised on the top. The protein samples 
were boiled in dissociation mix for 2 min before being loaded in parallel with molecular 
weight rainbow markers. Electrophoresis occurred in tank buffer (52mM Tris, 53mM 
glycine, 0.1% SDS) at 50V until the bromophenol blue dye had reached the bottom of 
the gel. The gel was then stained with Coomassie gel stain for at least lh. Protein bands 
were visualised by shaking the gel o/n in a solution of destain. Alternatively a silver 
staining procedure was be used (see Section 2.1.5).
For permanent storage, the gels were dried onto Whatman 3mm paper under vacuum on 
a Bio-Rad gel drier.
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2.1.5 TCA Precipitation
GuHCl causes SDS to precipitate out of solution and so samples containing GuHCl 
cannot be mixed directly with dissociation mix, for analysis by SDS-PAGE. The GuHCl 
was therefore removed by addition o f 5% TCA (trichloroacetic acid), followed by 
incubation on ice for 20 min. The solution was spun at 13000rpm for 15 min and the 
pellet washed with 100% ethanol, air dried and resuspended in dissociation mix. The 
sample could then be loaded onto a gel immediately, or stored at -20°C, until required.
2.1.6 Silver Staining
To detect protein bands by silver staining a series of solutions, detailed in Section 1.11, 
were used. The electrophoresed gel was first fixed in solution 1 for 25-30 min before 
being incubated, with gentle agitation, in solution 2 for 20-30 min. After washing for 3x 
10 min in solution 3, solution 4 was added for 15-20 min. The reaction was developed 
by addition of solution 5 which was stopped by the addition of 50mM EDTA when the 
bands had become evident.
2.1.7 Analysis of ^S Labelled Proteins
To visualise radioactive protein samples the polyacrylamide gel was dried down and 
placed in a cassette in contact with Kodak XS-1 film and incubated in the dark o/n and 
developed through a Kodak X-Omat Processor (model: ME3). Alternatively the gel was 
placed against an Image Screen (supplied by Molecular Dynamics) which had been 
wiped of all previous samples by exposure to an Image Screen Eraser (Molecular 
Dynamics) for 10 min. The polyacrylamide gel was placed against a blank screen for 4h- 
o/n. The gel profile was scanned into the Phospholmager (Molecular Dynamics) and the 
bands viewed on the PC using the ImageQuant programme.
2.1.8 Semi-dry Western Blotting
(i) Transfer
Proteins were transferred from a mini-protein polyacrylamide gel onto a nitro-cellulose 
membrane using 2117-Multiphor II Electrophoresis Unit (Pharmacia), with the surfaces 
coated in transfer buffer. The proteins were transferred for lh  at 40mA. Confirmation 
that transfer had occurred was monitored visually using Rainbow markers.
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The blot was stored at rt in transfer buffer until required.
(ii) Detection
Proteins were detected by a series o f washing and antibody reaction steps. The 
membrane was first placed in blocking buffer at 37°C for 30 min to reduce non-specific 
binding to the membrane. This was followed by 2x 5 minute washes in TTBS and the 
addition o f the primary antibody, diluted in antibody buffer, for 4h at 37°C. The 
membrane was washed (2x 10 min) in TTBS before addition o f the secondary antibody 
(usually GAM-HRP), diluted in antibody buffer, for at least 4h at 37°C. The blot was 
again washed in 5 min cycles at 37°C, twice in TTBS and twice in TBS. Visualisation 
occurred by enhanced chemiluminescence (ECL). The ECL developing reagents were 
applied to the membrane for 2 min. The developing reagents were supplied by 
Amersham international pic. Reagent 1 was mixed 1:1 with reagent 2 to give a volume 
equivalent to 0.125ml/cm2 o f membrane. The membrane was then exposed for 
approximately 5 sec to 1 min on Kodak X S-1 film.
(iii) Stripping
The nitro-cellulose membrane could be stripped and re-probed with the antibodies by 
bathing the blot in stripping buffer (Section 1.11) for 30-40 min at 55°C. It was then 
washed in TBS briefly ready for re-probing.
2.2 HSV-1 Virus Preparation and Manipulation
2.2.1 BHK Cell Culture
2.2.1.1 Estimation o f Cell Densities
All cell densities were estimated using a Nebauer counting chamber. Cells were counted 
under the light microscope and cells/ml values calculated.
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2.2.1.2 BHK Cl 3 Cells
(i) Passage
BHK cells were passaged routinely every 3-4 days in 850cm2 roller bottles. The cells 
were seeded at 2 x 107 in 100ml of ETCio with 5% CO2 atmospheric conditions. Roller 
bottles were rotated slowly at 37°C. Confluent monolayers were harvested after 2 
versene washes followed by trypsinisation with typsin/versene (1:4). A confluent 
monolayer typically yielded 1 x 108 cells.
Confluent BHK cells could be maintained in roller bottles in a viable state at 3 1°C for at 
least one week
(ii) Freezing and Storage
A healthy flask of 150cm2 BHK C l3 cells, was harvested and spun at 3000 rpm for 10 
min. The cells were resuspended in 3ml 40% ET-semm, 40% NBCS, 20% glycerol, 
aliquoted into 3 screw cap vials, placed in a polystyrene container and stored at -70°C 
o/n before transfer to liquid nitrogen.
(iii) Recovery
One vial of cells was defrosted and recovered into a large flask containing growth
medium and incubated at 37°C in 5% C 0 2. The medium was changed the following day
and when confluent, the monolayer o f cells was passaged as normal.
2.2.2 Preparation of High Titre Virus Stocks
Confluent monolayers of BHK C13 cells in roller bottles were used to grow high titre 
HSV-1 virus. Virus was infected at 0.001 pfu/cell in 50ml of ETC10 and incubated at 
31°C for 4-5 days. The cells were removed by gentle shaking and harvested in 225ml 
falcon tubes at 2000 rpm for 10 min using a Sorvall RT7 centrifuge. The supernatant 
and cell pellet were separated to produce two individual stocks.
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• Cell associated virus (CAV): the pellet was sonicated in 2ml o f ETCio per 850cm2 
roller bottle, and spun at 3000 rpm for 5 min in a Sorvall RT7 centrifuge, to pellet the 
cell debris. The supernatant was removed to 1.5ml reaction vials and stored as CAV 
stock.
• Cell released virus (CRV): the supernatant was spun in Sorvall GSA bottles at 12000 
rpm for 2h (Sorvall GSA rotor) and the pellet resuspended in 2ml o f ETCio per 
850cm2 roller bottle, by sonication. The CRV stock was aliquoted and stored in 
1.5ml screw cap reaction vials.
Both the CAV and CRV stocks were stored at -70°C.
2.2.3 Titration of Virus Stock
Stocks were titrated on 50mm dishes on approximately 80% confluent monolayers of 
BHK C13 cells. The cell medium was removed and replaced with lOOpl of virus serially 
diluted 10-fold in PBS complete, containing 5% NBCS. After lh at 37°C, the inoculum 
was removed, replaced with 4ml EM Cio and incubated at 37°C for 3-4 days. Staining 
with 4ml o f Giemsa for 15 min revealed clear plaques which could be counted using a 
dissection microscope and expressed as pfu/ml.
2.2.4 Sterility Checks of Virus Stock
Viral stocks were regularly monitored for their sterility by routine checks. A small 
amount (typically 5pi) of the stock was inoculated into bacterial medium eg TPB or 
fungal medium eg SAB and incubated at 28°C or 37°C for up to one week or until 
visible signs of contamination appeared. In addition, samples were also streak plated 
onto blood agar plates (supplied by E&O Laboratories Ltd) and generally incubated at 
28°C.
2.2.5 Preparation and Purification of Wild-type HSV-1 Capsids
2.2.5.1 Infection o f BHK Cl 3 Cells
Confluent cell monolayers o f BHK C l3 cells in roller bottles, were infected with 
5pfu/cell o f HSV-1 virus in 40ml of ETCio and incubated at 37°C for 18-24h.
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2.2.5.2 Purification o f Capsids
Capsids were purified using a modification o f the method of Booy et al, 1991. The 
infected cells were removed from the roller bottle by two washes with 30ml of PBS 
complete containing 1% NP40. The suspension was transferred to a 225ml falcon tube 
and centrifuged in a Sorvall RT7 at 2000 rpm for 10 min. 30ml of ice cold NTE, with 
1% NP40, was added to the pellet and incubated on ice for 10 min. Probe sonication 
using a Branson soniprobe, lysed the nuclei and released the capsids into the medium. 
The debris was pelleted at 2000 rpm for 10 min (in a Sorvall RT7 centrifuge) and the 
supernatant concentrated through a 5ml, 40% (w/v), sucrose cushion at 20000 rpm for 
lh  at 4°C in an AH629 rotor. The pellet was rinsed carefully with NTE, to remove 
residual sucrose, before resuspension in NTE. The capsids were then banded on a 
sucrose gradient:
• Small scale capsid preparations (2 roller bottles/gradient) were loaded onto 12ml 
gradients of 10-40% (w/v) sucrose in NTE and spun at 40000 rpm for 20 min in 
TsT41 rotor.
• large scale capsid preparations (5 roller bottles/gradient) were loaded onto 30ml 
gradients of 20-50% (w/v) sucrose in NTE. These were spun at 25000 rpm for lh  in 
AH629 rotor.
Gradient bands were viewed in a darkened room under a fibre optic light and removed 
by side puncture with an 18-gauge needle. A (top band), B (middle band), and C 
(bottom band) capsid preparations were pooled, diluted 10-fold in NTE and spun at 
24000 rpm at 4°C in a Sorvall TsT41 rotor for lh. Capsid pellets were resuspended in 
100-200pl of NTE or PBS by bath sonication and stored at -70°C until required. 
Correct capsid protein profiles were confirmed on a mini-gel as described in Section 
2.1.4.
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2.3 Baculovirus Preparation and Manipulation
2.3.1 Sf 21 Cell Culture
Cell densities were estimated as in Section 2.2.11.
(i) Passage
Sf 21 cell monolayers were passaged every 3-4 days in 150cm2 tissue culture flasks 
containing 50-75ml o f TC I00/5 medium. The cells were dislodged in 10ml of T C I00/5 
medium by sharply tapping the flask against the hand and pipetting up and down to 
disperse clumps. Yield from a confluent flask was typically 4-6 x 107 cells and new 
flasks were seeded by a 1:4 split.
Sf cell suspensions were set up from a confluent flask harvest in 850cm2 roller bottles 
containing 300ml of T C I00/5. The roller bottles were turned continuously (4 rpm) at 
28°C to prevent the cells adhering to the sides of the bottle. The cells reached a density 
o f 2-3 x 106 cells/ml after 4-5 days, when they were split 1:10 to seed a new roller 
bottle.
(ii)Freezing and Storage
A confluent flask of Sf cells was harvested in 10ml of T C I00/5 medium (as described 
above) and pelleted at 1500 rpm in a Sorvall RT7 centrifuge. The cell pellet was 
resuspended in 3ml o f 90% FCS, 10% DMSO and split between 3 screw cap vials. The 
cells were stored at -70°C for 3-4h before being transferred to liquid nitrogen.
(iii) Recovery
Sf cells were thawed rapidly at 37°C and spun at 3000 rpm to pellet the cells and 
remove the DMSO. The cells were resuspended in T C I00/5 and transferred to a 25cm2 
tissue culture flask, containing 10ml of TC I00/5 and incubated at 28°C o/n. The 
medium was then removed and replaced with fresh growth medium to remove any dead 
cells. Once the cells had formed a confluent monolayer, generally 4-5 days they were 
dislodged and transferred into 150cm2 flasks and passaged as normal.
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2.3.2 Preparation of Low Titre Virus Stock
A 25cm2 tissue culture flask was seeded with 1 x 106 cells in 10ml of T C I00/5 and 
incubated at 28°C until a 50% confluent monolayer was formed (2-3 days). The medium 
was then discarded and replaced with lOOpl of the plaque purified plate harvest (Section 
2.3.7.4) for lh  at rt. 10ml of fresh growth medium was added and the flask was 
incubated at 28°C for 4-5 days when extensive CPE was observed. The medium was 
harvested in a 15ml falcon tube at 2000 rpm (Sorvall RT7 centrifuge) for 5 min and the 
supernatant aliquoted into bijoux (5ml in each). This low titre stock was stored at 4°C 
and used to grow high titre stocks.
2.3.3 Preparation of High Titre Virus Stock
High titre baculovirus stocks were prepared in 300ml suspensions o f Sf21 cells in 
TCI 00/5 medium, which had reached a density of 5 x 103 cells/ml. Cells were infected at 
a moi of 0.1 pfu/cell with titred virus stock. The cells were incubated at 28°C for 4-5 
days. The medium was harvested by spinning in 225ml falcon tubes at 2000 rpm (Sorvall 
RT7 centrifuge) for 10 min to remove cells and debris. The virus was then pelleted from 
the supernatant at 12000 rpm for 2h in a Sorvall GSA rotor. The viral pellet was 
allowed to resuspend o/n at 4°C in 4ml of TC I00/5 and dispersed in a Kerry ultrasonic 
bath. The stocks were aliquoted into 1.5ml screw cap reaction vials. High titre 'working' 
stocks were stored at 4°C whereas the 'elite' stocks were stored at -70°C.
2.3.4 Titration of Virus Stock
Stocks were titrated on 35mm dishes on a uniform Sf cell monolayer (approximately 60- 
70%) (Brown & Faulkner, 1977). The cell medium was removed and replaced with 
lOOpl of virus diluted in TCI 00/5. The virus was diluted 10-fold, 10'2-10'6 for low titre 
stock and 10‘5-10'8 for high titre virus stock. After lh at rt, with periodic gentle 
agitation, the inoculum was removed and replaced with 1.5ml o f overlay which 
consisted of 50% T C I00/5 and 50% of 3% Seaplaque agarose, maintained at 45°C until 
required to prevent setting. Once the overlay had set on the plates, 1.5ml of T C I00/5 
medium was added. After 4-5 days at 28°C, the cells were stained with 1.5ml of neutral
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red stain (0.4% neutral red mixed 1:50 with TCI00/5) for 4-8h. The stain was poured 
off, the plates inverted and left to clarify o/n in the dark.
Distinct clear plaques could be visualised and counted either by eye or under lOx 
magnification on a dissecting microscope (Wild, Heerburgg). The titre was calculated at 
pfii/ml.
If recombinant virus plaques were to be identified through the loss of the lacZ marker 
gene, then 250pg o f X-gal was added to each ml of neutral red stain. The mixture of 
parental (/acZ-positive) and recombinant (lacZ-negative) viruses were separated as the 
recombinant produced clear plaques and the parental produced blue plaques on the pink 
background of non-infected cells.
2.3.5 Sterility Checks of Virus Stock
Both high and low titre virus stocks were regularly monitored for their sterility by 
routine checks as described in Section 2.2.4.
2.3.6 Confirmation of Expression of Baculovirus Proteins
The expression of baculovirus proteins was confirmed by an analytical protein gel. For 
radio-active labelling 35mm dishes were seeded with 6 x lCf Sf cells in 1.5ml of 
TC I00/5. The plates were incubated o/n at 28°C to from a 50% confluent monolayer (1 
x 106). The medium was removed and lOOpl of virus added at 5 pfu/cell for 1 hour 
before the addition o f 1.5ml of TC100/5. The plates were again placed at 28°C for 24- 
3Oh . The medium was then removed and replaced with 1ml of TC100.met for lh  prior to 
incubation in T C I00/5:TC100.met (1:4) containing 30pCi/ml of [:°S]-methionine for 18h 
at 28°C. The cells were gently pipetted off and transferred to a 1.5ml reaction vial, 
pelleted by a microfuge at 6500 rpm for 3 min, washed twice in PBS complete and 
resuspended in 1 OOpl of dissociation mix. The cell lysates were stored at -20°C before 
analysis by SDS-PAGE (see Section 2.1.6).
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2.3.7 Construction of Recombinant Baculoviruses 
2.3.7. 1 Preparation o f AcPAK6 DNA
AcPAK6 was used to infect 2 roller bottles containing 300ml of 2 x 105 Sf21 cells/ml at 
1 pfu/cell and harvested in the usual manner (Section 2.2.3). The pellet was resuspended 
in 2ml o f T C I00/5 medium by sonication with a Branson ultra soniprobe and 
reconcentrated in a SS34 rotor by centrifugation at 18000 rpm for 90 min at 4°C in a 
Sorvall RC-5B centrifuge. After resuspension in TE buffer (SDS 0.25%, proteinase K 
500pg/ml) o/n at 31°C, the DNA was phenol/chloroform extracted, chloroform 
extracted and precipitated in ethanol. The DNA pellet was resuspended at 37°C in 200pl 
o f dH20 .
2.3.7.2 Digestion of Ac PAK 6 DNA
25pg of AcPAK6 DNA was digested with 60 units of restriction enzyme Bsu36I in a 
100pl reaction mix containing lx  NEB 3 buffer and 100pg/ml acetylated BSA. The 
reaction mix was incubated at 37°C for 4-5h, treated for 30 min with 1 unit o f calf 
intestinal phosphatase, phenol:chloroform extracted, ethanol precipitated and the 
PAK6(Bsu361) DNA resuspended in 100pl of dH20  at 37°C.
Successful digestion was confirmed by digesting PAK6(Bsu361) DNA and PAK6 DNA 
with EcoRI and comparing the profiles on an analytical agarose gel. Correct digestion of 
the DNA was confirmed by a noticeable shift in a large fragment and the appearance o f a 
smaller band.
2.3. 7.3 Transfection of Viral DNA
Viral DNA was transfected on 60-70% confluent monolayers o f Sf21 cells in 35mm 
dishes using CELLFECTIN™ reagent (Life Technologies) and the protocol suggested by 
the manufacturer. Basically two reaction mixes were prepared, A and B, in 15ml falcon 
tubes:
• A 0.5pg PAK6(Bsu361) DNA, l-2pg plasmid DNA, lOOpl TC100.
• B 4pl CELLFECTIN™, lOOpl T C I00.
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A and B were then mixed gently, and incubated at rt for 30-45 min. The medium was 
decanted from the monolayers and the cells were washed once in TC I00 before the 
addition of the transfection mix. After incubation at 28°C for 5h, the mix was removed 
and replaced with 2ml o f TCI 00/10 and incubated for a further 72h at 28°C. Cells were 
harvested at 13000 rpm (microfuge) for 2 min and the supernatant medium transferred 
to a 1.5ml screw cap reaction vial for storage at -70°C until plaque purification.
2.3. 7.4 Plaque Picking and Purification
(i) Initial Plaque Isolate (iPI)
The transfection supernatant was titrated as a low titre stock as described in Section
2.3.2 and stained to reveal lacZ minus recombinants. Well isolated clear plaques were 
picked by removing a plug o f agarose with a pipette tip and washing it out in 250 pi of 
T C I00/5. The virus was released into the medium by 3x freeze-thawing and this initial 
plaque isolate stored at -70°C.
(ii) Final Plaque Harvest (fPH)
The iPI medium was plated and stained as described above, through at least another 2 
cycles, to produce the final plaque harvest (fPH).
(iii) Plate Harvest 1 (PHI)
100 pi o f the fPH was plated onto 50% confluent Sf21 cells on 35mm dishes and allowed 
to absorb at rt for lh  with periodic agitation. 1.5ml of TC100/5 was then added and the 
cells incubated at 28°C for 4-5 days. The PHI cells were harvested and lOOpl used as 
the inoculum to produce low titre and high titre virus stocks described in Section 2.3.2.
2.3.8 Preparation and Purification of Recombinant HSV-1 Capsids
2.3.8.1 In fection ofSf21 Cells
Roller bottles containing Sf21 cells at lx  106 cells/ml were infected with the appropriate 
recombinant baculovirus at 5pfu/cell and incubated at 28°C for 48-65h. Infected cells 
were harvested in 225ml Falcon tubes at 2000 rpm for 10 min using a Sorvall RT7 
centrifuge.
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2.3.8.2 Purification o f  Capsids
Capsids were purified as described in Section 2.2.5.2.
2.4 Oligomers
2.4.1 Cleavage and Storage of Oligonucleotides
(i) Cleavage
Oligonucleotides were removed from the synthesis column with ammonia [specific 
gravity = 0.88, (Fisons)] and deprotected at 55°C for 5h. The deprotected 
oligonucleotide was aliquoted equally between 3x 1.5ml reaction vials and the ammonia 
removed by evaporation o/n in a rotary drier.
(ii) Storage
The dried pellets were stored at -20°C until required for gel purification (Section 2.1.3).
2.4.2 Cleavage, Analysis and Storage of Oligopeptides
(i) Cleavage
The resin [see Section 1.3, (ii)] was first washed with a series of chemicals (tertiary amyl 
alcohol, acetic acid, tertiary amyl alcohol and 2x diethyl ether) to remove uncoupled 
oligopeptides. The resin was then thoroughly dried by passing N2 through it before the 
peptide was removed from the resin by cleavage with either Reagent K for 5h or Trp 
cleavage mixture for 7h, depending on the amino acid sequence of the peptide (see 
results). The cleavage mixture was collected from the column and mixed with 20ml of 
ether, to precipitate the oligopeptide, and spun at 10000 rpm (SS34 rotor) for 10 min. 
The oligopeptide pellet was washed twice in 20ml diethyl ether and solubilised in 25ml 
of dH20  [see (iii)]. The solution was freeze dried in a 100ml round-bottomed flask.
(ii) Storage
Oligopeptides were stored in their powdered form in sealed glass universals at -20°C. 
Upon removal from storage, they were pre-warmed to rt before opening to prevent 
condensation forming on the dried oligopeptide.
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(iii) Solubilisation
Oligopeptides, where possible, were dissolved in dH20  for analysis. Those which were 
not easily solubilised were treated with a small amount of either formic acid (if the 
peptide was basic) or ammonia vapour (if the peptide was acidic) to alter the pH and aid 
solubilisation.
(iv) Mass spectrometry
The Mr of each peptide was determined by mass spectrometry analysis. The 
oligopeptides were analysed by laser desorption mass spectrometric analysis. The 
peptide was dissolved at 1 mg/ml in dH20  and diluted in analysis buffer (70% acetonitril, 
0.1% TFA). 5mg of the matrix, alpha-cyano-4 hydroxycinnamic acid (ALDRICH), was 
dissolved in 500pl of the analysis buffer. The test peptide was mixed 1:1 with a control 
peptide and this solution was mixed 1:1 with the matrix. 1 pi of this mixture was spotted 
onto a Lasermat sample slide and left to dry for 10 min. The oligopeptides were 
analysed on a Finnigan MAT Lasermat. The peptide Mr were identified using the 
software on the PC and calibrated using the known peptide Mr.
2.5 Gene Cloning
2.5.1 Preparation of E coli Competent Cells
(i) BL21
1.6ml of a starter culture was added to 100ml of L-broth and incubated until the 
A6oo= 0 .2 -0 .3 . The bacteria were spun down at 3000 rpm (in a Sorvall RT7 centrifuge) 
for 10 min in 225ml Falcon tubes, resuspended in 40ml of sterile lOOmM CaCl2 and 
incubated on ice for 2h. A 13000 rpm spin followed in the SS34 rotor. The pellet was 
resuspended in 1ml of lOOmM sterile CaCl2 and incubated on ice for a further 2h. 80pl 
of the competent bacteria were aliquoted into 1.5ml reaction vials, and stored at -70°C 
until required for transformation procedures.
(ii) JM109
These were supplied in a form ready to use for transformations and required no further 
preparation. They were stored at -70°C.
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2.5.2 Transformation of Plasmid DNA
A single vial of E coli competent cells was used for each transformation reaction. The 
cells were thawed on ice and l-50ng of plasmid DNA added (generally lp.1 o f the 
ligation mix) and incubated on ice for 10 min.
(i) Electroporation
Competent cells were induced to take up DNA by subjecting the cells to a short 
electrical pulse. The cells containing the plasmid DNA were placed in a cold gene pulser 
cuvette (Bio-Rad) and electroporated at 1800V using the Hybaid 'Cell Shock' apparatus, 
lml o f SOC medium was added and the culture incubated at 37°C for lh  with agitation.
(ii) Heat shock
Competent cells were induced to take up DNA by heat shock at 42°C for 45-50 sec. 
The cells were then returned to the ice bath for 2 min before addition o f lml o f SOC 
medium followed by incubation at 37°C for lh with agitation.
lOOpil o f transformed cells in (i) or (ii) was plated onto L-broth agar + antibiotics plates, 
inverted and incubated at 37°C o/n.
2.5.3 Preparation of a Starter Culture
A starter culture was prepared by inoculating 20ml of L-broth + antibiotic with 
transformed bacteria from either:
• a single well isolated colony from an agar plate
• 20pl from a small scale preparation (Section 2.5.5)
• 5j.il from a glycerol stock (Section 2.2.4)
The culture was shaken at 37°C for 4h-o/n.
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2.5.4 Preparation of Glycerol Stocks
(i) Standard preparation
Normally a lml starter culture was spun at 6500 rpm (microfuge) for 4 min in a 1.5ml 
reaction vial. The supernatant was discarded and the pellet resuspended in 500pl of 
sterile bactopeptone (20% ): glycerol (80%) (1:1).
(ii) pET clones
As pET constructs were sensitive to high glycerol concentrations (ie >10%), the method 
was slightly varied. Bacterial cultures were grown to an A6oo=0.6-0.8 when 900pl of 
suspension was removed and mixed thoroughly with lOOpl of 80% glycerol.
All the stocks were stored at -70°C until required.
2.5.5 Small Scale Plasmid Preparation
A small scale plasmid preparation of DNA or a 'mini-prep' was prepared essentially as
described by Maniatis et al, 1982. Typically 12 well isolated transformed bacterial
colonies were picked from a plate and inoculated into 2ml of L-broth + antibiotic. They 
were incubated at 37°C, with shaking for at least 5h. 1.5ml of each suspension was 
transferred to a 1.5ml reaction vial and spun at 13000 rpm (microfuge) for 40 sec. The 
supernatant was discarded and the cell pellet resuspended in lOOpl o f solution 1 
(Section 1.11) by vigorous vortexing. Once the pellet had completely resuspended, 
200pl of freshly prepared solution 2 (Section 1.11) was added for 5 min to lyse the cells. 
150pl of ice cold solution 3 (Section 1.11) was added next and the mixture incubated on 
ice for 5 min. The cell debris was pelleted at 13000 rpm (microfuge) for 5 min and the 
resulting supernatant removed to a fresh 1.5ml reaction vial for phenol extraction and 
precipitation (Section 2.5.6 and 2.5.7). The DNA pellet was resuspended at 37°C in 
50pl of dH20  and typically 5pi would be used in a restriction enzyme confirmatory 
digest reaction.
2.5.6 PhenolrChloroform (1:1) Extraction of DNA
DNA samples were always extracted in volumes not less than 200pl. If the sample 
volume was less than this, the appropriate amount of dH20  was added.
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Phenol chloroform (1:1) was saturated with TE and a volume equal to that of the DNA 
solution was added. The mixture was then vortexed and centrifuged at either 13000 rpm 
or 3000 rpm in a microfuge for 5 min, depending on the volume. The top layer, 
containing the DNA was removed to a fresh tube ready for precipitation.
2.5.7 Ethanol / Isopropanol Precipitation of DNA
Sodium acetate (pH 5 .4) was added as 1/10 of the volume and one of two alcohols was 
used:
• isopropanol: an equal volume of isopropanol was added to that already in the tube to 
aid precipitation o f larger fragments of large fragments of DNA.
• ethanol: 2.5x the volume of ethanol was added to aid precipitation of smaller 
fragments of DNA.
The mixtures were incubated at -20°C for at least 30 min and the DNA pelleted at 
13000 rpm (microfuge) for 5 min or 3000 rpm (Sorvall RT7 centrifuge) for 10 min, 
depending on the size of the sample. The pellet was gently washed in 70% ethanol and 
dried on a rotary evaporator, ready for resuspension in dH20  at 37°C. Presence of DNA 
was confirmed on an analytical agarose gel and samples were stored at -20°C until 
required.
2.5.8 Restriction Endonuclease Digests of DNA
DNA was digested using the appropriate restriction enzyme(s) and corresponding 
reaction buffer under the conditions recommended by the manufacturer. Routinely, 10 
units o f enzyme was added per pg of DNA and incubation occurred at 37°C for 1 hour, 
unless another temperature was recommended. RNaseA was often included in the 
reaction mix, especially miniprep samples, at lOpg/ml to digest any residual RNA and 
prevent smearing on the analytical gel.
If the DNA required to be digested by 2 enzymes which reacted in incompatible buffers 
then 2 approaches were taken:
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•  a single digest would be carried out and after 1 hour the buffer would be 
appropriately modified, eg by the addition of salt, and the second enzyme would be 
allowed to act.
•  digests would be performed sequentially. The first enzyme was used on the DNA. A 
portion was checked on a gel and the remainder was phenol extracted and 
precipitated before being digested with the second enzyme.
All digests were confirmed by analytical agarose gel electrophoresis (Section 2.1.1).
2.5.9 Purification of DNA from an Agarose Gel Slice
DNA was extracted and purified from an agarose gel slice using the protocols from one 
o f several commercially available kits: Gene clean II (for fragments >1000 bp), 
Sephaglass bandprep kit (for fragments >200 bp), Mermaid kit (for fragments >50 bp).
2.5.10 Ligation of DNA
(i) Standard ligation
Appropriately digested DNA and vector strands were mixed 3:1 respectively in the 
presence o f lx  BRL ligation buffer and 1 unit o f T4 DNA ligase in a total volume of 
20pl. The ligation mix was incubated for at least 4h, often o/n, at 15°C.
(ii) Oligonucleotide ligation
Purified complementary oligonucleotides (0.5-1.Opg) were boiled in lx  BRL ligation 
buffer without ATP for 1 min. The mixture was then incubated at 37°C for 20 min 
before the addition o f the vector DNA (lpg ), 1 unit o f T4 DNA ligase and ImM ATP. 
The mixture was then incubated at 15°C as above.
Following any ligation reaction, the DNA would be stored at -20°C until required for a 
transformation reaction (Section 2.4.5).
2.5.11 Large Scale Plasmid Preparation
A starter culture (Section 2.5.3) was inoculated into 100ml o f L-broth + antibiotic and 
agitated at 37°C o/n. The bacterial cells were harvested at 6000 rpm for 15 min in a
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GSA rotor. DNA was purified using the standard 'midi' protocol for the Qiagen resin kit. 
DNA was isopropanol precipitated and resuspended in 200pl of dH20. The presence of 
DNA was confirmed by running 2-5pl on an agarose gel (Section 2.1.1).
2.5.12 Quantification of DNA
DNA was serially diluted 1:10, 1:50, 1:100 in dH20. The optical density was then 
measured on a mass spectrophotometer at A26o and A28o. The resultant stable A26o value 
was multiplied to convert to qg/ml based on the dilution factor and the conversion 
factors:
• oligonucleotide: 10D = 20pg/ml
• ds DNA: 10D = 50pg/ml
2.5.13 Site Directed Mutagenesis
A modified Kunkel method of site directed mutagenesis (Kunkel, 1985) was used to 
generate mutants with amino acid inserts. A series o f steps were performed to produce 
suitable DNA for the insertion of extra amino acids:
(i) Preparation of Uracil-enriched DNA
CJ236 duf ung (supplied by NEB) cells were transformed by electroporation with, for 
the purpose of this study, the pET plasmid. A single colony was picked into an L-broth 
+ Kan starter culture. This was incubated at 37°C, shaking o/n and sub-cultured into 
200ml o f fresh medium containing lOOpg/ml of uridine. After 30 min shaking at 37°C, 1 
x 1011 pfu/flask of M l3 R408 phage (supplied by Promega) was added followed by a 
further 9h incubation. The culture was spun at 9000 rpm for 10 min (GSA rotor) and the 
supernatant decanted and spun for a further 10 min. 0.25 volumes of 20% PEG-6000 in 
2.5M NaCl was added to the supernatant. The solution was incubated on ice for 30 min 
and pelleted at 12000 rpm for 15 min. The phage pellet was resuspended in 5ml of 
supernatant mix and pelleted at 7000 rpm for 15 min (SS34 rotor). After the supernatant 
had been thoroughly removed, the pellet was resuspended in 2 ml of TE and phenol 
chloroform extracted. After centrifugation, the aqueous layer (top) was further 
extracted, twice with phenol:chloroform:isoamylalcohol (24:24:1) and once with
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chloroform:isoamylalcohol (24:1). The aqueous layer was precipitated with 4M NaCl, 
50mM EDTA and 2.5 volumes of ethanol, for at least 2h at -20°C. The ss uracil- 
enriched DNA was concentrated at 13000 rpm (microfuge) for 10 min, dissolved in 
dH20 and stored at -20°C until required.
(ii) Annealing and Second Strand Synthesis
A series o f oligonucleotides (see Results, Chapter 5) were annealed to the ss uracil- 
enriched DNA. The oligonucleotides were first phosphorylated in lx kinase buffer, 
20mM ATP and T4 kinase, for 40 min at 37°C. The mixture was heat inactivated at 
70 °C for 10 min and the oligonucleotides stored at -20°C, until required.
0.5pig o f the ss uracil-enriched DNA was required to separately anneal l.Opg o f each 
phosphorylated oligonucleotide at 70°C, cooling to rt for lh. 30jil of a mix containing 
lx  ligation buffer, 0.5 units NEB ligase and 0.5 units T7 DNA polymerase, was added to 
the annealed DNA. The samples were incubated at rt for lh and 37°C for a further lh. 
The sample volumes were then increased to 200pil by the addition of 16pl of 50mM 
EDTA:4M NaCl. The DNA was phenol:chloroform extracted, ethanol precipitated and 
resuspended in 20jil o f dH20 and stored at -20°C until required.
The DNA was transformed into BL21 competent cells and selected on L-broth + Amp 
plates.
Expression of the modified proteins, incorporating the oligonucleotide sequences is 
described in Results, Chapter 5.
2.5.14 PCR
All PCR reactions were carried out using a Biometra Trio-Thermoblock machine. 50ptl 
mixes were prepared in dH20  and consisted of.
• 5|il each o f two purified oligonucleotide primers at 10qM/pl
• dNTPs to a final concentration of 200pM
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• 0.1 pg o f template DNA
• 5pil o f lOx reaction buffer (500mM KC1, lOOmM tris-HCl pH 8.3, 50mM MgCh)
• M gS04 to a final concentration o f 2mM
• 2 units o f Taq polymerase
The mixture was gently agitated and sealed with 200pl o f mineral oil to prevent 
evaporation. It is important to note that a control mixture was always set up in parallel 
with the reaction mixture and contained all the ingredients above except the DNA 
template.
The initial cycling temperatures were carried out as follows:
• 97°C for 2 min - to denature the DNA
• 50°C for 2 min - to anneal the primers
• 72°C for 2 min - to allow the primers to extend.
All 30 subsequent cycles were performed at the respective temperatures. Upon 
completion, the block was held at 10°C until the samples were removed.
The PCR samples were usually set up in triplicate to increase yield o f DNA. The 
products were confirmed on a agarose gel, containing the appropriate size markers, 
before gel purification.
2.5.15 Sequencing Analysis of DNA
Sequencing analysis was performed in house on an AB1 PRISMTM 377 DNA 
Sequencer. DNA was used at 200r|g per reaction.
2.6 Immunofluorescence Staining
2.6.1 Transfection of Plasmid DNA
All fluorescence experiments were performed with BHK C13 cells cultured as 
previously described. The cells were grown in lml o f EfCio on 13mm glass cover slips
- 6 8 -
Materials and Methods Chapter 2
in 24 well tissue culture dishes. The wells were seeded with 5 x 104 cells/ml or 1 x 105 
cells/ml and incubated o/n at 37°C. The wells which exhibited a 50% confluent 
monolayer were chosen for transfection by cationic liposome method (described by Rose 
et al, 1991). The transfection mix was prepared in 15ml falcon tubes: lp g  o f plasmid 
DNA mixed in 20pl o f Hbs (20mM HEPES, 150mM NaCl, pH7.4) with 6pl o f synthetic 
liposomes was allowed to interact for 10 min at rt. 500pl o f Optimem 1 (Gibco- 
BRL)was added and the mixture was added to the BHK cells. After 4-5h incubation at 
37°C, 500pl of ETCio was added and the cells were incubated o/n. Fixing of the cells 
involved removing the medium and replacing it with lml o f chilled (-20°C) methanol for 
a minimum of 30 min or until required for staining.
2.6.2 Staining
All subsequent steps were carried out in a humidified chamber at rt. Firstly all antibodies 
were diluted in solution A, (PBS complete containing 0.05% Tween 20 and 5% NBCS) 
and incubated on ice. (NB: for all double labelling experiments the 2 antibodies were 
mixed at this stage, prior to addition to the coverslips). Meantime, each coverslip was 
incubated in solution A for 10 min. It was then drained and 50pl o f the primary antibody 
added for a 45 min. The coverslips were carefully washed by 3x 10 sec washes in 
solution A. The secondary antibody (50pl), containing the dye conjugate, was reacted 
for a further 45 min. Again a series o f washing steps ensued consisting o f 5x 10 sec 
washes in solution A and 2x rinses in deionised water. The coverslips were then drained 
and mounted on glass microscope slides in Citifluor and sealed using clear nail varnish.
The slides were stored at 4°C wrapped in tin foil until required for viewing using a Zeiss 
Axioplan fluorescence microscope and photographed on Kodak Ektachrome Elite 400 
film.
2.7 Microscopic Analysis of Capsids
2.7.1 Electron Microscopic Examination of Capsids
To confirm the integrity o f capsids, they were examined under the electron microscope 
by negative staining. Approximately 2pl o f a capsid preparation was allowed to absorb
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onto parlodion-coated microscope grids. They were then negatively stained with 1% 
phosphotungstic acid and drained, before being air-dried and examined with a JEOL 
100S electron microscope.
2.7.2 Cryo-Electron Microscopy Examination of Capsids
All Cryo-EM analysis and 3D image reconstructions were performed by collaborators: 
Dr Wah Chiu and Dr Z Hong Zhou at The Baylor College of Medicine, Houston, Texas, 
USA
Details o f the method of data processing can be found in Zhou et al (1998b).
2.8 Quantification of Proteins
Protein concentrations were quantified in 2 ways:
(i) using a standard Bradford Assay as described in 'Bio-Rad Protein Assay Instruction 
Manual'. Protein concentrations were calculated against protein standards prepared with 
BSA.
(ii) by measuring OD values at A28o and calculating the amount of protein in mg/ml 
using the following calculation:
Extinction Coefficient = A28q
Mr X (protein concentration, mg/ml)
2.9 Sizing of Proteins
Proteins were sized using fast phase liquid chromatography (FPLC) on a Akta Purifier 
(Pharmacia) using a Superdex 75 column. Basically, the column was equilibrated with 
equilibration buffer o/n. The protein was injected at 0 .2mg/ml in a volume of 200pl. The 
samples were passed through the column at a flow rate ot lml/min and protein detected 
at 280nm. The resulting peaks were calibrated against known protein standards.
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2.10 Enzyme Linked Immunosorbent Assay (ELISA)
Wells o f a flat bottomed microtitre plate (Dynatech), were coated at 37°C o/n with the 
primary antigen (see Results, Chapter 5 for concentrations). All the recipes for buffers 
and solutions are detailed in Section 111.  The plates were washed 5x with wash 
solution and blocked with 200gl of blocking buffer for lh at 37°C. Again the plates 
were washed 5x in wash buffer and the secondary antigen added in the presence or 
absence of an inhibitory peptide. After incubation at rt for at least lh, the plates were 
washed 5x in wash solution and 50pl o f the primary antibody, in PBS, allowed to react 
at 37°C for lh. After washing 5x with wash solution, 50gl of the secondary antibody 
(usually GAM-HRP, in PBS) was added for lh at 37°C. Extensive washing followed 
(l Ox in wash solution) and lOOgl of the signal developer (supplied by Kindergaard & 
Perry Laboratories) was added. After 15-30 min of colour development, the A405 was 
read on a Multiskan plate reader (Titrtek, ICN Biomedicals). In most cases the results 
are duplicate determinations and the background A405 was determined by adding 
developer alone to the plate. This value was subtracted from final the readings.
2.11 Epitope Mapping by SPOTscan
The SPOTs procedure was performed using the SPOTscan kit (supplied by Pharmacia). 
The protocol in the kit was followed and is summarised in steps (i) -(vi).
(i) Generation of Pipetting Schedule
The desired sequence was entered into the SPOTscan programme on the PC together 
with the required peptide length and overlay for each SPOT. A pipetting and amino acid 
weighing schedule was automatically generated.
(ii) Peptide Synthesis
Each F-moc amino acid solution was weighed and dissolved in NMP (l-methyl-2- 
pyrolidinone). I pi o f the appropriate amino acid was added to each SPOT on the 
membrane, in a duplicate cycle, to double couple the reaction. Incubation at rt tor 15 
min followed each cycle.
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(iii) Washing Steps
Upon the completion o f each amino acid cycle, the membrane was bathed in a series of 
chemicals at rt:
• DMF - 2 min, to remove unbound amino acids and couple the reaction
• acetic anhydride - 5-10 min, to block any free amino acid groups that had not yet 
coupled
• DMF - 2 min, wash
• 20% piperidine in DMF - 5 min, deprotects ie exposes site ready for the addition of 
the next amino acid in the chain
• DMF - 2x 2 min, wash
• 1% bromophenol blue in DMF - added until SPOTs are restained for the next cycle 
(approximately 10 min)
• methanol - 2 min, final wash
The membrane was air dried and either, the next cycle begun immediately, or the 
membrane was stored at -20°C.
(iv) Side Chain Deprotection
If all the cycles had been completed, side chain deprotection was performed by a series 
o f washing steps at rt:
• DCM:TFA:TBS (1:1:0.002) - lh.
•  DCM - 4x 2 min
• DMF - 3x 2 min
• methanol - 4x 2 min
The membrane was allowed to air dry.
Deprotection was carried out immediately preceding the antibody assay.
- 7 2 -
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(v) Antibody Assay
The antibody assay was performed by first washing the membrane in TBS (2x 10 min). 
The membrane was then blocked with SPOTs Blocking Buffer (BB) (10% BB in T- 
TBS) o/n at rt. The membrane was washed (2x 5 min) in T-TBS and the test antibody
added at the optimal concentration (see Results, Chapter 3), for 3-4h. Washing (2x 5
min in T-TBS) preceded addition of the secondary GAM antibody (1:100), conjugated 
to HRP, for 2h. After 2x 10 min washes in T-TBS, the kit signal developer was added 
until a colour reaction developed.
(vi) Regeneration of SPOTs membrane
The SPOTs membrane could be stripped and re-probed with antibody. First the
membrane was washed in 2x dFhO, 2x DMF and 2x dFCO, for 5 min intervals.
Regeneration Buffer A (Section 1.11) was added for 3x 30 min. Regeneration Buffer B 
(Section 1.11) was then added for 3x 10 min. The membrane was rinsed in methanol, air 
dried and either re-probed immediately, or, stored at -20°C until required.
2.12 Purification of Antibody Supernatant by Ammonium Sulphate 
Precipitation
Antibody supernatant was mixed at 4°C with ammonium sulphate at l .56g/ml, for 20 
min. The solution was spun at 10000 rpm (GSA rotor) for 10 min and the pellet 
resuspended in sodium phosphate buffer at 25% of the starting volume. The solution 
was dialysed o/n against the sodium phosphate buffer at 4°C and the purified antibody 
was stored at -20°C until required.
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CHAPTER 3
A STUDY OF THE MULTIPLE INTERACTIONS CONTROLLING THE 
INTRACELLULAR LOCALISATION OF HSV-1 CAPSID PROTEINS 
BY IMMUNOFLUORESCENCE LABELLING
i
Results Chapter 3
1. Introduction
Capsid assembly is known to occur in the nucleus o f infected cells however, 
understanding the mechanism of assembly requires analysis of how the individual capsid 
proteins interact with each other. Immunofluorescence labelling is a very powerful 
technique to study the capsid protein-protein interactions. Nicholson et al (1994) had 
previously shown by fluorescence microscopy that VP5 and VP23 failed to localise 
efficiently to the nucleus either alone or in combination. This suggested that neither of 
these proteins have an intrinsic nuclear localisation signal. When VP5 was co-expressed 
with preVP22a it was efficiently transported to the nucleus, but the distribution o f VP23 
was unaffected.
To form a more complete picture of capsid protein-protein interactions this study 
undertook to utilise a plasmid based system to monitor the interactions o f VP 19c and 
VP26 with VP5, preVP22a and VP23.
The results o f extensive immunofluorescence studies (Rixon et al, 1996) are detailed in 
this chapter and pulled together with other published literature to draw conclusions 
about the way in which the capsid proteins interact with each other.
2. Construction of Expression Plasmids
2.1 VP23, VP5 and preVP22a
Plasmids expressing VP23 (pE18) or VP5 (pE19) were made by P Nicholson and a 
plasmid expressing preVP22a (pJK2) was made by J Kennard. Cloning o f these capsid 
genes is fully described in Nicholson et a! (1994).
2.2 VP19c and VP26
The UL38 ORF expressing VP 19c was cloned from pBJl82 (Nicholson et al, 1994) into 
pCMVIO (Stow et al, 1993) as a BamHI/Hindlll fragment to generate pE38.
The UL35 ORF expressing VP26 was made as a PCR product, KpnI/BamFII digested 
and ligated into the similarly digested pUC19 to generate pUCUL35. This was
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Figure 3.1: Two primers, 38T1F and 38T1B, were used to generate a PCR fragment 
encoding the UL38 ORF with the pp65 epitope tag at the N-terminus [panel (i)]. The 
complementary residues to the UL38 ORF are indicated by the vertical lines. The PCR 
product was BamHI/PstI digested and ligated with BamHI/PstI digested pCMVIO (ii). 
This resulted in the formation o f pE38Tl (iii), where the N-terminal 15 amino acids o f 
VP 19c were replaced by 11 amino acids including the pp65 epitope tag.
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EcoRI/BamHI digested to release the UL35 ORF and cloned into EcoRI/BamHI 
digested pCMVIO to generate pE35.
Both pE38 and pE35 were made by J Tatman and are fully described in Tatman el al 
(1994).
2.3 Epitope Tagged Versions of VP19c, VP5 and VP26
Good antibodies against some of the capsid proteins, in particular VP26 and VP 19c, 
were lacking. Also the epitope sites o f the available capsid protein antibodies had not 
been mapped and so it was not possible to gauge if the antibody would interact with any 
deletion mutants, where only portions of the protein were expressed. In view o f these 
points, an epitope tag was cloned into VP5, VP 19c and VP26. A number o f tag- 
antibody combinations were available. In the following experiments the HCMV pp65 
epitope tag (McLauchlan et al, 1994) was used and shall be referred to as pp65. Studies 
with this tag and several HSV proteins had shown that the antibody did not cross react 
with any HSV proteins and that this epitope on its own did not confer nuclear 
localisation on the host protein (McLauchlan et aI, 1994). In addition, an attempt was 
made to produce my own tag, using an anti-CAT antibody. This is detailed in Section 5.
2.3.1 VP19c
To insert an epitope tag into VP 19c, two primers, 38T1F and 38T1B, were made. 
38T1F corresponded to bases 40-73 of UL38 ORF (84570-84603 on the sequence of 
McGeoch et al, 1988). 38T1B was complementary to 31 bases o f UL38 ORF (85925- 
85955) and contained a PstI site at its 5' end [figure 3.1, panel (i)].
The two primers were used to generate a PCR product where VP 19c had 15 amino 
acids removed and replaced with 11 amino acids containing the sequence for the pp65 
epitope. The product was cloned as a BamHI/PstI fragment into BamHI/PstI digested 
pCMVIO to generate pE38Tl [figure 3.1, panels (ii) and (iii)]. This was made by A 
McGregor (Rixon et al, 1996).
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Figure 3.2: The GCG plotsimilarity programme was used to generate 
consensus predictions o f VP5 between Alphaherpesviruses (HSV-1, 
EHV-1, PRV and VZV), panel (i), Betaherpesviruses (HCMV and 
HHV-6), panel (ii), and Gammaherpesviruses (EBV, EHV-2 and HVS), 
panel (iii). A poorly conserved area, in all 3 subfamilies of herpesvirus, 
was detected between position 300 and 400. An Xhol site fell within this 
region in HSV-1 and its approximate position is marked with an arrow 
[panel (i)].
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F Rixon had shown that tagged VP 19c (pE38Tl) could be substituted for wt VP 19c to 
form phenotypically normal capsids in the baculovirus system (personal communication). 
This indicated that the presence of the epitope tag not did affect the normal behaviour of 
VP 19c and prevent it forming normal interactions with other capsid proteins.
2.3.2 VP5
To perform all subsequent cloning steps with both VP5 and VP26, it was necessary to 
remove the EcoRl site from an altered form of pCMVIO, designated pCMVlOBgl and 
fully described in Nicholson et al (1994). Removal of the EcoRI site was done by 
restriction enzyme digest followed by filling in the overhanging ends with large fragment 
polymerase and ligating to produce pCMVlOBglAEco.
2.3.2.1 Cloning into pCMVlOBglAEco
The UL19 ORF was isolated from pJN6 (Nicholson et al, 1994) as a Bglll fragment and 
ligated into Bglll digested pCMVl OBglAEco to generate pE19Bgl, see figure 3.3, panel
(i).
2.3.2.2 pp65 Epitope Tagged N- and C- Terminal Deletions of pE19Bgl
VP5 is reasonably well conserved between alpha herpesviruses. However, there is an 
area, approximately 300-400 amino acids from the N-terminus of the protein, which has 
very low homology, being variable in both sequence and length [figure 3.2, panel (i)]. 
This area of low homology is also found in the beta [figure 3.2, panel (ii)] and gamma 
[figure 3.2, panel (iii)] herpesvirus consensus. It was felt that this poorly conserved 
region would be the best place to insert an epitope tag into VP5, as it was probable that 
the precise sequence o f this region was not important for the structural integrity o f the 
protein. In order to insert the pp65 epitope tag this area, it was decided to first produce 
two terminal deletions, insert the appropriate enzyme sites and tag sequence using 
oligonucleotides and reconstruct the full-length VP5 protein.
(i) C-terminal deletion
To produce a C-terminal deletion, use was made o f the Xhol site located in the poorly 
conserved area [see figure 3.2, panel (i)]. pE19Bgl was Xhol/Xbal digested to remove 
the C-terminal 3181 bp sequences. This was replaced by two partially complementary
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Figure 3.3: This figure details the cloning strategy employed to create pp65 epitope 
tagged versions o f N- and C- terminal deletions o f VP5 and a full-length pp65 
tagged VP5. pE19Bgl [panel(i)] was first Xhol/Xbal digested, to remove the C- 
terminal sequences, and religated with two partially complementary oligonucleotides, 
19C-T(1) and 19C-T(2) (figure 3.4). This generated the N terminal portion o f UL19 
with the pp65 epitope tag inserted at the C-terminus, designated pSJM19N65 [panel
(ii)]. Similarly, pE19Bgl [panel(i)] was EcoRV/XhoI digested, to remove the N- 
terminal sequences, and religated with two partially complementary oligonucleotides, 
19N-T(1) and 19N-T(2) (figure 3.5). This generated the C terminal portion o f  UL19 
with the pp65 epitope tag inserted at the N-terminus, designated pSJM19C65 [panel
m i
To create full-length UL19, encoding the pp65 tag, pSJM19N65 [panels (ii) and 
pSJM19C65, panel (iii)] were EcoRI/Xbal digested. The fragment from pSJM19C65, 
containing the C-terminal portion o f UL19, was purified and ligated with purified 
pSJM19N65, containing the N-terminal portion of the fragment plus the vector. This 
reconstructed full-length UL19 with pp65 at an internal site, designated pSJM1965 
[panel(iv)].
Note, the diagrams are not drawn to scale
Figure 3.4: Sequence of Oligonucleotides 19C-T(1) and 
19C-T(2)
Xhol EcoRl
TCGAGCGCAAGACGCCCCGCGTCACCGGCGGAATTCAGTAGT
CGCGTTCTGCGGGGCGCAGTGGCGGCCTTAAGTCATCAGATC
R K T P R V T G G l  I Q *  xbsil
19C-T(1)
19C-T(2)
Figure 3.5: Sequence of Oligonucleotides 19N-T(1) and 19N- 
T(2)
EcoRV
M
Xhol EcoRl
ATCGCAATGCTCGAGCGCAAGACGCCCCGCGTCACCGGCGGAATTCAGG 19N-T( 1)
TAGCGTTACGAGCTCGCGTTCTGCGGGGCGCAGTGGCCGCCTTAAGTCCAGCT 19N-T(2)
R K V G G Q
AXho
Figure 3.4: This figure details the base pair and amino acid sequences which make 
up oligonucleotides 19C-T(1) and 19C-T(2). These oligonucleotides are for inserting 
the pp65 epitope tag (shown in the rectangle) at the C-terminus o f Xhol/Xbal 
digested pE19Bgl, to generate pSJM19N65.
Figure 3.5: This figure details the base pair and amino acid sequences which make 
up oligonucleotides 19N-T(1) and 19N-T(2). These oligonucleotides are for inserting 
the pp65 epitope tag (shown in the rectangle) at the N-terminus o f EcoRI/XhoI 
digested pE19Bgl, to generate pSJM19C65. This insertion results in the destruction 
o f the original Xhol site (ie AXhoI) and the generation o f a new Xhol site.
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Figure 3.6: Two primers, 35PCR (1) and 35PCR (2), were used to generate a PCR 
fragment encoding the UL35 ORF [panel (i)]. The complementary residues to the 
UL35 ORF, are indicated by the vertical lines. The PCR product was EcoRI/Xbal 
digested and ligated with EcoRI/Xbal pSJM19C65 [panel (ii)]. This resulted in the 
formation o f pE35Tl, which encodes the pp65 epitope sequence linked in-frame and 
up-stream o f the sequences encoding VP26.
This figure is not drawn to scale.
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oligonucleotides, 19C-T (1) and 19C-T (2) (figure 3.4), which also contained a stop 
codon and generated pSJM19N65 [figure 3.3, panel (ii)]. This construct contains the 
pp65 epitope tag sequences, linked to the 5’ 350 amino acids of the UL19 ORF. This 
generated a protein with the pp65 epitope at the C-terminus o f the N-terminal 1070 
amino acids of VP5.
(ii) N-terminal deletion
To produce an N-terminal deletion, use was again made of the Xhol site discussed 
previously. pE19Bgl was Xhol/EcoRV digested to remove the N-terminal 1123 bp 
sequences. This was replaced by two partially complementary oligonucleotides which 
destroyed the existing Xhol site and inserted a new one. These oligonucleotides, 19N-T 
(1) and 19N-T (2) (figure 3.5), also contained a start codon and generated pSJM19C65 
[figure 3.3, panel (iii)]. This construct contains the pp65 epitope tag sequences, linked 
to the 3’ 2961 nucleotides of the UL19 ORF. This generated a protein with the pp65 
epitope at the N-terminus of the C-terminal 987 amino acids of VP5.
2.3.2.3 pp65 Tagged Full-length VPS
The complete UL19 ORF containing the pp65 epitope tag was reconstructed by ligating 
the N- and C- terminal portions together [see figure 3.3, panel (iv)]. Firstly both 
pSJM19C65 and pSJM19N65 were EcoRI/Xbal digested and the appropriate fragments 
gel purified. The C-terminal portion released from pSJM19C65 (ie the smaller fragment 
consisting o f 3100 bp) was ligated with the N-terminus plus the vector fragment from 
pSJM19N65 (ie the larger fragment consisting of 4300 bp). This generated pSJM1965 
which contained the complete UL19 ORF with the pp65 epitope tag linked in frame at 
nucleotide 1070.
2.3.3 VP26
pSJM19C65 was used as a starting point for cloning VP26. The UL35 ORF was 
generated as a PCR product using oligonucleotides, 35PCR (1) and 35PCR (2), as 
primers [see figure 3.6, panel (i)].
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• 35PCR (1) corresponds to bases 4-25 o f the UL35 ORF (McGeoch et al, 1988) and 
incorporates an EcoRl site at the 5' end which is in the same frame as that in 
pSJM19C65.
• 35PCR (2) contains a Xbal site at its 5' end and is complementary to 20 bases down 
stream from the UL35 termination codon, between 70912-70932.
The UL35 PCR fragment was EcoRI/Xbal digested, gel purified and cloned into gel 
purified EcoRI/Xbal digested pSJM19C65 [figure 3.6, panel (ii)] to give pE35Tl [figure 
3.6, panel (iii)]. This generated VP26 tagged with the pp65 tag at its N-terminus.
3. Intracellular Distribution of Capsid Proteins
Immunofluorescence was performed on BHK C l3 cells as described in Methods, 
Section 2.6. To examine the intracellular distributions o f proteins, a series o f antibodies 
were used (see Materials, Section 1.10):
• LP12 for VP5 at 1:200 dilution
• 1060 for VP23 at 1:200 dilution
• 5010 for preVP22a at 1:100 dilution
• pp65 for pp65 epitope tagged clones at 1:300 dilution
• 5/24 supernatant for CAT208 epitope tagged clones at 1:32 dilution
• CAT208 for CAT208 epitope tagged constructs at 1:10, 1:100, 1:500— 
dilutions
• 20999 for preVP22a at 1:50 dilution
• FITC-GAM an anti-mouse antibody at 1 GOO dilution
• TRITC-GAR an anti-rabbit antibody at 1:100 dilution
• GAM-HRP an anti-mouse antibody at 1 GOO dilution
— rabbit
secondary
antibody
i— mouse
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Figure 3.7: Intracellular Distribution of 
VP19c
Figure 3.7: Cells were transfected with plasmid pE38Tl (VP19cpp65) and detected 
using the primary antibody, pp65 (1:300). Protein was visualised with FITC-GAM 
antiserum (1:100). VP19cpp65 was detected in the nuclei.
Magnification = x200
Figure 3.8: Intracellular Distribution of
VP23 and VP5 Alone
Figure 3.8: Cells were transfected with plasmids pE18 (VP23) [panel (i)], pE19 
(VP5) [panel (ii)] or, pSJM1965 (VP5pp65) [panel (iii)]. The distribution o f VP23 
was detected using the primary antibody 1060 (1:200), with VP5 and VP5pp65 
detected with LP12 (1:200) and pp65 (1:300) respectively. Proteins were visualised 
with FITC-GAM antiserum (1:100) and all were detected throughout the cell.
Magnification = panel (i) and panel (ii) x80
panel (iii) x260
Figure 3.9: Redistribution of VP5 and VP23 by
VP19c
(i)
Figure 3.9: Cells were co-transfected with plasmid pE38Tl (VP19cpp65) and either 
pE19 (VP5) [panel (i)] or pE18 [panel (ii)]. The distribution o f VP5 was detected 
using the primary antibody LP12 (1:200) with VP23 detected with 1060 (1:200). 
Proteins were visualised with FITC-GAM (1:100) and were detected in the nucleus 
in each case.
Figure 3.10: Redistribution of VP5pp65 to the
Nucleus by preVP22a
(i)
(ii)
' i
Figure 3.10: Cells were co-transfected with pSJM1965 (VP5pp65) and pJK2 
(preVP22a). Panels (i) and (ii) represent duplicate exposures of a single field. The 
distribution of VP5pp65 was detected using the primary antibody, pp65 (1:300) and 
preVP22a was detected with antibody 20999 (1:100). VP5pp65 was visualised with 
FITC-GAM (1:100) [panel (i)] and preVP22a was visualised with TRITC-GAR 
(1:100) [panel (ii)]. The proteins co-localised to the nucleus.
Magnification = x200
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3.1 Distribution of VP19c
As there was no antibody against VP 19c, the epitope tagged version pE38Tl was used 
in fluorescence studies. Following transfection and staining, VP 19c was found to be 
localised predominantly in the nucleus of infected cells (figure 3 .7).
3.2 Infiuence of VP19c on the Distribution of VP5 and VP23
Previous authors had shown that when VP5 and VP23 were expressed singly or co­
transfected in combination, they were seen distributed throughout the cell (Nicholson et 
al, 1994). The distribution patterns observed previously for the two proteins was 
confirmed in this study [figure 3.8, panels (i) and (ii)], which also showed that the pp65 
tag did not alter the distribution of VP5 [figure 3.8, panel (iii) shows a representative 
example]. To monitor the effect of the influence of VP 19c on the distribution of these 
two proteins, several co-localisation experiments were carried out.
3.2.1 VP19c + VP5
When pE38 (VP 19c) or pE38Tl (VP19cpp65) was co-transfected with pE19(VP5), 
VP5 localised to the nucleus. VP5 was observed with a distinctive punctate pattern 
[figure 3.9, panel (i)], indicating that the proteins had aggregated in the nucleus of 
infected cells. Exactly the same pattern of interaction was observed when pSJM1965 
was co-transfected with pE38 (not shown).
3.2.2 VP19c + VP23
When pE38 (VP19c) or pE38Tl (VP19cpp65) was co-transfected with pE18 (VP23), 
like VP5, the VP23 localised to the nucleus. Flowever, in contrast to the pattern 
observed with VP5, VP23 was uniformly distributed throughout the nucleus, although 
absent from the nucleoli [figure 3.9, panel (ii)].
3.3 Influence of preVP22a on the Distribution of VP5
Nicholson et al (1994) had shown that when VP5 was co-expressed with preVP22a, the 
VP5 co-localised to the nucleus with the preVP22a protein. A similar transfection was 
performed using pSJM1965 (VP5pp65). pSJM1965 was co-transfected with pJK2 
(preVP22a) and both proteins were found to be localised to the nucleus [see figure 3.10, 
panels (iii) and (iv)] confirming the data obtained by Nicholson et al.
Figure 3.11: Intracellular Distribution of VP26
(i)
(iii)
Figure 3.11: Cells were either infected singly with plasmid pE35Tl (VP26pp65) 
[panel (i)] or, co-transfected with pJK2 (preVP22a) [panels (ii) and (iii) represent 
duplicate exposures o f a single field]. The distribution of VP26pp65 was detected 
using the primary antibody, pp65 (1:300), with preVP22a detected with 20999 
(1:100). VP26pp65 was visualised with FITC-GAM (1:100) [panels (i) and (ii)] and 
was detected predominately in the cytoplasm in each case. preVP22a was visualised 
with TRITC-GAR (1:100) [panel (iii)] and was detected in the nucleus.
Magnification = x200
Figure 3.12: Redistribution of VP26 to the
Nucleus
Figure 3.12: Cells were co-transfected with plasmid pE35Tl (VP26pp65) with 
either pE19 (VP5) and pJK2 (preVP22a) [panels (i) and (ii) represent duplicate 
exposures of a single field] or, pE19 (VP5) and pE38 (VP 19c) [panel (iii)]. The 
distribution of VP26pp65 was detected using the primary antibody, pp65 (1:300), 
with preVP22a detected with 20999 (1:100). VP26pp65 was visualised with FITC- 
GAM (1:100) [panels (i) and (iii)] and was detected in the nucleus in each case. 
preVP22a was visualised with TRITC-GAR (1:100) [panel (ii)] and detected in the 
nucleus.
Magnification = x200
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3.4 Distribution of VP26
J Tatman had previously shown that when VP26, expressed from pE35, was detected 
with an anti-VP26 rabbit antibody, trpE-UL35, the protein was present throughout the 
entire cell, predominantly in the cytoplasm (Tatman, 1996). This indicated that the 
protein had no nuclear targeting signal. This contrasts strongly with the exclusively 
nuclear localisation observed by McNabb and Courtney (1992) using the same antibody 
on HSV infected cells.
When VP26 (pE35Tl) containing the pp65 epitope tag was transfected singly into cells 
and detected with the pp65 mouse monoclonal antibody, it was found to be distributed 
throughout the cell but, predominately in the cytoplasm, confirming the data o f Tatman 
[figure 3.11, panel (i)]. This showed that the epitope tag did not interfere with normal 
protein expression and behaviour.
3.4.1 Influence of Other Capsid Protein on the Distribution of VP26
VP26pp65 (pE35Tl) did not change its distribution when it was co-transfected with any 
one of the other capsid proteins; VP23, VP5, VP 19c or preVP22a. Figure 3.11 shows a 
typical example of the pattern observed, with VP26 found predominately in the 
cytoplasm and preVP22a localised to the nucleus [panels (ii) and (iii) respectively].
Since VP5, VP23 and VP26 all had very similar distribution patterns, it was impossible 
to determine, from this experiment, if the VP26 protein was co-localising and therefore 
interacting with either of these proteins.
3.4.2 Localisation of VP26 to the Nucleus
Multiple co-transfection assays were performed using all available combinations of 
capsid proteins to try and identify conditions under which VP26 would be localised to 
the nucleus. This revealed that the only conditions under which VP26 was translocated 
to the nucleus, was when VP5 (pE19) was also present in the nucleus.
When VP26 was co-transfected with VP5 and either preVP22a [figure 3.12, panels (i) 
and (ii)] or VP 19c [figure 3.12, panel (iii)], it was transported to the nucleus. Also, the
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Figure 3.13: Intracellular Distribution of VP5N65
and VP5C65
(i) VP5N65
(ii) VP5C65
Figure 3.13: Cells were co-transfected with either pSJM19N65 (VP5Npp65) and 
pJK2 (preVP22a) (panel (i), A and B represent duplicate exposures of a single field), 
or, pSJM19C65 (VP5Cpp65) and pJK2 (preVP22a) (panel (ii), C and D represent 
duplicate exposures o f a single field). The distribution of VP5Npp65 and VP5Cpp65 
was detected using the primary antibody, pp65 (1:300) and preVP22a was detected 
with 20999 (1:100). VP5pp65 (panel A) and VP5Cpp65 (panel C) were visualised 
with FITC-GAM (1:100) and found to be present throughout the cell. preVP22a 
(panels B and D) was visualised with TRITC-GAR (1:100) and found to be present 
in the nucleus.
Magnification = x260
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pattern o f interaction closely mapped that exhibited by VP5 (compare with figure 3 .9). 
Therefore, VP26 was uniformly present throughout the nucleus, except the nucleoli, 
when preVP22a was present however, defined spots were visible when VP 19c was 
included instead of preVP22a.
3.5 Distribution of N- and C- Terminal Deletions of VP5
When either the C-terminal deletion (pSJM19C65) or N-terminal deletion (pSJM19N65) 
o f VP5 were expressed singly, they were found distributed throughout the cell, 
sometimes absent from the nucleus (not shown). However, in contrast to the full length 
version of VP5, when either of the terminal deletions (VP5N65 or VP5C65) were 
expressed in combination with either preVP22a or VP 19c, they failed to co-localise to 
the nucleus (see figure 3.13)
4. Discussion of Immunofluorescence Data
As HSV-1 capsid assembly occurs in the nucleus of cells it is not surprising that many 
researchers have found the capsid proteins predominantly in the nucleus o f infected cells 
(Powell & Watson, 1975; Cohen et al, 1980; McNabb & Courtney, 1992). However, 
results presented in this chapter, together with data from Nicholson et al (1994) show 
that the concentration of capsid proteins in the nucleus is a result of multiple protein- 
protein interactions. It can also be concluded that, as the same pattern o f interaction was 
observed when the pp65 epitope tag was present or absent, there was no interference 
with normal protein-protein interactions attributable to the tag.
preVP22a and VP 19c each appear to carry an inherent nuclear localisation signal (NLS). 
The NLS of either has not been definitively mapped. NLS are often carried within 
hydrophilic regions o f a protein. For example, the T antigen of SV40 has a NLS defined 
by 7 amino acids, ie Pro-Lys-Lys-Lys-Arg-Lys-Val. Within this sequence there are 5 
consecutive positively charged residues. Within preVP22a, there is an area at 
approximately amino acid 120, which encodes Lys-Arg-Arg-Arg-Arg and could 
constitute a NLS. Similarly, within VP 19c there is an area at approximately amino acid 
415, which encodes Arg-Gln-Arg-Gln-Arg-Arg and this could also constitute a NLS.
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Other capsid proteins do not appear to carry their own NLS. Neither VP5 or VP23 have 
a clear NLS and are concentrated in the nucleus when they are co-transfected with 
preVP22a or VP 19c, indicating that their redistribution is the result o f a complex 
formation. However, when each protein is co-transfected with VP 19c, their nuclear 
distribution pattern significantly varies, with VP5 having a punctate appearance and 
VP23 appearing as uniform. This data strongly suggests that VP5 and VP23 are each 
exerting some influence on the distribution of VP 19c within the nucleus.
EM examinations o f insect cells infected with recombinant baculoviruses expressing 
combinations of VP 19c, VP5 or VP23, go some way to explaining these different 
distribution patterns. F Rixon and J Tatman (Rixon et al, 1996) analysed complexes 
formed when Sf cells were infected with AcUL18 (VP23), AcUL19 (VP5) and AcUL38 
(VP 19c) combinations. They found no novel structures when AcUL18+AcUL19 or 
AcUL18+AcUL38 were co-infected. However, co-infections of AcUL19+AcUL38 
resulted in the formation of a large number o f densely staining particles, distinct from 
recombinant capsids. The particles were uniform, and formed a basic capsid-like shell. 
The were initially identified as having a diameter of 70nm. Subsequent cryo-EM analysis 
has shown them to be basically icosahedral with a diameter of 880A and T=7 symmetry 
(Saad et al, 1999). (This aspect is discussed fully in Chapter 6 discussion.) These 
particles were present throughout the nucleus, frequently in large clusters. The clusters 
presumably account for the patchy and punctate distribution observed by VP5+VP19c 
immunofluorescence staining.
VP26 was only present in the nucleus when VP5 is also there and was not influenced by 
preVP22a or VP 19c alone. This pattern of interaction provides evidence that a direct 
interaction between VP5 and VP26 is occurring and is consistent with the finding that 
VP26 is present on the tips of the VP5 hexons (Booy et al, 1994; Trus et al, 1995; Zhou 
et al, 1994; 1995).
As VP5 is the major capsid protein, constituting 60-70% of the capsid mass, it is not 
surprising to find that this protein forms multiple interactions. In summary, VP5 can 
form complexes with VP26, VP 19c and preVP22a and effect their redistribution.
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However, the lack of interaction between VP5 and VP23 (Section 3.2) was surprising in 
view o f the fact that this protein constitutes part o f the triplex complex which links 
adjacent capsomeres (Newcomb et al, 1993). The absence of a VP5-VP23 interaction is 
consistent with the findings o f Nicholson et al (1994) and the lack o f visible structures in 
electron micrographs of baculoviruses expressing VP5 and VP23 (Rixon et al, 1996). 
Furthermore, the presence of VP5-VP19c 880qm particles (Rixon et al, 1996) suggests 
that VP23 is not essential for the interaction of the triplex with the capsomere but, VP23 
(together with VP5, VP 19c and the scaffold proteins) is essential for intact capsid 
formation (Desai et al 1993). It would seem likely that the binding of VP23 to VP 19c 
exerts a change in conformation of VP 19c which modulates the structural integrity of 
the capsid. It may be that VP23 can interact with VP5 but only in the context of an 
intact capsid.
A second surprising finding was that neither the N- and C- terminal deletions o f VP5 
were able to localise to the nucleus with VP 19c or preVP22a. This indicates that either:
• neither the N- nor C-terminal portions alone are sufficient to interact with preVP22a 
or VP19c.
•  the vital binding site has been disrupted during the cloning of the deletion mutants. As 
the full length tagged version of VP5, made by ligating the two terminal portions 
together, behaved like wild type VP5, inaccurate flanking sequences or cloning errors 
were not responsible for the lack of redistribution of either the N- or C- terminal 
portions.
•  the N- or C-terminal portions expressed alone do not have the same secondary 
structure as the N- and C-terminal portions expressed together in the complete VP5 
molecule, ie the deletion mutants are misfolded .
Certainly it is known that only a small portion of preVP22a (25 amino acids) is 
necessary its for interaction with VP5 (Kennard et al, 1995; Mastusick-Kumar, 1995; 
Thomsen et al, 1995; Hong et al, 1996) and recent cryo-EM data (Chapter 6 and Zhou 
et al, 1998a) has confirmed this. As no protein-protein interactions were evident with
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either o f these large terminal portions of VP5, it seems probable the conformation 
adopted by the intact molecule is needed for the protein to bind to other capsid proteins.
Obviously protein-protein interactions which occur in the capsid are extensive and 
complex. From this analysis, it is clear that proteins can exert an influence upon one 
another’s location and distribution patterns within an infected cell.
5. Production and Analysis of a New Epitope Tag, Chloramphenicol 
Acetyl Transferase (CAT)
5.1 Introduction
Since the pp65 tag was only available commercially and the supply was subject to some 
uncertainty, it was decided that it would be useful to map another epitope tag. There 
were several reasons for this line of thinking:
• The sequence could be incorporated into a cloning vector and used as an epitope tag.
• The new epitope could be synthesised as an oligopeptide and injected into rabbits to 
generate polyclonal antibodies for double labelling experiments.
• There would be a reliable source of antibody, over a long period of time with no 
concerns as to whether a company would continue to supply it.
•  Production of an anti-tag antibody in-house was a more economical alternative.
The Chloramphenicol Acetyl Transferase (CAT) protein was chosen for this purpose. 
This protein was ideally suited as the source of a tag as the enzyme is totally foreign to 
HSV-l and mammalian cells and so it was unlikely that the antibody would interact non- 
specifically with viral proteins. Also, there was a strong mouse monoclonal antibody 
available, 5/24, which could be used in the mapping procedure. This antibody was 
supplied by Dr Susan Graham who had shown it to work efficiently in Western blots.
The epitope was mapped using the SPOTscan technique which is fully described in 
Methods, Section 2.11. The SPOTscan technique is based on the Merrifield principles
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Figure 3.14: Schematic Representation of Stepwise 
Synthesis of Oligopeptides
(i) Nature's Way (ii) Laboratory Way
A + B
I
D + E
I
A-B + C
I
t
C + D-E
I
t
A-B-C + D 
I
t
B + C-D-E
I
▼
A-B-C-D +E 
I
\
A + B-C-D-E 
I
▼
a -b -c -d -e
▼
A-B-C-D-E
Figure 3.14: The figure shows a schematic representation o f stepwise oligopeptide 
synthesis. A, B, C... etc represent individual amino acids. The N-terminus is written on 
the left and the C-terminus on the right. Panel (i) shows stepwise synthesis from the N- 
to C- terminus and represents the normal process o f protein synthesis on an mRNA 
template. Panel (ii) shows stepwise synthesis from the C- to N-terminus and represents 
the most common route followed by chemical synthesis.
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(Merrifield, 1964) of solid phase oligopeptide synthesis. Merrifield proposed that an 
oligopeptide could be synthesised by attaching one end to a solid and stable surface (in 
this instance a nitrocellulose membrane) and elongating the chain in a stepwise manner. 
In this instance 9-fluorenylmethyloxycarbonyl (F-moc) amino acid anhydrides were used 
to synthesise the oligopeptides. The initial amino acid was anchored to a nitrocellulose 
membrane through an ester bond. The oligopeptide chain was extended by cleaving the 
F-moc protecting group, to create an active site, and adding the next amino acid in the 
sequence. A series of deprotection, washing and coupling steps were repeated for each 
succeeding amino acid, until the desired sequence was assembled.
In nature, proteins are synthesised from the amino terminus [see figure 3.14, panel (i)]. 
This strategy is not used in the laboratory, where elongation occurs from the carboxyl 
terminus [see figure 3.14, panel (ii)]. This is because commercially available chemicals 
make it easier to assign a permanent protecting group to the carboxyl function and 
temporary protecting groups to the amino groups. The temporary protecting groups are 
removed at intermediate stages for the subsequent addition of residues.
A series o f overlapping oligopeptides, spanning the entire sequence of CAT, were 
assembled on the membrane. They were assayed for their immunological activity and the 
positive SPOTs aligned to the sequence to identify the epitope site.
5.2 Optimisation of CAT Protein and 5/24 Antibody
Before the SPOTs mapping procedure could be performed, it was first necessary to 
optimise the conditions under which the mouse monoclonal antibody (5/24) would be 
active against the CAT protein. This was determined by ELISA reactions which are 
detailed in the following sections.
5.2.1 Optimisation of CAT protein
The CAT protein was used to coat microtitre wells and the system was optimised by 
testing a range of CAT protein concentrations against a range o f antibody 
concentrations. The CAT protein was tested at various dilutions from 5000ng to 5ng per 
well. The 5/24 antibody was available in two forms, ammonium sulphate purified
A 
40
5
Figure 3.15: Optimisation of CAT Protein to the 5/24 
Monoclonal Antibodies
(i): Optima! Concentration of CAT Protein Against Purified (1:10) 
and Supernatant (1:8) 5/24 Antibody
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Figure 3.15: This figure shows a summary of the data obtained when optimising the 
concentration of CAT protein to be used in ELISA reactions. Panel (i) shows the signal 
obtained with the various concentrations of CAT protein (x-axis) and the two antibody 
preparations. This pattern was seen when the purified antibody was reacted at a 1:10 
dilution (blue line) and the supernatant antibody was reacted at 1:8 dilution (pink line). 
The concentration of CAT protein chosen to be used in the assay system was 50ng/well. 
Therefore, the different antibody concentrations were assayed against 50ng of CAT 
protein, as shown the subsequent panels. Panel (ii) shows the absorbance obtained with 
o f various dilutions o f purified 5/24 antibody and panel (iii) shows the absorbance 
obtained with various dilutions of supernatant 5/24 antibody.
Figure 3.16: Optimisation of 5/24 Monoclonal Antibodies to 
50ng of CAT
(i): Optimisation of Purified 5/24 to 50ng of CAT
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Figure 3.16: This figure shows the A405 values obtained from testing a series of 
dilutions of both the purified [panel (i)] and supernatant [panel (ii)] 5/24 antibody, 
against 50ng of CAT protein. From panel (i) it is evident that the dilution o f purified 
antibody which gave the highest absorbance reading was 1:8. However, panel (ii) 
shows that the supernatant antibody can be diluted to 1:32 to give a similar optimal 
absorbance value.
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Methods, Section 2.12) and supernatant fractions. The purified antibody was 
sequentially diluted ten-fold from 1:10 to 1:100 000. The supernatant antibody was also 
diluted two-fold from neat to 1:32. The diluted antibodies were tested against the 
various dilutions of protein.
A large bank of data was obtained from these experiments and many graphs were 
plotted to determine the optimum CAT protein concentration required to coat the 
microtitre wells. However, only the relevant graphs are shown in figure 3.15. From the 
data obtained in these experiments, it was determined that a 1:8 dilution of supernatant 
5/24 and a 1:10 dilution of purified 5/24 reacted well, giving good response curves to a 
range of CAT protein dilutions, see panel (i).
There was a significant antibody-protein interaction detected when the CAT protein was 
used at 50-500ng/well. It was decided that 50ng/well would be designated as the 
standard concentration of protein to be used in the reactions as the increased value at 
500ng did not warrant lOx more protein being used per reaction.
5.2.2 Optimisation of 5/24 Antibody to 50ng of CAT Protein
The initial bank of experiments (described above) did not allow the optimal antibody 
dilutions to be determined from the range tested. Panels (ii) and (iii) o f figure 3.15 show 
the activities of various dilutions o f purified and supernatant antibody to 50ng of CAT 
protein. The experiment was extended to encompass a greater range of test antibody 
dilutions.
Both supernatant and purified forms of 5/24 were re-tested in an ELISA against 50ng of 
CAT protein. The antibodies were diluted 2-fold in PBS from neat to 1:32768. The 
results o f the assays are shown in figure 3.16.
When comparing panel (i) and (ii), it is evident that the supernatant antibody is more 
reactive against the CAT protein as it has the greatest absorbance at the lowest dilution. 
The supernatant was most active at 1:32 dilution, whereas the maximum activity
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Figure 3.17: For the SPOTscan Procedure; PC Generated 
Oligopeptide List and Pipetting Schedule for the CAT 
Sequence
(i) CAT Amino Acid Sequence
Sequence length: 219
Oligopeptide Length: 9
Offset: 1
Total number o f oligopeptides: 211
I oligopeptide 3 
I oligopeptide 2 |
oligopeptide 1 1
1: MEKKITGYTT VDISQWHRKE HFEAFQSVAQ CTYNQTVQLD
41: ITAFLKTVKK NKHKFYPAFI HILARLMNAH PEFRMAMKDG
81: ELVIWDSVHP CYTVFHEQTE TFSSLWSEYH DDFRQFLHIY
121: SQDVACYGEN LAYFPKGFIE NMFFVSANPW VSFTSFDLNV
161: ANMDNFFAPV FTMGKYYTQG DKVLMPLAIQ VHHAVCDGFH
2 01: VGRMLNELQQ YCDEWQGGA
(ii) Excerpt from PC Generated Oligopeptide List
SPO T/ Mr Sequence
Oligopeptide No.
1 1070 MEKKITGYT
2 1040 EKKITGYTT
3 1010 KKITGYTTV
4 997 KITGYTTVD..
208 1212 LQQYCDEWQ
209 1156 QQYCDEWQG
210 1084 QYCDEWQGG
211 1027 YCDEWQGGA
(iii) Excerpt from PC Generated Pipetting Schedule
Cycle 1
Amino SPOT Number 
Acid
A 1621 35 50 56 61 68 117 124 139 153 180 186 211
C 23 83 11 81 88 204
D 4 32 71 78 103 104 115 149 156 173 189 205 
E 12 15 64 73 89 92 100 121 132 199 206
F 14 17 36 47 51 65 87 94 105 108 126 130 135 136 145 148 158 159
163 191 ................
W 8 77 98 142 207 
Y 25 48 84 101 112 119 125 168 169 203
Figure 3.17: This figure details the information fed into the SPOTs programme and the 
data generated from the SPOTscan programme. Panel (i) shows the data generated from 
feeding the CAT amino acid sequence into the programme, together with the desired 
offset o f each oligopeptide. Panel (ii) shows an excerpt from the list, generated by the 
programme, detailing the molecular weight and amino acid sequence for each SPOT or 
oligopeptide. Panel (iii) shows an excerpt o f the pipetting schedule which was followed 
during Cycle 1, ie addition o f the initial amino acid in the chain. This schedule details 
which amino acid should be added to which SPOT, to generate the correct oligopeptide 
sequence.
Figure 3.18: SPOTs Membranes
(0
vii
(iii)
Figure 3.18: Three nitrocellulose membranes containing the nonopeptides, 1 to 211, 
[panels (i), (ii) and (ii)] were probed with the primary antibody 5/24 (1:32) and 
visualised with the secondary antibody GAM-HRP (1:100). SPOT numbered 208 
[panel (iii)] was significantly darker than the others, indicating a positive SPOT- 
antibody interaction. This SPOT was designated CAT208.
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observed for the purified antibody was at a 1:8 dilution [this was a reduction in activity 
from the previous experiment, see figure 3.15, panel (ii)].
Some more supernatant was subsequently purified by ammonium sulphate precipitation, 
but again a similar pattern o f activity was observed (results not shown). It was also 
reported by J Leslie (personal communication) that the purified anti-CAT antibody was 
extremely unstable and lost considerable activity upon storage. This also appears to be 
the case here. It was therefore decided to use the supernatant antibody, at 1:32 dilution, 
for immunological analysis of the oligopeptides on the SPOTs membrane.
5.3 Generation of Oligopeptides by SPOTscan Methodology
The CAT protein sequence is 219 amino acids in length [see figure 3.16, panel (i)] and 
was entered into the SPOTs programme on the PC to generate a list [figure 3.17, panel 
(ii)] and a pipetting schedule [figure 3.17, panel (iii)], for the synthesis of 211 
oligopeptides, each containing 9 amino acids, which spanned the entire sequence of 
CAT and overlapped by a single amino acid residue.
The oligopeptides were generated on the membrane by adding each amino acid to the 
appropriate SPOT in a duplicate cycle, to double couple the reaction. Between each 
cycle the membranes were washed, protected and deprotected (see Methods, Section 
2 . 11).
5.4 Antibody Assay of SPOTs Oligopeptides
Once the nonapeptides had been synthesised, the membrane was washed and the 
supernatant antibody, at 1:32 dilution, was added, allowed to react for 4h and washed. 
The secondary GAM-HRP antibody was added for 2h, washed and the reaction 
developed with the kit signal developer. After a 2h development period, SPOT 208 was 
significantly darker than the others (see figure 3.18) indicating that a positive 
oligopeptide-antibody reaction was occurring.
The membrane was stripped and the antibodies reacted as before and again the SPOT 
208 was clearly darker (data not shown), confirming that this oligopeptide, CAT208,
1 :
4 1 :
8 1 :
121
1 6 1
201
Figure 3.19: Position of CAT208 within the Amino Acid 
Sequence
MEKKITGYTT
ITAFLKTVKK
ELVIWDSVHP
SQDVACYGEN
ANMDNFFAPV
VGRMLNELQQ
VDISQWHRKE
NKHKFYPAFI
CYTVFHEQTE
LAYFPKGFIE
FTMGKYYTOG
YCDEWQGGA
HFEAFQSVAQ
HILARLMNAH
TFSSLWSEYH
NMFFVSANPW
DKVLMPLAIQ
CTYNQTVQLD
PEFRMAMKDG
DDFRQFLHIY
VSFTSFDLNV
VHHAVCDGFH
4
CAT208
Figure 3.19: The position o f oligopeptide 208, termed CAT208 within the complete 
CAT sequence is highlighted. This sequence reacted with the 5/24 anti-CAT antibody 
and is shown in the rectangle, between amino acids 207 and 216, near the C-terminus.
Table 3.1: Summary of 1013 Oligopeptide Sequences
Name Sequence Length (amino acids)
1013a LQQYCDEWQ 9
1013b LQQYCDEWQGGA 12
1013c LQQYCDEWQGGAG 13
1013d LNELQQYCDEWQGGA 15
Table 3.2: Summary of 1013 Oligopeptide Analysis
Name Cleavage
Condition
s
Predicted
Yield
(mg)
Actual
Yield
(mg)
Solubility Purity
(%)
1013a Reagent
K
18 . 91 6.80 dH20 62
1013b Reagent
K
21.80 6.54 dH20 + 
ammonia
1013c Reagent
K
22.69 5.78 dH20 + 
ammonia
46
1013d Reagent
K
27.36 7.72 dH20 + 
ammonia
52
1013c.2 Trp
Mixture
22.69 8.26 dH20 + 
ammonia
89
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was interacting with the antibody and so probably constituted the epitope site, or at least 
part o f it.
From the sequence data CAT208 corresponded to the sequence LQQYCDEWQ, 
present near the carboxy-terminus of the protein between amino acid 208 and 216 
(figure 3.19).
5.5 Oligopeptide Synthesis of CAT208
The positive nonapeptide CAT208 was synthesised on the PSSM-8 synthesiser on 4- 
branched TGA resin. This resin was selected as it produces multiple antigenic peptides 
MAP). The multimeric oligopeptides are more immunogenic, and so produce better 
antibodies, than the simple monomeric sequence alone. Three other oligopeptides were 
synthesised in parallel, which incorporated additional amino acid sequences on either 
side o f the proposed epitope (see Table 3.1). Oligopeptide 1013a constituted the 9 
amino acids only, oligopeptide 1013b had 3 additional amino acids at the C-terminus, 
oligopeptide 1013c had an additional 4 amino acids at the C-terminus and oligopeptide 
1013d had 3 additional amino acids at both the N- and C-terminus. These sequences 
were incorporated as it was possible that the epitope extended further than the nine core 
amino acids but, had not been picked up by the antibody assay of the SPOTs membrane, 
as the reaction was too weak.
These oligopeptides were cleaved in reagent K (as described in Methods, Section 2.4.2). 
Oligopeptide 1013a was the only oligopeptide which dissolved well in dH20 . 1013b, 
1013c and 1013d were negatively charged overall and dissolved in dH20  when ammonia 
was bubbled through them. The oligopeptides were dried down and their Mr analysed by 
mass spectrometry. All the oligopeptides were reasonably pure except 1013b (see table
3 .2) which, after several separate analyses, produced only random or nonsense readings, 
indicating that it was very impure. Several re-syntheses of the oligopeptide gave similar 
results (data not shown), indicating that this oligopeptide may be very unstable. It was 
therefore decided to proceed with the analysis of the oligopeptides, using only 1013a, 
1013c and 1013d.
A 
40
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3.20: Reactivity of Oligopeptides 1013 with 5/24 Antibody
Supernatant
(i): Reactivity of Oligopeptide 1013a with 5/24 Supernatant (1:32)
0.14
0.12
0.1
0.08o■'tf-
<  0.06
0.04
0.02
0
0 5 25 50 500
Concentration of Peptide 1013a (ng)
(ii): Reactivity of Oligopeptide 1013c with 5/24 Supernatant (1:32)
0.9
0.8
0.7
0.6
0 .4
0.3
0.2
0.1
0
0 25 505 500
Concentration of Peptide 1013c (ng)
(iii): Reactivity of Oligopeptide 1013d with 5/24 Supernatant (1:32)
0.3
0.25
0.2
0.15
0.1
0 .05
0
0 5 25 50 500
Concentration of Peptide 1013d (ng)
Figure 3.20: The A405 values o f oligopeptides 1013a, 1013c and 1013d, panels (i)
(ii) and (iii) respectively, to the 5/24 antibody supernatant at a 1:32 dilution. Note 
the differing scales on the y-axis.
A 
40
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Figure 3.21: Reactivity of Oligopeptide 1013c.2 with 5/24
Antibody Supernatant (1:32) Compared to Controls
0.6
0.5
0.4
0.3
0.2
0.1
Concentrator! of Peptideo 500
(ng/well)
-♦— P ep tid e  1013c.2  v 5/24  
(1:32)
C ontrol RT60 v 5 /24  (1;32) 
-O—  1013 c .2 v  con tro l S n
Figure 3.21: This figure shows the level o f Absorbance (4o5) detected when 
oligopeptide 1013c.2 and antibody 5/24 were reacted together and with a series o f 
controls. The blue line shows the A405 when 5/24 antibody supernatant, at 1:32 
dilution, was reacted with oligopeptide 1013c.2. The pink line shows the level o f 
A 4 0 5  detected when the 5/24 antibody was reacted with an unrelated control 
oligopeptide, RT60. The green line shows the A405 values obtained when 
oligopeptide 1013c.2 was reacted with an unrelated antibody, Sn.
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therefore decided to proceed with the analysis of the oligopeptides, using only 1013a, 
1013c and 1013d.
5.6 Reactivity of CAT208 Oligopeptides (1013a, 1013c, 1013d) with 5/24 
Antibody Supernatant
To confirm that the sequence mapped from the SPOTscan procedure was indeed the 
epitope of the 5/24 antibody, a series of ELISA reactions were performed with the 5/24 
antibody supernatant, at 1:32 dilution, and the oligopeptides 1013a, 1013c and 1013d. 
The results are detailed in figure 3.20, panels (i) to (iii).
Oligopeptide 1013a [panel (i)] did not react well with the antibody and the absorbance 
values were very low. This may be because the oligopeptide is so short and therefore not 
entirely exposed from the resin core. Similarly 1013d [panel (iii)] did not react well with 
the antibody, with the maximum absorbance value being only marginally higher. On the 
other hand, oligopeptide 1013c [panel (iii)] reacted efficiently with 5/24. The additional 
amino acid residues at the C-terminus of this oligopeptide, compared to 1013a, may be 
pushing the oligopeptide further out from the core so that it is more exposed and able to 
interact with the antibody successfully.
5.6.1 Confirmatory Analysis of Oligopeptide 1013c
As the initial synthesis had produced a lower than expected yield and purity of 
oligopeptide 1013c, it was re-synthesised to generate oligopeptide 1013c.2 (see table
3.2). As the sequence of 1013c.2 contained a tryptophane it was decided that an 
alternative cleavage mixture from Reagent K, specific to oligopeptides containing this 
amino acid, would be used to try and increase the yield (see Methods, Section 2.4.2). 
This time the oligopeptide was found to be 89% pure by mass spectrometry analysis. 
The activity of oligopeptide 1013c.2 was confirmed in a series of ELISA's. The 
oligopeptide activity was compared against two unrelated controls, a control 
oligopeptide (RT60 - supplied by K McCauley) and a control mouse monoclonal 
antibody (Sn - supplied by S Graham). The results are shown in figure 3.21, where it is 
clearly evident that the control oligopeptide is not cross-reacting with the 5/24 antibody 
and similarly the control antibody is not cross-reacting with CAT208 oligopeptide
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Table 3.3: Inoculation Schedule for the Production of Rabbit 
Polyclonals to oligopeptide 1013c.2
Inoculation Time (days)
Oligopeptide 1013c.2 + Freund's complete adjuvant 0
Oligopeptide 1013c.2 + Freund's incomplete adjuvant 15
Oligopeptide 1013c.2 + Freund's incomplete adjuvant 31
Oligopeptide 1013c.2 + Freund's incomplete adjuvant 78
Oligopeptide 1013c.2 + Freund's incomplete adjuvant 107
bleed rabbits 121
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epitope sequence against the mouse monoclonal antibody, 5/24, is contained within the 
amino acid residues LQQYCDEWQGGAG.
5.7 Production of Rabbit Polyclonal Antibodies to CAT208 Oligopeptide 
1013c.2
To try to generate rabbit polyclonal antibodies against the CAT epitope, oligopeptide 
1013c.2 was injected intramuscularly into 2 rabbits. All the animal work was performed 
by Gillian McVey and the inoculation schedule is shown in table 3.3.
The final bleed was taken and the blood allowed to clot. The rabbit blood clots were 
pelleted and the supernatant fractions tested in a series of ELISA reactions against 
oligopeptide I0l3c.2. No activity was detected at any dilution, from neat to 1:32768 
with either rabbit supernatant fractions. A proportion of each antibody supernatant was 
purified by ammonium sulphate precipitation (Methods, Section 2.12) and again tested 
in a series of ELISA reactions against oligopeptide 1013.2. Still no activity was evident 
(data not shown).
pE35T2 (for description see below, Section 5.8) was used in Western blot analysis 
against both purified and supernatant rabbit antibody fractions. No protein-antibody 
activity was detected (data not shown). The rabbit supernatants were also tested against 
a series of CAT tagged proteins (see Section 5.8) by immunofluorescence labelling. No 
specific labelling was observed, with only a large background of fluorescence picked up.
It can be concluded that no rabbit antibody against CAT208 was produced from either 
of the two rabbits injected with oligopeptide 1013.2. This suggests that the oligopeptide 
may be poorly immunogenic.
5.8 Construction of Plasmids Expressing CAT208
Before it was known that attempts to produce a rabbit antibody against the CAT epitope 
had failed, a series o f constructs encoding the tag sequence were made. Due to the 
nature o f the cloning strategy employed for making constructs containing the pp65
Figure 3.22:Construction of CAT208 Epitope Tagged UL19 
(VP5) and UL35 (VP26) in pCMVIOBglAEco
(i) Sequence of Oligonucleotides XcatE(1) and XcatE(2)
Xhol Seal
TCGAGCTACAACAGTACTGTGACCAATGGCAGGG XcatE(l)
G CA TG TTG TCA TG A C A CTG CTTA C CG TCC CTTA A  XcatE(2)
L Q Q Y C D E W Q  ----------
EcoRI
(ii) pSJM19CAT
Bgl EcoV Xho Ecol Xba
▼ t  t  ▼ ▼
N CAT C
(iii) pE35T2
Bgl EcoV Xho Ecol
▼ ▼
Xba
T
s t l s f i
N CAT
Figure 3.22: Constructs encoding the CAT208 epitope tag in pCMV 1 OBglAEco 
were constructed using two complementary oligonucleotides XcatE (1) and (2) 
[panel (i)] encoding the CAT208 tag amino acid sequence, which is marked 
underneath. These oligonucleotides were used to CAT208 tag the constructs shown 
in panels (ii) and (iii). The oligonucleotides were inserted following XhoI/EcoRI 
digestion, to remove the pp65 tag in each case. The presence o f the new tag was 
detected by Seal digestion.
The figure is not drawn to scale.
Figure 3.23: Construction of pET35CAT
(i) Sequence of Oligonucleotides NhiscatE (1) and NhiscatE (2)
Ncol
CATGGGCAGCAGCCATCATCATCATCATCACAACGAACTACAACAATACTGTGACGAATGGCAAATGGG
CCGTCGTCGGTAGTAGTAGTAGTAGTGTTGCTTGATGTTGTTATGACACTGCTTACCGTTTACCCTTAA 
| "H H H H H H i  [ l  Q Q Y C  D E W Q ~ ]
-----------------------------------------------  EcoRI
(ii) pET35CAT
Bgl Ncol
▼
Ecol
T
Xho
▼
T7 promoter
---------
N 6 x h is  CAT
Figure 3.23: Two complementary oligonucleotides, NhiscatE (1) and NhiscatE (2), 
[panel (i)] were used to incorporate 6xhis (dashed box) and CAT208 (solid box) 
tags into VP26 in pETmod (see Chapter 4, Section 2.1). The oligonucleotides were 
inserted following NcoI/EcoRI digestion o f pET35pp65 to remove the pp65 tag 
and generate pET35CAT [panel (ii)].
This figure is not drawn to scale.
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epitope tag (Section 2.3), it was relatively simple to manipulate these clones to 
incorporate the CAT208 sequence LQQYCDEWQ instead. The pp65 epitope had been 
cloned into the ORF's with unique restriction enzyme sites, Xhol and EcoRI, flanking it. 
This allowed digestion and removal of the pp65 tag and insertion of oligonucleotides 
encoding CAT208, with overhanging ends which were compatible with the Xhol and 
EcoRI sites. A restriction enzyme site, Seal, was also included in the oligonucleotide 
sequence to allow diagnostic digests to be performed to confirm the presence of the new 
oligonucleotide sequence. Two oligonucleotides, XcatE (1) and XcatE (2), were made 
[figure 3.22, panel (i)] and ligated into XhoI/EcoRI digested and gel purified pSJM1965 
and pE35Tl. This generated a two constructs in pCMVlOBglAEco (see Section 2.3.2) 
containing the CAT208 epitope tag [see figure 3.22, panels (ii) and (iii)]:
• pSJM19CAT - encodes the complete UL19 ORF with the CAT208 epitope in the 
same site as that occupied by the pp65 epitope in pSJM19pp65 (see Section 
2.3.2.3).
• pE35T2 - encodes the UL35 ORF with the CAT208 epitope in the same site as that 
occupied by the pp65 epitope in pE35Tl (see Section 2.3.2.4).
In addition, the CAT epitope was cloned into a bacterial expression vector pETmod 
(Chapter 4, Section 2). In this instance, oligonucleotides NhiscatE (1) and NhiscatE (2) 
[figure 3.23, panel (i)] were used to remove and replace the pp65 epitope in 
pET35pp65, encoding VP26 (see Chapter 4, Section 2.1), by NcoI/EcoRI digestion and 
ligation. The resulting construct was designated pET35CAT and encoded the 6xhis and 
CAT tags linked in frame to VP26 [figure 3.23, panel (ii)]. pET35CAT expressed 
protein to similar levels as pET35pp65 when treated in the same manner (Chapter 4, 
table 4.4). However, upon solubilisation and purification the VP26CAT protein was 
recovered at very low concentrations.
Figure 3.24: Western Blot of VP26CAT
VP26CAT
1 2  3 4 5 6 7 8 9
F ig u re  3 .2 4 : Nine clones of pET35CAT were induced at 37°C for 2h with 
ImM IPTG. Expression of VP26CAT protein was confirmed by Western blot 
analysis. The primary antibody, 5/24 (1:32), was detected with GAM-HRP 
(1:100) and visualised with the ECL developing reagents (see Methods, 
Section 2.17). The position of VP26CAT is marked by the arrow. This was 
determined by lining up the blot with the rainbow markers on the original 
polyacrylamide gel (not shown).
VP26CAT was detected in lanes 2, 4, 5, 8 and 9.
Figure 3.25: Intracellular distribution of 
VP5CAT and VP26CAT
Figure 3.25: Cells were transfected with plasmid pSJM19CAT (VP5CAT) [panel
(i)] or, pE35T2 (VP26CAT) [panel (ii)]. The distribution of the CAT constructs was 
detected with the primary antibody, 5/24 (1:32) and visualised with FITC-GAM. In 
both instances, the proteins were found throughout the cell but, VP26CAT was 
predominately localised in the cytoplasm.
Magnification = x200
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5.9 Analysis of CAT208 Constructs
5.9.1 Restriction Enzyme Digests
A series of restriction enzyme digests were performed on all the CAT208 constructs 
detailed in Section 5.8. The digestion profiles were examined on 1% agarose gels to 
confirm the presence the oligonucleotide insertions (data not shown). Profiles of 
pSJM19CAT, pE35T2 and pET35CAT showed evidence that the CAT208 epitope tag 
was present.
5.9.2 Western Blot Analysis
Nine clonal E coli isolates o f pET35CAT were induced with ImM IPTG and tested 
against supernatant 5/24 mouse monoclonal antibody (1:32) by Western blot. From the 
profiles (figure 3.24) it is clear that many of the clones expressed the CAT tag, with the 
VP26 protein detected at approximately 14700 Da. Clones numbered 2, 4, 5, 8 and 9 
reacted with the anti-CAT antibody supernatant. This confirms that these constructs 
contain the CAT208 epitope.
5.9.3 Immunofluorescence Labelling
Immunofluorescence was performed by singly transfecting BHK C13 cells with 
pSJM19CAT (VP5) and pE35T2 (VP26). 5/24 antibody supernatant was used at 1/32 
dilution and produced good fluorescence with both the VP5 and VP26 construct. In 
each case the protein was observed in the expected pattern of distribution and mirrored 
the results obtained earlier with the pp65 epitope constructs. VP5CAT and VP26CAT 
were both evident throughout the cell, with VP26CAT predominately in the cytoplasm 
[see figure 3.25, panels (i) and (ii)]. This confirms the presence o f the CAT208 epitope 
and the ability of the 5/24 mouse monoclonal antibody to work effectively in 
fluorescence studies.
6. Discussion of Mapping CAT208
Using the SPOTscan technique, it was possible to map the epitope site which interacted 
with the 5/24 anti-CAT antibody. Oligopeptide 208 encoded the sequence 
LQQYCDEWQ, which interacted with the antibody and was termed CAT208.
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The CAT208 sequence was incorporated into the ORF of UL19 and UL35 by insertion 
o f two overlapping oligonucleotides. The presence of the CAT208 sequence was 
confirmed by restriction enzyme digestion, Western blot analysis and
immunofluorescence studies.
When the CAT208 sequence was synthesised on the PSSM-8 oligopeptide synthesiser, it 
was found that an oligopeptide, 1013c (or re-synthesised 1013c.2), with 4 additional 
amino acids at the C-terminus, reacted more efficiently with the 5/24 antibody, than the 
9 amino acids mapped. This may be because the protein epitope sequence contained 
additional amino acids to those detected by the SPOTs technique.
Two rabbits were inoculated with oligopeptide 1013c.2. However, extensive analysis 
showed no evidence o f any anti-1013c.2 antibody being produced by either rabbit. It can 
only be concluded that since 1013c.2 was synthesised as a MAP on a 4-branched resin 
and inoculated in the presence o f an adjuvant, that it must have very low
immunogenicity.
Although it was not possible to produce rabbit antibodies, this work has successfully 
produced a new epitope tag, CAT208, which reacts with the 5/24 mouse monoclonal 
antibody. This tag can be used as a tool to label proteins which have no, or only poor,
antibodies against them and was used in this context to label VP5 and VP26. CAT
tagged VP5 and VP26 constructs were used in immunofluorescence studies and a 
bacterially expressed, epitope labelled VP26, was also used in Western blot analysis.
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CHAPTER 4 
PURIFICATION OF VP26 AND VP5
Figure 4.1: Example of a 6xhis Tag Sequence
his his his his his his
/ X / X / X / X / X / X5'  XXXXX CAT CAC CAT CAC CAT CAC X 3'
X GTA GTG GTA GTG GTA GTG XXXXX
Figure 4.1: The two combinations o f base pair sequences (ie CAT and CAC) 
encoding the amino acid histidine (his) are grouped. Six consecutive histidines 
represent a 6xhis tag and a possible combination o f residues is shown in this figure.
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1. Introduction
VP26 had been demonstrated to interact with VP5 by immunofluorescence (Rixon et al, 
1996) and in recombinant baculoviruses (Tatman et al, 1994; Thomsen et al, 1994). 
However, to study the interaction o f VP26 with VP5 at a molecular level, it was felt that 
it would be useful to express the VP26 protein in a bacterial expression vector. This is a 
powerful technique for cloning and expressing recombinant proteins and has several 
advantages:
• large quantities of protein are produced from a relatively small culture.
• the process is rapid.
• mutant versions o f VP26 were easily constructed and expressed.
The UL35 ORF was therefore cloned into a pET expression plasmid (supplied by 
Novagen). This plasmid contained a 6xhis tag (see figure 4.1) which could be utilised to 
purify the recombinant protein through a Ni2+ agarose column. The expression vector was 
modified to include a novel EcoRI site (designated pETmod), in the correct reading frame 
for subcloning the UL35 ORF. The UL35 ORF was isolated from pE35Tl (see Chapter 3, 
Section 2.3.3) and cloned into pETmod, placing the VP26 sequences downstream from 
the 6xhis tag. Finally, the N-terminal sequences were removed and replaced with an 
oligonucleotide encoding the pp65 and 6xhis tags.
As described in Section 3, a VP5 protein, also encoding a 6xhis tag, was generated in a 
baculovirus expression vector. The pp65 epitope tag had been cloned into pSJM1965 (see 
Chapter 3, Section 2.3.2) with unique restriction enzyme sites flanking it, therefore the 
pp65 tag could be easily removed and replaced with an oligonucleotide encoding the 
6xhis tag. The UL19 ORF, encoding the 6xhis tag was then subcloned into a baculo virus 
expression vector, pAcC129.1.
Expression o f 6xhis tagged versions o f VP5 and VP26 allowed both proteins to be 
isolated and purified rapidly. It was important to have pure and soluble proteins available
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Figure 4.2: The pET28a vector [panel (i)) was EcoRI/Ndel digested to inset 
oligonucleotides, pETmod (1) & pETmod (2) [see figure 4.3, panel (i)], which 
genetically modified the restriction enzyme sites for the cloning strategy and give 
pET28amod [panel (ii)]. This had a novel EcoRI site in the correct reading frame 
context for subcloning the UL35 ORF and also removed the T7 epitope tag sequence 
from the vector. The UL35 ORF was isolated as an EcoRI/XhoI fragment from 
pE35Tl (see Chapter 3, Section 2.3.2.4) and ligated into EcoRI/XhoI digested 
pET28amod. This placed the gene downstream of the 6xhis and the thrombin 
cleavage site (Thr) to generate pET35 [panel (iii)]. For expression of an epitope 
tagged version of VP26, the N-terminal sequences were removed and replaced with 
two complementary oligonucleotides [Nhis65 (1) and Nhis65 (2), see figure 4.3, 
panel (ii)]. These were made and inserted into NcoI/EcoRI digested pET35 to 
generate pET35pp65 [panel (iv)]. This construct encodes a 6-histidine tag and the 
pp65 epitope tag linked in-frame at the N-terminus of the VP26 protein.
This figure is not drawn to scale.
Figure 4.3: Oligonucleotides Required for Cloning the VP26 
Coding Sequence into a Bacterial Expression Vector
(i) pETmod
Ndel EcoRI
(1) TAT G G G AAT T C C G GAT C CAC TAG TAC
(2) ACCCTTAAGGCCTAGGTGATCATGTTAA
AEcoRI
(ii) Nhis65E
Ncol pp65
(1) CAT G G G C AG CAC C CAT CAT CAT CAT CAT CAC G C C GAGC G CT^GAC G C
(2) CCGTCGTGGGTAGTAGTAGTAGTAGTACGGCTCGCGTTCTGCG
6xhis
(1) CCCGCGTCACCGGCGGAATGGG
(2) GGGCGCAGTGGCCGCCTTACCCTTAA
EcoRI
Figure 4.3: The sequence of the oligonucleotides used in creating pET28amod 
[panel (i)] and pET35pp65 [panel (ii)], see figure 4.2. pETmod (1) and (2) were 
inserted into Ndel/EcoRI digested pET28a, to generate pETmod. This insertion 
destroyed the original EcoRI site (ie AEcoRI) and generated a new one.
Nhis65E (1) and (2) inserted the 6xhis and pp65 tag sequences into NcoI/EcoRl 
digested pET35 to generate pET35pp65, which encoded VP26 with the 6xhis and 
pp65 tags linked in-frame at the N-terminus.
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which could be used in a series o f interaction and structural studies (see Chapter 5). If the 
proteins were not in this form , it would be difficult to obtain accurate data about their 
properties. For example, in an interaction assay system, if contaminating proteins were 
present, they may participate in non-specific binding interaction, creating false positive 
results. Similarly if the proteins were in a soluble but denatured form, the secondary 
structure of the protein would be affected making interaction and structural analyses 
unsuccessful. So, to ensure that accurate data was produced from future studies, it was 
important at the outset to spend time and effort producing pure and soluble VP26 and 
VP5 proteins.
2. VP26
2.1 Construction of Expression Plasmid
2.1.1 pET28mod
The pET28a(+) [figure 4.2, panel (i)], supplied by Novagen, was modified for subsequent 
cloning procedures by the insertion o f synthetic oligonucleotides [figure 4.3, panel (i)] to 
generate pET28mod [figure 4.2, panel (ii)]. The pET28a(+) vector was Ndel/EcoRI 
digested and ligated with two complementary oligonucleotides pETmod (1) and pETmod
(2). This placed a novel EcoRI site in the correct reading frame context for sub-cloning 
the UL35 ORF, from pE35Tl, and simultaneously removed a T7 epitope tag sequence 
from the vector.
2.1.2 pET35pp65
The UL35 ORF was isolated as an EcoRI/XhoI fragment from pE35Tl (see Chapter 3, 
Section 2.3.3) and sub-cloned into EcoRI/XhoI digested pET28mod. This placed the 
VP26 sequences downstream of the 6xhis tag and thrombin cleavage site, generating 
pET35 [figure 4.2, panel (iii)]. For expression o f an epitope tagged version, two 
complementary oligonucleotides [Nhis65E (1) and Nhis65E (2)] [figure 4.3, panel (ii)] 
were made and inserted into NcoI/EcoRI digested pET35 to give pET35pp65 [figure 4.2, 
panel (iv)]. This construct encodes a 6xhis tag and the HCMV pp65 epitope tag linked in­
frame at the N-terminus of the VP26 protein, under the control of the strong 
bacteriophage T7 transcription promoter.
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Figure 4.4: Comparison of the Amino Acid Sequences of 
VP26 and VP26pp65
VP26 MAVPQFHRPSTVTTDSVR
VP26.pp65 MGSSHHHHHHAERKTPRVTGGMGIOAVPQFHRPSTVTTDSVR
ALGMRGLVLATNNSQFIMDNNHPHPQGTQGAVREFLRGQAAALTDLGLAHANNT
ALGMRGLVLATNNSQFIMDNNHPHPQGTQGAVREFLRGQAAALTDLGLAHANNT
FTPQPMFAGDAPAAWLRPAFGLRRTYSPFVVREPSTPGTP* 
FT PQ PMFAGDAPAAWLRPAFGLRRTYS P FVVREPSTPGTP *
Figure 4.4: Due to the presence o f additional sequences contributed by the pp65 
epitope (double underline) and the 6xhis (single underline) tags, VP26pp65 has 24 
amino acids at the N-terminus which are not present in wild-type VP26.
Figure 4.5: Expression of pET35pp65
97.4K 
66.OK
46.OK 
30.OK
21.5K 
14.7K
VP26pp65
Figure 4.5: Coomassie brilliant blue stained gel showing size markers (lane 1), 
uninduced pET35pp65 culture (lane 2) and ImM IPTG (37°C, 2h) induced 
pET35pp65 culture (lane 3), supernatant (lane 4) and pellet (lane 5) fractions. Ni- 
NTA purified VP26pp65 is shown in lane 6 and the position o f VP26pp65 is marked 
with an arrow.
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As there are extra amino acid residues contributed by the pp65 epitope and the 6xhis tags, 
VP26pp65 is larger than wild type VP26. There are 24 amino acid residues at the N- 
terminus of the tagged protein, which are not present in wild type protein (see figure 4 .4). 
This means that the Mr of VP26 is 12096 Da compared to a Mr of 14733 Da for 
VP26pp65.
2.2 Expression of VP26pp65
Since preparations of proteins in cells grown from glycerol stocks were often unstable (a 
common feature of the pET vector) better and more reproducible expression was 
obtained by transfecting pET35pp65 DNA into fresh bacteria each time. A single colony 
was then sub-cultured into 100ml growth medium in a 11 glass flask. This provided 
abundant aeration, important for good expression and induction. The bacteria were grown 
at 37°C, with agitation, until the A6oo=0.5. 500pl of'uninduced' (U) bacteria were then 
removed and pelleted. These bacteria contain a chromosomal copy of the T7 RNA 
polymerase gene under the control of lacUV5. The addition of IPTG induced expression 
o f the T7 polymerase which transcribed the target gene. IPTG was added to the batch 
culture, to a final concentration of ImM and incubation continued for 2-3 h, after which 
another 500pl of 'induced' (I) sample was removed and pelleted. The U and I samples 
were resuspended in lx  dissociation mix and analysed by SDS-PAGE (see figure 4.5, 
lanes 2 and 3). The remaining culture was harvested at 3000 rpm for 15 min in 225ml 
falcon tubes. The pellet was stored at -20°C until required.
It is clear from the gel (figure 4.5) that the expression levels of VP26pp65 protein were 
extremely high. When comparing the U and I tracks (lanes 2 and 3 respectively), 
VP26pp65 was the most abundant protein produced after induction with IPTG. It should 
be noted that this expression level was not consistently achieved if a glycerol stock was 
used to inoculate the culture, or a 100ml culture was grown up in a reaction vessel of less 
than a 11 capacity. If these less favourable conditions were used the protein would either 
fail to induce, or the expression levels were severely inhibited.
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Figure 4.6: Attempts to Solubilise VP26pp65
(i) Induction Time at 37°C
1 2 3 4 5 6 7 8 9  10 11
66.0K
4 6 . OK
3 0 . OK
21.5K
14.3K
(ii) Bacterial Density at 
Induction 
1 2 3 4 5 6 7  8 9
66.OK
46.OK
30.OK
21.5K
14.3K
(iii) Concentration of IPTG at 
Induction
1 2 3 4 5 6 7
(iv) Sonication Buffer
1 2 3 4 5 6 7
66.0K 66.OK
46. OK 46.OK
30.OK30. OK
21.5K2 1 . 5 K
14.3K14.3K
Figure 4.6: Panels (i) to (iv) are coomassie brilliant blue stained gels with 20pl o f 
each sample run per well. The arrow in each panel marks the expected position of 
VP26pp65.
Panel (i) lane 1 shows a typical example o f the level o f induction, at 37°C with ImM 
IPTG for 2h, as compared to the uninduced sample (lane 2). Lane 3 shows the size 
markers while lanes 4 to 11 represent alternate pellet and supernatant fractions after 
2h (lane 4 & 5), 4h (lane 6 & 7), 6h (lane 8 & 9) and o/n (lane 10 & 11) induction 
with ImM IPTG. In each case VP26pp65 was detected in the pellet fraction.
Panel (ii) lane 1 shows the size markers. Lanes 2 to 9 represent alternate supernatant 
and pellet fractions, after induction with ImM IPTG for 2h at 37°C, when the A6oo 
equaled, 0.5 (lanes 2 & 3), 0.4 (lanes 4 & 5), 0.3 (lanes 5 & 6) and 0.2 (lanes 8 & 9). 
In each case VP26pp65 was detected in the pellet fraction.
Panel (iii) lane 4 shows the size markers, while lanes 1, 2, 3 and 5 represent induced 
samples after 2h at 37°C with, O.lmM IPTG (lane 1), 0.2mM IPTG (lane 2), 0.5mM 
IPTG (lane 3) and ImM IPTG (lane 5). Lanes 6 and 7 represent the pellet fraction of 
the l.OmM and the 0.5mM, respectively, induced samples.
Panel (iv) lane 1 shows the size markers. Lanes 2 to 7 represent the pellet fractions 
after sonication in the presence o f the various ‘Good buffers’ (see table 4.1).
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2.3 Solubility of VP26pp65
The induced bacterial pellet, containing VP26pp65, was resuspended in Sonication Buffer 
[20mM tris-HCl (pH8.0), 10% glycerol, 0.1% NP40 (as recommended by the 
QIAexpressionist protocol, Qiagen)] by probe sonication for 5x 10 sec. The solution was 
spun at 10000 rpm in SM24 tubes to pellet the debris. However, the protein failed to 
solubilise and upon analysis by SDS-PAGE, VP26pp65 was consistently found in the 
insoluble pellet fraction and never in the soluble supernatant fraction (figure 4.5, lanes 5 
and 4 respectively).
As VP26pp65 was insoluble, extensive investigative measures were undertaken at each 
stage of the expression procedure, to try and reduce aggregation of the protein and 
therefore solubilise it. The ultimate aim was to produce pure and soluble VP26pp65 
which had native secondary structure and could be used in interaction and structural 
studies. Unfortunately, this task proved to be extremely difficult. Considerable time and 
effort was spent varying procedures under non-denaturing and eventually, denaturing 
conditions to produce suitable VP26pp65 protein. Some of the variations attempted are 
detailed in the following sections.
2.3.1 Temperature and Time of Induction
It had been reported (QIAexpressionist protocol, Qiagen) that varying the time and 
temperature of induction could result in the production of soluble protein.
A series o f 10ml cultures were set up and induced at 15°C, 20°C and 37°C. For each 
temperature, the culture were harvested after induction for 2h, 4h, 6h or o/n. The cells 
were resuspended in sonication buffer and spun as before. Supernatant and pellet fractions 
were compared on a minigel (15°C and 20°C fractions are not shown).
At each temperature and time point, the protein was detected in the pellet fraction alone 
[see figure 4.6, panel (i) as a representative example] showing that there had been no 
effect on the solubility of the protein. At both 15°C and 20°C, there was a slightly
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reduced yield of protein, as compared to 37°C (not shown). Induction for 2-4h at 37°C 
appeared to be a sufficient induction time for producing large amounts of protein.
2.3.2 Bacterial Density
The 'QIAexpressionist' protocol (Qiagen, also suggested that reducing the density of the 
bacterial culture at the time o f induction could help prevent protein aggregation. 
Therefore, the A600 at induction was varied from 0.2, increasing at 0.1 intervals, to 0.5. 
The induced samples were resuspended in sonication buffer by sonication, centrifuged and 
the resulting supernatant and pellet fractions analysed by SDS-PAGE [figure 4.6, panel 
(iii)]. Although the total amount of VP26pp65 induced, increased in line with the 
increasing cell density, there was no effect on protein solubility. In all cases VP26pp65 
was exclusively found in the pellet fractions.
2.3.3 Concentration of IPTG at Induction
The effects of varying the concentration of IPTG, during induction, was also tested 
[figure 4.6, panel (iii)]. IPTG was added at O.lmM, 0.2mM, 0.5mM and ImM, for 2h at 
37°C. The VP26pp65 protein did not induce significantly at levels below 0.5mM. Greatest 
induction was consistently observed at concentrations o f ImM. The bacterial cells were 
harvested and resuspended in sonication buffer. After analysis of supernatant and pellet 
fractions, it was clear that there was no effect on the solubility o f any of the induced 
proteins, which remained entirely in the pellet fraction (figure 4.6, lanes 6 and 7).
2.3.4 Time, Temperature and Concentration of IPTG at Induction
The time, temperature and concentration of IPTG at induction were varied in multiple
combinations however, the solubility of the VP26pp65 protein remained constant and was 
found exclusively in the pellet fractions (not shown).
2.3.5 Treatment with Various Buffers and pH Conditions
As it did not seem possible to produce soluble protein by varying conditions at the 
expression level, it was decided to try and solubilise the protein from the bacterial pellet. 
A 100ml culture was grown to A6oo=0.5 and induced, at 37°C for 2h, with IPTG. The 
suspension was aliquoted and harvested at 3000 rpm for 10 min in 15ml Falcon tubes. 
Attempts were then made to solubilise the VP26pp65 protein from the pellet fractions.
Table 4.1: ‘Good Buffers’ to Solubilise VP26pp65
GOOD BUFFER’ 
(20mM)
BUFFER
pH
Corresponding lane in 
figure 4.6, panel (iv)
MES 6.0 2
BIS IR IS 6.5 3
PIPES 7.0 4
HEPES 7.5 5
TRIS 8.0 (figure 4.5, lane 5)
CHES 9.0 6
CAPS 10.0 7
Table 4.1: All the 'Good Buffers’ (supplied by Sigma) were prepared at 20mM, in a 
solution containing 10% glycerol and 0.1% NP40. The pH of the buffer was altered 
using HC1 or NaOH as required. All the fractions were run on gels [see figures 4.5. 
lane 5 and 4.6, panel (iv)].
♦
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The bacterial pellet was probe sonicated, using a Branson soniprobe, in various detergent 
containing buffers with different pH values (see table 4.1). All the buffers used were 
described in the Sigma catalogue under 'Good Buffers'. The solutions were prepared with 
20mM o f the appropriate Good Buffer, 10% glycerol and 0.1% NP40. After the pellet 
had been thoroughly disrupted, the solution was centrifuged at 10000 rpm for 10 min in 
SM24 tubes and the supernatant and pellet fractions analysed by SDS-PAGE.
None o f the buffers solubilised the VP26pp65 protein as the protein was always 
exclusively present in the pellet fractions [figure 4.6, panel (iv)]and was not found in any 
o f the supernatant fractions. However, many contaminating bacterial proteins were 
differentially solubilised by the buffers, helping to clean up the VP26pp65 preparation. 
The results obtained with 20mM tris (pH 8.0) were as good as those with any other of the 
buffers tested. Therefore, it was decided that the original buffer used for sonication steps 
previously, 20mM tris (pH 8.0), 10% glycerol and 0.1% NP40, would be used to wash 
the bacterial pellet in all subsequent experiments. This will hence forth be referred to as 
the Sonication Buffer.
2.3.6 Treatment with Denaturant
Even trace amounts o f soluble VP26pp65 had not been detected in any of the supernatant 
fractions analysed in the previous sections. A large range of non-denaturing conditions, 
some recommended by Qiagen and others standard approaches to solubilising proteins 
during expression, had been extensively tested and failed. The time, temperature and 
conditions o f induction had been varied in multiple combinations. Several different buffers 
and pH conditions had been used to try and solubilise the protein from the bacterial pellet.
Until soluble protein was produced, it was impossible to proceed and purify the protein 
through Ni2+ agarose. The only avenue left open appeared to be to try and denature the 
protein and at some subsequent stage refold it. The QIAexpressionist protocol reported 
that denatured proteins could still be effectively purified through Ni2+ as the 6xhis tag was 
not affected. Therefore, the washed pellet o f an induced culture was resuspended in the 
presence o f a denaturant, 6M GuHCl. The pellet was resuspended, by probe sonication 
with a Branson soniprobe in Buffer A [6M GuHCl, lOOmM NaH2P04, lOmM tris
Figure 4.7: Treatment of VP26pp65 with 
6 M GuHCl
1 2
Figure 4.7: Coomassie brilliant blue stained gel showing pellet (lane 1) and 
supernatant (lane 2) fractions of a culture induced with ImM IPTG (2h, 37°C), 
washed in Sonication Buffer, resuspended in Buffer A [6M GuHCl, lOOmM 
NaH2P 0 4, lOmM tris (pH8.0)] and spun to separate the two fractions.
An arrow marks the position o f VP26pp65. Markers not shown.
Figure 4.8: Schematic Representation of the Interaction of 
6xhis Tagged Proteins with the Ni-NTA Resin
Recombinant
Protein
6xhis
NTA Resinc
J
Figure 4.9: Comparison of the Structures of Imidazole and
Histidine
(i) Imidazole (ii) Histidine
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Figure 4.8: Recombinant proteins encoding a 6xhis tag (yellow) bind to the 2 free 
ligand sites (grey circles) of Ni2+, which are not occupied by the NTA resin (blue). This 
immobilises the recombinant proteins on the Ni-NTA resin.
Figure 4.9: The structure o f imidazole [panel (i)] and the side arm o f histidine [panel
(ii)] are very similar.
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(pH8.0)]. The suspension was mixed end-over-end at rt for l-2h and spun at 10000 rpm 
for 10 min in SM24 tubes. The pellet and supernatant fractions were TCA precipitated 
and analysed by SDS-PAGE. This time, most of the protein was detected in the 
supernatant fraction (figure 4.7). This means that the greatest percentage o f VP26pp65 
had been solubilised and could now be purified.
2.4 Purification of VP26pp65
2.4.1 Binding of VP26pp65 to Ni-NTA Agarose
The presence of the 6xhis tag in the pET vector, allowed soluble VP26pp65 protein to be 
purified through a Ni2+ column, by affinity chromatography against the Ni2+ agarose. 
Qiagen supplied a Ni-NTA agarose which consisted of NTA (nitrilo-tri-acetic acid), a 
stable high capacity resin, with Ni2+ tightly complexed to it. Ni2+ has 6 ligand binding sites 
and the NTA occupies 4 o f these. This leaves 2 free sites to interact with the 6xhis tag 
(see figure 4.8). Binding of 6xhis tagged proteins to the charged agarose did not require 
functional protein structure and so the presence of the 6M GuHCl in the buffer did not 
interfere with binding.
Soluble 6xhis protein in Buffer A was typically mixed at rt for lh with 500pl of Ni-NTA 
which had been pre-equilibrated in Buffer A and resuspended as a 50% slurry (Ni-NTA 
has a binding capacity o f lOmg o f 6xhis tagged protein per ml of resin). The mixture was 
loaded onto a 0.8 x 4.0 cm poly-prep column (Bio-Rad) and allowed to settle. Unbound 
proteins were allowed to drain through the column by gravity. A series o f washing and 
elution steps followed.
Imidazole was used to elute the protein from the agarose. Imidazole has a similar 
structure to the side chain o f histidine (see figure 4.9) and so competes with and displaces 
the tagged proteins from the resin.
2.4.2 Denaturing Elution Conditions
As the previous work had shown VP26pp65 to be extremely insoluble, the protein was 
initially eluted from the column in the presence o f denaturant. It was felt that this
Figure 4.10: Elution of VP26pp65 with 
Imidazole and 8M Urea
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Figure 4.10: Coomassie brilliant blue stained gels. Panel (i) lane 1 shows the size 
markers while panels 2, 3 and 4 represent the elutions through Ni-NTA, with 
VP26pp65 bound. Buffer C (lane 2), Buffer D (lane 3) and Buffer E (lane 4), 
contained 8M urea and 20mM, 60mM or 200mM concentration of imidazole 
respectively. VP26pp65 was mainly eluted in Buffer E.
The position of VP26pp65 is marked with an arrow.
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approach had more chance of succeeding and at this stage it was important to test 
whether the Ni-NTA purification system would work.
8M urea was added to a phosphate buffer, Buffer B (8M urea, lOOmM NaH2P 0 4, lOmM 
tris HCL (pH8.0), suggested by Qiagen) and this was used to wash the resin. Urea was 
used, as oppose to 6M GuHCl, for two reasons. Firstly, it is a milder denaturant and 
secondly, it allowed fractions to be analysed directly on gels without the requirement for 
removing the GuHCl, which precipitates in loading buffer. A range o f concentrations of 
imidazole were used to see if any eluted the protein from the column. Imidazole at either 
20mM, 60mM or 200mM was mixed with Buffer B. The phosphate buffers containing 
imidazole and 8M urea were designated Buffers C-E (Materials, Section 1.11).
Buffer C, containing 20mM imidazole, removed many of the contaminating proteins 
(figure 4.10, lane 2). Background contamination can occur from proteins that contain 
neighbouring his residues and therefore have a low affinity for the Ni-NTA resin. Other 
proteins may be linked to 6xhis tagged proteins non-specifically or bind the resin non- 
specifically.
Buffer D, containing 60mM imidazole, removed a little VP26pp65 protein and most of 
the contaminating proteins which may have been more tightly bound (figure 4.10, lane 3).
Buffer E contained 200mM imidazole. This removed relatively clean VP26pp65 protein 
from the resin (see figure 4.10, lane 4). The contaminating proteins could be removed by 
more extensive washing o f the resin. Examination o f these fractions on a 15% minigel 
revealed that only a single band, o f the expected Mr for VP26pp65, was present (see 
figure 5.5, panel (iii), lane 5). This shows that the protein has been successfully eluted 
from the resin, in the absence o f any contaminating proteins. If  a 70- 100ml culture was 
induced, typically l-3ml o f 5mg/ml (by Bradford assay) of VP26pp65 protein would be 
produced.
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It was now clear that it was possible to produce soluble VP26pp65 bacterially expressed 
protein, which could be purified successfully through Ni2+ agarose. However, denaturant 
(8M urea) was present at all stages o f the purification process. It was essential to remove 
the 8M urea from the solution, whilst still keeping VP26pp65 soluble, for all subsequent 
analysis procedures.
2.4.3 Non-denaturing Elution Conditions
As a general rule, protein re-folding should take place slowly to avoid the formation of 
insoluble aggregates. A few approaches were therefore tried under non-denaturing 
conditions, to try and produce soluble, pure and non-denatured protein.
Trying to refold the protein on the column was potentially a valuable method, as it is 
known that immobilising one end of a protein can prevent the formation o f mis-folded 
aggregates, while the denaturant is removed. In this case, the N-terminus o f VP26pp65 
protein was attached to the Ni-NTA through the 6xhis tag. Many elution buffers were 
tested to try and remove non-denatured VP26pp65.
(i) Vary Imidazole Concentrations
Qiagen suggested the use o f a phosphate buffer [lOOmM NaH2P04, lOmM tris (pH 8.0)] 
containing imidazole for elution under non-denaturing conditions. Increasing 
concentrations of imidazole at 20mM intervals, from 20mM to 200mM, were added in the 
phosphate buffer to try and elute the protein from the resin.
However, the VP26pp65 protein was not eluted from the resin at any imidazole 
concentration when the denaturant was absent. Even 200mM concentrations of imidazole 
failed to remove any VP26pp65 from the column. As it was known that 200mM 
imidazole was sufficient to remove VP26pp65 from the resin under denaturing conditions, 
it was clear that the imidazole concentration was sufficiently stringent. It seemed clear 
that the protein had precipitated on the column and may have formed insoluble aggregates 
or multimers.
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(ii) Reduce Denaturing Conditions Slowly
Attempts were made to reduce the concentration of denaturant over subsequent washing 
and elution steps. This meant that 8M urea was present in the initial wash with phosphate 
buffer alone. This was reduced to 4M urea in the wash containing 20mM imidazole and 
2M urea, in the wash containing 60mM imidazole. No urea was present in the 200mM 
imidazole elution buffer.
This approach was used in the belief that re-folding should take place slowly. 
Unfortunately this proposal was also unsuccessful and failed to elute VP26pp65 from the 
column. The protein was assumed to have precipitated out again.
(iii) Vary pH and Imidazole Concentrations
It is known that reducing the pH causes histidine residues to become protonated and so 
dissociate from the Ni2+. The pH of the phosphate buffer was therefore varied with HC1 
and used at pH 8.0, pH 6.3, pH 5.9 and pH 4.5 (recommended by Qiagen). These buffers 
were designated Buffers 1 -4 respectively.
However, no VP26pp65 protein was eluted at any o f the pH values tested (data not 
shown). This re-reinforces the point that this protein is extremely insoluble and highly 
resistant to attempts at solubilisation
A final attempt was made to combine the approaches taken in (i) and (iii) and elute the 
protein from the column in the absence of denaturant. Imidazole at 20mM, 60mM and 
200mM was dissolved in the phosphate buffers 1-4, with varying pH values (pH 8.0, 6.3, 
5.9, and 4.5 respectively). This meant that 12 different elution buffers were used in a 
series o f experiments.
After carefully analysing all the wash and elution fractions on a 15% minigel, it was 
concluded that no VP26pp65 protein had been eluted from the Ni-NTA with any o f the 
buffers tested (data not shown).
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It was decided to revert back to the successful washing and elution conditions, outlined in 
Section 2.4.2, which were carried out in the presence of the denaturant, 8M urea, at all 
stages.
2.5 Re-naturation of VP26pp65
It had been possible thus far, to consistently produce bacterially expressed VP26pp65, in 
a very pure and soluble form from a 70-100ml culture. The only drawback was that the 
protein was in the presence of denaturant, therefore attempts were made to remove the 
8M urea by dialysis. Protein was dialysed against NTE. NTE was a suitable solution for 
the protein to be in, as it could be used in this form in ELISA reactions, capsid 
experiments, sizing and characterisation studies.
Initially a straight dialysis of VP26pp65 was tried. 500pl of protein, in buffer E, was 
dialysed against 1.51 of NTE at 4°C. The protein came out of solution within 10 min and a 
visible white precipitate was observed in the dialysis sack. Nevertheless, the dialysis was 
continued o/n and the solution spun at 80000 rpm for 10 min, in a Beckman TL100 ultra 
centrifuge, to pellet the precipitated protein. The supernatant fraction was carefully 
removed and examined by SDS-PAGE analysis. No soluble VP26pp65 was detected in 
the dialysed supernatant fraction indicating that all of the protein had precipitated out of 
solution.
Rapid dilution followed by slowly dialysis of the denaturant, has been reported to allow 
re-naturation of a protein to its native secondary structure. The conditions and extent of 
dilution vary for individual proteins.
lml ofVP26pp65 protein in Buffer E was diluted in NTE, 20-fold, 10-fold and 2-fold (ie 
added to 19ml, 9ml and lml of NTE respectively). The diluted proteins were dialysed at 
4°C o/n against 1.51 of NTE. After incubation the dialysis sacks were visually inspected. 
No protein precipitate was evident in the 1:10 or 1:20 dilution sacks. At 1:2 dilution a 
large amount of precipitate was visible.
As before, all the dilutions were spun at 80000 rpm for 10 min, in a Beckman TL100 ultra 
centrifuge, to ensure any precipitated protein was pelleted. The supernatant fractions were
Figure 4.11: Rapid Dilution and Dialysis of VP26pp65
l 2 3 4
Figure 4.11: Coomassie brilliant blue stained gel showing VP26pp65 supernatant 
fractions. Lane 1 shows the size markers while lanes 2, 3 and 4 represent the Ni2+ 
purified VP26pp65, rapidly diluted, 1:2 (lane 2), 1:10 (lane 3) and 1:20 (lane 4) in NTE 
(ie added 1ml o f purified VP26pp65 to 1ml, 9ml and 19ml o f NTE respectively), 
dialysed o/n at 4°C and spun at 80000 rpm for 10 min.
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removed and analysed by SDS-PAGE (figure 4.11). No protein was evident from the 1:20 
dilution (lane 4) and only a very faint band was detected for the 1:10 dilution (lane 3). 
This may purely reflect a quantitative problem, in that the protein was so dilute that it was 
unable to be detected, rather than it had precipitated out. A band was observed at the 1:2 
dilution (lane 2). However, a Bradford assay detected protein concentrations between 
only 0.5-1 mg/ml. This meant that only 20-40% of the total protein inserted into the 
dialysis sack had remained in solution.
As there appeared to be less problem with precipitation at the 1:10 and 1:20 dilutions 
attempts were made to concentrate VP26pp65 by reducing the volume after dialysis. Two 
approaches were used in parallel:
(i) Some o f the solution was spun through Centricon-10 spin tubes (Amicon). These tubes 
had a molecular weight cut-off o f 10000 Da. This meant that anything above this weight, 
ie VP26pp65 at approximately 14700 Da, would be retained by the filter. The tubes were 
spun at 10000 rpm in an SM24 rotor, until 5ml of solution had been concentrated to 1ml.
(ii) Some o f the solution was concentrated using Ultra-thimbles (Scleicher & Shuell). The 
thimbles also had a molecular weight cut-off of 10000 Da and so were able to retain 
VP26pp65 (14700 Da). In this case, the solution was concentrated by extracting liquid 
through the thimble walls, by means of a vacuum pump. Again, 5ml was concentrated 
down to 1ml.
Both of these attempts were unsuccessful and the concentration of protein was not 
increased as the volume was decreased. It can only be assumed that the protein was 
precipitating out of solution. In the case of the centricon tubes, the protein may have 
stuck to the filter and with the Ultra-thimbles, it may have stuck to the thimble walls.
Since diluting the VP26pp65 protein 2-fold in NTE, and slowly dialysing it at 4°C o/n, 
had resulted in a usable yield of protein, this approach was used for all future analyses 
(Chapter 5).
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Figure 4.12: pSJM1965 [panel (i)], described in figure 3.3, was XhoI/EcoRI digested, 
to remove the pp65 tag, and ligated with oligonucleotides NhisE (IB) and NhisE (2B) 
[panel (ii)] to generate pSJM19his [panel (iii)]. This construct was Bgllll digested, to 
release the 4200 bp UL19 fragment, and ligated with Bglll digested pAcC129.1. This 
generated pAcC119his, which was designated 191A after plaque purification.
Not drawn to scale.
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3. VP5
3.1 Construction of Expressing Baculovirus
To produce a 6xhis tagged version o f VP5 in a baculovirus expression vector, a series of 
cloning steps were performed. pSJM1965 (described in Chapter 3, Section 2.3.2) was 
EcoRI/XhoI digested to remove the pp65 tag sequences, which were replaced with two 
complementary oligonucleotides, NhisE (IB) and NhisE (2B), to generate pSJM19his 
(see figure 4.12). The oligonucleotides encoded a 6xhis tag and an Ncol site for ease of 
detection. Once the insertion had been confirmed, by restriction enzyme digestion (not 
shown), the UL19 ORF was isolated as a Bglll fragment and sub-cloned into a Bglll 
digested baculovirus expression vector, pAcC129.1 (Livingston & Jones, 1989). This 
generated pAcC119his [see figure 4.12, panel (iv)]. Again, the correct construct was 
confirmed by a series o f restriction enzyme digests.
3.2 Production of a Recombinant Baculovirus Expressing VP5his (ie 
191 A)
A large scale plasmid preparation o f pAcCL19his was made (see Methods, Section 
2.5.11) and the DNA used to transfect S£21 cells with viral DNA using CELLFECTIN 
reagents (Methods, Section 2.3.7). The resulting recombinant virus was plaque purified 
through several rounds o f plate harvests (as described in Methods, section 2.3.7.4). It was 
important at this stage to clearly label each plaque and a simple numbering system was 
employed. The final positive viral plaque, which was used as the inoculum to produce 
titred virus stock, was designated 19 (for UL19), from initial plaque 1 and final plaque A, 
ie the recombinant plaque purified baculovirus was termed 191 A.
3.3 Expression of 191A
191A was inoculated into 300ml o f Sf 21 cells (2xl05/ml) at 0.1 pfu/ml. The cells were 
incubated at 28°C for 4-5 days and harvested at 3000 rpm for 10 min. The pellet was 
resuspended in 2.5ml o f PBS complete. Soluble protein was released by 3 rounds of 
freeze thawing followed by a brief sonication in a Kerry ultrasonic bath. The solution was 
spun at 13000 rpm for 5 min and the supernatant, containing the 191A protein, was 
stored at -20°C until required.
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Figure 4.13: Coomassie brilliant blue stained gel with the size markers represented in 
lane 1. Freeze thawed baculovirus supernatant, in PBS, expressing 191 A, was loaded 
onto Ni-NTA resin, washed in 4x5ml PBS (lanes 2, shows a sample of the 1st PBS 
wash) and 5xlml PBS + 5mM imidazole (lanes 3 and 4, show the 1st and last PBS + 
5mM imidazole washes respectively). The protein was eluted in 3x1 ml volumes of 
PBS + 30mM imidazole (lanes 5 and 6 show the 1st and final elutions respectively).
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3.4 Purification of 191A
3.4.1 Binding and Elution of 191A from Ni-NTA Agarose
The 191A supernatant was mixed with 500pl of Ni-NTA, pre-equilibrated in PBS, as 
described in Section 2.4.1.
The 191A protein bound to the Ni-NTA resin was loaded onto a 0.8x4.0cm poly-prep 
column (Bio-Rad). The mixture was left to settle and the unbound protein allowed to 
drain through the column by gravity. The resin was then washed with 20ml (ie 4x5ml 
volumes) o f PBS complete. 1x5ml volumes o f PBS complete containing 5mM imidazole 
removed any non-specifically or weakly bound proteins. The 191A protein was eluted 
from the column in 3xlml volumes o f PBS complete, containing 30mM imidazole. The 
protein was eluted in a soluble and relatively pure form, in the absence o f denaturant and 
required no further purification (figure 4.13).
4. Discussion
The properties o f the Ni-NTA purified VP5 (191 A) and VP26 (VP26pp65) proteins 
contrasted significantly. The VP5 protein was expressed in a baculovirus system and was 
soluble in PBS. On the other hand, the VP26 protein was expressed in a bacterial 
expression system and was extremely insoluble under standard non-denaturing conditions. 
It is difficult to ascertain exactly why this protein was so insoluble. There are, for 
example, no Cys residues which could cross-link and cause aggregation. It should be 
noted however, that the contrast in solubilities between VP5 and VP26 cannot be 
attributed to the different expression systems used. VP26 has been expressed in the 
baculovirus system. Both Tatman et ol, 1994, and Thomsen et al, 1994, found that VP26 
was relatively insoluble in this system and often difficult to express. It may be that the 
VP26 protein has a complex secondary structure which is difficult to fold, or it may be 
that the structure is very unstable when it is not present in its native confirmation within 
the capsid structure.
It is important to realise that the epitope tags included in these constructs should not be 
altering or interfering with the properties o f VP5 or VP26. Immunofluorescence studies 
(detailed in Chapter 3) showed that the tagged proteins behaved in an identical manner to
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Table 4.2: Summary of the Conditions Tested to Solubilise
VP26pp65
CONDITION VARIED PROTEIN
SOLUBILITY
Temperature of induction 
eg 15°C, 20°C, 37°C 1C
+/- Time of induction 
eg 2 hrs -> o/n X
Concentration of IPTG at induction 
eg 0.1 mM 2mM X
Temperature, time, concentration of IPTG at 
induction ie multiple combinations X
Aeoo at induction 
eg 0.2 —> 0.5 X
Buffers in sonication 
eg MES, CAPS etc X
pH of elution buffers 
eg pH 4.5 -> pH 8.0 X
Use denaturant to solubilse and purify 
le 6M GuHCI / 8M Urea ✓
Table 4.3: Summary of the Purification Protocol for VP26pp65
(pET35pp65)
Step Procedure
1 from a single colony of BL21 cells transfected with pET35pp65, 
grow a 100ml culture, in a 11 flask, to A6oo=0.5, at 37°C shaking
2 induce culture: ImM IPTG, 2-4h, 37°C shaking
3 harvest: 3000 rpm, 10 min
4 resuspend pellet in 10ml of Sonication Buffer by probe sonication
5 spin: 10000 rpm, 10 min
6 resuspend pellet in 10ml of Buffer A by sonication, mix lh, rt
7 spin: 10000 rpm, 10 min
8 mix supernatant with 500pl of pre-equilibrated Ni-NTA, lh, rt
9 load onto column, wash: Buffer B (20ml)
Buffer C (10ml) 
Buffer D (10ml)
10 elute VP26pp65 protein: Buffer E (3 ml)
11 dilute protein 2-fold in NTE
12 dialyse protein against NTE
13 spin: 80000rpm, 10 min
14 remove supernatant fraction: SOLUBLE VP26pp65 IN NTE (0.5- 
l.Omg/ml)
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wild type proteins in several different transfection experiments. This strongly supports the 
idea that the presence o f extra amino acid sequences at these points of the respective 
genes, does not alter normal protein functioning (see Chapter 5 for clarification of this 
point for VP26pp65).
One wish had been to purify VP26pp65 at concentrations high enough for structural 
analysis, especially NMR. For this purpose concentrations greater than lOmg/ml were 
needed. To solubilise the VP26pp65 protein a large range of approaches were tried and 
these are summarised in table 4.2. Although a variety of solubilisation and purification 
conditions were tested, it was only possible to produce soluble and non-denatured 
VP26pp65 protein at concentrations of 0.5-1.Omg/ml. A complete summary of the 
expression and purification protocol is detailed in table 4.3. Although the quantities of 
soluble protein produced were not high enough for NMR analysis, they were good 
enough to utilise in interaction assay systems (see Chapter 5). The time and effort were 
well spent.
It is interesting to speculate as to why VP26 is so insoluble, compared to the larger VP5 
molecule. When examining the 3D image reconstructions of capsids, it is evident that the 
VP5 molecules exist within the capsomeres as finger-like structures which appear to have 
limited contact with each other (Zhou et a/7 1998b). This is in stark contrast to VP26 
which lies on top of the hexon and when looking down appears to cover the upper surface 
o f the hexon. These observations could indicate that VP5 has only a small proportion of 
its mass involved in binding, whereas a large proportion of VP26 may be involved in 
binding. It is therefore likely that VP26 has many hydrophobic domains covering a large 
percentage o f its surface area and in the absence of VP5, to guide correct assembly, it 
forms aggregates in solution.
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CHAPTER 5
C H A R A C TE R IS A T IO N  OF VP26pp65 AND M A PPIN G  THE  
PO IN TS OF IN TE R A C TIO N  BETW EEN VP 26 A N D  VP5
Results Chapter 5
1. Introduction
There were several approaches taken to study the interaction of VP26 with VP5 and 
these shall be discussed in this chapter.
VP26 had been shown to be located at the tips of the hexons and not pentons (Booy et 
al, 1994; Trus et al, 1995; Zhou et al, 1994, 1995). However, since VP5 makes up both 
the hexons and pentons, the mechanism which excludes VP26 from the pentons is not 
clear. Several suggestions have been made to address this dilemma; Trus et al (1995) 
have proposed that there may be conformational differences between VP5 hexons and 
VP5 pentons, which only allow VP26 to attach to the hexons; Zhou et al (1995) 
suggested that VP26 may form hexamers in solution, which will then geometrically only 
fit onto the hexon tips and not the penton tips.
To investigate the properties o f VP26 and the interaction with VP5 in more detail, the 
bacterially expressed protein VP26pp65 (described in Chapter 4) was utilised in a series 
of assay systems. The initial study undertook to validate that the soluble and purified 
VP26pp65 protein was structurally and functionally correct and could attach to VP26- 
capsids. This was followed by a series of experiments to examine the structure, 
oligomeric status and binding properties if VP26pp65 with VP5. Together with cryo- 
EM analyses, a clearer picture of the molecular mechanism of VP26-VP5 interaction 
was revealed.
2. Functional Validity of VP26pp65
2.1 Reattachment of VP26pp65 to VP26 Minus (VP26-) Capsids
From immunofluorescence studies (Chapter 3) it was clear that the presence o f extra 
sequences at the N-terminus, contributed by the pp65 epitope tag, did not interfere with 
the binding of VP26 to VP5. SDS-PAGE analysis of the purified VP26pp65 (Chapter 
4), had confirmed that the bacterially expressed protein was in a very pure form, as only 
a single band was evident, running at the correct Mr (14733 Da). Throughout the 
purification process, VP26pp65 was in the presence of denaturant which would have
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disrupted the structure. It was hoped that following dialysis to remove the denaturant, 
the protein would re-fold correctly. To determine if this was the case and whether the 
VP26pp65 protein was functional, capsids lacking VP26 (VP26- capsids) were made 
and the VP26pp65 protein mixed with these to see if it would bind at the correct 
location.
2.1.1 Preparation of Capsids
Capsids lacking VP26 (VP26- capsids) were prepared in two ways:
(i) GuHCl Stripped HSV-1 Capsids
Normal wild type capsids were made in BHK C l3 cells (Methods, Section 2.25). The 
VP26 protein was then stripped from these capsids by treatment with 2M GuHCl, or 4M 
urea, as described by Newcomb and Brown, 1991. They had shown that greater than 
95% o f VP26 and VP22a could be removed by this treatment with only limited loss of 
other capsid proteins. It should be noted that the pentons were also removed during this 
treatment but, the hexons remained intact. Subsequently, cryo-EM analysis (Booy et al, 
1994) revealed that these capsids were structurally intact and their icosahedral symmetry 
was not affected. They went on to demonstrate that VP26, removed in this manner, 
could be re-attached to the stripped capsids at the correct location.
It was assumed that if re-natured VP26pp65 had the correct secondary structure and 
was functional, it would reattach to unoccupied binding sites of native VP26, in both the 
VP26- recombinant capsids and the GuHCl stripped capsids. Initially GuHCl stripped 
capsids were used in the VP26 re-attachment experiments as these were easier to 
produce in large quantities and at high concentrations, than the recombinant capsids. 
Wild type capsids were therefore diluted to 1.0-1.5 mg/ml in NTE containing 2M 
GuHCl and mixed for 30 min at 4°C. The capsids were pelleted through 1ml of a 40% 
(w/v) sucrose cushion at 50000 rpm for 15 min, in Beckman 11x34mm tubes. This 
pelleted capsids and left the stripped proteins above the sucrose cushion [see figure 5.5, 
Panel (i)]. The pellet was washed, resuspended in NTE and stored at -70°C until 
required for re-attachment experiments.
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Figure 5.1: pAcAB3 Baculovirus Transfer Vector
EcoRI (10096)
BstEII (922)
AlwNI (9326)
ori
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Seal (8369)
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Bell (2231)Am p
Ndel (7678)
EcoRI (7455)
polyhedrin prom oter
p10 prom oter
Nael (3769) 
B elli (4454)
Eael (7227)
p10 prom oter
EcoRI (4448)
HindllI (6439)
Hindlll (5393) StuI (4704)
BamHI (4960)
Xbal (4709)
Smal (4955)
Figure 5.1: This shows pAcAB3, a baculovirus transfer vector, which consists of 
10096 base pairs. There are 3 promoters (represented by the triangles), a single origin 
o f replication (rectangle) and an ampicillin resistance (AmpR) gene (large arrow). The 
restriction enzyme sites and their location are marked around the plasmid, with the 
unique sites underlined.
This figure is not drawn to scale.
Figure 5.2: Cloning Strategy to Generate pAcAB3.1
pAcUL26.5 + Bglll 
j  DIGEST 
UL26.5 (Bglll) = 1 0 7 1 bp
pAcAB3 +BamHI 
|  DIGEST 
pAcAB3 (BamHI)
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pAcAB3.1
EcoRI
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A m p
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p10 prom oter
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p10 prom oter
EcoRI
Hindll I
UL26.5
StuI
Sinai Xbal
Figure 5.2: This shows the cloning strategy used to insert Bglll digested UL26.5 
(1071 base pairs), from pAcUL26.5 (J Tatman, 1996), into BamHI digested 
pAcAB3. This ligation resulted in the loss of the Bglll site and generated a vector 
encoding UL26.5 (yellow box) which was designated pAcAB3.1.
This figure is not drawn to scale.
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(ii) Recombinant Capsids
J Tatman (Tatman et al, 1994) had cloned all the capsid genes into the baculovirus 
transfer vector, pACNPV, and created recombinant baculoviruses each expressing a 
single capsid gene. She had also shown that capsids lacking VP26 could be made and 
purified using this system. However, it was very time consuming to grow and titre virus 
stock for each capsid protein. Belyaev & Roy (1993) had reported that more than one 
foreign gene could be cloned into the baculovirus expression vector, with the successful 
expression o f target proteins. It was felt that producing a baculovirus construct which 
encoded more than one capsid protein was an attractive prospect and would be 
extremely useful. The task o f growing and titering many viruses individually would be 
reduced. A triple construct was therefore made which expressed VP5 (UL19), 
preVP22a (UL26.5) and VP19c (UL38).
The cloning procedure was performed using the strategies described in Methods. 
Basically, the ORF of UL26.5, UL38 and UL19 were removed from a series o f 
constructs, by digestion and ligated into a version of the baculovirus expression vector 
pAcAB3 (Pharmingen). The expression vector is shown is figure 5.1. It is 10096 base 
pairs and contains several unique restriction enzyme sites for cloning the desired genes. 
These are located downstream from three strong promoters, two plO promoters and one 
polyhedrin promoter. Each o f these were used to clone a single capsid protein ORF 
under their control, therefore ensuring high expression levels of each protein.
Initially pAcUL26.5 (Tatman et al, 1994) was Bglll digested, to release a 1071 base pair 
fragment containing the UL26.5 ORF. This was cloned into BamHI digested pAcAB3 
(see figure 5.2). When Bglll and BamHI overhanging ends are ligated, the resulting 
sequence is not recognised by either enzyme. The BamHI site was therefore lost from 
the plasmid, designated pAcAB3.1. A series o f diagnostic restriction enzyme digests 
were performed to confirm the correct orientation of UL26.5 ie should be read from 
right to left, under the control o f a pi 0 promoter.
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Figure 5.3: Cloning Strategy to Generate pAcAB3.4
pAcUL38 i- Xbal/HincIII pAcAB3.1 + Xbal/StuI 
|  DIGEST |  DIGEST
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LIGATE
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A m p
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polyhedrin prom oterEcoRI
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p10 prom oter
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UL38
Hindi 11
UL26.5
Sinai Xbal
Figure 5.3: This shows the cloning strategy used to insert Xbal/HincIII digested 
UL38 (1482 base pairs), from pBJ382 (Nicholson et al, 1994), into Xbal/StuI 
digested pAcAB3.1. This ligation resulted in the loss of the StuI site and generated a 
double vector encoding UL26.5 (yellow box) and UL18 (blue box) which was 
designated pAcAB3.4.
This figure is not drawn to scale.
Figure 5.4: Cloning Strategy to Generate pAcAB3.6
pAcUL19 + Bglll 
|  DIGEST
UL19 (Bglll) = 4185bp
pAcAB3.4 + Bglll
|  DIGEST
pAcAB3.4 (Bglll)
LIGATE
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ori
A m p
Bglll
UL19p 10 prom oter
EcoRI polyhedrin prom oter
Bglll
p 10 prom oter
EcoRI
UL38
Hindlll UL26.5
Smal Xbal
Figure 5.4: This shows the cloning strategy used to insert Bglll digested UL19 
(4185 base pairs), from pBJ196 (Nicholson et al, 1994), into Bglll digested 
pAcAB3.4. This ligation was the final step in creating a triple construct expressing 
UL26.5 (yellow box), UL18 (blue box) and UL19 (red box) which was designated 
pAcAB3.6.
This figure is not drawn to scale.
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Xbal/HincII digestion of UL38, from pBJ382 (Nicholson et al, 1994), released a 1482 
base pair fragment containing the UL38 ORF. Ligation of this fragment into Xbal/StuI 
digested pAcAB3.1, resulted in the rebuilding of the Xbal site, but the loss of the StuI 
site from the plasmid (see figure 5.3), termed pAcAB3.4. Consequently, the UL38 gene 
was placed under the control of the polyhedrin promoter and orientated from left to 
right.
Finally, pAcAB3.4 was Bglll digested and ligated with Bglll digested UL19 to generate 
pAcAB3.6 (see figure 5.4). The UL19 ORF was isolated from pBJ196 (Nicholson et al,
1994) as a 4185 base pair fragment. The correct orientation, ie encoded from left to 
right under the control of a plO promoter, was confirmed by a series o f restriction 
enzyme digests.
The pAcAB3.6 plasmid DNA, together with Bsu 361 digested pAK6 baculovirus DNA, 
was transfected on Sf21 cells with CELLFECTIN reagent (see Methods, Section 2.3.7). 
Recombinant virus was isolated through 3 rounds o f plaque purification to produce low 
titre pAcAB3.6 virus stock (see Methods, Section 2.3.2). The expression of all three 
capsid proteins was confirmed on an analytical protein gel and high titre stocks were 
subsequently grown (Methods, Section 2.3.3).
To produce VP26- capsids, 300ml of Sf21 cells were infected with 5pfu/cell (as 
described in Methods, Section 2.3.8) of the recombinant baculoviruses pACUL18, 
pAcUL26 and pAcAB3.6 and harvested 48-65h post infection. Upon purification 
through a sucrose gradient, a distinct single B capsid band was observed. This showed 
that pAcAB3 .6 could be successfully used in the production of recombinant capsids.
To serve as control samples, capsids containing VP26 (VP26+ capsids) were also made 
in two ways:
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Figure 5.5: Attachment of VP26pp65 to VP26- Capsids
(i)
66.OK 
46.OK
30.OK 
21.5K
Figure 5.5: Silver stained gels. Panel (i) shows wild type B capsids (lane 2) and 
capsids which have been stripped of their VP26 protein (ie VP26- capsids) by 
treatment with GuHCl (lane 3).
Panels (ii) and (iii) show attachment of VP26pp65 to GuHCl stripped VP26- 
capsids, to generate VP26pp65+ capsids:
In panel (ii), lane 1 represents purified VP26pp65 protein, lanes 2 and 3 show the 
profile of wild type B capsids and lanes 4-13 show the gradient fractions (collected 
from the bottom to the top, respectively) following reattachment o f VP26pp65 to 
capsids (ie VP26p65+ capsids).
In panel (iii) the capsids were not banded on a gradient but pelleted through a 40% 
(w/v) sucrose cushion. Lane 1 shows wild type B capsids, lane 2 VP26-capsids and 
lane 3 the pelleted VP26pp65+ capsids. Lane 5 shows purified VP26pp65 for 
comparison purposes.
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(iii) Wild Type HSV-1 capsids; made by infecting BHK C13 cells with HSV-1 virus (see 
Methods, Section 2.2.5).
(iv) Fully Recombinant Capsids; made by infecting S£21 cells with recombinant 
baculoviruses expressing all the capsid proteins (see Methods, Section 2.3 .8).
2.1.2 Attachment of VP26pp65 to VP26- Capsids
Since 6 copies of VP26 are present on the tips of each hexon, 900 copies of this protein 
are present in each capsid. VP26 therefore constitutes approximately 6.7% of the total 
capsid mass. Based on these calculations, VP26pp65 was mixed with VP26- capsids (ie 
either pAcUL35 minus recombinant capsids or GuHCl stripped capsids) in slight excess, 
at concentrations equivalent to 9% of the total capsid mass, to ensure that the vacant 
hexon binding sites would be saturated.
VP26pp65 in NTE was mixed with capsids, in a volume of approximately 200pl, and 
rotated end-over-end at rt for 2h. To determine if VP26pp65 had attached to the capsids 
samples were purified on 10-40% sucrose gradients. An extremely faint capsid band was 
evident. This was attributable to the small quantity of capsids used on a 13ml gradient. 
Therefore 0.5ml fractions were collected across the gradient by puncturing the bottom 
o f the tube. The samples were spun at 13000 rpm for 10 min in a microfuge, to pellet 
the capsids, resuspended in lx  loading buffer and analysed on a 15% PAGE minigel. 
Gradient fractions were run in parallel with wild-type B capsids, purified VP26pp65 and 
molecular weight markers. Proteins were visualised by silver staining (Methods, Section 
2.1.5) as shown in figure 5.5, panel (ii).
It is clear from the gel that the VP26pp65 protein has attached to the VP26- capsids, 
generating VP26pp65+ capsids. A protein of the expected Mr (14700Da) was evident. 
There was no doubt that the VP26, attached to the VP26- capsids, represented 
VP26pp65 for two reasons. The presence o f the bacterially expressed protein was 
confirmed by its greater molecular weight, due to the extra tag sequences at the N-
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terminus, compared to wild-type VP26 (see figure 4.4) and a Western blot was 
performed which detected the pp65 tag of VP26pp65 (not shown).
Analysing fractions on gradients takes large amounts of sample and much analysis. Now 
that it had confirmed that the VP26pp65 protein was attaching to capsids, an alternative 
purification procedure was developed. The VP26pp65+ capsids were pelleted through 
200pl o f a 40% (w/v) sucrose cushion, at 50000 rpm for 15 min in a Beckman 
ultracentrifuge (rotor TLS 55). The pellet was washed in NTE and re-concentrated by 
spinning at 50000 rpm as above. This time the pellet was resuspended in lx loading 
buffer and run on the minigel in parallel with wild-type capsids, VP26- capsids, purified 
VP26pp65 and the appropriate molecular weight marker. The protein bands were 
visualised by Coomassie brilliant blue staining (Methods, Section 2.1.4). Again the 
presence of VP26pp65 was confirmed attached to the capsids, displaying the desired 
molecular weight, which was greater that wild-type VP26 [figure 5.5, panel (iii)]. In 
addition, when visually examining both the gradient and pellet fraction of VP26pp65+ 
capsids on the respective gels [ie figure 5.5, panels (ii) and (iii)], it seemed that the 
VP26pp65 protein was present at a similar molar ratio as VP26 in wild-type capsids. As 
previously mentioned, the VP26 protein constitutes approximately 6% of the total 
capsid mass and so it should be present as a fairly minor band in a capsid protein profile. 
This was indeed the case for the VP26pp65+ capsids purified by both methods. 
Although the various capsid protein concentrations were not quantified, the VP26pp65 
was not present in great excess, which would be indicative of non-specific binding.
As purifying the capsids by gradient fractions and simple pelleting produced similar 
results, pelleting became the method of choice for purifying VP26pp65+ capsids as the 
samples tended to be more concentrated and easier to analyse.
2.1.3 Cryo-EM Analysis of VP26pp65+ Capsids
It was clear from the minigel analysis of VP26pp65+ capsids that VP26pp65 had 
attached to VP26- capsids. To confirm that the VP26pp65 protein had attached to 
capsids at the correct location and was not non-specifically bound, it was necessary to
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Figure 5.6: Location of VP26pp65 on 
the Capsid
Figure 5.6: This image shows the difference map observed when the mass density 
o f the 3D reconstruction of VP26- capsids was mathematically subtracted from that 
o f capsids containing VP26pp65 (ie VP26pp65+ capsids). The residual star shaped 
masses represent 6 copies of VP26pp65 and confirms their location at the tips of the 
hexons.
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visualise the structure. Dr Wah Chiu and Dr Hong Zhou performed cryo-EM analysis 
and 3D computer reconstructions on a series o f recombinant capsid samples. VP26+ 
recombinant capsids, VP26pp65+ recombinant capsids and VP26- recombinant capsids 
were all sent to them for analysis.
They had previously visualised the location of wild-type VP26 on capsids (Zhou et al,
1995) by mass difference analysis o f capsids lacking VP26 and wild-type capsids. This 
showed VP26 on the tips of the VP5 hexons, but absent from the pentons. Six copies of 
VP26 were present on each hexon and formed a star shaped arrangement.
If  VP26pp65 had attached to the capsids at the correct location, then an identical star­
shaped difference pattern would be expected. This was indeed the case when 
VP26pp65+ capsids were examined. Figure 5.6, panel (ii), shows the difference map 
observed when the mass density o f the 3D reconstructions o f VP26- capsids was 
mathematically subtracted from that o f VP26pp65+ capsids. It is evident that the 
residual star shaped masses closely resembles those seen by Zhou et al, 1995, and 
confirms the location o f VP26pp65 proteins on the tips of the hexons.
This confirms that the bacterially expressed VP26pp65 protein has reacted correctly 
with the capsids. It shows indubitably that purified VP26pp65 in NTE has the ability to 
adapt the correct secondary structure and therefore is functionally and structurally valid.
3. Identification of the N-terminus of VP26pp65
As previously described (Chapter 4, Section 2.1.2) VP26pp65 has 24 amino acids 
present at the N-terminus o f the protein, which are not present in the wild-type protein. 
These additional sequences increase the mass o f VP26pp65 by approximately 20%. 
They clearly do not interfere with secondary structure or prevent correct attachment of 
this protein to the capsid. If the additional mass was present in an ordered conformation, 
it should be possible to detect it in the capsid structure by cryo-EM analysis and 3D 
image reconstruction. A study was therefore undertaken to try and visualise this extra 
mass and thus identify the N-terminal region of VP26.
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Figure 5.7: Comparison of 3D Image Reconstructions of
VP26-, VP26+ and VP26pp65+ Capsids
Figure 5.7: Panels (i), (ii) and (iii) show images generated from VP26- 
recombinant capsids (column A), VP26+ recombinant capsids (column B) and 
VP26pp65+ recombinant capsids (column C). To look for the presence of 
additional masses, hexons were computationally isolated for each capsid type 
(Panel (ii) shows the top view and panel (iii) shows the side view), and 
difference maps between them generated. The location of VP26 was revealed 
by the difference map between VP26+ and VP26- hexons (shown in green, 
column B). The same procedure was used to produce a difference map 
between VP26pp65+ and VP26- hexons (shown in green, column C). Each 
VP26 difference map was then rendered symmetric by 6-fold averaging and 
the VP26pp65+ hexon and VP26+ hexon compared. This revealed an area of 
extra mass in the VP26pp65+ hexons (shown in pink, column C).
Figure 5.8: Location of an Extra Mass in Averaged
Hexons of VP26pp65+ Capsids
(i) Side View
(ii) Top View
Figure 5.8: The areas of extra mass detected by the difference image o f VP26pp65+ 
capsids and firstly, wild type B capsids (area shown in pink) and secondly, fully 
recombinant capsids (area shown in purple), was present at the same location on the 
hexon. Panel (i) shows the top view and panel (ii) the side view, o f the VP26pp65+ 
hexon.
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To look for the presence of additional mass in VP26pp65, hexons were computationally 
isolated and averaged from each capsid type. Difference maps were then generated (see 
figure 5.7). These were rendered symmetric by a six-fold averaging procedure and the 
structures examined for the presence o f consistent differences.
Figure 5.7, column A represents VP26- capsids, column B represents VP26+ (or wild 
type) capsids and column C represents VP26pp65+ capsids. The difference map 
between VP26- capsids and wild type capsids, is represented in green, panels (ii) and
(iii), column B. Here the expected star-shaped arrangement o f VP26 is evident. 
Similarly, when the difference map between VP26pp65+ capsids and VP26- capsids was 
generated, a star-shaped arrangement was also seen (panels (ii) and (iii), column C).
When the VP26pp65+ capsid reconstruction (column C) was compared with the wild- 
type reconstruction (column B), a difference map was produced which pin-pointed an 
area o f extra mass present only in the capsids containing the VP26pp65 protein (column 
C, area shown in pink). The VP26pp65+ capsid reconstruction was then compared with 
the fully recombinant reconstruction and the difference map again highlighted an area of 
extra mass in the VP26pp65+ capsids (figure 5.8, area shown in purple). The areas of 
extra mass detected from both difference maps were superimposable (figure 5.8) and 
present in the part o f the hexon known to be formed by VP26. Since no other consistent 
differences were observed between VP26+ capsids and VP26pp65+ capsids, this 
strongly suggests that the area of extra mass detected, correlates directly with the 
location o f the N-terminus, where the tag sequences were inserted into VP26pp65.
4. Characterisation of VP26pp65
As it was now evident that my purified bacterially expressed VP26pp65 protein was a 
suitable model for native VP26, I wanted to study the properties o f the protein further. 
Nothing was known about the oligomeric status o f the protein or content o f the 
secondary structure.
Figure 5.9: Elution Profile of VP26pp65 from the 
Superdex 75 Column
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Figure 5.9: This shows the profile detected when VP26pp65 was analysed by FPLC 
using a Superdex 75 column. The VP26pp65 was added at 0.2mg/ml in NTE. The 
elution positions o f the 14kDa lysozyme, 24kE)a trypsin and 66kE)a BSA markers are 
shown at the top of the profile.
Each box on the x-axis (elution volume) represents approximately 2ml.
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4.1.1 Oligomeric Status of VP26pp65
As mentioned previously, the mechanism by which VP26 attaches to the VP5 hexons 
and not pentons is not clear. One theory (Zhou et al, 1995) suggested that VP26 
spontaneously forms hexamers in solution which will only fit onto the hexons. To test 
this theory, the VP26pp65 protein was sized by FPLC through a Superdex 75 column 
(see Methods, Section 2.9) to determine its oligomeric status in solution. The column 
was equilibrated o/n in equilibration buffer (20mM tris-HCl pFI 8.0, 500mM NaCl, 5% 
glycerol, ImM DTT) and samples were passed through the column at lml/min with 
protein detected at 280nm.
Known protein standards were diluted to 0.2mg/ml and run through the column. Their 
traces were plotted and used to calibrate the system. Lysozyme has a Mr of 14 kDa and 
the peak was detected 9.4cm from the starting point. Trypsin has a Mr of 24 kDa and 
produced a peak 8.0cm from the starting point. BSA has Mr of 66 kDa and produced a 
peak 6 .6cm from the starting point.
The purified and soluble VP26pp65 protein was diluted to 0.2mg/ml in 200pl, as for 
protein standards, and loaded onto the column. Unfortunately, the signal for VP26pp65 
was much lower than expected, probably due to its insoluble nature, causing the protein 
to precipitate out on the column. However, two peaks were detected which were 
confirmed to be attributable to VP26pp65 by Western blot analysis, with the anti-pp65 
antibody, of the eluted column fractions.
Although the signal produced by VP26pp65 was weak, the pattern of peaks gave an 
indication of the oligomeric status of the protein (see figure 5.9). The first peak was 
seen 7.6cm from the start and the second peak 9.5cm from the start. No other prominent 
peaks were detected. Measuring the points (in cm) from the VP26pp65 protein trace and 
extrapolating them against the known standards, the approximate Mr o f the protein 
could be estimated. The first peak eluted at a slightly higher Mr than trypsin, suggesting 
a Mr of approximately 30 kDa. The second peak was eluted very close to the lysozyme, 
indicative of a Mr o f approximately 14 kDa. VP26pp65 has a Mr of 14733 Da and so
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Figure 5.10: Alignments of the amino acid sequences of three alphaherpesvirus 
[panel(i)] and three betaherpesvirus [panel (ii)] VP26 counterparts, generated by the 
GCG programme Pileup. VZV has 100 additional amino acids (100 aas) at the C- 
terminus, which are unrepresented in the other proteins. The consensus prediction 
(con) is shown in bold underneath each of the alignments.
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this suggested that the protein is forming monomers (expected Mr=approx 14700 Da) 
and dimers (expected Mr=29400 Da). There was a stronger trace picked up for the 
monomer peak than the dimer peak which may be indicative o f a mainly monomeric 
population. It is difficult to draw accurate conclusions about the proportion of 
monomers to dimers in the solution but the ratio appears to be approximately 3:1 
(monomer:dimer). There was no evidence o f any hexameric structures in the solution.
4.1.2 Secondary Structure of VP26pp65
The secondary structure of VP26 is unknown for HSV-1 or any of the other VP26 
homologues in alpha and beta herpesviruses. To try and gain an insight into the 
properties o f HSV-1 VP26, the sequences o f 3 alpha herpesvirus (HSV-1, EHV-1 and 
VZV) VP26 counterparts were fed into the GCG programme, Pileup, to generate an 
alignment and consensus [see figure 5.10, panel (i)]. The same approach was taken to 
generate an alignment for 3 beta herpesvirus (HCMV, HHV-6 and HHV-7) VP26 
counterparts [figure 5.10, panel (ii)]. The proteins within each family are not highly 
conserved in sequence or in length, indeed VZV has an additional 100 amino acids at the 
C-terminus, which are not represented in the other proteins. The HCMV protein shown 
here has recently been identified as the small capsid protein and the gene encoding it is a 
positional homologue o f the HSV-1 gene, UL35 (Gibson et al, 1996). This suggests that 
this protein has a similar role in the HCMV capsid. Apart from the extra sequence of 
VZV, the poorest area of conservation occurs at the N-terminus for both the alpha and 
beta herpesviruses.
Upon examination of the sequence comparisons, it is notable that there is no detectable 
sequence homology between the alpha herpesviruses [panel (i)] and the beta herpesvirus 
counterparts [panel (ii)].
The secondary structure of VP26 was initially predicted by feeding the sequence into the 
neural network based protein predict program, EMBL, Heidelberg (Rost & Sander, 
1994). This program scores the likelihood o f amino acid sequences to form a-helix (H), 
(3-sheet (E) or random loop (L) using multiple alignments of related but non-identical
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Figure 5.11: Consensus protein predictions (EMBL, Heidelberg) for the alpha (HSV-1, 
EHV-1, VZV) and beta (HCMV, HHV-6, HHV-7) VP26 homologues, beginning with 
the first methionine in each sequence. H represents predicted a-helix, E, J3-sheet and L, 
loop. Panel (i) shows the predictions for lower, and panel (ii) for higher stringency 
assignments of secondary structure.
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solved structures. This generates a consensus prediction o f their secondary structure. 
The program assigns a score to each amino acid prediction with a 9 equal to a high 
probability prediction and 1 equal to a poor probability prediction. The programme can 
also assign different stringency levels for the secondary structure predictions produced. 
The alignment or consensus for the 3 alpha and 3 beta herpes viruses (mentioned above) 
was sent for analysis by this programme. The predictions are shown in figure 5.11. What 
is surprising about these predictions is that although the amino acid sequences for each 
protein varied significantly, the predicted secondary structure for each protein follows a 
very similar pattern. For example, the consensus prediction for the alphaherpesviruses 
follows a pattern of a-helix, followed by an area of (3-sheet, then a-helix again etc. This 
is exactly the same pattern predicted for the consensus of the betaherpesviruses. The 
consensus o f the structural predictions of the alpha and beta herpesviruses is shown in 
figure 5.11, starting with the first methionine in each pileup. Panel (i) shows the 
predictions for lower stringency and panel (ii) shows the predictions for higher 
stringency of the secondary structure. The pattern o f predicted structure is extremely 
similar between the alpha and beta herpesviruses and generates a picture o f the proteins 
with extensive loop at both the N- and C-termini with alpha helix in the middle.
Unfortunately this predicted model appears to be wrong, from subsequent CD analysis, 
performed after this work was completed (see Discussion, Section 6). However, it did 
prove useful in interpreting the inhibition and mutation studies described below.
5. Mapping of the Points of Interaction Between VP26 and VP5 
5.1 Development of an ELISA Assay Using VP26 Inhibitory Oligopeptides
I felt that it would be interesting to develop an ELISA system to study the interaction of
VP26 with VP5. This had several advantages over the capsid attachment experiments. 
Firstly, several different interaction conditions could be tested simultaneously, in one 
experiment on a single microtitre plate and so this was a rapid assay system. Secondly, 
the quantities o f protein required for each interaction study were reduced as the assays 
are generally extremely sensitive, this was a considerable advantage due to the difficulty 
o f producing soluble VP26pp65 protein. Thirdly, oligopeptide blocking and mutagenesis
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Fi
gu
re
 
5.
12
: 
M
ic
ro
tit
re
 
Pl
ate
 
Pl
an
 
fo
r 
EL
IS
A 
of 
VP
26
- 
Ca
ps
id
s 
an
d 
VP
26
pp
65
o 0 3zL
LO 0 3
3 .
o
LO CM
o O o
03
CM
-
o
T—
0 3
0 0
h -
CD
i n
CO
CM
-
< CD o a LU LL CD X
C/3 ^  
cp O
cd m
CM (D  C  
CL CL O  
>  CL 03
' 40 „  0  "D <D 
OP CM t/3 £  
t -  CL a  o  
>  TO COo
CM
LO’
CD
LO
CM
CO
CM
"3"
CD
CM
CO
CD
CO
3
CD
to;o
'toa.ttso
■
CO
CM
%
oco
o
Figure 5.12: This is a schematic representation of a microtitre plate showing details the 
contents of each well. Column A was blank and used to calibrate the readings against 
the developing reagent alone. The shaded area was coated with VP26- capsids, o/n at 
37°C, at the concentrations shown (NB, initial concentration of VP26- capsids was 
approximately 2mg/ml) and reacted, in duplicate with the 3 amounts (0.50p.g, 0.25pg, 
O.lOpg) of VP26pp65. Control wells were also included. These contained VP26- 
capsids, PBS and VP26pp65 which were added to the wells o/n at 37°C. These had no 
VP26pp65 added to them at subsequent stages.
Figure 5.13: Optimisation of ELISA Conditions for the
Interaction of VP26pp65 with VP26- Capsids
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Figure 5.13: 0.5pg [panel (i)], 0.25pg [panel (ii)] and 0.1 pg [panel (iii)] o f VP26pp65 
protein was reacted against VP26- stripped capsids, diluted from 1:8- 2-fold- to 1:128, 
in an ELISA type assay.
(NB Initial concentration of VP26- capsids was approximately 2mg/ml)
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assays could be developed to map the points of interaction. Lastly, the assays were 
initially set up using VP26- capsids to ensure that the ELISA system worked. However, 
once this had been established, a system was developed which utilised VP5 (191 A) and 
VP26pp65 and had no requirement for capsids. This reduced the effort required to 
produce VP26- capsids.
5.1.1 Optimising ELISA Conditions; VP26- Stripped Capsids + VP26pp65
The ELISA protocol detailed in Methods, Section 2.10 was followed. Stripped VP26-
capsids, at 2mg/ml, were diluted 2-fold in NTE from 1:8 to 1:512. The diluted capsids 
were used to coat the microtitre wells o/n at 37°C. NTE alone was used to coat control 
wells. After blocking non-specific binding sites with BSA, VP26pp65, at an initial 
concentration of lmg/ml, was diluted and added to the wells at 0.50pg, 0.25pg and 
0.1 Opg per well, for lh  at 37°C (see mictrotitre plan, figure 5.12). Unbound VP26pp65 
was washed off with PBS containing 0.1% Tween 20 and the primary antibody, pp65, 
added at 1:800 dilution. Binding was detected with the secondary antibody, GAM- 
peroxidase conjugate (1:800), and the signal developer (supplied by Kindergaard & 
Perry Laboratories) The activity was detected at A405 on a Multiskan plate reader 
(Titrtek; ICN Biomedicals).
Figure 5 .13 shows the results obtained from a series of experiments. Panel (i), (ii) and 
(iii) show the absorbance values obtained when 0.50pg, 0.25pg and O.lOpg respectively, 
o f VP26pp65 protein was tested against the various dilutions of stripped capsids. From 
these graphs it is evident that in each case, 1:8 gave the highest A405 values. It is clear 
that either 0.50pg or 0.25pg o f VP26pp65 protein per well, produced a high absorbance 
value, at 0.77 and 0.74 respectively. Since the signal with less VP26pp65 protein was as 
strong, 0.25pg was chosen as the optimal VP26pp65 concentration for this assay. Note, 
an A405 of <0.05 was detected for the control wells containing no VP26- capsids.
This series of experiments showed that it was possible to develop an ELISA based 
system to study the interaction between VP26 and capsids. However, a large amount of
- 1 2 0  -
Figure 5.14: Optimisation of ELISA Conditions for the
Interaction of VP26pp65 with VP5 (191 A)
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Figure 5.14: 0.5pg [panel (i)], 0.25pg [panel (ii)] and 0.1 jig [panel (iii)] o f 
VP26pp65 protein was reacted against 191 A, used neat (N) and diluted from 1:2, 2- 
fold, to 1:512, in an ELISA type assay.
(NB The initial concentration of 191A was approximately lmg/ml).
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effort was required to produce VP26- capsids for this system since either wild type 
GuHCl stripped capsids, or VP26- recombinant capsids had to be made. The task of 
making capsids involved labour intensive procedures to grow and titrate virus stocks, 
passage and maintain cell lines and harvest and purify capsids. It was decided that a 
working ELISA system which could utilise VP5 alone, with VP26pp65 would be 
extremely useful.
5.1.2 Optimising ELISA Conditions; Purified VP5 (191A) + VP26pp65
As described in Chapter 4, Section 3, UL19 had been cloned, with a 6xhis tag, into a
baculovirus expression vector. VP5 (191 A) was expressed to high levels in the Sf21 
cells. The protein was readily solubilised and purified through Ni-NTA in low 
concentration o f imidazole in PBS. 191A was therefore an ideal protein to use in the 
development o f a new VP26-VP5 interaction ELISA system.
Purified 191 A, at 1 mg/ml, was used neat and diluted 2-fold in PBS, from 1:2 to 1:512, 
and used to coat the microtitre wells, o/n at 37°C. Wells containing PBS alone were 
included as controls. VP26pp65 was again used at 0.50pg, 0.25pg and O.lOpg per well 
and reacted with the primary pp65 antibody. Absorbance values were detected by 
addition o f the secondary antibody and signal developer.
Figure 5.14, illustrates the results obtained from a series of experiments. Firstly, the 
most important point to note is that this approach has been successful and an interaction 
has been detected between 191A and VP26pp65. Panels (i), (ii) and (iii) show the 
Absorbance values obtained when 0.50pg, 0.25pg and 0.1 Opg respectively, of 
VP26pp65 protein were tested against the various dilutions of 191 A. From this figure, it 
is clear that either 0.50pg or 0.25 pg o f VP26pp65 per well, produces a good interaction 
with VP5 (191 A). The optimal conditions were set by the lowest dilutions of 191A and 
VP26pp65 which gave the highest Absorbency values. Panel (i) shows that 191 A, 
diluted to 1:4, with VP26pp65, at 0.50pg, gave the overall highest reading of A4o5=0.74. 
However, this was not significantly higher than the value obtained when less 191A ( 1:8 
dilution) was reacted with less VP26pp65 (0.25pgAvell). In this instance the A405= 0.69
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Figure 5.15: Panel (i) shows the UL35 amino acid sequence with the 10 overlapping 
oligopeptides displayed below. Panel (ii) details the specific length and name for each 
oligopeptide sequence.
Table 5.1: Summary of 35/1-35/10 Oligopeptide Analysis
Name Predicted Yield 
(mg)
Actual Yield 
(mg)
Purity (%)
35/1 44.25 36.10 70.00
35/2 41.49 34.87 88.22
35/3 44 . 63 40.29 74.70
35/4 42.47 31.00 80.24
35/5 43.91 29.14 91.94
35/6 40.38 36. 90 98.8
35/7 43.17 36. 94 84.58
35/8 43.75 30.40 74.40
35/9 44.03 32.90 94.86
35/10 60.89 34.80 90.77
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[see panel (ii)]. The optimal conditions for this ELISA reaction were therefore 
designated as:
• 191A = 1:8 of 1 mg/ml
• VP26pp65 = 0.25ug/well
This system shows that intact capsids are not required for VP26 to interact with VP5 
and it was possible to set-up an interaction study in their absence.
5.1.3 Blocking the Interaction of VP5 -VP26 With UL35 Oligopeptides
As VP26 is a relatively short protein, consisting of only 112 amino acids, it was possible
to produce short oligopeptides which spanned the entire sequence of UL35. It was 
proposed that these oligopeptides could be used in the VP5-VP26 ELISA system to try 
and block the interaction between the two proteins. By disrupting the binding site, it 
would be possible to map the parts of VP26 important in its interaction with VP5.
5.1.3.1 Synthesis o f  UL35 Oligopeptides
A series of 10 oligopeptides were made which spanned the entire sequence of UL35. 
The oligopeptides overlapped by 10 amino acids [see figure 5.15, panel (i)] and were all 
20-mers except 35/5 and 35/10 [see figure 5.15, panel (ii)]. 35/5 was only 19 amino 
acids in length as its C-terminus contained 3 alanines in succession. It was felt that it 
might be difficult to correctly couple 3 identical and sequential amino acid residues at a 
terminal end. The oligopeptide was therefore shortened to 19 amino acids to remove 1 
o f the alanines. The final oligopeptide, 35/10, was 22 amino acids in length to ensure 
that entire sequence o f UL35 was represented. All the oligopeptides were synthesised on 
the PSSM-8 synthesizer (see Methods, Section 1.3) as amines, except 35/10, which was 
synthesised as an acid as it constituted the C-terminal end. The oligopeptides were all 
cleaved for 5h in Reagent K (Methods, Section 2.4.2) and dissolved in dH20 . A good 
yield and purity was obtained for each (see table 5.1).
5.1.3.2 Blocking ELISA; Disruption o f VP5-VP26 Interaction
For ELISA reactions, a ImM stock of each oligopeptide was prepared in 1ml o f dH20.
Before blocking assays were set-up, all 10 oligopeptides were tested in duplicate against
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Figure 5.16: Oligopeptide (35/1 - 35/10) Interaction with
pp65 Antibody
VP26
191A pp65 1 2 3 4 5 6 7 8 9  10
A 
B
Figure 5.17: Oligopeptide (35/1 - 35/10) Inhibition of the 
VP26 - VP5 Interaction
(i) ELISA Wells
B
(control)
(ii) A405 Values
1.4
control
0.8
0.6
0.4
0.2
0.0
all 35/1 35/2 35/3 35/4 35/5 35/6 35/7 35/8 35/9 35/10
OLIGOPEPETIDES
Figure 5.16: To confirm that that oligopeptides 35/1 to 35/10 did not cross 
react with the pp65 antibody, a microtitre plate was coated with each 
oligopeptide in duplicate (see wells 1-10, rows A and B respectively). These 
were reacted with the pp65 antibody in an ELISA type assay. No reaction was 
detected and absorbance values were comparable with the negative control 
(see rows A and B, 191 A). A positive control, containing the VP26pp65 
protein was included to validate the assay (see rows A and B, VP26pp65)
Figure 5.17: Panel (i) shows the results of an ELISA assay when all the 
oligopeptides were tested together (row A, first well) and individually, ie 
oligopeptides 35/1 to 35/10 are found in row A, wells 2 to 11, from left to 
right respectively. The oligopeptides were used to inhibit the binding between 
VP26pp65 and VP5. An example of a control well, with no oligopeptide 
present is shown in row B.
Panel (ii) shows the A405 values obtained for the assay. The control well 
produced a consistent A405 of approximately 1.2 over several repeats 
(represented by the dashed line). However, the presence of the oligopeptides 
caused a variation in absorbance (refer to text, section 5.1.3.2).
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the anti-pp65 antibody, to ensure that they did not cross-react with it. The microtitre 
wells were coated with 50p moles of each oligopeptide, o/n at 37°C. VP26pp65 (1:8) 
and 191A (1:8) were included as positive and negative controls. The pp65 antibody was 
reacted at 1:800 and detected with the GAM-conjugate and the signal developer.
It is clear from figure 5.16 that the only positive signal with the pp65 antibody, was 
when VP26pp65 was used to coat the wells. In this instance, the A405=0.7. In all other 
wells no reactivity was seen and the A405 <0.05.
To set up the blocking ELIS As, microtitre wells were coated o/n at 37°C with 191 A, as 
previously described. The VP26pp65 protein was added to each well at 0.25pg in 
parallel with either a single peptide, or all 10 oligopeptides together, each at 50p moles 
per well. This set up a competition assay where VP26pp65 and the oligopeptide would 
compete for the binding site on 191 A. As the protein and oligopeptide were added in 
parallel, each had an equal chance of binding to 191 A. VP26pp65 and the appropriate 
oligopeptide were reacted with 191A for lh at 37°C. A control row, containing VP5 
and VP26pp65 alone, with no oligopeptide, was also included for comparison purposes. 
The reaction was developed with GAM-conjugate and the signal developer.
Figure 5.17 (panel (i), row B) shows that there was no inhibition in binding between 
VP5 and VP26 when no oligopeptide was present. In this case the A405 >1.0. However, 
it can be seen that 3 overlapping oligopeptides, 35/4, 35/5 and 35/6, were causing the 
greatest reduction in binding, with the A405 less than half the control value at <0.5 [panel
(ii)]. Oligopeptide 35/1 was also causing a consistent reduction in Absorbance, 
comparable with the levels observed for oligopeptides 35/4-35/6. When the 3 successive 
wells and 35/1 were compared visually with the control well (VP26pp65 + 191A alone) 
it is obvious that there was a significant reduction in the colour development.
An apparent increase in binding activity was observed in the well containing 35/3. The 
Absorbance values recorded exceeded that of the positive control wells. This was a 
consistent feature which cannot be explained as none of the oligopeptides cross-reacted
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Figure 5.18: The solid line in panels (i) and (iii) represents the position of the 
oligopeptides, 35/4 to 35/6, which caused an inhibition in the binding of 
VP26pp65 to VP5.
Panel (i) represents the UL35 ORF. The * in panel (ii) represents the amino 
acid sequences which are conserved between the alpha herpesviruses and panel
(iii) shows the protein predict (Heidelberg) for the alphaherpesviruses.
Figure 5.19: Location of Restriction Enzyme Sites in UL35
Ncol EcoRI
I  I
pET35pp65: mgsshhhhhhaerktprvtggmgiqavpqfhr
MscI
I
pstvttdsvralgmrglvlatnnsqfimdnnhphpqgtqgavref
Sac 11 EagI
1 I
lrgqaaaltdlglahanntfpqpmfagdapaawlrpafglrrtys 
Xhol
I
pfvvrepstpgtp
Figure 5.19: The amino acid sequence o f VP26pp65 is shown with the positions 
corresponding to unique restriction enzyme sites used in the mutagenesis studies, 
marked by the arrows. The extra sequences in pET35pp65, contributed by the 6xhis 
(double underline) and pp65 (single underline) tags, are also shown.
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Figure 5.20: pET35pp65 [panel (i)] was EcoRI/MscI digested and ligated with the 
complementary oligonucleotides in either panel (ii), (iii) or (iv). This generated 3 N 
terminal deletion mutants respectively. PET35-N has the N terminal 24 amino acids 
deleted. PET35N18 has 18 amino acids deleted at the N terminus. PET35N9 has 9 
amino acids deleted at the N terminus.
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with the pp65 antibody. Apparently, this is a phenomenon which has been previously 
reported to occur using oligopeptides in this type o f blocking ELISA reaction (Howard 
Marsden; personal communication).
The well containing all the oligopeptides together showed a significant decrease in 
binding activity, comparable with the levels observed for oligopeptides 35/4-35/6. It 
seems probable that this reduction in binding would be attributable to the additive effect 
of having multiple inhibitory oligopeptides present.
The fact that 3 consecutive overlapping oligopeptides produced a decrease in binding of 
VP26pp65 to VP5 (191 A) strongly suggests that this area is important for the binding of 
VP26 to VP5. The amino acid sequence encoded by these oligopeptides is located 
between positions 31-70 (see figure 5.18). This is an area with very poor amino acid 
sequence conservation between the alpha herpesviruses [panel (ii)]. However it, includes 
a region of predicted alpha helix (EMBL, Heidelberg) for all 3 alpha herpesviruses 
[panel (iii)]. Furthermore, all the alpha and beta herpesviruses have a similar predicted 
secondary structure, yet poor amino acid sequence homology.
5.2 Attachment of VP26 Mutants to VP26- Capsids
In order to confirm that the region of VP26 contained within oligopeptides 35/4-35/6 
was required for the interaction with VP5 and to further define the sequences important 
for the binding of VP26 to capsids, a series of mutants was constructed. Both insertion 
and deletion mutants of pET35pp65 were made to produce mutated VP26pp65 protein 
for use in an interaction assay system.
5.2.1 Construction of Deletion Mutants
UL35 had several restriction enzyme sites, well spaced and positioned throughout the 
gene (see figure 5.19). These were used to digest and remove portions of the UL35 
ORF thus creating a series o f deletion mutants.
Firstly, deletions of the N-terminal portion of the protein were constructed (see figure 
5.20). An EcoRI/MscI digest, followed by the insertion of two small complementary
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Figure 5.21: pET35pp65 [panel (i)] was Eagl/Xhol digested and ligated with the 
complementary oligonucleotides in either panel (ii), (iii) or (iv). This generated 3 C 
terminal deletion mutants respectively. PET35-C has the C terminal 26 amino acids 
deleted. PET35C18 has 18 amino acids deleted at the C terminus. PET35C9 has 9 
amino acids deleted at the C terminus.
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oligonucleotides, 35NTdel (1) and 35NTdel (2), created pET35-N [see panel (ii)]. This 
removed 24 amino acids from the N-terminus. An identical approach was used to 
generate two other N-terminal deletions. This time after the EcoRI/MscI digest, larger 
oligonucleotides were used to re-build defined portions of the UL35 native sequence. 
pET35N18 was generated by inserting two complementary oligonucleotides, 35N18 (1) 
and 35N18 (2) [panel (iii)], which rebuilt all of the native UL35 amino acid sequence 
between the restriction enzyme sites, except for 18 of the N-terminal residues. Similarly, 
pET35N9 was created by inserting the complementary oligonucleotides 35N9 (1) and 
35N9 (2) [panel (iv)], which regenerated all the appropriate native amino acid residues 
except 9, at the N-terminal end.
Secondly, a series o f C-terminal deletions were made using an identical strategy to that 
described above (see figure 5.21). An Eagl/Xhol digest, followed by the insertion of 
two very small complementary oligonucleotides, 35CTdel (1) and 35CTdel (2), created 
pET35-C [see panel (ii)]. This removed 26 amino acids from the C-terminus. An 
identical approach was used to generate 2 other C-terminal deletions. This time, after 
the Eagl/Xhol digest larger oligonucleotides were used to re-build defined portions of 
the UL35 native sequence. pET35C18 was generated by inserting two complementary 
oligonucleotides, 35C18 (1) and 35C18 (2) [panel (ii)], which rebuilt all o f the native 
UL35 amino acid sequence between the restriction enzyme sites, except for 18 of the 
most C-terminal residues. Similarly, pET35C9 was created by inserting the 
complementary oligonucleotides 35C9 (1) and 35C9 (2) [panel (iv)], which regenerated 
all the appropriate native amino acid residues except 9, at the C-terminal end.
5.2.2 Expression and Purification
Unfortunately, all o f the deletion mutant proteins were very difficult to induce and their 
expression levels were highly variable. Even when glycerol stocks were not used, for 
fear o f plasmid instability, but DNA was transfected each time to produce fresh colonies 
for starter cultures, the expression levels were still poor and any protein which was 
expressed was extremely insoluble. It was thought that the high expression levels of 
pET35pp65 been a factor which had contributed to the protein's insolubility but this 
explanation could not be used for the deletion mutants. The same denaturing and
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solubilisation protocol used for VP26pp65 was followed and the protein was purified 
through Ni-NTA resin (as Chapter 4, table 4.4). However, there was an extremely poor 
purification yield in all cases. Virtually no protein, even in Buffer E, containing 200mM 
imidazole and 8M urea, was eluted. This suggested the deletion mutants were even more 
insoluble than the full length VP26pp65 protein or, that they were not sufficiently 
concentrated to be detected.
As so much time had already been spent developing the solubilisation procedure for 
VP26pp65, it was decided to concentrate on the development of insertion mutants, in 
the hope that these would prove more successful and could be utilised in an assay 
system.
5.3 Construction of Insertion Mutants
Insertional mutants o f VP26pp65 were constructed using the modified Kunkel method 
o f site directed mutagenesis (Kunkel, 1985) (see Methods, Section 2.5.13). This was a 
rapid and efficient site-specific approach which allowed the insertion o f specific bases 
into the UL35pp65 ORF. The approach involved manipulating single stranded viral 
DNA, from M l3 phage, grown in an E coli dut' ung strain. The deficiency o f the dut 
gene, which encodes dUTPase, resulted in an increase o f dUTP. UTP competed with 
TTP for incorporation into the DNA. Due to the absence o f the ung gene, which 
encodes uracil glycosylase, incorporated uracil was not removed. The M l3 phage 
template ssDNA therefore contained a significant amount of uracil residues, ie 20-30 per 
genome. Primers containing the modified sequences were then annealed to the ssDNA 
and the elongation reaction performed with TTP and no dUTP. The resulting dsDNA 
phage contained one strand o f the native sequence, with uracil residues, and one strand 
with the mutant insertion, and no uracils. This phage was grown in E coli dut'  ung . The 
presence of uracil glycosylase removed the uracil bases from the template strand, 
creating lethal abasic sites. This favoured selection o f the mutant strand containing the 
extra inserted sequences.
Figure 5.22: Sequence and Location of 3x Glycine (3xG)
Insertion Primers
(i) pET35pp65.1: rightward 5’ to 3’, position 28 to 66 (bp)
ATCGGTGGTAACGGTaccgccaccGCTGGGGCGTGAAA
(ii) pET35pp65.2: rightward 5’ to 3’, position 58 to 96 (bp)
CATGCCAAGCGCCCGgccgccaccGACGCTATCGGTGGT
(iii) pET35pp65.3: rightward 5’ to 3’, position 63 to 138 (bp)
CTGAGAGTTATTGGTaccgccaccGGCCAAGACGAGCCC
(iv) pET35pp65.4: rightward 5’ to 3’, position 142 to 180 (bp)
CTGGGGGTGCGGGTGgccggtaccGTTGTTATCCATGAT
(v) pET35pp65.5: rightward 5’ to 3’, position 193 to 231 (bp)
GCGGAGAAACTCCCGgccgccaccCACGGCCCTTGGGT
(vi) pET35pp65.6: rightward 5’ to 3’, position 232 to 270 (bp)
ACCAAGGTCCGTCAGgccaccgccgGCCGCCGCCTGACC
(vii) pET35pp65.7: rightward 5’ to 3’, position 274 to 312 (bp)
CTGCGGGGTAAAGGTaccgccaccGTTGTTCGCGTGGGC
(viii) pET35pp65.8: rightward 5’ to 3’, position 322 to 358 (bp)
CCGCAACCAGGCGGCgccaccgccCGGGGCGTCGCCCGC
(ix) pET35pp65.9: rightward 5’ to 3’, position 367 to 405 (bp)
AAACGGTGAATAGGTaccgccaccGCGCCGCAGGCCAAA
(x) pET35pp65.10: rightward 5’ to 3’, position 418 to 456 (bp)
CGGGCCTCACGGGGTaccgccaccCCCGGGCGTCGAAGG
(xi) Location of 3xG insertions in pET35pp65
pET35pp65 mgsshhhhhhaerktprvtggmgiqavpqfhr 
PP LLLLLLL
1 2 3 4 5
Kpnl EagI Kpnl Kpnl EagI
GGG GGG GGG GTG GGG
V  V V V V
pstvttdsvralgmrglvlatnnsqfimdnnhphpqgtqgavref
LLLLLL.HHHHHH...L .EEEEE.. .... LLLLLLLL .HHHHHH
6 7 8 9
EagI Kpnl Narl Kpnl
GGG GGG GGG GGG
V V V V
lrgqaaaltdlglahanntfpqpmftagdapaawlrpafglrrty 
HH . . HHHHHHHHHH . LLLLLLL...... LLLL___ LLLLL . . LL
10
Kpnl
GGG
spfvvrepM:pgtp 
LLLLL LLLL
Figure 5.22: The sequence of the oligonucleotides are shown in panels (i)-(x). The 
native UL35 sequence is shown in capital letters, while the 3xG coding insert is 
represented in lower case letters. The position of the insertions (1-10) within the UL35 
ORF sequence genome is detailed in panels (i) to (x) and their approximate location in 
pET35pp65 marked with an arrow in panel (xi). The restriction enzyme sites which are 
generated as a result o f these insertions are shown.
Panel (xi) also shows the extra sequences in pET35pp65, contributed by the 6xhis 
(single underline) and pp65 (double underline) tags, the location of the sequence 
mapped by the inhibitory oligopeptides, 35/4-35/6, (represented by the dashed line) and 
the protein predict (PP) generated by EMBL, Heidelberg (with L representing loop, H, 
a-helix and E, p-sheet).
Figure 5.23: Sequence Data for pET35pp65.1
5’
1 CAT T GT G GAG C G GAT AAC AAT T C C C C T C T AGAAAAT AAT T T T GT T T AAC T T T AAGAAT GAGA 
59 TACCANGGGTTNNCAGCCATCATCATCATCATCACNCCGAGCGCAAGACGCCCCGCGTCACC 
1 1 7  GGCGGAATGGAATTCAGGCCNTCCCGCAATTTCACCGCCCCACCGGTGGCGGTACCGTTACC 
2 3 3  ACCGATAGCGTCCGGGCGCTTGGCATGCNCGGGCTCNTCTTGGNCACCNATAACTCTCAGTT 
TATCNTGGATAACAACCNCCCGCACCCCNNGGGNACCCNANGGGNCGTGNGGGAATTTCTCC2 9 1
CTCGGTCNNGGGGGGGGGCCTNANAGAACNTTTNTTTTTNTNCACNCNAACANNCNTTTTTA
3 4 9
CCCCCACCNTNTTTTTTTTCGGGGCGANACCCCGCCCCCTTGGTTNTNTGGCCCCCCTTTTT
407
GGCTTNCNGGGGGCNCCNNNTCNCCCNCTTTGTTCTTTCNAAAAACCTTTTAACCCCCCGGG
4 6 5
AACCCCNTTAAGNCCCNGGGGAATTCCNCTCNTGGGGTGTTTCCTNTAAATCTAANAAACCT 
5 2 3  TNTNGGGCGCACTCCNAAANCCACCACCCACACCAACTNAAATTTNCGGGTGCCTAACANAA 
5 8 1  NCCCCAAAAAGGAAAACTNNAATTTGGCTTNTTNCCCCCCNCTGAAACAACTCAACCAACAA 
63 9  TNAACCCCCTTTGGGGGCCTNTTANAACCGGGTCCTTGAAAGGGTTTTTTTGGTTTCANACG 
69 7  GAAGGAAATTATTTTCCCGAATTNGNGCAANCNGGGAACCCCCCCTNTTCCCNGGGGCCCTT 
755 TANACCCCGNNCGGGTNTTNGTTGGTTTACTCCCCCCAACGTTNACCNTN
8 1 3  3’
8 7 1
Figure 5.23: Sequence data for pET35pp65.1. The position o f the 6x his tag is 
shown by the solid line and the position of the 3x glycine insert is confirmed by the 
dashed line. A, T, C and G represent the four DNA bases and N represents a base 
undefinable during the sequence analysis.
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This approach was used to construct 10 mutants in pET35pp65 namely, pET35pp65.1- 
pET35pp65.10 (see figure 5.22). All had extra sequences which, when inserted, allowed 
the creation of a restriction enzyme site. This constituted insertion of 3 glycine residues 
(3xG) at all the points indicated in the figure, except for pET35pp65.4 which had a GTG 
insertion, ie glycine, threonine, glycine (to allow the creation of a restriction enzyme 
site). However, for simplicity all the mutants will be referred to as containing a 3xG 
insert.
The 3xG residues were inserted at points throughout the UL35 ORF, based on the 
protein prediction (EMBL, Heidelberg) because at this stage the CD data, which gave a 
different interpretation of the structure (see Discussion and Wingfield et al, 1997), was 
not available. 3xGs were chosen as they would disrupt a predicted alpha-helical 
secondary structure.
An attempt was made to insert at least one 3xG insert within each predicted motif o f the 
sequence [see figure 5.22, panel (xi)]. So, for example, pET35pp65.1 had an insert in 
the N-terminal loop region, pET35pp65.2 had an insert in the N-terminal (3-sheet region 
and pET35pp65.3 had an insert in the N-terminal a-helix region etc. The presence o f the 
inserts was confirmed firstly by restriction enzyme digestion (data not shown) and then 
sequence analysis (see figure 5.23 as a representative example). It was hoped that this 
approach would disrupt the structure o f the binding site(s) and allow the points of 
interaction between VP26 and VP5 to be definitively mapped. It should be noted that 
the inhibitory peptide sequences o f 35/4-35/6, spanned the amino acids where insertion 
points numbered 4, 5 and 6 occurred, ie pET35pp65.4-pET35pp65.6.
5.3.1 Expression and Purification
Unlike the deletion mutants, the 3xG mutants were expressed to high levels when 
induced with ImM IPTG (the VP26 mutant proteins shall henceforth be designated 
VP26pp65.1 -  VP26pp65.10). The mutant proteins were all insoluble and so were 
denatured and purified through Ni-NTA in the manner described for pET35pp65 (see 
Chapter 4, Section 2.4). Good yields, typically 5-10mg/ml, were obtained from the initial
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Figure 5.24: Elution of VP26pp65 3xG Mutants in 
200mM Imidazole
VP26pp65
Figure 5.25: Generation of VP26- Capsids by 
Treatment with 4M Urea
VP26pp65
VP26
VP 19c
VP21
VP22a
VP23
VP24
Figure 5.24: Coomassie brilliant blue stained gel with the size marker in lane 
1. Lanes 2 to 7 represent Ni-NTA purified, 200mM imidazole (Buffer E), 
fractions (elution 1 and 2 respectively) of the VP26pp65 protein carrying a 
3xG insert (ie VP26pp65.1 [lanes 2 and 3], VP26pp65.2 [lanes 4 and 5] and 
VP26pp65.3 [lanes 6 and 7]).
Figure 5.25: Coomassie brilliant blue stained gel. Lane 1 shows wild type B 
capsids and lane 2 shows VP26- capsids, which have been stripped of their 
VP26 through treatment with 4M urea. Lane 3 shows soluble VP26pp65 
protein.
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elution in Buffer E (figure 5.24). However, unlike the VP26pp65 protein, none of the 
mutants remained substantially soluble when dialysed against NTE.
5.4 Development of an Interaction Assay System for 3xG Mutants and 
VP26- Capsids
It was decided not to use the ELISA system, developed in Section 5.1, to study the 
interaction o f the 3xG mutants with either VP5 or VP26- capsids as none of the mutant 
proteins were soluble in NTE with no urea present. As the ELISA had been optimised in 
the absence o f urea, it would have been necessary to find conditions for removing the 
8M urea from each o f the 10 mutant proteins. Time constraints did not allow this avenue 
to be considered.
It had been reported (Newcomb et al, 1993) that extraction of B capsids with 4M urea 
removed VP26, some penton (approximately 10%) and scaffold, leaving otherwise 
structurally intact capsids. As the 3xG mutant proteins were soluble in urea, it was felt 
that it might be easier to generate VP26- capsids using this method (Section 2.1), and 
bind the mutant proteins in the presence of urea. M Kikitadze (University o f Edinburgh) 
had reported (personal communication) that VP26 had a largely stable secondary 
structure, by CD analysis, in concentrations up to 2M urea.
5.4.1 Production of VP26- capsids by Treatment with 4M Urea
B capsids in NTE, at approximately 1 Omg/ml, were diluted to 1 -2mg in 4M urea, with
0.05M DTT present. The solution was mixed end-over-end at rt for lh. The capsids 
were then pelleted through 25% (w/w) sucrose at 28000 rpm for lh. The sucrose layer 
was carefully removed and the pellet washed and resuspended in lOOpl o f NTE by 
sonication in a Kerry sonibath. 5 pi was run on a minigel to confirm that the VP26 
protein had been removed (figure 5.25) and VP26- capsids had been generated. These 
were stored at -20°C until required.
5.4.2 Attachment of 3xG Proteins (VP26pp65.1 -  VP26pp65.10) to VP26- Capsids
As the quantities o f B capsids available were small and the task o f making more was
time consuming, an assay system was developed which utilised very small quantities o f 
capsids.
VP26pp65
VP26pp65
Figure 5.26: Mini Gradients and Western Blots of 
VP26pp65+ Capsids and VP26- Capsids Mixed with 3xG
VP26pp65 Constructs
<  VP23
VP26pp65
<  VP23
Figure 5.26: Mini gradients were viewed under fibre optic light (A panels) and 
200pl fractions collected from the bottom to the top of the tube. The fractions were 
run sequentially on an SDS gel from left (bottom of the gradient) to right (top of the 
gradient). The blots were probed with pp65 antibody (B panels) and anti-VP23 
antibody (C panels).
Panel (i) shows the results obtained for VP26pp65+ capsids.
Panel (ii) shows a representative example (ieVP26pp65.3) of the results obtained 
when the 3xG mutant proteins VP26pp65.3, VP26pp65.4 and VP26pp65.7 to 
VP26pp65.10 were mixed with VP26- capsids.
Panel (iii) shows a representative example (ieVP26pp65.1) of the results obtained 
when the 3xG mutant proteins VP26pp65.1, VP26pp65.2, VP26pp65.5 and 
VP26pp65.6 were mixed with VP26- capsids.
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(i) Production o f ‘Mini gradients’
The initial step in the development procedure was to produce very small sucrose 
gradients. Previously 13ml, 10-40%, sucrose gradients had been used, which made it 
difficult to distinguish small amounts o f capsid (see Section 2.1.2). The process was 
scaled down and 2ml ‘mini gradients’ were prepared by layering 1ml of 40% (w/w) 
sucrose and 1ml o f 10% (w/w) sucrose in a Beckman 11x34 mm tube and mixing at 
18000 rpm for 1 min at an angle of 80°, on a Gradient Master 106 (Biocomp 
Instruments Inc).
(ii) Attachment o f 3xG Mutant Proteins to VP26- Capsids
Preparations were made by adding 2ul o f 8M urea, and lOul of the appropriate 3xG 
mutant protein (or VP26pp65 control), in 8M urea (Elution buffer E) to 70ul o f NTE. 
14ul o f the VP26- capsids, in 4M urea, were added last to generate a final urea 
concentration o f 1M. The solution was mixed, end-over-end, at rt for lh.
(iii) Purification o f Capsids Containing 3xG mutant Proteins
The 1 OOpl preparations [stage (ii)] were each overlayed on to a mini gradient and spun 
at 20000 rpm for 1 h, at 4°C, in the Beckman TL400 ultracentrifuge, to band the capsids. 
The gradients were viewed under a fibre optic light in a darkened room.
5.4.3 Attachment of VP26pp65.1 to VP26pp65.10 to VP26- Capsids
The control protein VP26pp65, in a final concentration o f 1M urea, attached
successfully to the VP26- capsids. A visible band was evident on the mini gradient [see 
figure 5.26, panel (i) A]. 200pl fractions were dripped across it and analysed by Western 
blot. VP26pp65 was detected in several fractions [figure 5.26, panel (i) B]. To confirm 
that the protein was attached to the capsids, the fractions were also probed with an anti- 
VP23 antibody (186, from D McClelland). VP23 was detected in comparable fractions 
to that which had contained VP26pp65 [figure 5.26, panel (i) C], confirming that the 
VP26pp65 protein was attached to the capsids. These result showed that the assay 
system was successful and capsids could be banded on the mini gradients. In addition
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VP26pp65 alone was detected at the top o f the gradient (panel (i) B, right hand side), 
indicative o f residual protein which had not attached to the capsids.
The pattern o f interaction for the 10, 3xG mutant proteins varied. Visible bands, 
comparable with the control sample, were clearly evident for preparations containing 
VP26pp65.3, VP26pp65.4 and VP26pp65.7 to VP26pp65.10 [see figure 5.26, panel (ii) 
A, as a representative example). 200pl gradient fractions were collected and analysed by 
Western blot [see figure 5.26, panel (ii) B, as a representative example]. The 3xG 
VP26pp65 proteins was detected in fractions which coincided with the detection of 
VP23 (using 186 antibody) [see figure 5.26, panel (ii) B], confirming that the mutant 
proteins were attached to the capsids. Again, unattached VP26pp65 mutant protein was 
detected at the top of the gradient (panel (ii) B, right hand side). However, no capsid 
bands were evident on the gradient when VP26pp65.5 and VP26pp65.6 were present 
and only extremely faint bands, or in some experiments no band at all, were evident for 
VP26pp65.1 or VP26pp65.2 (see figure 5.26, panel (iii) A, as a representative example). 
200pl fractions were also collected across these gradients and analysed by Western blot. 
The VP26pp65 protein was only detected at the very top o f the gradient [see figure 
5.26, panel (iii) B], indicating that it had not bound to the capsids. When the fractions 
were probed with anti-VP23 antibody (186), no capsids were detected in any o f the 
fractions.
The experiment was repeated using VP26- capsids mixed with either VP26pp65 
(control), VP26pp65.3 (which had banded on the gradient) or VP26p65.5 (which had 
not banded on the gradient. This time, all the fractions were not banded but were spun 
through a 25% (w/v) sucrose cushion (28 OOOrpm, lh) and analysed by western blot, gel 
electrophoresis and negative staining.
Each blot was probed with anti-VP23 antibody (186) and then the anti-pp65 antibody 
(pp65). As expected VP26 was found to be attached to capsid in the samples which had 
been mixed with VP26pp65 and VP26pp65.3 [not shown, similar pattern to figure 5.26, 
panels (i) and (ii)]. However, unlike the gradient banding experiment, VP26pp65.5 was
Figure 5.27: Confirmation of Attachment of
VP26pp65.5 (3xG mutant) to VP26- Capsids
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Figure 5.27: VP26pp65.5+ capsids were analysed by western blot. The presence of 
capsids was confirmed with anti-VP23 antibody (186) [see panel (i)]. The blot was 
then probed with anti-pp65 antibody The VP26pp65.5 protein was detected in the 
same lane as VP23 [see panel (ii)] confirming that VP26pp65.5 had attached to 
VP26-capsids.
The protein profile o f the VP26pp65.5+ caspids is shown in the coomassie brilliant 
blue stained gel (panel (iii), lane A) and the position of VP26pp65.5 is marked with 
an arrow. [The marker is shown in panel (iii), lane B],
Figure 5.28: Electron Micrographs of
VP26pp65+ Capsids and VP26pp65.5+ Capsids
(i) VP26pp65+ Capsids
(ii) VP26pp65.5+ Capsids
Figure 5.28: VP26pp65+ capsids [panel (i)] and VP26pp65.5+ capsids [panel (ii)] 
were viewed by negative staining.
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found to be attached to the capsids and VP23 and VP26 were detected in the same lane, 
[see figure 5.27, panels (i) and (ii)]. Analysis of these fractions by SDS-PAGE 
confirmed that the VP26pp65 proteins had attached to the capsids in each case (see 
figure 5.27, panel (iii), as a representative example).
Examination o f all fractions by negative staining (see figure 5.28) revealed that, even 
although samples containing VP26pp65.5 had not banded on gradients, they were 
formed and intact in all cases. VP26- capsids which had been mixed with VP26pp65 
[panel (i)], VP26pp65.3 [not shown] or VP26pp65.5 [panel (ii)] did not differ in 
appearance from wild type capsids, at this resolution.
6. Discussion
6.1 Function validity of VP26pp65
It was possible to confirm that the soluble bacterially expressed protein, VP26pp65, in 
NTE (described in Chapter 4) was structurally and functionally valid. The protein bound 
correctly to VP26- capsids at the tips of the VP5 hexons and not pentons. Even though 
VP26pp65 was added in slight excess, the penton sites remained unoccupied. This 
mimicked the pattern of wild-type and fully recombinant capsids (Trus et al, 1995; Zhou 
et al, 1995). Therefore the extra 25 amino acid residues at the N-terminus o f VP26, 
attributed by the 6xhis and pp65 tags, do not interfere with the binding o f VP26pp65 to 
capsids. This shows that this region of the protein can have additional sequences added 
without the binding to capsids being affected. This is highly indicative that the specific 
amino acid sequence at the N-terminus, are not important for the correct binding of 
VP26 to the capsid. Recent data (Desai & Person, 1998) has shown that the 270 amino 
acid green fluorescent protein (GFP) can be attached to the N-terminus o f VP26 and not 
disrupt the binding o f the protein to capsids. This further confirms that this area o f the 
protein is not important for binding.
6.2 Possible Location of the N-terminus of VP26
The presence o f the extra mass, contributed by the 6xhis and pp65 tags, proved to be an 
asset to the analysis. This region was mapped by comparing VP26pp65 containing 
hexons with wild type VP26 containing hexons. Cryo-EM and computational data
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analysis revealed an area o f extra mass, present only in VP26pp65 hexons. It is 
important to realise that the extra mass detected is not large enough to constitute all 24 
o f the extra amino acids present in the tags. It may be that this region is the only visible 
part o f the additional sequences. The rest of the sequence may be in the from of a 
flexible loop or some other unresolved structure or, it may be that some amino acids are 
folded inside the protein and so are not visible on the surface.
This technique is a potentially useful way for orientating proteins within a complex 
structure. It is not known how 6 copies of VP26 on the hexon interact with each other. 
Attempts at crystallisation and NMR have proved unsuccessful (personal 
communication; M Kirkitadze, University o f Edinburgh) due to the insoluble nature of 
the protein and the problems involved in producing high concentrations. This means that 
the structure o f a single molecule o f VP26 is unknown and it is not clear when looking 
at the star shaped ring o f 6x VP26, where one molecule starts and another one stops. 
Zhou et al (1995) suggested that the protein has a large and small domain contained 
within each monomer. The type o f approach taken in this study, may pin-point the 
location o f the N-terminus o f VP26 and helps us to begin building a picture o f how the 
VP26 proteins are interacting with the capsids and each other.
6.3 Oligomeric Status and Secondary Structure of VP26
Examination o f the oligomeric status of VP26pp65, suggested that the protein consisted
of monomers and dimers in solution. No evidence o f any hexamerisation was detected 
which would have supported the model o f Zhou et al, 1995, where a VP26 hexamer can 
only fit onto a VP5 hexamer and not pentamer. Instead it would seem that although all 
capsomeres are primarily composed o f the same protein, VP5 in hexons must be 
conformationally different from the VP5 in pentons and the difference must define a 
VP26 binding site. Evidence for a difference between hexons and pentons is supported 
by data which shows that distinct monoclonal antibodies label either the hexons or 
pentons and do not cross-react with either structure (Trus et al, 1992). However, this 
does not fully explain how the VP26-VP5 ELISA reaction worked. VP5 (191 A) has not 
been accurately sized in solution and so it is not known whether this protein 
spontaneously forms hexons and/or pentons. It is possible that VP26pp65 was only
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interacting with VP5 which had hexamerised. Alternatively, a monomer or dimer of VP5 
might bind to VP26 but, upon undergoing conformational changes involved in forming 
hexon and penton capsomeric subunits, the penton arrangement could lose its ability to 
interact with VP26. Recent results produced by sizing VP5 by its light scattering 
properties, have suggested that the protein spontaneously forms multimers (B Barnes; 
personal communication) but, it was not possible to distinguish between 5-mer and 6- 
mer arrangements. This data supports the theory that VP26 is binding to preformed VP5 
hexons. However, Newcomb et aI (1999) have published conflicting data which 
suggests that purified VP5, from the baculovirus expression system, forms monomers in 
solution. Therefore the stage at which VP26 binds to VP5 is not clear.
Fluorescence data presented in this thesis (Chapter 3) has shown that VP26 is only 
found to be nuclear when VP5 is also nuclear, ie in the presence o f preVP22a or VP 19c. 
This shows that VP26 itself does not carry a nuclear localisation signal and is in fact 
mainly in the cytoplasm when transfected alone. It is possible that VP26-VP5 + either 
preVP22a or VP 19c, is transported as a complex to the nucleus, or, the complex may 
assemble within the nucleus and be held there. The precise order o f events is unclear.
Again the oligomeric status o f VP5 in the nucleus of infected cells during fluorescence 
studies is not known. Single VP5 molecules may be present in the nucleus with and 
without VP26 attached. Those VP5's without VP26 could form the pentamers at the 
vertices and those containing VP26 would form the hexamers. However, is known that 
VP26 is not required to form a structurally intact capsid shell (Tatman et al, 1994; 
Thomsen et al, 1994) and so it is not VP26 which is directly governing the formation of 
hexamers of VP5. Alternatively, VP26 may be attached to all the VP5 molecules and 
released when the pentomeric conformation is formed. Or, the VP26 may only attach to 
pre-formed hexamers of VP5. VP26 is small enough to be transported in and out of the 
nucleus by diffusion through the nuclear pores (ie it is <90kDa). The protein may move 
at random until it encounters VP5 in a hexameric form, at which time it binds.
Results Chapter 5
Newcomb et al, 1994, have developed a cell free assembly system in which they were 
able to detect capsid intermediates. They have proposed a model whereby partial 
capsids, containing VP5, scaffold and triplex, from segments which grow into spherical 
procapsids. This undergoes a spontaneous structural transformation and angularises to 
form polyhedral capsids, closely resembling B capsids (Newcomb et al, 1996). 
Unfortunately VP26 was not incorporated in the cell free assembly system and so it does 
not help us determine at which stage the protein binds. The authors suggest that the 
protein may be binding to sedimentable material in cell free extracts and so was not 
available. With knowledge of how insoluble the protein is, it may simply be precipitating 
out o f the PBS reaction mixture. The findings in this thesis suggest a model where VP5 
does not require to be present in an angularised capsid for VP26 to interact. VP26 does 
not form a spontaneous hexameric ring but appears to react in monomers or dimers. The 
oligomeric status o f the VP5 which it is reacting with must be defined in future studies 
to help pin-point the stage at which VP26 is binding.
After this work had been completed, a paper was published by Wingfield et al (1997), 
which suggested a different secondary structure to the predicted one. This group had 
attempted and failed to express VP26 directly in E coll. Instead, they expressed it fused 
to the C-terminus o f GST. When isolated from the fusion protein, they found VP26 
reacted very like VP26pp65. It was extremely insoluble, had to be extracted in GuHCl 
and re-folded by dialysis in the presence of CHAPS detergent. They took a similar 
approach to that described here and confirmed that their protein was functional by 
attachment to VP26- recombinant capsids. Cryo-EM and 3D image reconstructions 
revealed 'six horns o f density around the rim of each hexon' indicative o f correctly bound 
VP26.
Using CD analysis o f purified VP26 they found that the protein formed a reversible 
monomer-dimer interaction. The spectrum estimated the secondary structure o f the 
protein to be 80% (3-sheet and 13-15% a-helix. This closely matched the finding o f D
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McClelland (this Institute) & M Kirkitadze (University of Edinburgh) who had produced 
a spectrum using a concentrated sample of VP26 from pET35 (Chapter 4, table 4.4). 
Their measurements suggested 70% |3-sheet and 20% a-helix. These patterns were in 
stark contrast to the protein prediction which suggested only 20% p-sheet and 45% a - 
helix. This prediction held true for all the VP26 homologues o f the a -  and (3- 
herpesviruses, even though their native amino acid sequences varied considerably. It was 
not clear from the published data exactly which proteins constituted the bank at 
Heidelberg, against which structures were calculated. It is probable that it consists 
largely o f readily soluble and non-structural proteins. These would not be the best model 
to use for determining the structure o f VP26pp65, a highly insoluble protein which 
interacts within a large complex molecule. Also, there were no homologues of VP26 in 
the database, apart from other herpesvirus VP26’s. It is not possible to confirm if the 
protein predict was inaccurate for the other VP26 homologues, as no data had been 
published to the contrary. However, as the programme predicted all 3 a -  and all 3 p- 
herpesviruses to have an almost identical structure, despite different amino acid 
sequences, the suggestion is that these proteins may have a similar charge and spacing 
distribution which produced this protein prediction in the first place. Obviously different 
amino acid residues can fold to form a similar structure. It is not difficult to imagine that 
the area which constitutes the binding site on VP26, to the capsids, involves not just a 
specific amino acid sequence but, a defined secondary structure. It must be considered 
that when VP26 is choosing to bind selectively to the VP5 hexons, there must be a 
binding site on these capsomers which is not present on the VP5 pentons. The hexons 
themselves must also vary in conformation due to their quasiequivalent environment. 
VP26 therefore must adjust slightly to fit onto P, C and E hexons and it is here that its 
basic secondary structure may play an important role in helping amino acid residues to 
bind.
6.4 Mutations of VP26pp65
It is interesting to speculate as to why the deletion mutants were so insoluble and 
induced so poorly. Deleting amino acids at the terminal ends of VP26pp65 made it even 
more insoluble than the wild-type VP26pp65 protein. This may indicate that it is the 
central portion o f the protein, which this work has suggested is the possible binding site
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with capsids, which is the contributing to its insolubility. So, when the N- or C-terminal 
'soluble' potions are deleted, the protein is left with the insoluble residues and so 
precipitates. If the central portion of the protein does indeed constitute the binding site 
with capsids, it is not unreasonable to speculate that this area may have a more defined 
and 'rigid' secondary structure to allow it to function correctly and interact specifically. 
On the other hand, recent data (Kirkitadze et al, 1998) has suggested that VP23 may be 
in a molten globule state. This means that the protein has a poorly defined structure 
initially to allow it to be flexible while the capsid assembles. Once all the major 
components are in place, the protein becomes more stable and the structure more 
defined. In this instance the VP26 binding site would be quite flexible and in the absence 
o f the N and C terminus to stabilise the structure, the protein aggregates to a greater 
extent.
For insertional mutagenesis, glycines were chosen as the inserts before it became clear 
that the protein prediction was wrong. If it had been known that the protein consisted of 
mainly (3-sheet and not a-helix, a different insertion may have been chosen. For example 
alanines were not chosen as they have a tendency to form a-helix and so they would not 
have caused such disruption in an a-helical protein. The use of glycines did not prevent 
further experimentation and it was possible to purify the mutant proteins in 8M urea (see 
table 4.4, Chapter 4) use them in the assay systems.
6.5 Amino Acid Residues Important for Binding VP26 to VP5
To try and map the amino acid sequences involved in the interaction of VP26 with VP5,
two approaches were taken. Inhibitory ELISA reactions, involving short oligopeptides 
which spanned the UL35 ORF, were developed and a series o f reattachment 
experiments, involving insertional mutants, were used. These preliminary results mapped 
an area which appeared to be important for binding.
The oligopeptides 35/4 to 35/6, spanning amino acids 31 to 70, significantly blocked the 
interaction of VP26 with VP5 in a series o f ELISA assays. Oligopeptide 35/1, spanning 
amino acids 1 to 20, also caused a less pronounced inhibition in binding. Similarly, the 
mutant proteins VP26pp65.5 and VP26pp65.6, with inserts at amino acid 50 and 60
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respectively, totally disrupted capsids banding on a mini gradient. Mutants VP26pp65.1 
and VP26pp65.2, with inserts disrupting at amino acid 10 and amino acid 20 
respectively, disrupted capsid banding to a lesser extent, with faint bands generally 
visible.
Failure to see capsid bands on a gradient was an interesting and unexpected result. The 
presence o f the mutant protein obviously interferes with the sedimentation pattern of the 
capsids. It is difficult to speculate on what has happened to the capsids. At first it was 
thought that the mutant proteins may have disrupted the capsids and caused them to 
fragment. It is hard to envisage how this would occur in view o f the extreme external 
location o f the VP26 protein and the fact that VP26- capsids are known to be stable 
(Zhou et al, 1995; Newcomb et al, 1995). EM examination of pelleted capsids proved 
this theory to be incorrect as normal looking capsids were identified from samples which 
had not banded on the gradient. Another possibility is that the mutant proteins have 
caused the capsids to aggregate. As the predicted binding site has been disrupted within 
these VP26 proteins, perhaps they are partially binding to capsids and non-specifically 
cross-linking them, causing them to aggregate and thus pellet to the bottom of the 
gradient.
These results strongly support the idea that the area between amino acid residues 
between 31 and 70, and possibly more specifically 40 and 60, on VP26, are important 
for the proteins binding to VP5. Exactly which amino acids interact with which part of 
VP5 remains to be determined. It must also be considered that amino acid residues 
between 1 and 20, on VP26, may play a less significant role in the binding of VP26 to 
VP5. Since in both experimental approaches taken, this area was highlighted. It is 
unlikely that the extreme N-terminal 5 residues are involved in any binding as these were 
disrupted by insertion of the pp65 and 6xhis tags. It has been shown that insertion o f a 
tag into this area does not alter the capacity of VP26 to bind to capsids normally 
(Section 2). Perhaps a very short sequence of residues at the N-terminus is important. 
This warrants further study. The 50 amino acids at the C-terminus do not seem to play a 
role in the binding o f VP26 to VP5. Neither the oligopeptides spanning this region, nor
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the 3xG insertions, which disrupted this area, caused any effect on the binding of VP26 
to VP5.
The main area of importance for binding of VP26 to capsids appears to fall within amino 
acids 40 to 60. This area falls within a region of poor sequence homology between the 
a -  and (3- herpesviruses yet one which was strongly predicted to be alpha-helical in all. 
Although it now seems unlikely that this region is in fact alpha-helical, it is interesting to 
speculate that some common feature in the secondary structure o f this region may play a 
significant role in the binding of VP26 to VP5.
CHAPTER 6
IDENTIFICATION OF THE SITES OF INTERACTION 
BETWEEN THE SCAFFOLD AND THE OUTER SHELL IN
HSV 1 CAPSIDS
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1. Introduction
Complete formation of HSV-1 capsids requires the presence of intact scaffold. 
However, the method of capsid assembly and the mode of action of the scaffold is 
poorly understood. This chapter describes an approach taken, using high resolution 
cryo-EM and 3D image processing, which has allowed identification of the points of 
contact between the scaffold and outer capsid shell (Zhou et al, 1998a). The results in 
this chapter were attained through a collaboration between myself, Dr F J Rixon 
(Institute of Virology) and scientists in Houston, principally Dr W Chiu and Dr H Zhou 
(see Zhou et al, 1998a).
Three types of capsid exist, A (empty), B (containing scaffold) and C (containing viral 
DNA). Pulse-chase experiments performed with cells infected with EHV-1 have 
indicated that B capsids are the progenitors of A and C capsids (Perdue et al, 1976), 
with A capsids the result o f unsuccessful packaging of DNA. However, recent 
investigations have suggested that the process may not be as simple as this. Newcomb et 
al, 1994, have isolated procapsid intermediates in the assembly process (see Chapter 7, 
Conclusion for further details).
Formation and processing of B capsid scaffold involves 3 proteins, VP21, VP24 and 
VP22a, which are encoded by 2 overlapping genes (see Chapter 1, Introduction, section 
4.4.1.5). Based on the phenotypical appearance o f this scaffold, B type capsids can be 
sub-divided into 2 distinct types:
• Large cored capsids, which contain VP22a which has not been cleaved by the 
protease and is termed preVP22a
• Small cored capsids, which contain VP22a in the cleaved form.
The scaffold protein, preVP22a, interacts with the major capsid protein, VP5, through 
its C-terminal 25 amino acids (Kennard et al, 1995; Matusick-Kumar et al, 1995; Hong 
et al, 1996). Cleavage by the viral protease of these 25 amino acids generates VP22a. 
This is an essential step which breaks the link between the scaffold and shell. Large 
cored B-capsids are hence converted to small cored B-capsids. However, if the protease
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is inactivated or absent, the large cored phenotype remains and DNA cannot be 
packaged.
To investigate these B-capsid variants in more detail, small and large cored B-capsids 
were generated and analysed.
2. Preparation of Capsids
Large and small cored B-capsids were required for this analysis and were prepared in 
two different ways:
2.1 Small cored B capsids
Small cored B capsids are the form which predominate in a wild type HSV-l infection. 
BHK C l3 cells were therefore virally infected, at 5pfu/cell for I6h at 37°C, and capsids 
purified on a 10-40% sucrose gradient (see Methods, Section 2.2.5). It has previously 
been found that baculovirus generated small cored B capsids and wild type B capsids 
have identical structures (H Zhou; personal communication).
2.2 Large Cored B-capsids
To produce capsids with uncleaved VP22a, ie preVP22a, it was necessary to generate 
capsids in the absence o f active protease. The baculovirus system was therefore used 
(see Methods, Section 2.3.8). S£21 cells were co-infected, at 5 pfu/cell for 48-65h, with 
baculoviruses AcUL19(VP5), AcUL18(VP23), AcUL26.5(preVP22a), AcUL35(VP26) 
and AcUL38(VP19c) (Tatman et al, 1994). The absence of the protease, encoded by 
UL26, resulted in only large cored capsids being produced. These were designated 
protease minus capsids.
Separate batches o f large cored capsids were purified in 2 ways. One batch was purified 
through a sucrose gradient in exactly the same manner as that described in Methods, 
Section 2.2.5.2. A second batch was also purified in this manner, except that NP40 was 
not included at any stage o f  the purification procedure. This is because it had been
Figure 6.1: Comparison of Wild type and 
Protease Minus Capsids’ Protein Profiles
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Figure 6.1: SDS gel o f purified wild type capsids (left) and recombinant baculovirus 
expressed protease minus capsids (right). In the absence of an active protease, the 
major scaffolding protein is present in the unprocessed form, preVP22a, and the 2 
autoproteolytic products of the protease, VP21 and VP24 are absent.
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reported that the interactions between VP5 and preVP22a were detergent sensitive 
(Hong et al, 1996).
2.3 SDS-PAGE Analysis of Small and Large Cored Capsids
Both small and large cored capsids were analysed by SDS-PAGE on a 15% gel. It is
clear from figure 6.1 [panel (i)] that the expected protein profiles were detected for each 
capsid type. The wild type capsids (lane 1) were composed of the 7 capsid proteins, 
whereas the protease minus capsids (lane 2) expressed the scaffold protein in the 
uncleaved form as preVP22a. Also VP21 and VP24 were absent from these capsids as 
no protease was present.
3. Analysis of Wild Type and Protease Minus Capsids
To determine the difference between wild type and protease minus capsids, cryo-EM 
analysis was undertaken by our collaborators at Baylor College of Medicine, Houston, 
Texas. Dr W Chiu and Dr H Zhou performed all the cryo-EM and produced the 3D 
image reconstructions. It was hoped that at a high resolution, the points of contact 
which were occurring between preVP22a and VP5, and not evident in the wild type 
capsids, would be detected and identified.
It should be noted at this point, that no differences were observed between capsids 
purified in the presence or absence of NP40 and the results presented in the subsequent 
section apply equally to both batches of capsids.
3.1 Symmetry of Wild Type and Protease Minus Capsids
3.1.1 Comparison of Capsid Shells
Both wild type and protease minus capsids were analysed by electron microscopy (not 
shown). They appeared very similar at this resolution, with an electron dense internal 
core, representative of the scaffold. Indeed, when the 3D structure was generated by 
cryo-EM analysis, the external structures appeared to be virtually identical with pentons 
at the vertices, p, e and c hexons and each of the 6 types of triplex (not shown, images 
were identical to figure 1.6, Chapter 1). This indicated that the state of the internal 
scaffold (ie cleaved or uncleaved) did not affect the ability of the capsid to form an 
icosahedral shell.
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Figure 6.2: Comparison of the Outer Shells and Internal 
Cores of Wild Type and Protease Minus Capsid 
Reconstructions
20 120 220 320 420 520 620
Radius (A)
r r o n ts
20 120 220 320 420 520  620
Radius (A)
Figure 6.2: Panel A and panel B show one central 4.67A thick section o f wild type 
and protease minus capsids receptively. The numbers 2, 3 and 5 indicate the 
symmetry at these points. The densities at the same radius were averaged to show 
the density distribution plots (panel C) for each capsid type (blue line represents 
protease minus capsids and the red line represents wild type B capsids). The arrow 
indicates an additional density peak, close to the capsid shell o f protease minus 
capsids. The disagreement factor was calculated and plotted (panel D) for 2 
independent reconstructions o f each capsid type (solid line represents wild type B 
capsids and the dashed line represents protease minus capsids.
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3.1.2 Comparison of Capsid Mass Distributions
One central 4.67A thick section was isolated for the wild-type and protease minus 
capsids [see figure 6.2, panels A and B, respectively]. The core structures for the two 
capsid types are clearly different. In order to examine the mass distributions within the 
capsid cores further, radial density plots were produced (figure 6.2, panel C). This 
revealed that the distribution o f density between 70-330A radii, ie the core region, was 
lower in the protease minus capsids than the wild-type. This was indicative of a 
substantial radial translocation o f protein mass as a result o f proteolytic cleavage of the 
capsid and confirmed the appearance of the large and small cored phenotypes. An area 
o f extra mass, at 340-450A, was present in the protease minus capsids and completely 
absent from the wild-type capsids. This area corresponded to a location just underneath 
the capsid shell. In contrast, the distribution patterns for the capsid shell area (460- 
625A) was remarkably similar and matched the observation from the 3D image 
reconstructions, which showed that protease minus capsids had virtually identical shells 
to wild type capsids. This confirms that the shell areas of the protease minus and wild- 
type capsids do not undergo any radial density dislocation upon proteolysis of the 
scaffold.
Two independent reconstructions o f each capsid type produced almost identical profiles 
and so confirmed that the data was statistically significant and that the detection o f extra 
mass in the protease minus capsids real.
3.1.3 Structural Disagreement Factor
Based on the fact that the 3D reconstructions have icosahedral symmetry, it was 
expected that there would be close agreement between 2 independent reconstructions of 
wild-type capsids and 2 independent reconstructions of protease minus capsids, in the 
regions o f icosahedral symmetry. Therefore the structural disagreement factor between 
the 2 reconstructions o f each capsid type was plotted and is shown in figure 6.2, panel 
D.
The region o f capsid shell (440A-620A) had extremely good agreement between like 
capsid types and supported the data of the density plots and 3D image reconstructions,
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Figure 6.3: Identification of Additional Attached Mass in
Protease Minus Capsids
Figure 6.3: Panel A and B show one central 4.67A thick section o f wild type and 
protease minus capsids respectively. The regions enclosed by the dashed boxes were 
enclosed by the dashed boxes were enlarged to generate panel C and panel D. A 2- 
fold axis is indicated by the dashed red line. The red arrow heads in panel D 
designate the additional rod like densities present in the protease minus capsids.
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which deemed these areas to have good icosahedral symmetry and no variation in 
structure. On the other hand, there is a high disagreement factor below 440A, showing 
that there is no icosahedral symmetry in this area for either the wild-type or the protease 
minus capsids. This showed that the scaffold itself does not posses icosahedral symmetry 
either in its cleaved or uncleaved form. The formation of an icosahedral capsid shell is 
therefore not dependent on assembly around an icosahedral scaffold.
3.2 Identification of the Points of Contact Between Scaffold and Shell
3.2.1 Visual Inspection
Upon visual inspection, it is evident from the micrograph sections of the wild-type and 
protease minus capsids (figure 6.3, panels A and B respectively), that there are sharp 
drops in mass just under the inner capsid shells. The absence of matter in this area is 
confirmed by the low readings obtained in the density plots (figure 6.2, panel C).
This suggests that there is very little contact between the scaffold and shell. However, it 
is known that there is an absolute requirement for the interaction of VP5 with preVP22a 
for the production o f sealed capsids (Kennard et al, 1995; Matusick-Kumar et a/, 1995). 
To try and locate the positions o f these vital interaction points within the capsid, a 
portion of the inner and outer shell was computationally isolated, from each capsid type, 
between radii 430A-630A (figure 6.3, panels A and B) and enlarged (figure 6.3, panels 
C and D). Examination o f these 2 shells revealed firstly that the outer shell areas were 
very similar, as expected. Secondly, additional masses, which appeared to be attached to 
VP5, were present in the protease minus capsids. These rods extended inwards towards 
the capsid core for approximately 40A before the resolution was lost. No similar 
densities were observed in the wild-type capsids indicating that these represented the 
points of contact between preVP22a and VP5.
Other differences were noted in the internal densities between the capsid types however, 
these did not represent points o f contact with the capsid floor and appeared to have a 
more random nature. Unlike the attached densities, the other masses were not
Figure 6.4: Visualisation of Additional Densities
Attached to the Floor of Protease Minus Capsids
Figure 6.4: A region consisting of one penton, one c, e and p hexon and each o f the 
six triplexes was computationally isolated from wild type (panels A and B) and 
protease minus (panels C and D) capsid reconstuctions. The sections were viewed 
inside the capsid shell (panels A and C) and from one side (panels B and D). The 
additional masses present in the protease minus capsids are shown in white. For 
clarity, any densities which do not make contact with the capsid floor have been 
removed.
Figure 6.5: Contact Points of Scaffolding Proteins 
on the Capsid Floor
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Figure 6.5: The additional densities from the protease minus capsids were 
superimposed on the inner surface of the shell o f wild type B capsids (panels A and 
B, areas shown in white). For clarity, only those densities that were within a radial 
distance of 10A from the shell are shown. Panel B shows a stereo pair o f an enlarged 
region surrounding the c hexon (indicated by the dotted rectangle in panel A).
Panels C and D are schematic representations o f one triangular face o f the capsid 
floor, as viewed from inside (panel C) and outside (panel D) of the capsid. The dark 
filled circles designate the points of contact of the scaffold protein and shell. The 
larger circles are indicative o f extensive contacts, whereas the smaller ones represent 
less extensive ones.
Figure 6.6:
Figure 6.6: A schematic representation of one triangular face of a protease minus 
capsid is depicted with examples of the various morphological components 
highlighted in colour [p, e and c hexons (green) penton (red) and triplexes 
(aquamarine)]. The white circles designate the points of contact of the scaffold 
protein and shell. The larger circles are indicative of extensive contact, whereas the 
smaller ones represent less extensive contacts. The separation between members of 
each major pair o f connections is 37A.
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consistently observed at the same location and appeared to have a more random or 
disordered pattern. These will not be discussed further.
3.2.2 Analysis of Asymmetric Units
To give a better indication o f how the extra masses, in the protease minus capsids, were 
distributed, all unattached densities were removed, leaving only the material which was 
icosahedrally ordered and in close contact with the capsid shell. A region was 
computationally isolated for each capsid type (see figure 6.4) which consisted o f a 
penton (red), one o f each o f the p, e and c hexons (green) and one of each of the 6 types 
o f triplexes (aquamarine). This area was enlarged and rotated so that the internal (panels 
A and C) and side views (panels B and D) could be seen. The capsid floor is shown in 
purple and the extra masses, present in only the protease minus capsids are shown in 
white.
To increase clarity o f the points o f contact further, the additional masses were trimmed 
back to approximately 1OA from the floor and superimposed onto wild-type B-capsids 
(figure 6.5, panel A). This indicated that the most prominent attached masses were 
located beneath four o f the triplexes, which surround the c hexon. The enlarged view of 
this area (figure 6.5, panel B) showed that all the contact points occurred at junctions 
between the floor domains o f adjacent hexons, with both extensive and smaller contacts 
evident.
Figure 6.5 (panels C and D) show a schematic representation o f an icosahedral face from 
the outside and inside respectively. The position of the extensive contacts are shown 
underneath triplexes Tb, Tc and Te (large circles), and the smaller points o f contact 
were evident at the third quasi-equivalent position under these triplexes (small circles). 
Triplex Tf, has a different pattern o f small contacts and Td has only a single small 
density. No extra densities were detected underneath the pentonal triplex Ta. The 
separation between each major point o f contact on a triplex was estimated to be 37 A 
(figure 6.6).
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4. Discussion
These results have allowed the probable points o f contact between the preVP22a and 
VP5 to be identified. Difference analysis studies between protease minus and wild-type 
capsids, has identified 40A rod-like structures. These densities are present only in the 
protease minus capsids, which have large cores and contain uncleaved preVP22a. They 
extend inwards towards the capsid core and appear to be present mainly underneath the 
triplexes surrounding the c hexon. In the wild-type small cored capsids, preVP22a has 
been cleaved by the protease, losing its C-terminal 25 amino acids and breaking the 
interaction between scaffold and shell. In these capsids no extra densities were seen 
attached to the capsid floor.
The group in Texas also analysed large cored capsids prepared from tsl201. Tsl201 has 
a lesion in the protease gene which results in an inactive protease at the non-permissive 
temperature (Preston et al, 1983). This prevents cleavage o f the scaffold and blocks 
DNA packaging. As a result, large cored B capsids accumulate. However, this step is 
reversible. A downshift in temperature in the presence o f inhibitors o f protein synthesis, 
results in the conversion o f large cored B capsids to a mixture o f A, small core B capsids 
and C capsids. This pattern is concurrent with the pattern observed for wild-type 
infections and shows that large cored B capsids are competent for packaging.
When these large cored tsl 201 B capsids were compared to the wild type and protease 
minus recombinant capsids. It was found that extra densities were present in similar 
positions in the large cored t s l201 mutants and the protease minus capsids. However, 
due to difficulties in purifying large cored t s l201 capsids, the resolution o f the 
reconstructions was much lower.
No differences were observed in any of the data between capsids prepared in the 
presence or absence o f NP40. The VP5-preVP22a interaction in vitro had been shown 
to be detergent sensitive (Hong et al, 1996). This indicates that the VP5-preVP22a 
interaction, within the context o f the capsid, is more stable. Either the proteins form a
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slightly different confirmation within the capsid in vivo, or, the interaction may be 
‘hidden’ or embedded in a hydrophobic pocket which is not accessible to the detergent.
All o f the data presented in this Chapter (see also Zhou et al, 1998) suggests that 
preVP22a does not form extensive contacts with the capsid floor, which is almost 
entirely composed o f VP5. This is not surprising in view of the fact that the interaction 
is occurring through only 25 amino acids at the C-terminus o f preVP22a. As the 25 
amino acids do not appear to be retained after proteolysis (A Davison; personal 
communication) this is highly suggestive that the ordered rod-like domains, present in 
only the protease minus capsids, correspond to the points o f contact in the uncleaved 
scaffold and represent the C-terminus o f preVP22a.
The extra densities detected extend for approximately 40A towards the capsid core. This 
converts to an amino acid length o f 25-30 amino acids in an alpha-helical conformation. 
However, the mass o f each density accounts for more than the 25 amino acids known to 
be required for the VP5-preVP22a interaction. This means that either, the scaffold 
domain which, interacts with VP5, is larger than previously thought, or, that more than 
one preVP22a molecule is participating in the interaction. Data has been published 
which supports the latter conclusion and suggests that the 25 amino acids o f preVP22a 
bind more efficiently to VP5 as a parallel homo-dimer (Pelletier et al, 1997). Using an 
assumption that each point o f contact represents 2 molecules o f preVP22a, the number 
o f copies o f scaffold protein was calculated from the data presented in this chapter.
Three pairs o f well defined rod-like densities were observed for each asymmetric unit 
and these were assumed to be the C-terminal 25 amino acids o f a preVP22a dimer. 
Therefore 12 molecules o f preVP22a were present for each asymmetric unit. As 60 units 
constitute a capsid, this leads to an estimation o f 720 scaffold molecules attached to the 
capsid. However, 3-fold averaging at T f may have obscured the position o f contacts but, 
if a dimer is also proposed to occur at this location, this gives a figure o f 800 scaffolding 
proteins. This number falls short o f the biochemical prediction o f 1200 copies of 
preVP22a in B capsids (Newcomb et al, 1993). However, it has been reported that
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functional scaffolds can be made using mixtures of preVP22a and VP22a (Oien et al, 
1997). VP22a cannot interact with VP5 and would not be accounted for in the above 
calculation. It would therefore appear that incorporation of scaffold into capsids is not 
dependant on binding to VP5 and the scaffold binding to itself may be important for 
determining the overall dimensions of the structure which are necessary for correct 
capsid assembly. Certainly, work presented in this chapter has illustrated that formation 
of an icosahedral scaffold is not a prerequisite for the formation of an icosahedral shell.
Another interesting point, which was highlighted by this study, is the fact that the 
separation distance between each pair o f extensive extra mass connections, is 37A 
(figure 5.6). Shieh et al (1996) and Tong et al (1996) have suggested that the crystal 
structure of the HCMV protease domain exists as a dimer, with 2 catalytic domains 
spaced 36.5A apart. This obviously correlates closely with the spacing observed in 
HSV-1 preVP22a connections. This data is highly provocative and one may speculate 
that the extra mass may represent the protease domain in HSV-1.
In conclusion, the stage at which the scaffold is cleaved and DNA is packaged as yet 
remains unclear but, this study has allowed the probable points o f preVP22a-VP5 
interaction to be mapped and visualised within the capsid. Using cryo-EM and 3D image 
reconstruction techniques to visualise and pin-point such small interactions within a 
complex particle had not previously been possible at this low a resolution (13-15A). 
This approach therefore takes another step towards solving the nature of the protein- 
protein interactions within the HSV-1 capsid.
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CHAPTER 7 
CONCLUSION
Figure 7.1: Pattern of Capsid Protein-Protein Interactions
VP26
(UL35)
VP5 VP23
(UL19) (UL18)
Nucleus
VP19C
(UL38)
preVP22a
(UL25.5)
Figure 7.1: The capsid protein-protein interactions suggested by the
immunofluorescence studies (this thesis; Rixon et al, 1996; Nicholson et al, 1994) and 
electron microscope analysis (Rixon et al, 1996; Tatman et al, 1994; Thomsen et al, 
1994; Kennard et al, 1995) are shown by the solid lines. The dashed line separates 
those proteins which have an intrinsic capacity to localise to the nucleus and those 
which do not.
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Drawing on all the results within this thesis, together with published literature, it is 
possible to comment on the inherent roles of the respective capsid proteins and how 
they may be interacting with and influencing each other.
1 The Pattern of the Capsid Protein-Protein Interactions
Immunofluorescence data has given an indication of the nature of the interactions 
which are occurring between capsid proteins and their inherent distribution patterns 
within an infected cell (summarised in figure 7.1). Two capsid proteins, preVP22a (the 
scaffold protein) and VP 19c (a component of the triplex), carry an inherent NLS, while 
VP5, VP23 and VP26 do not. A series o f complex protein-protein interactions therefore 
occur which allow capsid assembly to occur in the nucleus. Not surprisingly, VP5 is 
central to this scheme as it interacts with 3 different capsid proteins, enabling it to 
fulfill its role as the MCP. These results allow a model for the interaction patterns 
within the capsid to be drawn (figure 7.1).
Although the pattern of protein interactions, determined from immunofluorescence 
studies, appears to be correct [cryo-EM (Zhou et al, 1994), baculovirus (Tatman et al, 
1994; Thomsen et al, 1994) and yeast 2-hybrid studies (Desai & Person, 1996)] support 
this pattern o f interaction) it cannot tell us anything about the interaction patterns o f the 
proteins within the context of the capsid shell. Here, the capsid environment enforces 
symmetry and influences positioning. Also, the oligomeric status and assembly 
pathway cannot be determined by this line of experimentation.
2 A Study of the Interaction of VP26 with VP5
To look at capsid protein interactions in more detail, the smallest capsid protein, VP26, 
and its interaction with VP5 was targeted as interesting to study and map. The method, 
by which VP26 attached to hexons, but not pentons, was not understood and as the 
VP26 protein was small, it could be readily manipulated. Also, the external location of 
VP26 on capsids, allowed it to be removed and replaced for development of assay 
systems.
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It was not foreseen that this small protein would be extremely insoluble, making 
experimentation approaches lengthy and difficult. However, full-length VP26 protein 
was produced in a bacterial expression system and purified through a Ni-NTA column.
Determinations o f the secondary structure of purified VP26, by CD analysis, showed it 
to be approximately 70% j3-sheet and 20% a-helix (D McClelland & M Kirkitadze; 
personal communication; Wingfield et al, 1997). This contrasted strongly with the 
predicted secondary structure (Protein Predict, Heidelberg).
The oligomeric status of VP26 appeared to be monomeric or dimeric in solution. This 
allowed speculation that, VP26 spontaneously formed hexamers and so only attached to 
VP5 hexons, to be dispelled. Instead it would seem that it is the conformation o f the 
VP5 molecule which governs the specificity o f VP26,s location. This project used 
purified VP5 and VP26- capsids as tools to study VP26. Much work remains to be done 
to determine the nature and status of VP5. This would help to determine if VP26 can 
only interact with pre-formed hexons or, if it interacts with all VP5 molecules, 
becoming detached when the penton arrangement forms. Very recent data has shown 
that although the location of VP26 on the tips of the hexons exposes it to the tegument 
layer, it does not interact with it (Zhou et al, 1999). 3D image reconstructions o f virions 
have revealed that the interaction between the capsid and tegument is confined to the 
pentonal vertices (Zhou et al, 1999). The occupation of the hexons with VP26 may 
make it inaccessible for tegument binding.
VP26 appears to interact most strongly with VP5 through an area between amino acids 
31 and 70. This area has very poor homology among the alphaherpesviruses. However, 
this area does have a strongly conserved predicted secondary structure. While this 
prediction is inaccurate, it may be indicative o f an important role for the secondary 
structure of the binding site.
Amino acids 1-20 may also play a role in the binding of VP26 to VP5. Cryo-EM 
reconstructions show that a large portion of VP26 is in contact with VP5. The VP26 
protein is a flattened molecule that appears to have a large surface area in contact with
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Figure 7.2: Large cored B capsids, which have not undergone proteolytic cleavage 
are schematically represented in panel (i). The capsid shell is shown in yellow and the 
internal scaffold is shown in red. The red lines, which connect the scaffold to the 
shell, represent the 25 amino acids of preVP22a. After proteolytic cleavage [panel 
(ii)], the contact between the scaffold and shell is broken and small cored B capsids 
are formed. It is probable that the 25 amino acid contacts are lost at this stage (A 
Davison; personal communication) however, these have been included as it is not 
clear exactly when they are lost.
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VP5. This type o f structure is indicative of the J3-sheet formation, suggested by 
Wingfield el al (1997), and not the a-helical one suggested by the protein predict. The 
high hydrophobic content of the protein is probably responsible for the computer 
prediction. Cryo-EM analysis o f capsids containing mutant VP26 proteins will shortly 
be underway. These will help to clarify the interaction pattern in more detail.
The points of interaction between adjacent VP26 molecules was not studied and this is 
also a future aspect to be considered. However, the probable location o f the N-terminus 
was visualised by cryo-EM analysis. This approach opens an experimental pathway to 
study how the VP26 molecule is orientated within the capsid by visualising the location 
o f extra amino acid sequences which have been inserted into the UL35 gene.
3 A Study of the Interaction of Scaffold with VP5
The scaffold is only attached to VP5 in the uncleaved form (preVP22a) when it is 
present in capsids as a large core. When the protein is cleaved by the protease (VP22a) 
the C-terminal 25 amino acids appear to be lost and the connection is broken, 
producing small cored capsids (figure 7.2).
As both large and small cored capsids can be purified, it was possible to examine and 
compare both types by cryo-EM and 3D image reconstructions. Difference maps 
revealed several areas of extra mass in the protease minus capsids, attached to VP5 
underneath the triplexes surrounding the c hexon. These probably represent the contact 
points between scaffold and shell, with 2 copies of preVP22a predicted to be present at 
each major interaction point.
There was no evidence to suggest that an icosahedral scaffold was required to form an 
icosahedral capsid shell. To understand how an apparently disordered scaffold may be 
influencing a highly ordered shell, it is first necessary to understand how individual 
proteins influence each other.
4 Inherent Properties of VP5, VP19c, VP23 and Scaffold
Baculovirus studies, using single, and combinations, o f capsid proteins, and 
immunofluorescence data have provided clues as to the inherent properties of particular
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proteins and the way in which they influence each other. This aspect is summarised in 
the following section.
4.1 VP5 and VP19c
When the shell proteins VP5 and VP 19c are co-expressed, they form densely staining 
spherical 90nm particles (Rixon et al, 1997). Very recent cryo-EM reconstructions have 
shown that these particles do have a defined structure and appear to be 880A in 
diameter (Saad et al, 1999). Distinct capsomeric subunits are evident in the form of 
distorted hexons and pentons. The structure has T=7 icosahedral symmetry, which 
contrasts with the T=16 symmetry associated with mature capsids. The bacteriophage, 
P22, forms similar small particles when the scaffold has been mutated (Lenk et al, 
1975; Earnshaw & King, 1978).
It would appear that these shell proteins have an inherent ability to self assemble into 
an icosahedral structure however, accessory proteins are required to mediate the correct 
curvature of the capsid shell. In this respect, VP23 and the scaffold are involved in 
forcing the shell proteins into a different confirmation.
4.2 VP23
The exact function of the triplex protein VP23 remains unclear but, fluorescence data 
(Chapter 3 and Nicholson et al, 1994) and yeast 2-hybrid studies (Desai & Person, 
1996) have indicated that it does not interact directly with VP5. Thomsen et al (1994) 
claimed that VP22a did not interact with VP5 in the absence of VP23 and suggested 
that VP23 was required for this interaction. Fluorescence studies have shown that this is 
clearly not the case. Also as protease was present in the Thomsen study, it is likely that 
the 25 amino acids essential for the interaction of preVP22a with VP5 (Preston et al, 
1994) had been cleaved.
So, what is the function o f VP23? When the shell proteins VP5, VP 19c and VP23 are 
co-expressed, partial or incomplete shell structures are formed and no 90nm particles 
formed by VP5 and VP 19c) are observed. This shows that the triplex protein is altering 
the curvature of the shell but cannot guide the formation o f an icosahedral capsid. 
[Scaffold proteins are required to form the correctly assembled capsid (Tatman et al,
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1994; Thomsen et al, 1994)]. Nevertheless, VP23 is influencing the interaction of VP5- 
VP19c and the publication of the reconstruction of the 880A particles (Saad et al, 1999) 
has suggested that VP23 appears to connect the body of the triplex to the capsid floor. 
Since the capsid floor is composed of predominately VP5, this strongly suggests that 
VP23 is interacting directly with VP5. Although no such interaction has been detected 
by previous studies (see above) it may be that this interaction is only formed in mature 
capsids, when the VP5 floor is adopts a different conformation to that found in 
procapsids. VP23, in the triplex, could therefore act to fix and stabilise this region of 
the capsid floor.
4.3 Scaffold
Preston et al (1994) have shown that when the scaffold encoding genes, UL26 and 
UL26.5, are co-expressed, circular scaffold-like structures, similar to capsid cores, (40- 
60r|m in diameter) are formed. Similar structures have been widely reported in both 
HSV-1 and HSV-2 infections (Atkinson et al, 1978; Miyamoto 1971; Roizman 1969; 
Nii et al, 1968a, 1968b) and were reported as occasionally occurring in cells infected 
with all 6 recombinant baculoviruses (Tatman, 1996). Scaffold-like 60r|m spheres have 
also been prepared from VP22a extracted in 2M GuHCl from B capsids (Newcomb & 
Brown, 1991).
Kennard et al, 1995 found that when preVP22a was expressed alone, few scaffold-like 
structures were observed. Instead, fibrillar structures, which aggregated together, were 
evident. However, when preVP22a was co-infected with VP5 indistinct structures, 
different from scaffolds, were observed. No fibrillar aggregates were visible suggesting 
that the interaction with VP5 was preventing aggregation of the scaffold and allowing a 
more defined or precise structure to form.
The above observations indicate that the proteins expressed by UL26 and UL26.5 have 
an inherent capacity to form scaffold-like structures. However, as it is known that 
VP22a does not participate in capsid assembly, these structures are not intermediates of 
the capsid assembly pathway. Although preVP22a alone cannot form scaffold like 
structures, more defined structures are evident when VP5 is present. It is possible that 
UL26 has a role in limiting the number of copies of protease which can be incorporated
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Figure 7.3: This is a suggested pathway for in vitro assembly of HSV 1 capsids. 
Assembly is thought to begin with an early partial capsid, which expands into a late 
partial capsid and finally a spherical procapsid. The procapsid angularises to form 
the mature polyherdral capsid.
Reproduced from Newcomb et al (1996).
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into the scaffold, resulting in the formation of scaffold-like structures, as opposed to 
aSgregates> while VP5 is influencing the morphology and curvature of the scaffold (see 
Section 6). Therefore the constraint on the size of the scaffold may act as the factor 
which determines the size of the capsid.
So, to summarise the data cited to explain the formation of the capsid, it would appear 
that VP5 and VP 19c have the inherent capacity to form an icosahedral shell. VP23 is 
important for defining the correct curvature of the shell and scaffold is required to 
guide assembly o f the shell proteins and ultimate size of the capsid. But, how is the 
scaffold fulfilling its role? The answer to this question may be contained in the recently 
proposed procapsid assembly model.
5 HSV-1 Procapsid Assembly Model and Analogies with 
Bacteriophage
Newcomb et al (1994; 1996) have developed a cell free assembly system which has 
allowed intermediates to be isolated during capsid assembly. They have proposed a 
model, (summarised in figure 7.3) whereby arc-like structures, containing preVP22a, 
VP 19c, VP5 and VP23, form after a short incubation time. Such structures may 
correspond to the partial capsids which had been previously observed in electron 
micrographs of HSV-1 infected cells (Nii et al, 1968a, 1968b). Upon further 
incubation, these partial capsids become spherical structures, which have been 
designated procapsids. Even although the protease was present, the scaffold at this 
stage was not cleaved and the procapsids contained a large cored scaffold. The in vitro 
system has recently been used to show that VP5 and the scaffolding proteins form a 
complex during assembly (Newcomb et al, 1999). These may act as building blocks of 
the procapsids.
3D cryo-EM has shown that these procapsids have distorted hexons and a very open 
structure. They differ from wild-type capsids, which have narrow axial channels and 
hexagonal hexons (Zhou et al, 1994). The procapsids are also relatively unstable, being 
sensitive to reductions in temperature, ie they fall apart at 2°C. Upon incubation at rt 
these procapsids spontaneously angularise into the familiar polyhedral type capsids.
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As the procapsids are extremely unstable and thermo labile it is interesting to speculate 
as to why the virus forms such an intermediate and how it spontaneously reconforms. 
The formation of procapsids, is not unique to HSV-1. Indeed, it is a well characterised 
assembly pathway for many dsDNA bacteriophages. For example, capsid assembly of 
P22 initiates from a portal protein (gpl), which sits at a vertex. The 47kDA coat protein 
(gp5) and the 34kDa scaffold protein (gp8) copolymerise, in association with other 
minor proteins, to form a spherical procapsid. The scaffold protein then exits from the 
procapsid while the DNA enters through the portal vertex. How the scaffold exits is not 
known however, holes or channels at the centre of the hexamers and pentamers were 
detected in the initial 3D image reconstructions o f the procapsids (Prasad et al, 1993). 
These are not in the mature capsid. It is speculated that these channels are the exit 
points for gp8 (Greene & King, 1994). A 19A structure o f procapsids, containing 
scaffold, confirmed the presence o f these channels (Thuman-Commike et al, 1996) and 
gave further support to the hypothesis that these are important for scaffold exit.
Exit o f the scaffold and entry o f DNA is coupled with shell expansion and formation of 
the expected T=7 icosahedral capsid (Prevelige & King, 1993). If scaffold is absent, 
limited assembly o f apparently normal capsid shells will occur, at a greatly reduced 
rate, but aberrant spiral and small capsids with T=4 symmetry are also formed 
(Thuman-Commike et al, 1996). Recent electron cryomicroscopy images o f scaffold 
containing and scaffold lacking procapsids (Thuman-Commike et al, 1999) have 
suggested that specific interactions form between coat proteins and scaffold proteins. 
Together these provide overlapping sets of binding interactions, which drive the 
formation o f the procapsid.
The main difference between the assembly o f P22 procapsids and HSV-1 procapsids is 
that the HSV-1 procapsids have a similar diameter (120r|m) to the icosahedral capsid 
(125rjm) and so do not undergo an expansion. Three main proposals have been put 
forward to explain why the bacteriophage capsids expand during DNA packaging:
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• Steven et al (1991,1992) proposed that there are subunit to subunit motions which 
are required for packaging and so the structure requires to be flexible. After DNA has 
been successfully packaged, the proteins ‘lock’ into position and stabilise the structure
• Eamshaw & Casjens (1980) suggested the capsid forms around a scaffold to prevent 
random cytoplasmic proteins being incorporated into the growing structure, which 
would disrupt it. The initial stage of the procapsid is therefore very compact while the 
shell proteins assemble. Once the proteins are in place the virus specific scaffold is 
removed and the structure expanded to allow DNA packaging.
• King & Chiu (1997) proposed that the scaffold exit, shell expansion and DNA 
packaging were directly coupled. They suggested that because the DNA in phage is 
injected into cells upon infection, leaving the capsid intact, the DNA must be free to 
leave the capsid and not tightly associated with the inner capsid shell. However, initial 
entry and organisation o f the DNA within the shell may require binding to the capsid 
subunits. Any such binding sites would require to be exposed for entry but then either 
lost, inactivated, or removed at a subsequent stage. They therefore suggest that the coat 
proteins in the procapsid contain these binding sites and when they swivel and the 
structure expands as the icosahedron is formed, the binding sites are lost
So why does HSV-1 not undergo expansion? This is a difficult problem to address 
however, it is important to realise that although analogies do exist between P22 and 
HSV-1, they are two distinct viruses whose capsids require to exist in distinct 
environments.
HSV-1 capsids are assembled in the nucleus o f infected cells and surrounded by 
tegument and envelope before exiting the host cell. In contrast, P22 capsids constitute 
the external shell o f  the bacteriophage and are left intact when DNA is injected into the 
host cell. Even different phage vary in their mechanism for losing scaffold from the 
capsid. P22 scaffold leaves uncleaved and is recycled, whereas T4 and X scaffold is 
proteolysed into small fragments and lost well in advance of DNA packaging (Ontorato 
& Showe, 1975; Ray & Murialdo, 1975). No potential ‘exit’ holes are visible in these 
phage (Dokland & Murialdo, 1993). Since the assembly and packaging pathway can 
vary between different bacteriophage, it is not surprising that the model for P22 does
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not fit exactly to HSV-1. The reason that HSV-1 does not undergo head expansion is 
because it does not require to do so to fulfil its function. Therefore, expansion is not 
fundamental to DNA packaging but is specific to some aspects of phage assembly.
Newcomb et al (1996) suggest that the procapsid is the precursor for all capsid types. 
However, as the cell free assembly system is an iti vitro model, whether the procapsids 
can package DNA cannot be determined, using this approach. Trus et al (1996) found 
that only preVP22a was present in polyhedral capsids which had matured from 
procapsids. If procapsids mature into polyhedral capsids without the cleavage of 
preVP22a, what does this tell us about the procapsid as the starting point for capsid 
maturation? All evidence suggests that DNA cannot be packaged in the absence of 
preVP22a cleavage. It may be the case therefore, that the conversion o f procapsid to 
polyhedral capsid in vitro is not mimicking the situation in vivo. The best model 
available for studying scaffold in vivo is by using the tsl201 HSV-1 mutant (Preston et 
al, 1983). As previously described (Chapter 6, Discussion), t s l201 has a lesion in the 
protease gene which inactivates the protease at the non-permissive temperature causing 
large cored capsids to accumulate. However, this step is reversible with a downshift in 
temperature resulting in the conversion of large cored B capsids to a mixture of A, 
small core B capsids and C capsids. All experiments to date, have shown that the 
capsids isolated from ts l201, have been icosahedral. However this did not rule out the 
possibility that procapsids were being lost during the purification procedure. Very 
recent investigations have shown that the great majority of assembly products o f ts l 201 
infection are thermolabile and unstable, indicative of a procapsid form (Rixon & 
McNab, 1999). It seems likely therefore, that procapsids are in fact an intermediate in 
HSV-1 assembly. This model can be used to fit the data obtained in this thesis. 
However, until an in vitro packaging model has been developed the exact mechanism 
of capsid assembly cannot be determined.
6 Proposed Model for Capsid Assembly
Obviously the pathway o f capsid assembly, scaffold cleavage and DNA packaging is 
very complex. Newcomb et al (1996) have shown that the capsid proteins 
spontaneously interact to form partial shells which come together to form procapsid. As 
previously mentioned, icosahedral 880A particles are formed in the absence of scaffold.
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The scaffold therefore appears to be involved in defining the curvature and ultimate 
size o f the capsid. It is interesting that the work presented in this chapter has mapped 
the points scaffold and shell interact to beneath the triplexes. High resolution cryo-EM 
of the capsid, to 13 A, has shown that there is an extensive network of triplexes forming 
4 types o f interaction with VP5 (Zhou et al, 1998). Interactions o f different types 
designated strong, weak, tail and arm interactions were all observed. The major points 
o f scaffold contact appear underneath one strong and one very weak, or arm, triplex 
interaction in each case. It is thought that the triplex proteins play an important role in 
ordering the capsomeres and VP23 is thought to mediate the curvature o f the capsid 
shell (Saad et al, 1999). In the procapsid the triplexes and capsomeres are loosely 
bound and the capsid floor is not well formed (Newcomb et al, 1996) making the 
structure very unstable and fragile. This is in stark contrast to the robust nature o f the 
icosahedral capsid. The transformation must require structural rearrangement into a 
more stable form. Some o f  the proteins in the procapsid may therefore require to be 
inherently flexible and able to move to achieve the icosahedral shape.
Recent data has suggested that VP23 is in a molten globule, or, partially folded state 
(Kirkitadze et al, 1998). This would allow the protein to be flexible in the procapsid 
intermediate, before it was locked into its final form by an undefined trigger. It is 
known that VP23 and VP 19c (the triplex proteins) can form complexes in the absence 
o f any other capsid proteins (Spencer et al, 1998). It is therefore possible, that it is 
VP 19c which induces the structural rearrangement o f VP23. The presence of a molten 
globule in viral structures is not unique to HSV-1. Two proteins o f P22 have been 
described as having a molten globule state (Tescke & King, 1993).
The scaffold protein itself could therefore be playing the important role of stabilising 
the structure. This situation is analogous to the spokes of a bicycle wheel where the 
spokes are helping to define the curvature. The scaffold may not adopt a precise 
structure but provide the overall dimensions and tension necessary to ensure correct 
shell formation. The subsequent intermediate steps o f conversion from large cored 
procapsids to icosahedral type capsids are unclear. It can be envisaged that coming 
together o f 2 copies o f preVP22a pulls the VP5 capsomeres together and thus the
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Figure 7.4: Possible Mechanism of preVP22a in the 
Procapsid to Capsid Transition
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Figure 7.4: The procapsid has a much more open structure [panel (i)] than the mature 
capsid [panel (ii)] and neighbouring hexons, shown in yellow, are not tightly bound. 
The scaffold protein (preVP22a), shown in red, may act to stabilise the structure, with 
2 copies coming together and helping the VP5 capsid floor to form. The triplexes, 
shown in turquoise, help to bind the VP5 molecules together and appear to be located 
above the points o f contacts between scaffold and shell in the mature capsid.
This figure is not drawn to scale.
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capsid floor is expanded (see figure 7.4). This action results in the transformation of 
procapsid to capsid. Certainly if the scaffold’s role is to stabilise the structure, without 
forming extensive contacts, it would seem reasonable to assume that it may be 
interacting with the shell proteins at the weakest links on the capsid floor. The nature of 
the contact points is such that a single scaffold protein is not interacting with a single 
hexon. Instead it seems likely that the scaffold may be forming contacts at areas in the 
capsid floor where several VP5 molecules come together. The scaffold would therefore 
be acting as an extra securing point, reinforcing and stabilising the contact points. The 
UL26 product in turn will be limiting the size of the scaffold and thus capsid. Once the 
scaffold has helped the capsid floor to form, the VP23 molecule will act as extra 
cement, helping to stabilise and guide correct conformation. This model is speculative 
and this type o f detail remains to be resolved.
The stage at which VP26 binds to capsids is not clear. When VP26 was included in the 
cell free assembly model, it did not form part of either the procapsid or capsid. 
However, this may have been attributable to its highly insoluble nature under these 
experimental conditions, as oppose to a reflection of its binding pattern. There is no 
reason, based on available data, to assume that VP26 would not bind to VP5 hexons 
during the assembly stages in vivo. The exact function of VP26 is unknown however, 
its external location on the capsid might suggest that it is important for interacting with 
the surrounding tegument. However, recent visualisation, by cryomicroscopy, of the 
capsid tegument interaction in intact virions has shown that tegument binding is 
confined to the vicinity o f the pentonal vertices (Zhou et al, 1999). It seems that the 
occupation of VP26 at the hexonal tips results in this site being unavailable for 
tegument binding. If the protein is shown not to be present in vivo on procapsids, 
therefore only attaching to angularised capsids, it may have a role in locking the 
polyhedral capsid in place. As yet, the role of VP26 remains to be resolved
To conclude, clearly the process of capsid assembly is extremely complex, with many 
proteins interacting and influencing each other simultaneously. However, this thesis has 
provided an insight into some of the properties of these proteins. VP26 has been 
purified and its oligomeric status determined. Probable points o f contact with VP5, both
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purified and within the context of the capsid, have also been mapped together with the 
location of the N-terminus. The points of contact of between scaffold and shell have 
been visualised, which has allowed further clarification of the capsid structure. The 
probable location o f many capsid proteins within transfected cells has been determined, 
in parallel with the pattern of interaction which is occurring. During the course of all 
this work, many useful assay systems have been developed which can be adapted to 
further study the caspid protein interactions and draw a clearer and more precise pattern 
of events in the process o f capsid assembly.
REFERENCES
References
REFERENCES
Ablashi, D.f Balanchandran, N., Josephs, S, Hung, C., Krueger, G., Kramarsky, B., 
Salahuddin, S., and Gallo, R. (1991): Genetic polymorphism, growth properties, and 
immunologic variants in humanherpesvirus-6 isolates. Virology 184, 545-552.
Ace, C., Dalrymple, M., Ramsay, F., Preston, V., and Preston, C. (1988): Mutational analysis 
of the herpes simplex virus type 1 trans-inducing factor Vmw65. Journal of General Virology 
69, 2595-2605.
Ace, C., McKee, T., Ryan, J., Cameron, J., and Preston, C. (1989): Construction and 
characterisation of a herpes simplex type 1 mutant unable to transinduce immediate-early 
gene-expression. Journal of Virology S3, 2260-2269.
Addison, C., Rixon, F. J., Palfreyman, J. W., O'Hara, M., and Preston, V. G. (1984): 
Characterization of a herpes simplex virus type-1 mutant which has a temperature-sensitive 
defect in penetration of cells and assembly of capsids. Virology 138, 246-259.
Ali, M., Farghani, B., and Cantin, E. (1996): Characterisation of an essential HSV-1 protein 
encoded by the UL25 gene reported to be involved in virus penetration and capsid assembly. 
Virology 216, 278-283.
Almedia, J., Lang, D., and Talbot, P. (1978): Herpesvirus morphology: Visualisation of a 
structural subunit. Intervirology 10, 318-320.
Asher, Y., Heller, M., and Becker, Y. (1969): Incorporation of lipids into herpes simplex virus 
particles. Journal of General Virology A, 65-76.
Atkinson, M., Barr, S., and Timbury, M. (1978): The fine structure of cells infected with 
temperature sensitive mutants of herpes simplex virus type 2. Journal of General Virology 40, 
103-119.
Avitable, E., Di Gaeta, S., Torrisi, M., Ward, P., Roizman, B., and Campadelli-Fiume, G. 
(1995): Redistribution of microtubules and golgi apparatus in herpes simplex virus infected 
cells and their role in viral exocytosis. Journal of Virology 69, 7472-7482.
Baines, J., and Roizman, B. (1992): The cDNA of UL15, a highly conserved herpes simplex 
virus 1 gene, effectively replaces the two exons of the wild-type virus. Journal of Virology 66, 
5621-5626.
Baines, J., Poon, A., Rovnak, J., and Roizman, B. (1994): The herpes simplex virus 1 UL15 
gene encodes two proteins and is required for cleavage of genomic viral DNA. Journal of 
Virology SB, 8118-8124.
Baker, T. S., Newcomb, W. W., Booy, F. P., Brown, J. C., and Steven, A. C. (1990): Three- 
dimensional structures of maturable and abortive capsids of equine herpesvirus 1 from 
cryoelectron microscopy. Journal o f Virology 64, 563-573.
Balachandran, N., Harnish, D., Killington, R., Bacchetti, S., and Rawls, W. (1981): Monoclonal 
antibodies to 2 glycoproteins of herpes simplex virus type 2. Journal of Virology 39, 438-446.
Batchelor, A., and O'Hare, P. (1992): Localisation of cis-acting sequence requirements in the 
promoter of the latency associated transcripts of herpes simplex virus type 1 required for cell 
type specific activity. Journal of Virology 66, 3563-3582.
References
Batterson, W., and Roizman, B. (1983): Characterisation of the herpes simplex virion 
associated factor responsible for the induction of alpha genes. Journal of Virology 46 371- 
377.
Batterson, W., Furlong, B., and Roizman, B. (1983): Molecular genetics of HSV. VIII. Further 
characterisation of a temperature sensitive mutant defective in release of viral DNA and in 
other stages of viral reproductive cycle. Journal of Virology 45, 397-407.
Belyaev, A., and Roy, P. (1993): Development of baculovirus triple and quadruple expression 
vectors- coexpression of 3 or 4 bluetongue virus proteins and the synthesis of bluetongue 
virus-like particles in insect cells. Nucleic Acids Research 21, 1219-1223.
Ben-Porat, T., and Kaplan, A. (1971): Phospholipid metabolism of herpesvirus infected and 
uninfected rabbit kidney cells. Virology 45, 252-264.
Beswick, T. (1962): The origin and use of the word herpes. Medical History 6, 214-300.
Black, B., and Center, M. (1979): DNA binding properties of the major core protein of 
adenovirus 2. Nucleic Acid Research 6, 2339-2353.
Booy, F. P., Newcomb, W. W., Trus, B. L., Brown, J. C., Baker, T. S., and Steven, A. C. 
(1991a): Liquid-crystalline, phage-like packing of encapsidated DNA in herpes simplex virus. 
Cell 64, 1007-1015.
Booy, F. P., Newcomb, W. W., Trus, B. L., Brown, J. C., Baker, T. S., and Steven, A. C. 
(1991b): The DNA in herpes simplex virus capsids is arranged in parallel bundles with an 
inter-duplex spacing of 2.6 nm. Biophys. J. 59, 193a.
Booy, F. P., Trus, B. L., Newcomb, W. W., Brown, J. C., Conway, J. F., and Steven, A. C. 
(1994): Finding a needle in a haystack: detection of a small protein (the 12-kDa VP26) in a 
large complex (the 200-MDa capsid of herpes simplex virus). Proceedings of the National 
Academy of Sciences o f the U.S.A. 91, 5652-5656.
Booy, F., Trus, B., Davison, A., and Steven, A. (1996): The capsid architecture of channel 
catfish virus, an evolutionarily distant herpesvirus, is largely conserved in the absence of 
discernible sequence homology with herpes simplex virus. Virology 215, 134-141.
Braun, D., Roizman, B., and Pereira, L. (1984): Characterisation of post-translational products 
of herpes simplex virus gene 35 proteins binding to the surfaces of full capsids but not empty 
capsids. Journal o f Virology 49, 142-153.
Brenner, S., and Horne, R. W. (1959): A negative staining technique for high resolution 
electron microscopy of viruses. Biochimica et Biophysica Acta 34, 103-110.
Britt, W. (1996a): Human cytomegalovirus overview: the virus and its pathogenicity. Baillieres 
Clinical Infectious Diseases 3, 307-325.
Britt, W. (1996b): Human cytomegalovirus infection during pregnancy. Baillieres Clinical 
Infectious Diseases 3, 327-343.
Bronstein, J. C., Weller, S. K., and Weber, P. C. (1997): The product of the UL12.5 gene of 
herpes simplex virus type 1 is a capsid-associated nuclease. Journal of Virology 71, 3039- 
3047.
References
Brooks, L., Wilson, A., and Crooks, T. (1997): Kaposi's sarcoma-associated herpesvirus 
(KSHV) / human herpesvirus 8 (HHV8)- A new human tumor virus. Journal of Pathology 182, 
262-265.
Brown, M., and Faulkner, P. (1977): A plaque assay for nuclear polyhedrosis viruses using a 
solid overlay. Journal o f General Virology 36, 361-364.
Brown, S., Ritchie, D., and Subak-Sharpe, J. (1973): Genetic studies with herpes simplex virus 
type 1. The isolation of temperature sensitive mutants, their arrangement into 
complementation groups and recombination analysis leading to a linkage map. Journal of 
General Virology 18, 329-346.
Browne, H., Bell, S., Minson, T., and Wilson, D. W. (1996): An endoplasmic reticulum-retained 
herpes simplex virus glycoprotein H is absent from secreted virions: evidence for 
reenvelopment during egress. Journal of Virology 70, 4311-4316.
Bruckner, R., Crute, J., Dodson, M., and Lehman, I. (1991): The herpes simplex virus 1 origin 
binding protein: A DNA helicase. Journal of Biological Chemistry 266, 2669-2674.
Buckmaster, A., Scott, S., Sanderson, M., Boursnell, M., Ross, N., and Binns, M. (1988): Gene 
sequence and mapping data from Mareks disease virus and herpesvirus of turkeys- 
Implications for herpesvirus classification. Journal of General Virology SB, 2033-2042.
Bush, M., Yager, D., Gao, M., Weisshart, K., Marcy, A., Coen, D., and Knipe, D. (1991): 
Correct intranuclear localisation of herpes simplex virus DNA polymerase requires the viral 
ICP8 DNA binding protein. Journal of Virology 65, 1082-1089.
Cai, W., Person, S., Warner, S., Zhou, J., and DeLuca, N. (1987): Linker-insertion nonsense 
and restriction site mutations of the gB glycoprotein gene of herpes simplex type 1. Journal of 
Virology 61, 714-721.
Cai, W., Gu, B., and Person, S. (1988): Role of glycoprotein B of herpes simplex virus type 1 
in viral entry and cell fusion. Journal of Virology 62, 2596-2604.
Calder, J., and Stow, N. (1990): Herpes simplex virus helicase-primase: The UL8 protein is not 
required for DNA-dependant ATPase and DNA helicase activities. Nucleic Acids Research 18, 
3573-3578.
Calder, J., Stow, E., and Stow, N. (1992): On the cellular localisation of the components of the 
herpes simplex virus type 1 helicase-primase complex and the viral origin-binding protein. 
Journal of General Virology 73, 531-538.
Campadelli-Fiume, G., Arsenakis, M., Farabegoli, F., and Roizman, B. (1988): Entry of herpes 
simplex virus 1 in BJ cells that constitutively express viral glycoprotein D is by endocytosis and 
results in the degradation of the virus. Journal of Virology 62, 159-167.
Campadelli-Fiume, G., Farabeoli, F., Di Gaeta, S., and Roizman, B. (1991): Origin of 
unenveloped capsids in the cytoplasm of cells infected with herpes simplex type 1. Journal of 
Virology SB, 1589-1595.
Campbell, M., Palfreyman, J., and Preston, C. (1984): Identification of herpes simplex virus 
DNA which encode a trans-acting polypeptide responsible for stimulation of immediate early 
transcription. Journal of Molecular Biology 180, 1-19.
Challberg, M. (1986): A method for identifying the viral genes required for herpes DNA 
replication. Proceedings of the National Academy of Sciences of the U.S.A. 83, 9094-9098.
References
Challberg, M. (1991): Herpes simplex virus DNA replication. Seminars in Virology 2, 247-256.
Chang, Y., Cesarean, E., Pessin, M., Lee, F., Culpepper, J., Knowles, D., and Moore, P. 
(1994): Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's 
sarcoma. Science 266, 1865-1869.
Chase, C., Lohff, C., and Letchworth, G. (1993): Resistance and susceptibility of bovine cells 
expressing herpesviral glycoprotein D homologs to herpesviral infections. Virology 194, 365- 
369.
Cheng, P., Banfield, B., and Tufaro, F. (1991): Brefeldin A arrests the maturation and egress 
of herpes simplex virus particles during infection. Journal of Virology SB, 1893-1904.
Clements, J., Watson, R., and Wilkie, N. (1977): Temporal regulation of herpes simplex virus 1 
transcription: Location of transcripts on the viral genome. Cell 12, 275-285.
Cohen, G. H., Ponce de Leon, M., Diggelmann, H., Lawrence, W. C., Vernon, S. k., and 
Eisenberg, R. J. (1980): Structural analysis of the capsid polypeptides of herpes simplex virus 
types 1 and 2. Journal of Virology 34, 521-531.
Colby, W. W., and Shenk, T. (1981): Adenovirus type 5 virions can be assembled in vivo in the 
absence of detectable polypeptide IX. J. Virol. 39, 977-980.
Conley, A., Knipe, D., Jones, P., and Roizman, B. (1981): Molecular genetics of herpes 
simplex virus. VII. Characterisation of a temperature sensitive mutant produced by in vitro 
mutagenesis and defective in DNA synthesis and accumulation of gamma polypeptides. 
Journal o f Virology 37, 191 -206.
Cook, M., and Stevens, J. (1973): Pathogenesis of herpes simplex neuritis and ganglionitis in 
mice. Evidence of axonal transport of infection. Infection and Immunity 7, 272-276.
Costa, R., Draper, K., Banks, L., Powell, K., Cohen, G., Eisenberg, R., and Wagner, E. (1983): 
High resolution characterisation of herpes simplex type 1 transcripts encoding alkaline 
exonuclease and a 50000 dalton protein tentatively identified as a capsid protein. Journal of 
Virology AS, 591-603.
Costa, R., Cohen, G., Eisenberg, R., Long, D., and Wagner, E. (1984): Direct demonstration 
that the abundant 6-kilobase herpes simplex virus type 1 mRNA mapping between 0.23 and
0.27 map units encodes the major capsid protein VP5. Journal of Virology AS, 287-292.
Costanzo, F., Campadelli-Fiume, G., Foa-Tomasi, L., and Cassai, E. (1977): Evidence that 
herpes simples virus DNA is transcribed by cellular RNA polymerase B. Journal of Virology 21, 
996-1001.
Coulter, L., Moss, H., Lang, J., and McGeoch, D. (1993): A mutant of herpes simplex virus 
type 1 in which the UL13 protein kinase gene is disrupted. Journal of General Virology 74, 
387-395.
Crute, J., Mocarski, E., and Lehman, I. (1988): A DNA helicase induced by herpes simplex 
virus type 1. Nucleic Acids Research 16, 6585-6596.
Crute, J., and Lehman, I. (1989): Herpes simplex virus-1 DNA polymerase. Identification of an 
intrinsic 5'-3' exonuclease with ribonuclease H activity. Journal of Biological Chemistry 264, 
19266-19270.
References
Crute, J., Tsurumi, T., Zhu, L., Weller, S., Olivio, P., Challberg, M., Mocarski, E., and Lehman,
I. (1989): Herpes simplex virus 1 helicase-primase: A complex of three herpes-encoded gene 
products. Proceedings of the National Academy of Sciences of the U.S.A. 86, 2186-2189.
Crute, J., and Lehman, I. (1991): Herpes simplex virus-1 helicase-primase. Physical and 
catalytic properties. Journal o f Biological Chemistry 266, 4484-4488.
Dargan, D. J. (1986): The structure and assembly of herpesviruses, pp. 359-437. In J. R. 
Harris, and R. W. Horne (Eds): Electron microscopy of proteins. 5 viral structure, Academic 
Press Inc., London.
Darlington, R., and Moss, L. (1968): Herpesvirus envelopment. Journal of Virology 2, 48-55.
Davidson, A., and Taylor, P. (1987): Genetic relations between Varicella zoster 
virus and Epstein Barr virus. Journal of General Virology 68, 1067-1079.
Davison, A., and Wilkie, N. (1981): Nucleotide sequences of the joint between the L and S 
segments of herpes simplex viruses type 1 and 2. Journal of General Virology 55, 315-331.
Davison, A., and Wilkie, N. (1983): Location and orientation of homologous sequences in the 
genomes of five herpes viruses. Journal of General Virology 64, 1927-1942.
Davison, A. (1983): DNA sequence of the Us component of the varicella zoster of the varicella 
zoster virus genome. The EMBO Journal 2, 2203-2209.
Davison, A. (1992): Channel catfish v irus -A  new type of herpesvirus. Virology 186, 9-14.
Davison, M. D., Rixon, F. J., and Davison, A. J. (1992): Identification of genes encoding 2 
capsid proteins (VP24 and VP26) of herpes simplex virus type-1. Journal of General Virology 
73, 2709-2713.
Davison, A., and Davison, M. (1995): Identification of structural proteins of channel catfish 
virus by mass spectrometry. Virology 206, 1035-1043.
Davison, A. (1998): The genome of salmonid herpesvirus 1. Journal of Virology 72, 1974- 
1982.
Davison, A., Sauerbier, W., Dolan, A., Addison, C., and McKinnell, R. (1999): Genomic studies 
of the Lucke tumor herpesvirus (RaHV-1). Journal of Cancer Research and Clinical Oncology 
125, 232-238.
Deatly, A., Spivack, J., Lavi, E., and Fraser, N. (1987): Reactivation from an immediate early 
region of the type 1 herpes simplex virus genome is present in the trigeminal ganglia of 
latently infected mice. Proceedings o f the National Academy of Sciences of the U.S.A. 84, 
3204-3208.
Deiss, L., Chou, J., and Frenkel, N. (1986): Functional domains within the a sequence 
involved in the cleavage-packaging of herpes simplex virus DNA. Journal of Virology 59, 605- 
618.
Delius, H., and Clements, J. (1976): A partial denaturation map of herpes simplex virus type 1 
DNA: Evidence for the inversion of the unique DNA regions. Journal of General Virology 33, 
125-133.
References
Desai, P., Schaffer, P., and Minson, A. (1988): Excretion of non-infectious virus particles 
lacking glycoprotein H by a temperature sensitive mutant of herpes simplex type 1: evidence 
that gH is essential for virion infectivity. Journal of General Virology 69, 1147-1156.
Desai, P., Deluca, N., Glorioso, J., and Person, S. (1993): Mutations in herpes simplex type 1 
genes encoding VP5 and VP23 abrogate capsid formation and cleavage of replicated DNA. 
Journal of Virology 67, 1357-1364.
Desai, P., and Person, S. (1996): Molecular interactions between the HSV-1 capsid proteins 
as measured by the yeast two-hybrid system. Virology 220, 516-521.
Desai, P., and Person, S. (1998): Incorporation of the green fluorescent protein into the herpes 
simplex virus type 1 capsid. Journal of Virology 72, 7583-7567.
Desai, P., DeLuca, N., and Person, S. (1998): Herpes simplex virus type 1 VP26 is not 
essential for replication in cell culture but influences production of infectious virus in the 
nervous system of infected mice. Virology 247, 115-124.
Dilanni, C., Drier, D., Deckman, I., McCann, P., F, L., Roizman, B., Colonno, R., and 
Cordingley, M. (1993): Identification of the herpes simplex virus-1 protease cleavage sites by 
direct sequence analysis of autoproteolytic cleavage products. Journal of Biological Chemistry 
268, 2048-2051.
Dingwell, K., Brunetti, C., Hendricks, R., Tang, Q., Tang, M., Rainbow, A., and Johnson, D.
(1994): Herpes simplex virus glycoprotein E and glycoprotein I facilitate cell to cell spread in 
vivo and across junctions of cultured cells. Journal of Virology 68, 834-845.
Dixon, R., and Schaffer, P. (1980): Fine structure mapping and functional analysis of the 
temperature sensitive mutants in the gene encoding the herpes simplex virus type 1 
immediate early protein VP175. Journal of Virology 36, 189-203.
Dodson, M., Crute, J., Bruckner, R., and Lehman, I. (1989): Over expression and assembly of 
the herpes simplex type 1 helicase-primase in insect cells. Journal of Biological Chemistry 
264, 20835-20838.
Dodson, M., and Lehman, I. (1991): Association of DNA helicase primase 
activities with a subassembly of the herpes simplex virus 1 helicase-primase composed of the 
UL5 and UL52 gene products. Proceedings of the National Academy of Sciences of the U.S.A. 
88, 1105-1109.
Dokland, T., and Murialdo, H. (1993): Structural transitions during maturation of bacteriophage 
lambda capsids. J. Mol. Biol. 233, 682-694.
Dolyniuk, M., Wolff, E., and Kieff, E. (1976): Proteins of Epstein-Barr virus. II. Electrophoretic 
analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide- 
containing components of enveloped virus. Journal of Virology 18, 289-297.
Earnshaw, W., and King, J. (1978): Structure of phage P22 coat protein aggregates formed in 
the absence of the scaffolding protein. J Mol Biol 126, 721-747.
Earnshaw, W. C., and Casjens, S. R. (1980): DNA packaging by the double-stranded DNA 
bacteriophages. Cell 21, 319-331.
References
Eberle, R., and Courtney, R. (1980): gA and gB glycoproteins of herpes simplex virus type 1: 
two forms of a single polypeptide. Journal of Virology 36, 665-675.
Efstathiou, S., Kemp, S., Darby, G., and Minson, A. (1989): The role of herpes simplex virus 
type 1 thymidine kinase in pathogenesis. Journal of General Virology 70, 869-879.
Eggers, M., Bogner, E., Agricola, B., Kern, H., and Radsak, K. (1992): Inhibition of human 
cytomegalovirus maturation by brefeldin A. Journal of General Virology 73, 2679-2692.
Elliott, G., and O'Hare, P. (1997): Intracellular trafficking and protein delivery by a herpesvirus 
structural protein. Cell 88, 223-233.
Elliott, G., and O'Hare, P. (1999): Live cell analysis of a green fluorescent protein tagged 
herpes simplex virus infection. Journal of Virology 73, 4110-4119.
Everett, R. (1984): Transactivation of transcription by herpesvirus products. Requirement for 
two HSV-1 immediate early polypeptides for maximum activity. EMBO 3, 3135-3141.
Everett, R. (1986): The products of herpes simplex virus type 1 (HSV-1) immediate early 
genes 1, 2 and 3 can activate HSV-1 genes expression in trans. Journal of General Virology 
67, 2507-2513.
Everett, R., O'Hare, P., O'Rourke, D., Barlow, P., and Orr, A. (1995): Point mutations in the 
herpes simplex virus type 1 Vmw110 ring finger helix affect activation of gene expression, viral 
growth and interaction with PML containing nuclear structures. Journal of Virology 69, 7339- 
7344.
Everett, R., Meredith, M., Orr, A., Cross, A., Kathoria, M., and Parkinson, J. (1997): A novel 
ubiquitin specific protease is dynamically associated with the PML nuclear domain and binds 
to a herpesvirus regulatory protein. EMBO 16, 1519-1530.
Fenwick, M., and Clark, J. (1982): Early and delayed shut-off of host protein synthesis in cells 
infected with herpes simplex virus. Journal of General Virology 61, 121-125.
Fenwick, M. (1984): The effects of herpesvirus on cellular macromolecular synthesis. In H. 
Fraenkel-Conrat, and E. Wagner (Eds): Virology, Plenium Publishing Corporation, New York.
Forrester, A., Farrell, H., Wilkinson, G., Kaye, J., Davis-Poynter, N., and Minson, T. (1992): 
Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H 
coding sequences deleted. Journal o f Virology 66, 341-348.
Frenkel, N., Schirmer, L., Wyatt, L., Katsafanas, G., Roffman, E., Danovich, R., and June, C. 
(1976): Anatomy of herpes simples virus DNA. VI. Defective DNA originates from the S 
component. Journal of Virology 20, 527-531.
Frenkel, N., Schirmer, E., Wyatt, L., Katsalanas, G., Roffman, E., Danovich, R., and June, C. 
(1990): Isolation of a new herpesvirus from CD4+ T cells. Proceedings of the National 
Academy of Sciences of the U.S.A. 87, 748-752.
Friedrichs, W., and Grose, C. (1986): Varicella zoster virus p32/p36 complex is present in both 
the viral capsid and the nuclear matrix of the infected cell. Journal of Virology 57, 155-164.
Fuller, M., and King, J. (1981): Purification of the coat and scaffolding protein from procapsids 
of bacteriophages P22. Virology 112, 529-547.
References
Furlong, D., Swift, H., and Roizman, B. (1972): Arrangement of herpes virus deoxyribonucleic 
acid in the core. Journal of Virology 10, 1071-1074.
Galisteo, M., and King, J. (1993): Conformational transformations in the protein lattice of 
phage P22 procapsids. Biophysical Journal 65, 227-235.
Gallo, M., Dorsky, D., Crumpacker, C., and Parris, D. (1989): The essential 65kD DNA-binding 
protein of herpes simplex virus stimulates the virus encoded DNA polymerase Journal of 
Virology S3, 5023-5029.
Gao, M., Matusick-Kumar, L., Hurlburt, W., DiTusa, S., Newcomb, W., Brown, J., McCann, P., 
Ill, Deckman, I., and Colonno, R. (1994): The protease of herpes simplex virus type 1 is 
essential for functional capsid formation and viral growth. Journal of Virology 68, 3702-3712
Gelb, L. (1990): Varicella zoster virus, pp. 2011-2054. In B. Fields, and D. Knipe (Eds): 
Virology, 2nd edition, Raven Press, New York.
Geraghty, R., Krummenacher, C., Cohen, G., Eisenberg, R., and Spear, P. (1998): 
Alphaherpesvirus entry mediated by poliovirus receptor related protein 1 and poliovirus 
receptor. Science.
Gibson, W., and Roizman, B. (1972): Proteins specified by herpes simplex virus.VIII. 
Characterisation and composition of multiple capsid forms and sub-types of 1 and 2. Journal 
of Virology 10,1044-1052.
Gibson, W., Baxter, M., and Clopper, K. (1996): Cytomegalovirus 'missing' capsid protein 
identified as heat agreeable product of human cytomegalovirus UL46. Journal of Virology 70, 
7454-7461.
Gibson, W., Clopper, K., Britt, W., and Baxter, M. (1998): Human cytomegalovirus (HCMV) 
smallest capsid protein identified as a product of a short open reading frame located between 
UL48 and UL49. Journal o f Virology 70, 5680-5663.
Gottlieb, J., Marcy, A., Coen, D., and Challberg, M. (1990): The herpes simplex virus type 1 
UL42 gene product: A sub-unit of DNA polymerase that functions to increase processivity. 
Journal of Virology 64, 5976-5987.
Greber, U. R., Willetts, M., Webster, P., and Helenius, A. (1993): Stepwise dismantling of 
adenovirus 2 during entry into cells. Cell 75, 477-486.
Greene, B., and King, J. (1994): Binding of scaffold subunits within the P22 procapsid lattice. 
Virology 205, 188-197.
Grutter, M., and Franklin, R. (1974): Studies on the molecular weight of the adenovirus type 2 
hexon and its subunit. Journal of Molecular Biology 89, 163-178.
Haar, L., and Skulstad, S. (1994): The herpes simplex virus type 1 particle: Structure and 
molecular functions. APMIS 102, 321-346.
Haffey, M., and Spear, P. (1980): Alteration in glycoprotein gB specified by mutants and their 
partial revertants in herpes simplex virus type I and relationship to other mutant phenotypes. 
Journal of Virology 35, 114-128.
Haguenau, F., and Michelson-Fiske, S. (1975): Cytomegalovirus: Nucleocapsid assembly and 
core structure. Intervirology 5, 293-299.
References
Harris-Hamilton, E., and Bachenheimer, S. (1985): Accumulation of herpes simplex virus type 
1 RNAs of different kinetic classes in the cytoplasm of infected cells. Journal of Virology 53, 
144-151.
Hayward, S., Jacob, R., Wadsworth, R., and Roizman, B. (1975): Anatomy of herpes simplex 
virus DNA: Evidence for four populations of molecules that differ in the relative orientations of 
their long and short components. Proceedings of the National Academy of Sciences of the 
U.S.A. 72, 4243-4247.
Hayward, G. (1993): Immediate early gene regulation in herpes simplex virus. Seminars in 
Virology A, 15-23.
Heilman, C., Zweig, M., Stephenson, J., and Hampar, B. (1979): Isolation of a nucleocapsid 
polypeptide of herpes simplex virus types 1 and 2 possessing immunologically type-specific 
and cross-reactive determinants. Journal of Virology 29, 34-42.
Heine, J., Honess, R., Cassai, E., and Roizman, B. (1974): Proteins specified by herpes 
simplex virus. XII. The virion polypeptides of type 1 strains. Journal of General Virology 14, 
640-651.
Hernandez, T., and Lehman, I. (1990): Functional interaction between the herpes simplex-1 
DNA polymerase and UL42 protein. Journal of Biological Chemistry 265, 11227-11232.
Herold, B., WuDunn, D., Sotcys, N., and Spear, P. (1991): Glycoprotein C of herpes simplex 
virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. Journal of 
Virology 65, 1090-1098.
Hidaka, Y., Sukuma, S., Kumano, Y., Minagawa, H., and Mori, R. (1990): Characterisation of 
glycoprotein C-negative mutants of herpes simplex virus type I isolated from patients with 
keratitis. Archives of Virology 113,195-207.
Hill, T. (1985): Herpesvirus latency, pp. 175-240. In B. Roizman (Ed.): The herpesvirus, 
Plenum Publishing Corp, New York.
Hill, J., Sedarati, F., Javier, R., Wagner, E., and Stevens, J. (1990): Herpes simplex virus 
latent phase transcription facilities in vivo reactivation. Virology 174, 17-125.
Hill, A., Jugovic, P., York, I., Russ, G., Bennit, J., Yewdell, J., Ploegh, H., and Johnson, D.
(1995): Herpes simplex virus turns off TAP to evade host immunity. Nature 375, 411-415.
Ho, D., and Mocarski, E. (1989): Herpes simplex virus latent RNA (LAT) is not required for 
latent infection in the mouse. Proceedings of the National Academy of Sciences of the U.S.A. 
86, 7596-7600.
Hohn, B. (1983): DNA sequences necessary for packaging of bacteriophage 1 DNA. 
Proceedings o f the National Academy of Sciences of the U.S.A. 80, 7456-7460.
Homa, F. L., and Brown, J. C. (1997): Capsid assembly and DNA packaging in herpes simplex 
virus. Medical Virology 7, 107-122.
Honess, R., and Roizman, B. (1974): Regulation of herpesvirus macromolecular synthesis I. 
Cascade regulation of the synthesis of three groups of viral proteins. Journal of Virology 14, 8- 
19.
References
Hong, Z., Beaudet-Miller, M., Durkin, J., Zhang, R., and Kwong, A. D. (1996): Identification of 
a minimal hydrophobic domain in the herpes simplex virus type 1 scaffolding protein which is 
required for interaction with the major capsid protein. Journal of Virology 70, 533-540.
Horne, R., Brenner, S., Waterson, A., and Wildy, P. (1959): The icosahedral form of an 
adenovirus. Journal of Molecular Biology 1, 84-86.
Hosokawa, K., and Sung, M. (1976): Isolation and characterisation of an extremely basic 
protein from adenovirus type 5. Journal o f Virology 17, 924-934.
Hsu, H., Solovyev, I., Colombero, A., Elliot, R., Kelley, M., and Boyle, W. (1997): ATAR, a 
novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5*. 
Journal of Biological Chemistry 272, 13471-13474.
Hutchinson, L., Browne, H., Wargent, V., Davis-Poynter, N., Primorac, S., Goldsmith, K., 
Minson, A., and Johnson, D. (1992): A novel herpes simplex virus protein, gL, forms a 
complex with glycoprotein H (gH) and affects normal folding and surface expression of gH. 
Journal of Virology 66, 2240-2250.
Irmiere, A., and Gibson, W. (1985): Isolation of human cytomegalovirus intranuclear capsids, 
characterisation of their protein constituents, and demonstration that the B-capsid assembly 
protein is also abundant in non-infectious enveloped particles. Journal of Virology 56, 277-283.
Jacob, R., Morse, L., and Roizman, B. (1979): Anatomy of herpes simplex virus DNA. XII. 
Accumulation of head-to-tail concatamers in nuclei of infected cells and their role in the 
generation of the four isomeric arrangements of viral DNA. Journal of Virology 29, 448-457.
Javier, R., Stevens, J., Dissette, V., and Wagner, E. (1988): A herpes simplex virus transcript 
abundant in latently infected neurons is dispensable for establishment of the latent state. 
Virology 166, 254-257.
Johnson, D., and Ligas, M. (1988): Herpes simplex viruses lacking glycoprotein D are unable 
to inhibit virus penetration: quantitative evidence for virus specific cell surface receptors. 
Journal of Virology 62, 4605-4612.
Johnson, D., Burke, R., and Gregory, T. (1990): Soluble forms of herpes simplex virus 
glycoprotein D bind to a limited number of cell surface receptors and inhibit virus entry into 
cells. Journal of Virology 62, 1347-1354.
Jones, F., and Grose, C. (1988): Role of cytoplasmic vacuoles in varicella-zoster virus 
glycoprotein trafficking and virion envelopment. Journal of Virology 62, 2701-2711.
Karger, A., and Mettenleiter, T. (1993): Glycoproteins gill and gp50 play dominant roles in the 
biphasic attachment of pseudorabies virus. Virology 194, 654-664.
Kennard, J., Rixon, F. J., McDougall, I. M., Tatman, J. D„ and Preston, V. G. (1995): The 25 
amino acid residues at the carboxy terminus of the herpes simplex virus type 1 UL26.5 protein 
are required for the formation of the capsid shell around the scaffold. Journal of General 
Virology 76, 1611-1621.
Kinq J., and Casjens, S. (1974): Catalytic head assembling protein in virus morphogenesis. 
Nature 251, 112-119.
References
King, J., and Chiu, W. (1997): The procapsid-to-capsid transition in double-stranded DNA 
bacetriophage, pp. 288-311. In W. Chiu, R. Burnett, and R. Garcea (Eds): Structural biology of 
viruses, Oxford University Press, New York.
Kirkitadze, M., Barlow, P., Price, N., Kelly, S., Boutell, C., Rixon, F., and McClelland, D. 
(1998): The herpes simplex virus triplex protein, VP23, exists as a molten globule. Journal of 
Virology 72, 10066-10072.
Knopf, K. (1979): Properties of Herpes simplex virus DNA polymerase and characterisation of 
its associated exonuclease activity. European Journal of Biochemistry 62, 4096-4103.
Koslowski, K., Shaver, P., Wang, X., Tenney, D., and Pederson, N. (1997): The pseudorabies 
virus UL28 protein enters the nucleus after coexpression with the herpes simplex virus UL15 
protein. Journal of Virology 71 , 9118-9123.
Kristensson, K., Lycke, E., Roytta, M., Svennerholm, B., and Vahlne, A. (1986): Neuritic 
transport of herpes simplex in rat sensory neurons in vitro. Effects of substances interacting 
with microtubular function and axonal flow (nocodazole, taxol and erythro-9-3-(2- 
hydroxynonyl)-adenine). Journal of General Virology 67, 2023-2028.
Kunkel, T. (1985): Rapid and efficient site-specific mutagenesis without phenotypic selection. 
Proceedings of the National Academy of Sciences of the U.S. A 82, 488-492.
Kwon, B., Tan, K., Ni, J., Oh, K., Lee, Z., Kim, K., and al, e. (1997): A newly identified member 
of the tumor necrosis factor receptor superfamily with a wide tissue distribution and 
involvement in lymphocyte activation. Journal of Biological Chemistry 272, 14272-14276.
Kwong, A., Kruper, J., and Frenkel, N. (1988): Herpes simplex virus virion host shut off 
function. Journal o f Virology 62, 912-921.
Ladin, B., Ihara, S., Hampl, H., and Ben-Porat, T. (1982): Pathway of assembly of herpesvirus 
capsids: an analysis using DNA temperature sensitive mutants of Pseudorabies virus. Virology 
116, 554-561.
Lee, W., and Fuller, A. (1993): Herpes simplex virus type 1 and pseudorabies virus bind to a 
common saturable receptor on vero cells that is not heparan sulphate. Journal o f Virology 67, 
5088-5097.
Lemaster, S., and Roizman, B. (1980): Herpes simplex virus phosphoproteins. II. 
Characterisation of the virion protein kinase and of the polypeptides phosphorylated in the 
virion. Journal of Virology 35, 798-811.
Lenk, E., Casjens, S., Weeks, J., and King, J. (1975): Intracellular visualisation of precursor 
capsids in phage P22 mutant infected cells. Virology 68, 182-199.
Leslie, J., Rixon, F. J., and McLauchlan, J. (1996): Overexpression of the herpes simplex virus 
type 1 tegument protein VP22 increases its incorporation into virus particles. Virology 220, 60- 
68 .
Levine, A. (1992): Viruses. Scientific American Library. New York.
Levy, J. (1997): Three new human herpesviruses (HHV6, 7, and 8). Lancet 349, 558-563.
References
Ligas, M., and Johnson, D. (1988): A herpes simplex virus mutant in which glycoprotein D 
sequences are replaced by B-galactosidase sequences binds to but is unable to penetrate into 
cells. Journal of Virology 62, 1486-1494.
Lillycrop, K., Estridge, J., and Latchman, D. (1993): The octamer binding protein Oct-2 inhibits 
transactivation of the herpes simplex virus immediate early genes by the virion protein 
Vmw65. Virology 196, 888-891.
Little, S., Jofre, J., Courtney, R., and Schaffer, P. (1981): A virion associated glycoprotein 
essential for infectivity of herpes simplex virus type I. Virology 115, 149-160.
Liu, F., and Roizman, B. (1991a): The promoter, transcriptional unit, and the coding 
sequences of herpes simplex virus 1 family 35 proteins are contained within the UL26 ORF. 
Journal of Virology 65, 206-212.
Liu, F., and Roizman, B. (1991b): The herpes simplex virus 1 gene encoding a protease also 
contains within its coding domain the gene encoding the more abundant substrate. Journal of 
Virology 65, 5149-5156.
Liu, F., and Roizman, B. (1992): Differentiation of multiple domains in the herpes simplex virus 
1 protease encoded by the UL26 gene. Proceedings of the National Academy of Sciences of 
the U.S.A. 89, 2076-2080.
Livingston, C., and Jones, I. (1989): Baculovirus expression vectors with single strand 
capacity. Nucleic Acids Research 17, 2366-2370.
Longnecker, R., and Roizman, B. (1986): Generation of an inverting herpes simplex virus 1 
mutant lacking the L-S junction a sequences, an origin of DNA synthesis and several genes 
including those specifying the glycoprotein E and the alpha 47 gene. Journal o f Virology 58, 
583-591.
Lycke, E., Hanmark, M., Johansson, M., Krotwil, A., Lycke, J., and Svennerholm, B. (1988): 
Herpes simplex infection of the human sensory neuron. An electron microscopic study. 
Archives of Virology 101, 87-104.
MacLean, C., Dolan, A., Jamieson, F., and McGeoch, D. (1992): The myristylated virion 
proteins of herpes simplex virus type 1: Investigation of their role in the virus life cycle. Journal 
o f General Virology 73, 539-547.
MacPherson, I., and Stoker, M. (1962): Polyoma transformation of hamster cell clones: an 
investigation of genetic factors affecting cell competence. Virology 16, 147-151.
Maizel, J. V., White, D. O., and Scharff, M. D. (1968): The polypeptides of adenovirus. II. 
Soluble proteins, cores, top components and the structure of the virion. Virology 36, 126-136.
Maniatis, T., Fritsch, E., and Sambrooke, J. (1982): Molecular cloning; A laboratory manual. 
Cold Spring Harbour Laboratory. New York.
Marsden, H., Campbell, M., Haar, L., Frame, M., Parris, D., Murphy, M., Hope,
R., Muller, M., and Preston, C. (1987): The 65000-mr DNA-binding and virion trans-inducing 
proteins of herpes simplex virus type 1. Journal o f Virology 61 , 2428-2437.
References
Marsters, S., Ayres, T., Skubatch, M., Gray, C., Rothe, M., and Ashkenazi, A. (1997): 
Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, 
interacts with members of the TNRF-associated factor family and activates the transcription 
factors NF-KB and AP-1*. Journal of Biological Chemistry 272, 14029-14032.
Martinez, R., Sarisky, R. T., Weber, P. C., and Weller, S. K. (1996): Herpes simplex virus type 
1 alkaline nuclease is required for efficient processing of viral DNA replication intermediates. 
Journal of Virology 70, 2075-2085.
Matsuura, Y., Possee, R., Overton, H., and Bishop, D. (1987): Baculovirus expression vectors: 
the requirements for high level expression of proteins, including glycoprotiens. Journal of 
General Virology 68, 1233-1250.
Matthews, D., and Russell, W. (1995): Adenovirus protein-protein interactions: Molecular 
parameters governing the binding of protein VI to hexon and the activation of the adenovirus 
23K protease. Journal of General Virology 76, 1959-1969.
Matusick-Kumar, L., Newcomb, W. W., Brown, J. C., McCann III, P. J., Hurlburt, W., 
Weinheimer, S. P., and Gao, M. (1995): The C-terminal 25 amino acids of the protease and its 
substrate ICP35 of herpes simplex virus type 1 are involved in the formation of sealed capsids. 
Journal of Virology 69, 4347-4356.
McGeoch, D. J., Dalrymple, M. A., Davison, A. J., Dolan, A., Frame, M. C., McNab, D., Perry, 
L. J., Scott, J. E., and Taylor, P. (1988): The complete DNA sequence of the long unique 
region in the genome of herpes simplex virus type 1. Journal o f General Virology 69, 1531- 
1574.
McGeoch, D., Cook, S., Dolan, A., Jamieson, F., and Telford, E. (1995): Molecular phytogeny 
and evolutionary timescale for the family of mammalian herpesviruses. Journal of Molecular 
Biology 247, 443-458.
McLauchlan, J., Addison, C., Craigie, M. C., and Rixon, F. J. (1992a): Noninfectious L- 
particles supply functions which can facilitate infection by HSV-1. Virology 190, 682-688.
McLauchlan, J., and Rixon, F. J. (1992b): Characterization of enveloped tegument structures 
(L particles) produced by alphaherpesviruses: integrity of the tegument does not depend on 
the presence of capsid or envelope. Journal of General Virology 73, 269-276.
McLauchlan, J., Liefkins, K., and Stow, N. (1994): The herpes simplex virus type 1 UL37 gene 
product is a component of virus particles. Journal of General Virology 75, 2047-2052.
McLean, G., Abbotts, A., Parry, M., Marsden, H., and Stow, N. (1994): The herpes simplex 
virus type 1 origin binding protein interacts specifically with the viral UL8 protein. Journal of 
General Virology 75, 2699-2706.
McNab, D., and Courtney, R. (1992): Analysis of the UL36 open reading frame encoding the 
large tegument protein (ICP1/2) of herpes simplex virus type 1. Journal o f Virology 66, 7581- 
7584.
McNab, A. R„ Desai, P., Person, S., Roof, L. L., Thomsen, D. R., Newcomb, W. W., Brown, J. 
C., and Homa, F. L. (1998): The product of the herpes simplex virus type 1 UL25 gene is 
required for encapsidation but not for cleavage of replicated viral DNA. Journal of Virology 72, 
1060-1070.
References
Mehta, A., Maggioncalda, J., Bagasra, O., Thikkavarapu, S., Saikumari, P., Valyinagy, T., 
Fraser, N., and Block, T. (1995): In situ DNA PCR and RNA hybridisation detection of herpes 
simplex sequences in trigeminal ganglia of latently infected mice. Virology 206, 633-640.
Mellerick, D., and Fraser, N. (1987): Physical state of the latent herpes simplex virus genome 
in a mouse model system: Evidence suggesting an episomal state. Virology 158, 265-275.
Meredith, M., Orr, A., Elliott, M., and Everett, R. (1995): Separation of sequence requirements 
for HSV-1 Vmw110 multimerisation and interaction with a 135kDa cellular protein. Virology 
209, 174-187.
Merrifield, B. (1964): Solid phase peptide synthesis. Biochemistry 3, 1385-1390.
Merrifield, B. (1986): Solid phase peptide synthesis. Science 232, 341-344.
Miller, G. (1990): Epstein Barr virus: Biology, pathogenesis and medical aspects, pp. 1843- 
1887. In B. Fields, D. Knipe, and e. al (Eds): Virology, 2nd edition, Raven Press, New York.
Mitchison, T. (1988): Microtubule dynamic and kinetochrome function in mitosis. Annual 
Reviews in Cell Biology 4, 527-549.
Miyamoto, K., and Morgan, C. (1971): Structure and development of viruses as observed in 
the electron microscope. XI. Entry and uncoating of herpes simplex virus. Journal of Virology 
8, 910-918.
Miyamoto, K. (1971): Mechanism of intranuclear crystal formation of herpes simplex virus as 
revealed by the negative staining of thin sections. Journal of Virology 8, 534-550.
Mocarski, E., and Roizman, B. (1981): Site-specific inversion sequence of the herpes simplex 
virus genome: domain and structural features. Proceedings of the National Academy of 
Sciences of the U.S.A. 78, 7047-7051.
Mocarski, E., and Roizman, B. (1982): Structure and role of herpes simplex virus DNA termini 
in inversion, circularisation and generation of virion DNA. Cell 31, 89-97.
Monini, P., de Lellis, L., Fabris, M., Rigolin, F., and Cassai, E. (1996): Kaposi's sarcoma- 
associated herpesvirus-like DNA sequences in prostate tissue and human serum. New 
England Journal o f Medicine 334, 1168-1172.
Monoto, A. (1992): Acute respiratory infections, pp. 125-131. In J. Last, and R. Wallace (Eds): 
Maxcy-Rosenau-Last Public Health and Preventative Medicine, Appleton & Lange, Nowalk.
Montgomery, R., Warner, M., Lum, B, and Spear, P. (1996): Herpes virus 1 entry into cells 
mediated by a novel member of the TNF/NGF receptor family. Cell 87, 427-436.
Morgan, C., Ellison, S., Rose, H., and Moore, D. (1954): Structure and denvelopement of 
viruses as observed in the electron microscope. I. Herpes simplex virus. Journal of 
Experimental Medicine 100, 195-202.
References
Morgan, C., Rose, H., Holden, M., and Jones, E. (1959): Electron microscopic observations on 
the development of herpes simplex virus. Journal of Experimental Medicine 110, 643-656.
Morgan, C., Rose, H., and Mednis, B. (1968): Electron microscopy of herpes simplex virus 
type 1 entry. Journal of Virology 2, 507-516.
Nahmais, A., and Dowdle, W. (1968): Antigenic and biological differences in herpesvirus 
horn in is. Programs in Medical Virology 10, 110-115.
Newcomb, W. W., Brown, J. C., Booy, F. P., and Steven, A. C. (1989): Nucleocapsid mass 
and capsomer protein stoichiometry in equine herpesvirus 1: scanning transmission electron 
microscopic study. Journal of Virology 63, 3777-3783.
Newcomb, W. W., and Brown, J. C. (1991): Structure of the herpes simplex virus capsid: 
effects of extraction with guanidine hydrochloride and partial reconstitution of extracted 
capsids. Journal of Virology 65, 613-620.
Newcomb, W. W., Trus, B. L., Booy, F. P., Steven, A. C., Wall, J. S., and Brown, J. C. (1993): 
Structure of the herpes simplex virus capsid: molecular composition of the pentons and the 
triplexes. Journal of Molecular Biology 232, 499-511.
Newcomb, W. W., Homa, F. L., Thomsen, D. R., Ye, Z., and Brown, J. C. (1994): Cell-free 
assembly of the herpes simplex virus capsid. Journal of Virology 68, 6059-6063.
Newcomb, W. W., and Brown, J. C. (1994): Induced extrusion of DNA from the capsid of 
herpes simplex virus type-1. Journal of Virology 68, 433-440.
Newcomb, W. W., Homa, F. L., Thomsen, D. R., Booy, F. P., Trus, B. L., Steven, A. C., 
Spencer, J. V., and Brown, J. C. (1996): Assembly of the herpes simplex virus capsid: 
characterization of intermediates observed during cell-free capsid formation. Journal of 
Molecular Biology 263, 432-446.
Newcomb, W., Homa, F., Thomsen, D., Trus, B., Cheng, N., Steven, A., Booy, F., and Brown, 
J. (1999): Assembly of the herpes simplex virus procapsid from purified components and 
identification of small complexes containing the major capsid and scaffolding proteins. Journal 
of Virology 73,4239-4250.
Nicholson, P., Addison, C., Cross, A. M., Kennard, J., Preston, V. G., and Rixon, F. J. (1994): 
Localization of the herpes simplex virus type 1 major capsid protein VP5 to the cell nucleus 
requires the abundant scaffolding protein VP22a. Journal of General Virology 75, 1091-1099.
Nii, S., Morgan, C., and Rose, H. M. (1968a): Electron microscopy of herpes simplex virus. II. 
Sequence development. Journal o f Virology 2, 517-536.
Nii, S., Morgan, C., and Hsu, K. (1968b): Electron microscopy of herpes simplex virus. IV. 
Studies with ferritin conjugated antibodies. Journal o f Virology 2, 1172-1184.
Nishioka, Y., and Silverstein, S. (1978): Alterations in the protein synthetic apparatus of friend 
erythroleukimia cells infected with vesicular stomatitis virus or herpes simplex virus. Journal of 
Virology 25, 422-426.
O'Donnell, M., Elias, P., and Lehman, I. (1987): Processive replication of single stranded DNA 
templates by the herpes virus-induced DNA polymerase. Journal of Biological Chemistry 262, 
4252-4259.
References
O'Hare, P., and Hayward, G. (1985): Evidence for a direct role for both the 175000- and 
110000- molecular weight immediate early proteins of herpes simplex virus in the 
transactivation of delayed early promoters. Journal of Virology 53, 751-760.
Oien, N., Thomsen, D., Wathen, N., Newcomb, W., Brown, J., and Homa, F. (1997): Assembly 
of herpes simplex virus capsids using the human cytomegalovirus scaffold protein: critical role 
of the C terminus. Journal o f Virology 71, 1281-1291.
Olivio, P., Nelson, N., and Challberg, M. (1988): Herpes simplex virus DNA replication: The 
UL9 gene encodes an origin binding protein. Proceedings of the National Academy of 
Sciences of the U.S.A. 85, 5414-5418.
Onorato, L., and Showe, M. (1975): Gene gp21 protein-dependent proteolysis in vivo of 
purified gene gp22 product of bacteriophage T4. Journal of Molecular Biology 92, 395-412.
Palmer, E., Martin, M., and Gary, G. (1975): The ultra structure of disrupted herpesvirus 
nucleocapsids. Virology 65, 260-265.
Patel, A., and MacLean, J. (1995): The product of the UL6 gene of herpes simplex virus type 1 
is associated with virus capsids. Virology 206, 465-478.
Patel, A. H., Rixon, F. J., Cunningham, C., and Davison, A. J. (1996): Isolation and 
characterization of herpes simplex virus type 1 mutants defective in the UL6 gene. Virology 
217, 111-123.
Pelletier, A., Do, J., Brisebois, L., Lagace, L., and Cordingley, M. (1997): Self-association of 
herpes simplex virus type 1 ICP35 is via coiled- coil interactions and promotes stable 
interaction with the major capsid protein. Journal o f Virology 71, 5197-5208.
Penfold, M., Armati, P., and Cunningham, A. (1994): Axonal transport of herpes
simplex virions to epidermal cells: evidence for a specialised mode of virus transport and
assembly. Proceedings of the National Academy of Sciences of the U.S.A. 91, 6529-6533.
Perdue, M., Cohen, J., Kemp, M., Randall, C., and O'Callaghan, D. (1975): Characterisation of 
three species of nucleocapsid of equine herpesvirus type 1 (EHV-1). Virology 64, 187-204.
Perdue, M., Cohen, J., Randall, C., and O'Callaghan, D. (1976): Biochemical studies on the 
maturation of herpesvirus nucleocapsid species. Virology 74, 194-208.
Person, S., and Desai, P. (1998): Capsids are formed in a mutant virus blocked at the 
maturation site of the UL26 and UL26.5 open reading frames of herpes simplex virus type 1 
but are not formed in a null mutant of UL38 (VP19C). Virology 242, 193-203.
Pertuiset, B., Boccara, M., Cebrain, J., Berthelot, N., Chousterman, S., Puvion-Dutilleul, F., 
Sisman, J., and Sheldrick, P. (1989): Physical mapping and nucleotide sequence of a herpes 
simplex virus type 1 gene required for capsid assembly. Journal of Virology, 2169-2179.
Poffenberger, K., and Roizman, B. (1985): A non-reverting genome of a viable herpes simplex 
virus 1: Presence of head-to-tail linkages in packaged genomes and requirements for 
circularisation after infection. Journal of Virology 53, 587-595.
References
Poffenberger, K., Idowu, A., Frasersmith, E., Raichlen, P., and Herman, R. (1994): A herpes 
simplex virus type 1 ICP22 deletion mutant is altered for virulence and latency in vivo. 
Archives of Virology 139, 111-119.
Pokinghorne, I., and Roy, P. (1995): Transient expression in insect cells using a recombinant 
baculovirus synthesising bacteriophage T7 RNA polymerase. Nucleic Acids Research 23, 188- 
191.
Polvino-Bodnar, M., Orberg, P., and Schaffer, P. (1987): Herpes simplex virus type 1 oriL is 
not required for virus replication or for establishment and reactivation of latent infection in 
mice. Journal of Virology 61 , 3582-3535.
Poon, A., and Roizman, B. (1993): Characterisation of a temperature sensitive mutant of the 
UL15 ORF of herpes simplex virus 1. Journal of Virology 67, 4497-4503.
Post, L., Mackem, S., and Roizman, B. (1981): Regulation of alpha genes of herpes simplex 
virus: Expression of chimeric genes produced by fusion of thymidine kinase with alpha gene 
promoters. Cell 24, 555-565.
Powell, K., and Watson, D. (1975): Some structural antigens of herpes simplex type 1. Journal 
of Gen era I Virology 29, 167-178.
Powell, K., and Purifoy, D. (1977): Nonstructural proteins of herpes simplex virus. I. 
Purification of the induced DNA polymerase. Journal of Virology 24, 618-626.
Prasad, B. V. V., Prevelige, P. E., Marietta, E., Chen, R. O., Thomas, D., King, J., and Chiu, 
W. (1993): Three-dimensional transformation of capsids associated with genome packaging in 
a bacterial virus. J. Mol. Biol. 231, 65-74.
Preston, C. (1979): Abnormal properties of an immediate early polypeptide in cells infected 
with the herpes simplex virus type 1 mutant tsK. Journal of Virology 32, 357-369.
Preston, V. G., Coates, J. A. V., and Rixon, F. J. (1983): Identification and characterization of 
a herpes simplex virus gene product required for encapsidation of virus DNA. Journal of 
Virology 45, 1056-1064.
Preston, C., Frame, M., and Campbell, M. (1988): A complex formed between cell 
components and an HSV-1 structural polypeptide binds to a viral immediate early regulatory 
DNA sequence. Cell 52, 425-434.
Preston, V. G., Rixon, F. J., McDougall, I. M., McGregor, M., and Al-Kobaisi, M. F. (1992): 
Processing of the herpes simplex virus assembly protein ICP35 near its carboxy terminal end 
requires the product of the whole of the UL26 reading frame. Virology 186, 87-98.
Preston, V. G., Al-Kobaisi, M. F., McDougall, I. M., and Rixon, F. J. (1994): The herpes 
simplex virus gene UL26 proteinase in the presence of the UL26.5 gene product promotes the 
formation of scaffold-like structures. Journal of General Virology 75, 2355-2366.
Prevelige, P., and King, J. (1993): Assembly of bacteriophage P22: A model for ds DNA virus 
assembly. Programmes of Medical Virology 40, 206-221.
References
Purves, F., and Roizman, B. (1992): The UL13 gene of herpes simplex virus encodes the 
functions for post-translational processing associated with phosphorylation of the regulatory 
protein alpha-22. Proceedings of the National Academy of Sciences of the U S A  89 7310- 
7314.
Puvion-Dutilleul, F., Pichard, E., Laither, M., and Leduc, E. (1987): Effect of hydrating agents 
on DNA organisation in herpes viruses. Journal of Histochemistry & Cytochemistry 35 635- 
645.
Quinlan, M., Chen, L., and Knipe, D. (1984): The intranuclear location of a herpes simplex 
virus DNA-binding protein is determined by the status of viral DNA replication. Cell 36, 857- 
868 .
Quinlan, M., and Knipe, D. (1985): Stimulation of expression of a herpes simplex DNA binding 
protein by two viral functions. Molecular and Cellular Biology 5, 957-963.
Quinn, J., and McGeoch, D. (1985): DNA sequence of the region in the genome of herpes 
simplex virus type 1 containing genes for DNA polymerase and the major DNA binding protein. 
Nucleic Acids Research 13, 8143-8163.
Ray, P., and Murialdo, H. (1975): The role of gene Nu3 in bacteriophage lambda head 
morphogenesis. Virology 64, 247-263.
Rice, S., and Knipe, D. (1993): Genetic evidence of two distinct transactivation functions of 
herpes simplex virus alpha protein ICP27. Journal of Virology 64, 1704-1715.
Rice, S., Long, M., Lam, V., Schaffer, P., and Spencer, C. (1995): Herpes simplex virus 
immune protein ICP22 is required for viral modification of host mRNA polymerase II and 
establishment of the normal transcription program. Journal of Virology 69, 5550-5559.
Rixon, F. J., Atkinson, M. A., and Hay, J. (1983): Intranuclear distribution of herpes simplex 
virus type-2 DNA synthesis: examination by light and electron microscopy. Journal of General 
Virology 64, 2087-2092.
Rixon, F. J., Cross, A. M., Addison, C., and Preston, V. G. (1988): The products of herpes 
simplex virus type-1 gene UL26 which are involved in DNA packaging are strongly associated 
with empty but not with full capsids. Journal of General Virology 69, 2879-2891.
Rixon, F. J., Davison, M. D., and Davison, A. J. (1990): Identification of the genes encoding 
two capsid proteins of herpes simplex virus type 1 by direct amino acid sequencing. Journal of 
General Virology 71, 1211-1214.
Rixon, F. J., Addison, C., and McLauchlan, J. (1992): Assembly of enveloped tegument 
structures (L particles) can occur independently of virion maturation in herpes simplex virus 
type 1-infected cells. Journal of General Virology 73, 277-284.
Rixon, F. J. (1993): Structure and assembly of herpesviruses. Seminars in Virology 4, 135- 
144.
Rixon, F. J., Addison, C., McGregor, A., Macnab, S. J., Nicholson, P., Preston, V.
G., and Tatman, J. D. (1996): Multiple interactions control the intracellular localization of the 
herpes simplex virus type 1 capsid proteins. Journal o f General Virology 77, 2251-2260.
References
Rixon, F., and McNab, D. (1999): Packaging-competent capsids of a herpes simplex virus 
temperature sensitive mutant have properties similar to those of in vitro assembled 
procapsids. Journal of Virology 73, 5714-5721.
Roberts, M., White, J., Grutter, M., and Burnett, R. (1986): Three dimensional structure of the 
adenovirus major coat protein. Science 232, 1148-1151.
Roffman, E., Albert, J., Goff, J., and Frenkel, N. (1990): Putative site for the acquisition of 
human herpesvirus 6 virion tegument. Journal of Virology 64, 6308-6313.
Roizman, B. (1969): The herpesvirus- A biochemical definition of the group, pp. 1-79. In W. e. 
a. Arber (Ed.): Current Topics in Microbiology and Immunology, Springer Verlag, Berlin.
Roizman, B., and Furlong, D. (1974): The replication of herpesviruses, pp. 229-403. In H. 
Fraenkel-Conrat, and R. Wagner (Eds): Comprehensive Virology, Plenium Press, New York.
Roizman, B. (1979): The structure and isomerisation of herpes simplex virus genomes. Cell 
16,481-494.
Roizman, B., Carmicheal, L., Deinhardt, F., Nahmais, A., Plowright, W., Rapp, F., Sheldrick, 
P., Takahashi, M., and Wolf, K. (1981): Herpesviridae: Definition, provisional nomenclature 
and taxonomy. Intervirology 16, 201-217.
Roizman, B., and Sears, A. (1990): Herpes simplex viruses and their replication, pp. 1795- 
1841. In B. Fields, and D. Knipe (Eds): Virology, Raven Press Ltd, New York.
Roizman, B., Desrosier, R., Fleckenstein, B., Lopez, C., Minson, A., and Studdert, M. (1992): 
The family herpesviridae: An update. Archives of Virology 123, 425-449.
Roizman, B. (1996): The function of herpes simplex virus genes- A primer for genetic 
engineering of novel vectors. Proceedings of the National Academy of Sciences o f the U.S.A. 
93, 11307-11312.
Roizman, B., and Sears, A. (1996): Herpes simplex viruses and their replication, pp. 2231- 
2295. In B. Fields, D. Knipe, P. Howley, and e. al (Eds): Fields Virology, Raven publishers, 
Philadelphia.
Rose, J., Buoncore, L., and Whitt, M. (1991): A new cationic liposome reagent mediating 
nearly quantitative transfection of animal cells. Biotechiques 10, 520-525.
Rost, B., and Sander, C. (1994): Combining evolutionary information and neural networks to 
predict protein secondary structure. Proteins-Structure Function and Genetics 19, 55-72.
Ruigrok, R. W. H., Barge, A., Albiges-Rizo, C., and Dayan, S. (1990): Structure of the 
adenovirus fibre II. Morphology of single fibres. J. Mol. Biol. 215, 589-596.
Saad, A., Zhou, Z., Jakana, J., Chui, W., and Rixon, F. (1999): Roles of the triplex and 
scaffolding proteins in HSV-1 capsid formation suggested by the structures of recombinant 
particles, awaiting publication.
Salahuddin, S., Ablashi, D., Markham, P., Josephs, S., Sturzenegger, S., Kaplan, M., Halligan, 
G., Biberfeld, P., Wongstaal, F., Kramarsky, B., and Gallo, R. (1986): Isolation of a new virus, 
HBLV, in patients with lymphproliferative disorders. Science 234, 596-601.
References
Salmon, B., and Baines, J. (1988): Herpes simplex virus DNA cleavage and packaging; 
Association of multiple forms of UL15 encoded proteins with B capsids requires at least the 
UL6, UL17 and UL28 genes. Journal of Virology 72, 3045-3050.
Salmon, B., Cunningham, C., Davison, A. J., Harris, W. J., and Baines, J. D. (1998): The 
herpes simplex virus type 1 U|J7 gene encodes virion tegument proteins that are required for
cleavage and packaging of viral DNA. Journal of Virology 72, 3779-3788.
Sarimento, M., Haffey, M., and Spear, P. (1979): Membrane proteins specified by herpes 
simplex viruses. III. Role of glycoprotein VP7 (B2) in virion infectivity. Journal of Virology 29, 
1149-1158.
Sawtell, N., Poon, D., Tansky, C., and Thompson, R. (1998): The latent herpes simplex virus 
type 1 genome copy number in individual neurons is virus specific and correlates with 
reactivation. Journal of Virology 72, 5343-5350.
Schirmer, E., Wyatt, L., Yamanishi, K., Rodriguez, W., and Frenkel, N. (1991): Differentiation 
between two distinct classes of virus now classified as human herpesvirus 6. Proceedings of 
the National Academy of Sciences of the U.S.A. 88, 5922-5926.
Schrag, J. D., Prasad, B. V. V., Rixon, F. J., and Chiu, W. (1989): Three-dimensional structure 
of the HSV-1 nucleocapsid. Cell 56, 651-660.
Schroder, C., Stegmann, B., Lauppe, H., and Kaerner, H. (1975): An unusual defective 
genotype derived from herpes simplex virus strain AGN. Intervirology 6, 270-284.
Sevenni, A., Morgan, A., Tovell, D., and Tyrrell, D. (1994): Study of the structure of replicative 
intermediates of HSV-1 DNA by pulse-field gel electrophoresis. Virology 200, 248-435.
Seven, B., Landini, M., and Govoni, E. (1988): Human cytomegalovirus morphogenesis: An 
ultrastructural study of the late cytoplasmic phases. Archives of Virology 98, 51-64.
Sheldrick, P., and Berthelot, N. (1974): Inverted repetitions in the chromosome of herpes 
simplex virus. Cold Spring Harbour Symposium on Quantitative Biology 9, 667-678.
Shenk, T. (1996): Adenoviridae and their replication, pp. 2111-2148. In B. Fields,
P. Howley, and D. Knipe (Eds): Virology, Raven Press, New York.
Shieh, H., Kurumbail, R., Stevens, A., Stegeman, R., Sturman, E., Pak, J., Wittwer, A., 
Palmier, M., Wiegand, R., Holwerda, B., and Stallings, W. (1996): Three-dimensional structure 
of human cytomegalovirus protease. Nature 384, 288.
Smibert, C., Popova, B., Xiao, P., Capone, J., and Smiley, J. (1994): Herpes simplex virus 
VP16 forms a complex with the virion host shut off protein vhs. Journal o f Virology 68, 2339- 
2346.
Smith, C., Marchetti, M., Edmonson, P., and Schaffer, P. (1989): Herpes simplex virus type 2 
mutants with deletions in the intergenic region between ICP4 and ICP22/47: Identification of 
nonessential cis-acting elements in the context of the viral genome. Journal of Virology 63, 
2036-2047.
Sodeik, B., Ebersold, M., and Helenius, A. (1997): Microtuble mediated transport of incoming 
herpes simplex virus capsids to the nucleus. Journal of Cell Biology 136, 1007-1021.
References
Spear, P., and Roizman, B. (1972): Proteins specified by herpes simplex virus. V. Purification 
and structural proteins of the herpes virion. Journal of Virology 9, 143-159.
Spear, P. (1976): Membrane proteins specified by herpes simplex virus I. Identification of four 
glycoprotein precursors and their products in type 1 infected cells. Journal of Virology 17, 991- 
1008.
Spear, P. (1993): Entry of alphaherpesviruses into cells. Seminars in Virology 9, 143-159.
Spencer, J. V., Newcomb, W. W., Thomsen, D. R., Homa, F. L., and Brown, J. C. (1998): 
Assembly of the herpes simplex virus capsid: preformed triplexes bind to the nascent capsid. 
Journal of Virology 72, 3944-3951.
Spivack, J., and Fraser, N. (1988): Expression of herpes simplex type 1 (HSV-1) latency 
associated transcripts and transcripts affected by deletion in mutant HFEM: Evidence for a 
new class of genes. Journal of Virology 62, 3281-3287.
Stackpole, C. (1969): Herpes type virus of the frog renal adenocarcinoma. I. Virus 
development in tumor transplants maintained at low temperatures. Journal of Virology 4, 75- 
93.
Stannard, L. M., Fuller, A. O., and Spear, P. G. (1987): Herpes simplex virus glycoproteins 
associated with different morphological entities projecting from the virion envelope. Journal of 
General Virology SB, 715-725.
Steiner, I., Spivack, J., O'Boyle, D., Lavi, E., and Fraser, N. (1988): Latent herpesvirus typel 
transcription in the human trigeminal ganglia. Journal of Virology 62, 493-496.
Steiner, I., Spivack, J., Deshmane, S., Ace, C., Preston, C., and Fraser, N. (1990): A herpes 
simplex virus type 1 mutant containing a non-transducing Vmw65 protein establishes latent 
infection in vivo in the absence of viral replication and reactivates efficiently when expanded in 
trigeminal ganglia. Journal of Virology 64, 1630-1634.
Steiner, I., and Kennedy, P. (1995): Herpes simplex virus latent infection in the nervous 
system. Journal of NeuroVirology 1, 19-29.
Steven, A., Roberts, C., Hay, J., Bisher, M., Pun, T., and Trus, B. (1986): Hexavalent 
capsomeres of herpes simplex type 2: symmetry, shape, dimensions and oligomeric status. 
Journal of Virology 57, 578-584.
Steven, A. C., Bauer, A. C., Bisher, M. E., Robey, F. A., and Black, L. W. (1991): The 
maturation-dependent conformational change of phage T4 capsid involves the translocation of 
specific epitopes between the inner and the outer capsid surfaces. J Struct Biol 106, 221-36.
Steven, A. C., Greenstone, H. L., Booy, F. P., Black, L. W ., and Ross, P. D. (1992): 
Conformational changes of a viral capsid protein. Thermodynamic rationale for proteolytic 
regulation of bacteriophage T4 capsid expansion, co-operativity, and super-stabilization by soc 
binding. J Mol Biol 228, 870-84.
Steven, A. C. (1993): Conformational change: an alternative energy source? Exothermic 
phase transition in phage capsid maturation. Biophys J 65, 5-6.
References
Stevenly, W. (1975): Virus induced proteins in pseudo-rabies infected cells. II. Proteins of the 
virions and nucleocapsid. Journal of Virology 16, 944-950.
Stevens, J., Wagner, E., Devi, -. R., GB, Cook, M., and Feldman, L. (1987): RNA 
complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. 
Science 235, 1056-1059.
Stevens, J., Haarr, L., Porter, D., Cook, M., and Wagner, E. (1988): Prominence of the herpes 
simplex virus latency associated transcript in trigeminal ganglia of seropositive humans. 
Journal of Infectious Disease 158, 17-22.
Stewart, P. L., Fuller, S. D., and Burnett, R. M. (1993): Difference imaging of adenovirus: 
Bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO J. 
12, 2589-2599.
Stow, N. (1982): Localisation of an origin of DNA replication within the TRS/IRS repeated 
region of the herpes simplex virus type 1 genome. EMBO 1, 863-867.
Stow, N., and McMonagle, E. (1983): Characterisation of the TRS/IRS origin of DNA
replication of herpes simplex virus type 1. Virology 130, 427-438.
Stow, N., Hammarstein, O., Arbuckle, M., and Elias, P. (1993): Inhibition of herpes simplex
virus type 1 DNA replication by mutant forms of the origin binding protein. Virology 196, 413-
418.
Subak-Sharpe, J., and Dargan, D. (1998): HSV molecular biology: General aspects of herpes 
simplex virus molecular biology. Virus Genes 16, 239-251.
Swanstom, R., and Wagner, E. (1974): Regulation of synthesis of herpes simplex type 1 virus 
mRNA during productive infection. Virology 60, 522-533.
Sydiskis, R., and Roizman, B. (1967): The disaggregation of host polyribosomes in productive 
and abortive infection with herpes simplex virus. Virology 32, 678-686.
Szilagyi, J. F., and Cunningham, C. (1991): Identification and characterization of a novel non- 
infectious herpes simplex virus-related particle. Journal of General Virology 72, 661-668.
Tatman, J. D., Preston, V. G., Nicholson, P., Elliott, R. M., and Rixon, F. J. (1994): Assembly 
of herpes simplex virus type 1 capsids using a panel of recombinant baculoviruses. Journal of 
General Virology 75, 1101-1113.
Tatman, J. (1996): An investigation into the structure and assembly of the herpes simplex 
virus type 1 (HSV-1) capsid using the baculovirus expression system: MRC Institute o f 
Virology, University of Glasgow, Glasgow.
Terry-Allison, T., Montgomery, R., Whitbeck, J., Xu, R., Cohen, G., Eisenberg, R., and Spear, 
P. (1998): HVEM, a co-receptor for herpes simplex virus entry, also participates in virus 
induced cell fusion. Journal of Virology.
Teschke, C. M., and King, J. (1993): Folding of the phage P22 coat protein in vitro. 
Biochemistry 32, 10839-47.
References
Thomsen, D. R., Roof, L. L., and Homa, F. L. (1994): Assembly of herpes simplex virus (HSV) 
intermediate capsids in insect cells infected with recombinant baculoviruses expressing HSV 
capsid proteins. Journal o f Virology 68, 2442-2457.
Thuman-Commike, P., Greene, B., Jakana, J., Prasad, B., King, J., Prevelige, P., and Chiu, 
W. (1996): Three-dimensional structure of scaffolding-containing phage P22 procapsids by 
electron cryo-microscopy. Journal of Molecular Biology 260, 85-98.
ThumanCommike, P., Greene, B., Malinski, J., Burbea, M., McGough, A., Chiu, W., and 
Prevelige, P. (1999): Mechanism of scaffolding-directed virus assembly suggested by
comparison of scaffolding-containing and scaffolding-lacking P22 procapsids. Boiphysical 
Journa l! B, 3267-3277.
Tong, L., Qian, C., Massariol, M., Bonneau, P., Cordingley, M., and Lagace, L. (1996): A new 
serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. 
Nature 383, 272-275.
Trousdale, M., Steiner, I., Spivack, J., Deshman, S., Brown, S., MacLean, A., Subak-Sharpe, 
J., and Fraser, N. (1991): In vivo and in vitro reactivation impairment of herpes simplex virus 
type 1 latency associated variant in a rabbit eye model. Journal of Virology, 6989-6993.
Trus, B. L., Newcomb, W. W., Booy, F. P., Brown, J. C., and Steven, A. C. (1992): Distinct 
monoclonal antibodies separately label the hexons or the pentons of herpes simplex virus 
capsid. Proceedings of the National Academy of Sciences of the U.S.A. 89, 11508-11512.
Trus, B., Homa, F., Booy, F., Newcomb, W., Thomsen, D., Cheng, N., Brown, J., and Steven, 
A. (1995): Herpes simplex virus capsids assembled in insect cells infected with recombinant 
baculoviruses: Structural authenticity and localisation of VP26. Journal of Virology 69, 7362- 
7366.
Trus, B. L., Booy, F. P., Newcomb, W. W., Brown, J. C., Homa, F. L., Thomsen, D. R., and 
Steven, A. C. (1996): The herpes simplex virus procapsid: structure, conformational changes 
upon maturation, and roles of the triplex proteins VP19c and VP23 in assembly. Journal of 
Molecular Biology 263, 447-462.
Van Genderan, I., Brandimarti, R., Torrisi, M., Campadelli, G., and Van Meer, G. (1994): The 
phospholipid composition of extracellular herpes virions differs from that of host cell nuclei. 
Virology 200, 831-836.
Van Grunsven, W., Van Heerde, E., De Haard, H., Spaan, W., and Middledorp, J. (1993): 
Gene mapping and expression of 2 immunodominant Epstein-Barr virus capsid proteins. 
Journal of Virology 67, 3908-3916.
Van Oostrum, J., and Burnett, R. (1985): Molecular composition of the adenovius type 2 virion. 
Journal of Virology 56, 439-448.
Varmuza, S., and Smiley, J. (1985): Signals for site specific cleavage of HSV DNA: Maturation 
involves two specific cleavage events at sites distal to the recognition sequences. Cell 41, 
793-802.
Vaughn, J., Goodwin, R., Tompkins, G., and McCawley, P. (1977): The establishment of 2 cell 
lines from the insect Spodoptera fugiperda (Lepidoptera: Nucleotidae) in vitro. Virology 16, 
147-151.
References
Vaughn, P., Banks, L., Purifoy, D., and Powell, K. (1984): Interactions between herpes simplex 
virus DNA binding proteins. Journal o f General Virology 65, 2033-2041.
Vernon, S., Lawrence, W., and Cohen, G. (1974): Morphological components of herpesvirus 1. 
Intercapsomeric fibrils and the geometry of the capsid. Intervirology 4, 237-248.
Vernon, S., Lawrence, W., Long, C., Cohen, G., and Rubin, B. (1978): Herpesvirus vaccine 
development: studies of virus morphological components. In A. Voller, and H. Friedman (Eds): 
New trends and developments in vaccines, MTP Press, Lancaster.
Vernon, S., Ponce de Leon, M., and Cohen, G. (1981): Morphological components of 
herpesvirus. III. Localisation of herpes simplex virus type 1 nucleocapsid polypeptides by 
immune electron microscopy. Journal of General Virology 54, 39-46.
Vlazny, D., Kwong, A., and Frenkel, N. (1982): Site-specific cleavage and packaging of herpes 
simplex virus DNA and the selective maturation of nucleocapsids containing full-length viral 
DNA. Proceedings of the National Academy of Sciences of the U.S.A. 79, 1423-1427.
Wadsworth, S., Hayward, G., and Roizman, B. (1976): Anatomy of herpes simplex virus DNA. 
V. Terminally repetitive sequences. Journal of Virology 17, 503-512.
Wagner, E., and Roizman, B. (1969): Ribonucleic acid synthesis in cells infected with herpes 
s i m p I ex. Journal of Virology 4, 36-46.
Warner, M., Geraghty, R., Martinez, W., Montgomery, R., Whitbeck, J., XU, R., Eisenberg, R., 
Cohen, G., and Spear, P. (1998): A cell surface protein with herpesvirus entry activity (HveB) 
confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex 
virus type 2 and pseudorabies virus. Virology 246, 179-189.
Weber, J. (1976): Genetic analysis of adenovirus type 2. III. Temperature sensitivity of 
processing of viral proteins. Journal of Virology 17, 462-471.
Weinheimer, S., Boyd, B., Durham, S., Resnick, J., and O'Boyle, D. (1992): Deletion of the 
VP16 open reading frame of herpes simplex virus type 1. Journal o f Virology 66, 258-269.
Weinheimer, S., McCann, P., Ill, O'Boyle, D., II, Stevens, J., Boyd, B., Drier, D., Yamanaka, 
G., Dilanni, C., Deckman, I., and Cordingley, M. (1993): Autoproteolysis of herpes simplex 
virus type 1 protease releases an active catalytic domain found in intermediate capsid 
particles. Journal of Virology 67, 5813-5822.
Weller, S., Spadaro, A., Scaffer, J., Murray, A., Maxam, A., and Scaffer, P. (1985): Cloning, 
sequencing, and functional analysis of ori L, a herpes simplex type 1 origin of DNA synthesis. 
Molecular and Cellular Biology 5, 930-942.
Weller, S., Carmicheal, E., Aschmann, D., Goldstein, D., and Schaffer, P. (1987): Genetic and 
phenotypic characterisation of mutants in four essential genes that map to the left half of HSV- 
1 UL DNA. Virology 161, 198-210.
Weller, S. (1991): Genetic analysis of HSV genes required for genome replication, pp. 10S- 
135. In E. Wagner (Ed.): Herpesvirus transcription and its regulation, CRC Press, Boca Raton.
Weller, S. (1995): Herpes simplex virus DNA replication and genome maturation, pp. 189-213. 
In G. Cooper, R. Temin, and B. Sugden (Eds): The DNA Provirus- Howard Temin's Scientific 
Legacy, American Society for Microbiology, Washington DC.
References
Whealy, M., Card, J., Meade, R., Robbins, A., and Enquist, L. (1991): Effect of brefeldin A on 
alphaherpesvirus membrane protein glycosylation and virus egress. Journal of Virology 65, 
1066-1081.
Whitley, R., and Schlitt, M. (1991): Encephalitis caused by herpesviruses, including B virus, 
pp. 41-69. In W. Scheld, R. Whitley, and D. Durack (Eds): Infections of the central nervous 
system, Raven Press, New York.
Wildy, P., Russell, W., and Horne, R. (1960): The morphology of herpesvirus. Virology 12, 
201- 222 .
Wildy, P. (1973): Herpes: History and classification. In A. Kaplan (Ed.): The herpesvirus, 
Academic Press, New York.
Wilkie, N. (1973): The synthesis and sub-structure of herpesvirus DNA: The disruption of alkali 
labile single strand interruptions in HSV-1 DNA. Journal of Virology 20, 222-233.
Wilkie, N. (1976): Physical maps for herpes simplex virus type 1 DNA for restriction 
endonuclease Hindlll, Hpa-1 and Xba. Journal of Virology 20, 222-233.
Wingfield, P. T., Stahl, S. J., Thomsen, D. R., Homa, F. L., Booy, F. P., Trus, B. L., and 
Steven, A. C. (1997): Hexon-only binding of VP26 reflects differences between the hexon and 
penton conformations of VP5, the major capsid protein of herpes simplex virus. Journal of 
Virology 71, 8955-8961.
Wolf, K., and Darlington, R. (1971): Channel catfish virus: A new herpesvirus of ictalurid fish. 
Journal of Virology 8, 525-533.
Wu, C., Nelson, N., McGeoch, D., and Challberg, M. (1988): Identification of herpes simplex 
virus type 1 genes required for origin dependent DNA synthesis. Journal of Virology 62, 435- 
443.
WuDunn, D., and Spear, P. (1989): Initial interaction of herpes simplex virus with cells is 
binding to heparin sulphate. Journal of Virology 63, 52-58.
Yei, S., Chowdhury, S., Bhat, B., Conley, A., Wold, W., and Batterson, W. (1990): 
Identification and characterisation of the herpes simplex virus type-2 gene encoding the 
essential capsid proteins ICP32A/P19c. Journal of Virology 199, 1124-1134.
Yu, D., Sheaffer, A. K., Tenney, D. J., and Weller, S. K. (1997): Characterization of ICP6:lacZ 
insertion mutants of the UL15 gene of herpes simplex virus type 1 reveals the translation of 
two proteins. Journal of Virology 71, 2656-2665.
Yu, D., and Weller, S. (1998): Herpes simplex type 1 cleavage and packaging proteins UL15 
and UL28 are associated with B but not C capsids during packaging. Journal of Virology 72, 
7428-7439.
Zezulak, K., and Spear, P. (1984): Mapping of the structural gene for the herpes simplex virus 
type 2 counterpart of herpes simplex type 1 glycoprotein C and identification of a type 2 
mutant which does not express this protein. Journal of Virology 49, 741-747.
References
Zhang, X., Efstathiou, S., and Simmons, A. (1994): Identification of novel herpes simplex virus 
replicatitive intermediates by field inversion gel electrophoresis: Implications for viral DNA 
amplification strategies. Virology 202, 530-539.
Zhou, Z. H., Prasad, B. V. V., Jakana, J., Rixon, F. J., and Chiu, W. (1994): Protein subunit 
structures in the herpes simplex virus A-capsid determined from 400 kV spot-scan electron 
cryomicroscopy. Journal o f Molecular Biology 242, 456-469.
Zhou, Z. H., He, J., Jakana, J., Tatman, J. D., Rixon, F. J., and Wah, C. (1995): Assembly of 
VP26 in herpes simplex virus-1 inferred from structures of wild-type and recombinant capsids. 
Nature Structural Biology 2, 1026-1030.
Zhou, Z. H., Macnab, S. J., Jakana, J., Scott, L. R., Chiu, W., and Rixon, F. J. (1998a): 
Identification of the sites of interaction between the scaffold and the outer shell in HSV-1 
capsids by difference electron imaging. Proceedings of the National Academy of Sciences of 
the U.S.A. 95, 2778-2783.
Zhou, Z. H., Chiu, W., Haskell, K., Spears, H. J., Jakana, J., Rixon, F. J., and Scott, L. R. 
(1998b): Refinement of herpesvirus B-capsid structure on parallel supercomputers. 
Biophysical Journal 74, 576-588.
Zhou, Z., Chen, D., Jakana, J., Rixon, F., and Chiu, W. (1999): Visualisation of 
tegument/capsid interactions and DNA in intact Herpes simplex virus type 1 virions. Journal of 
Virology 73, 3210-3218.
Zweerink, H., and Neff, B. (1981): Immune response after exposure to varicella zoster virus: 
characterisation of virus-specific antibodies and their corresponding antigens. Infection and 
Immunity 31, 436-444.
Zweig, M., Heilman, C., and Hampar, B. (1979a): Identification of disulphide-linked complexes 
in the nucleocapsid of herpes simplex virus type 2. Virology 94, 442-450.
Zweig, M., Heilman, C., Rabin, H., Hopkins, R., Naubauer, R., and Hampar, B. (1979b): 
Production of monoclonal antibodies against nucleocapsid proteins of herpes simplex virus 
types 1 and 2. Journal of Virology 32, 676-678.
